



C:\STNEXP4\QUERIES\09830559a.str



L10



09/830,559
Please atom nte
can.

chain nodes :

13 15 16 17 19 21 22 23 24 25 26 27 28 29 30 32

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds :

1-16 2-17 3-24 4-23 5-13 6-22 7-26 8-25 9-13 10-19 11-27
12-21 13-15 16-28 28-29 28-30 30-32

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :

2-17 10-19 12-21 13-15 28-29 28-30 30-32

exact bonds :

1-16 3-24 4-23 5-13 6-22 7-26 8-25 9-13 11-27 16-28

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:C,O,N,X

G2:C,O,S,N,Cl,Br,F,I





G3:C,H,O,S,N,Cl,Br,F,I

G4:C,O,N,Si

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:CLASS 15:CLASS 16:CLASS 17:CLASS
19:CLASS

	21:CLASS	22:CLASS	23:CLASS	24:CLASS	25:CLASS	26:CLASS
27:CLASS	28:CLASS	29:CLASS	30:CLASS	32:CLASS		



chain nodes :

13 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 35 38 39 41 42 43 44 45 46
47

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds :

1-35 2-38 3-44 4-43 5-13 6-42 7-47 8-46 9-13 10-39 11-45 12-41 13-15 16-17 17-18 17-19
20-22 21-23 22-25 23-24 24-26 25-27 25-29 26-28 26-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :

1-35 2-38 10-39 12-41 13-15 16-17 17-18 17-19 25-27 25-29 26-28 26-30

exact bonds :

3-44 4-43 5-13 6-42 7-47 8-46 9-13 11-45 20-22 21-23 22-25 23-24 24-26

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12





G1:C,H,O,N

G2:[*1],[*2],[*3]

G3:CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,CN,NO2,O,S,N,CO2H,COOH,X,Hy

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom
13:CLASS15:CLASS16:CLASS17:CLASS18:CLASS19:CLASS20:CLASS21:CLASS22:CLASS23:CLASS
24:CLASS25:CLASS26:CLASS27:CLASS28:CLASS29:CLASS30:CLASS35:CLASS38:CLASS39:CLASS
41:CLASS42:CLASS43:CLASS44:CLASS45:CLASS46:CLASS47:CLASS



chain nodes :
13 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 35 38 39 41 46 47 48 49 50
51

ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12

chain bonds :
5-13 9-13 13-15 16-17 17-18 17-19 20-22 21-23 22-25 23-24 24-26 25-27 25-29 26-28 26-30

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :
13-15 16-17 17-18 17-19 25-27 25-29 26-28 26-30

exact bonds :
5-13 9-13 20-22 21-23 22-25 23-24 24-26

normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:C,H,O,N

G2:[*1],[*2],[*3]

G3:CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,CN,NO2,O,S,N,CO2H,COOH,X,Hy

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom
13:CLASS15:CLASS16:CLASS17:CLASS18:CLASS19:CLASS20:CLASS21:CLASS22:CLASS23:CLASS
24:CLASS25:CLASS26:CLASS27:CLASS28:CLASS29:CLASS30:CLASS35:CLASS38:CLASS39:CLASS
41:CLASS42:Atom 43:Atom 44:Atom 45:Atom 46:CLASS47:CLASS48:CLASS49:CLASS50:CLASS
51:CLASS52:Atom 53:Atom 54:Atom 55:Atom 56:Atom 57:Atom

Welcome to STN International! Enter x:x

LOGINID:sssptau129pxo

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 MAY 10 CA/CAPlus enhanced with 1900-1906 U.S. patent records
NEWS 5 MAY 11 KOREAPAT updates resume
NEWS 6 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 7 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPlus and
USPATFULL/USPAT2
NEWS 8 MAY 30 The F-Term thesaurus is now available in CA/CAPlus
NEWS 9 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 10 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 11 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12 JUL 11 CHEMSAFE reloaded and enhanced
NEWS 13 JUL 14 FSTA enhanced with Japanese patents
NEWS 14 JUL 19 Coverage of Research Disclosure reinstated in DWPI
NEWS 15 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 16 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 17 AUG 30 CA(SM)/CAPlus(SM) Austrian patent law changes

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 23:33:52 ON 04 SEP 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.31

2.31

FILE 'REGISTRY' ENTERED AT 23:40:33 ON 04 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 SEP 2006 HIGHEST RN 905815-43-2
DICTIONARY FILE UPDATES: 3 SEP 2006 HIGHEST RN 905815-43-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\09830559.str

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
Structure attributes must be viewed using STN Express query preparation.

=> s 11
SAMPLE SEARCH INITIATED 23:41:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12300 TO ITERATE

16.3% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 239355 TO 252645
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> search 11
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 23:41:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 244764 TO ITERATE


100.0% PROCESSED 244764 ITERATIONS 1 ANSWERS

SEARCH TIME: 00.00.03

L3 1 SEA SSS FUL L1

=> d 13

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 256379-90-5 REGISTRY
 ED Entered STN: 18 Feb 2000
 CN Acetic acid, [4-[1-[3-(carboxymethoxy)-4-chlorophenyl]]-2,2,2-trichloroethyl]-3-methylphenoxy]- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C19 H16 Cl4 O6
 SR CA
 LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	169.72	172.03

FILE 'CAPLUS' ENTERED AT 23:42:27 ON 04 SEP 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Sep 2006 VOL 145 ISS 11
 FILE LAST UPDATED: 3 Sep 2006 (20060903/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 1 L3

=> d 14 fbib ab hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:780157 CAPLUS

DN 132:122347

TI Synthesis and antimicrobial screening of 1,1,1-trichloro-2-[3-(carboxymethoxy)-4-chlorophenyl]-2-(carboxyaryl/carboxymethoxyaryl)ethanes

AU Purohit, D. M.; Shah, V. H.

CS Chemistry Department, Saurashtra University, Rajkot, 360005, India

SO Journal of the Institution of Chemists (India) (1999), 71(1), 37-39

CODEN: JOICA7; ISSN: 0020-3254

PB Institution of Chemists (India)

DT Journal

LA English


AB Title compds. such as I were prepared from benzyl alc. derivative II and substituted benzenes in the presence of concentrated sulfuric acid. The products were active against Gram pos. and neg. bacteria and fungi.

IT 256379-90-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antimicrobial activity of)

RN 256379-90-5 CAPLUS

CN Acetic acid, [4-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-3-methylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

9.25

181.28

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.75

-0.75

FILE 'REGISTRY' ENTERED AT 23:48:01 ON 04 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 SEP 2006 HIGHEST RN 905815-43-2
DICTIONARY FILE UPDATES: 3 SEP 2006 HIGHEST RN 905815-43-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\09830559c.str

L5 STRUCTURE UPLOADED

=> d 15
L5 HAS NO ANSWERS
L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
Structure attributes must be viewed using STN Express query preparation.

=> s 15
SAMPLE SEARCH INITIATED 23:48:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 13212 TO ITERATE

15.1% PROCESSED 2000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 257354 TO 271126
PROJECTED ANSWERS: 46 TO 482

L6 2 SEA SSS SAM L5

=> search 15
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 23:48:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 263279 TO ITERATE

100.0% PROCESSED 263279 ITERATIONS 491 ANSWERS
SEARCH TIME: 00.00.07

L7 491 SEA SSS FUL L5

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.38	348.66
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

FILE 'CAPLUS' ENTERED AT 23:48:59 ON 04 SEP 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Sep 2006 VOL 145 ISS 11
 FILE LAST UPDATED: 3 Sep 2006 (20060903/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 17

L8 168 L7

=> d 18 fbib ab hitstr 1-168

L8 ANSWER 1 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:637799 CAPLUS
 DN 145:56261
 TI The thyroid hormone receptor- β agonist GC-1 induces cell proliferation in rat liver and pancreas
 AU Columbano, Amedeo; Pibiri, Monica; Deidda, Manuela; Cossu, Costanza; Scanlan, Thomas S.; Chiellini, Grazia; Muntoni, Sandro; Ledda-Columbano, Giovanna M.
 CS Department of Toxicology, Oncology and Molecular Pathology Unit, University of Cagliari, Cagliari, 09124, Italy
 SO Endocrinology (2006), 147(7), 3211-3218
 CODEN: ENDOAO; ISSN: 0013-7227
 PB Endocrine Society
 DT Journal
 LA English
 AB Thyroid hormones regulate cell growth, cell differentiation, and metabolic functions via interaction with the thyroid hormone nuclear receptors (TRs). Recently, a small class of halogen-free high-affinity thyroid hormone agonists has been developed that are highly selective for the TR β subtype. Because of the selective hyperthyroidism generated by one of these agonists, GC-1, this compound has the potential to be developed as a new therapeutic agent for the treatment of a variety of metabolic disturbances, including lipid disorders and obesity; thus, it becomes

important to determine whether GC-1 has other unknown effects on potential target organs. The purpose of this study was to investigate the effect of GC-1 on cell proliferation in rat liver and pancreas. Rats treated with GC-1 (50 or 100 µg/100 g) were killed at different time points. Hepatic and pancreatic cell proliferation was monitored by immunohistochem. determination of bromodeoxyuridine incorporation. The

expression


of cell cycle-related genes was analyzed by Northern and Western anal. The results show that GC-1 strongly stimulates rat hepatocyte proliferation in the absence of tissue injury. Although GC-1-induced hepatocyte proliferation was associated with a rapid increase in cyclin D1 mRNA levels, no change in the expression of c-jun and c-fos was observed. GC-1 also induced massive pancreatic cell proliferation. The results indicate that the TRβ-selective agonist GC-1 is a strong mitogen for hepatocytes and pancreatic acinar cells. Furthermore, they suggest that the TRβ receptor is the mediator for the mitogenic activity of thyroid hormone and other thyromimetics.

IT 211110-63-3, GC-1

RL: PAC (Pharmacological activity); BIOL (Biological study)
(thyroid hormone receptor-β agonist GC-1 induction of cell proliferation in rat liver and pancreas)

RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:600032 CAPLUS

DN 145:203061

TI A Functionally Orthogonal Ligand-Receptor Pair Created by Targeting the Allosteric Mechanism of the Thyroid Hormone Receptor

AU Hassan, A. Quamrul; Koh, John T.

CS Department of Chemistry and Biochemistry, University of Delaware, Newark, DE, 19716, USA

SO Journal of the American Chemical Society (2006), 128(27), 8868-8874

CODEN: JACSAT; ISSN: 0002-7863

PB American Chemical Society


DT Journal

LA English


AB Nuclear receptors are ligand-dependent transcription factors that are of interest as potential tools to artificially regulate gene expression. Ligand binding induces a conformational change involving helix-12 which forms part of the dimerization interface used to bind transcriptional coactivators. When triiodothyronine (T3) binds the thyroid hormone receptor (TR) it indirectly contacts helix-12 through intermediary residues His(435) and Phe(451) termed a His-Phe switch. The mutant TRβ(H435A) is nonresponsive to physiol. concns. of T3 but can be activated by the synthetic hormone analog QH2 which potently activates His

435→Ala mutant at concns. that do not activate the wild-type receptors TR α and TR β . QH2 does not show antagonist behavior with the wild-type TRs. QH2's functionally orthogonal behavior with TR β (H435A) is preserved on the three consensus thyroid hormone response elements.


IT 211110-63-3, GC-1
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (functionally orthogonal ligand-receptor pair created by targeting allosteric mechanism of thyroid hormone receptor)
 RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



IT 904925-48-0P 904925-49-1P 904925-50-4P
 904925-51-5P 904925-52-6P 904925-53-7P
 904925-54-8P
 RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (functionally orthogonal ligand-receptor pair created by targeting allosteric mechanism of thyroid hormone receptor)
 RN 904925-48-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 904925-49-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 904925-50-4 CAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 904925-51-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 904925-52-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 904925-53-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 904925-54-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




IT 904925-71-9 904925-72-0 904925-73-1
 904925-78-6 904925-79-7 904925-80-0
 904925-81-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (functionally orthogonal ligand-receptor pair created by targeting
 allosteric mechanism of thyroid hormone receptor)
 RN 904925-71-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 904925-72-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 904925-73-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 904925-78-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 904925-79-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 904925-80-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 904925-81-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:453901 CAPLUS
DN 145:145324
TI Diphenylmethane skeleton as a multi-template for nuclear receptor ligands:
Preparation of FXR and PPAR ligands

AU Kainuma, Masahiko; Kasuga, Jun-ichi; Hosoda, Shinnosuke; Wakabayashi, Ken-Ichi; Tanatani, Aya; Nagasawa, Kazuo; Miyachi, Hiroyuki; Makishima, Makoto; Hashimoto, Yuichi
 CS Institute of Molecular and Cellular Biosciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-0032, Japan
 SO Bioorganic & Medicinal Chemistry Letters (2006), 16(12), 3213-3218
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 AB Novel, potent farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor α (PPAR α) agonists were obtained by using a diphenylmethane skeleton as a substitute for a steroid skeleton.
 IT 898253-45-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of diphenylmethyl ethers as farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor α (PPAR α) agonists)
 RN 898253-45-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:410214 CAPLUS
 DN 144:422710
 TI Photoacid generation type photoresist component with acid-cleavable dissolution inhibiting groups
 IN Shiono, Daiju; Hirayama, Taku; Ogata, Toshiyuki; Hada, Hideo
 PA Tokyo Ohka Kogyo Co., Ltd., Japan
 SO PCT Int. Appl., 58 pp.

CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006046383	A1	20060504	WO 2005-JP18143	20050930
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
				JP 2004-315601	A 20041029
				JP 2004-378248	A 20041227
				JP 2005-50722	A 20050225
				JP 2005-212904	A 20050722

AB Disclosed is a resist composition containing a compound obtained by substituting a part or all of hydrogen atoms in the phenolic hydroxyl groups of a polyvalent phenolic compound (a) which has two or more phenolic hydroxyl groups and a mol. weight of 300-2500 with at least one group selected from the group consisting of acid-cleavable dissoln. inhibiting groups represented by the general formulas $-(CH_2)_nCO_2R_1$ or $-CHR_3OR_2$ below (wherein R1 and R2 independently represent a branched or cyclic alkyl group which may contain a heteroatom, R3 represents a hydrogen atom or a lower alkyl group, and n' represents an integer of 1-3).


IT 884498-07-1 884498-08-2 884498-14-0
 RL: TEM (Technical or engineered material use); USES (Uses)
 (photoacid generation type photoresist component with acid-cleavable dissoln. inhibiting groups)

RN 884498-07-1 CAPLUS
 CN Acetic acid, 2,2',2'',2'''-[methylenebis[[6-[2-[(2-methyltricyclo[3.3.1.1^{3,7}]dec-2-yl)oxy]-2-oxoethoxy]-3,1-phenylene]methyldynebis[(2,5-dimethyl-4,1-phenylene)oxy]]]tetrakis-, tetrakis(2-methyltricyclo[3.3.1.1^{3,7}]dec-2-yl) ester (9CI) (CA INDEX NAME)

PAGE 1-B




PAGE 2-A




RN	884498-08-2	CAPLUS
CN	Acetic acid, 2,2',2'',2'''-[methylenebis[[6-[2-[(2-methyltricyclo[3.3.1.1 ^{3,7}]dec-2-yl)oxy]-2-oxoethoxy]-3,1-phenylene]methylidynebis[(2-cyclohexyl-5-methyl-4,1-phenylene)oxy]]]tetrakis-, tetrakis(2-methyltricyclo[3.3.1.1 ^{3,7}]dec-2-yl)	


ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B







RN 884498-14-0 CAPLUS
 CN Acetic acid, 2,2',2'',2'''-[[5-methyl-2-[2-[(2-methyltricyclo[3.3.1.1^{3,7}]dec-2-yl)oxy]-2-oxoethoxy]-1,3-phenylene]bis[methylene[6-[2-[(2-methyltricyclo[3.3.1.1^{3,7}]dec-2-yl)oxy]-2-oxoethoxy]-3,1-phenylene]methyldynebis[(2,5-dimethyl-4,1-phenylene)oxy]]]tetrakis-, tetrakis(2-methyltricyclo[3.3.1.1^{3,7}]dec-2-yl) ester (9CI) (CA INDEX NAME)



PAGE 2-A



PAGE 3-A



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:374223 CAPLUS
 DN 144:412501
 TI Preparation of 3(5)-acylaminopyrazole derivatives for use as therapeutic agents, particularly antitumor agents
 IN Pevarello, Paolo; Orsini, Paolo; Traquandi, Gabriella; Varasi, Mario; Fritzen, Edward L.; Warpehoski, Martha A.; Pierce, Betsy S.; Brasca, Maria Grabriella
 PA Pharmacia Italia S.p.A., Italy; Pharmacia & Upjohn Company LLC
 SO U.S., 41 pp., Cont.-in-part of U.S. Ser. No. 372,831, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7034049	B1	20060425	US 2002-48486	20020501
			US 1999-372831	B2 19990812
			WO 2000-US6699	W 20000505
WO 2001012189	A1	20010222	WO 2000-US6699	20000505
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 1999-372831	A 19990812
US 6218418	B1	20010417	US 2000-667603	20000922
			US 1999-372831	A1 19990812
			US 2000-560400	A1 20000428

PATENT FAMILY INFORMATION:

FAN 2001:137023

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012189	A1	20010222	WO 2000-US6699	20000505
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 1999-372831	A 19990812
CA 2383555	AA	20010222	CA 2000-2383555	20000505
			US 1999-372831	A 19990812
			WO 2000-US6699	W 20000505
AU 2000049714	A5	20010313	AU 2000-49714	20000505
			US 1999-372831	A 19990812
			WO 2000-US6699	W 20000505
EP 1202733	A1	20020508	EP 2000-931906	20000505
EP 1202733	B1	20051005		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
			US 1999-372831	A 19990812
			WO 2000-US6699	W 20000505
BR 2000013143	A	20020611	BR 2000-13143	20000505
			US 1999-372831	A 19990812
			WO 2000-US6699	W 20000505
JP 2003507329	T2	20030225	JP 2001-516535	20000505

EE 200200065	A	20030415	US 1999-372831	A	19990812
			WO 2000-US6699	W	20000505
			EE 2002-65		20000505
			US 1999-372831	A	19990812
NZ 517237	A	20040227	WO 2000-US6699	W	20000505
			NZ 2000-517237		20000505
			US 1999-372831	A	19990812
			WO 2000-US6699	W	20000505
AT 305782	E	20051015	AT 2000-931906		20000505
			US 1999-372831	A	19990812
			WO 2000-US6699	W	20000505
ES 2249270	T3	20060401	ES 2000-931906		20000505
			US 1999-372831	A	19990812
US 6218418	B1	20010417	US 2000-667603		20000922
			US 1999-372831	A1	19990812
			US 2000-560400	A1	20000428
NO 2002000684	A	20020403	NO 2002-684		20020211
			US 1999-372831	A	19990812
			WO 2000-US6699	W	20000505
HR 2002000128	A1	20030430	HR 2002-128		20020212
			US 1999-372831	A	19990812
			WO 2000-US6699	W	20000505
ZA 2002001511	A	20030311	ZA 2002-1511		20020222
			US 1999-372831	A	19990812
BG 106480	A	20020930	BG 2002-106480		20020305
			US 1999-372831	A	19990812
			WO 2000-US6699	W	20000505
US 7034049	B1	20060425	US 2002-48486		20020501
			US 1999-372831	B2	19990812
			WO 2000-US6699	W	20000505

OS MARPAT 144:412501

AB Compds. (e.g., N-(5-cyclopropyl-1H-pyrazol-3-yl)-2,2-diphenylacetamide) which are 3-amino-pyrazole derivs. represented by formula I (wherein R = C3-C6 cycloalkyl group optionally substituted by a straight or branched C1-C6 alkyl or arylalkyl group; R1 = a straight or branched C1-C6 alkyl, C2-C4 alkenyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, arylalkyl, arylcarbonyl, aryloxyalkyl or arylalkenyl group, each of which may be optionally further substituted) are claimed. A process for preparing the 3-aminopyrazole derivs. comprises: (a) reacting RCO₂R₂ (R₂ = alkyl), with MeCN in the presence of a basic agent, to obtain RC(O)CH₂CN; (b) reacting RC(O)CH₂CN with hydrazine hydrate to obtain an 3-amino-5-R-1H-pyrazole; (c) oxidizing the 3-amino-5-R-1H-pyrazole to obtain the nitro analog; (d) reacting the nitro compound with tert-butoxycarbonyl anhydride (Boc₂O) to obtain the N-Boc derivative which was reduced; (e) reacting this amino compound with R₁C(O)X (X = OH or a suitable leaving group) to obtain the N₁-Boc-protected I; and (g) hydrolyzing this intermediate in an acidic medium to obtain I. The compds. are useful for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases (no data is given). Pharmaceutical compns. containing I are also claimed.


IT 326822-92-8P, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-2-[5-(2,6-difluorobenzyl)-2-methoxyphenyl]acetamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3(5)-acylaminopyrazole derivs. for use as therapeutic agents, particularly antitumor agents)

RN 326822-92-8 CAPLUS

CN Benzeneacetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-5-[(2,6-difluorophenyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:269747 CAPLUS
DN 144:286715
TI Thyroid hormone analogs and their polymeric conjugates, alone or in
combination with other drugs, as modifiers of angiogenesis
IN Mousa, Shaker A.; Davis, Faith B.; Davis, Paul J.
PA Ordway Research Institute, USA
SO PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006031922	A2	20060323	WO 2005-US32813	20050915
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM US 2004-943072 A2 20040915 US 2005-670534P P 20050413				

AB Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compns. of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed. Imaging agents are also claimed for diagnosing a neurodegenerative disease comprising a labeled thyroid hormone analog that binds to transthyretin.


IT 211110-63-3, 3,5-Dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxyacetic acid
RL: DGN (Diagnostic use); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thyroid hormone analogs and their polymeric conjugates, alone or in combination with other drugs, as modifiers of angiogenesis)

RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




L8 ANSWER 7 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:259105 CAPLUS
 DN 144:364308
 TI Analysis of thyroid hormone receptor β A mRNA expression in *Xenopus laevis* tadpoles as a means to detect agonism and antagonism of thyroid hormone action
 AU Opitz, Robert; Lutz, Ilka; Nguyen, Ngoc-Ha; Scanlan, Thomas S.; Kloas, Werner
 CS Department of Inland Fisheries, Leibniz-Institute of Freshwater Ecology and Inland Fisheries, Berlin, D-12587, Germany
 SO Toxicology and Applied Pharmacology (2006), 212(1), 1-13
 CODEN: TXAPA9; ISSN: 0041-008X
 PB Elsevier
 DT Journal
 LA English
 AB Amphibian metamorphosis represents a unique biol. model to study thyroid hormone (TH) action in vivo. In this study, we examined the utility of thyroid hormone receptors α ($TR\alpha$) and β A ($TR\beta$ A) mRNA expression patterns in *Xenopus laevis* tadpoles as mol. markers indicating modulation of TH action. During spontaneous metamorphosis, only moderate changes were evident for $TR\alpha$ gene expression whereas a marked up-regulation of $TR\beta$ A mRNA occurred in hind limbs (prometamorphosis), head (late prometamorphosis), and tail tissue (metamorphic climax). Treatment of premetamorphic tadpoles with 1 nM 3,5,3'-triiodothyronine (T3) caused a rapid induction of $TR\beta$ A mRNA in head and tail tissue within 6 to 12 h which was maintained for at least 72 h after initiation of T3 treatment. Developmental stage had a strong influence on the responsiveness of tadpole tissues to induce $TR\beta$ A mRNA during 24 h treatment with thyroxine (0, 1, 5, 10 nM T4) or T3 (0, 1, 5, 10 nM). Premetamorphic tadpoles were highly sensitive in their response to T4 and T3 treatments, whereas sensitivity to TH was decreased in early prometamorphic tadpoles and strongly diminished in late prometamorphic tadpoles. To examine the utility of $TR\beta$ A gene expression anal. for detection of agonistic and antagonistic effects on T3 action, mRNA expression was assessed in premetamorphic tadpoles after 48 h of treatment with the synthetic agonist GC-1 (0, 10, 50, 250 nM), the synthetic antagonist NH-3 (0, 40, 200, 1000 nM), and binary combinations of NH-3 (0, 40, 200, 1000 nM) and T3 (1 nM). All tested concns. of GC-1 as well as the highest concentration of NH-3 caused an up-regulation of $TR\beta$ A expression. Co-treatment with NH-3 and T3 revealed strong antagonistic effects by NH-3 on T3-induced $TR\beta$ A mRNA up-regulation. Results of this study suggest that $TR\beta$ A mRNA expression anal. could serve as a sensitive mol. testing approach to study effects of environmental compds. on the thyroid system in *X. laevis* tadpoles.
 IT 447415-26-1, NH 3
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (NH 3; thyroid hormone receptor β A mRNA expression in *Xenopus laevis* tadpoles as a means to detect agonism and antagonism of thyroid hormones)



IT 211110-63-3, GC-1
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(thyroid hormone receptor β A mRNA expression in *Xenopus laevis*
tadpoles as a means to detect agonism and antagonism of thyroid
hormones)

RN	211110-63-3	CAPLUS
CN	Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-(9CI) (CA INDEX NAME)	



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:192211 CAPLUS
DN 144:254238
TI Preparation of phosphonic acid-containing liver-selective thyromimetics
effective against metabolic diseases
IN Erion, Mark D.; Jiang, Hongjian; Boyer, Serge H.
PA USA
SO U.S. Pat. Appl. Publ., 253 pp., Cont.-in-part of Appl. No.
PCT/US04/039024.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006046980	A1	20060302	US 2005-137773	20050526
				US 2003-523830P	P 20031119
				US 2004-598524P	P 20040803
				WO 2004-US39024	A2 20041119
	WO 2005051298	A2	20050609	WO 2004-US39024	20041119
	WO 2005051298	A3	20050811		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
 SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG

US 2003-523830P P 20031119
 US 2004-598524P P 20040803

PATENT FAMILY INFORMATION:

FAN 2005:490263

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051298	A2	20050609	WO 2004-US39024	20041119
WO 2005051298	A3	20050811		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2003-523830P	P 20031119
			US 2004-598524P	P 20040803
AU 2004293013	A1	20050609	AU 2004-293013	20041119
			US 2003-523830P	P 20031119
			US 2004-598524P	P 20040803
			WO 2004-US39024	W 20041119
CA 2546601	AA	20050609	CA 2004-2546601	20041119
			US 2003-523830P	P 20031119
			US 2004-598524P	P 20040803
			WO 2004-US39024	W 20041119
EP 1689383	A2	20060816	EP 2004-811701	20041119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
			US 2003-523830P	P 20031119
			US 2004-598524P	P 20040803
			WO 2004-US39024	W 20041119
US 2006046980	A1	20060302	US 2005-137773	20050526
			US 2003-523830P	P 20031119
			US 2004-598524P	P 20040803
			WO 2004-US39024	A2 20041119

OS MARPAT 144:254238

AB The present invention relates to phosphonic acid-containing T3 mimetics (shown as I; other related Markush structures described in claims; variables defined below; e.g. [[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]methyl]phosphonic acid (shown as II)), stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome X

and diabetes. For I: G = O-, -S-, -Se-, -S(O)-, -S(O)2-, -CH2-, -CF2-, -CHF-, -C(O)-, -CH(OH)-, -NH-, and -N(C1-C4 alkyl)- or CH2 linked to any of the preceding groups; T = -(CRA2)k-, -CRb:CRb(CRA2)n-, -(CRA2)nCRb:CRb-, -(CRA2)CRb:CRb(CRA2)-, -O(CRb2)(CRA2)n-, -S(CRb2)(CRA2)n-, -N(Rc)(CRb2)(CRA2)n-, -N(Rb)C(O)(CRA2)n-, -(CRA2)nCH(NRbRc)-, -C(O)(CRA2)m-, -(CRA2)mC(O)-, -(CRA2)C(O)(CRA2)n-, -(CRA2)nC(O)(CRA2)-, -C(O)NH(CRb2)(CRA2)p- and -(CH2)nC(O)N(Rb)C(Ra)2-; k = 0-4; m = 0-3; n = 0-2; p = 0-1. Each Ra = H, (un)substituted -C1-C4 alkyl, halogen, -OH, (un)substituted -OC1-C4 alkyl, -OCF3, (un)substituted -SC1-C4 alkyl, -NRbRc, (un)substituted C2-C4 alkenyl, and (un)substituted C2-C4 alkynyl; each Rb = H and (un)substituted C1-C4 alkyl; each Rc = H and (un)substituted C1-C4 alkyl, (un)substituted C(O)C1-C4 alkyl, and -C(O)H; R1 and R2 = halogen, (un)substituted C1-C4 alkyl, (un)substituted S-C1-C3 alkyl, (un)substituted C2-C4 alkenyl, (un)substituted C2-C4 alkynyl, -CF3, -OCF3, (un)substituted OC1-C3 alkyl, and cyano; R3 and R4 = H, halogen, -CF3, -OCF3, cyano, (un)substituted C1-C12 alkyl, (un)substituted C2-C12 alkenyl, (un)substituted C2-C12 alkynyl, (un)substituted (CRA2)maryl, (un)substituted (CRA2)mcycloalkyl, (un)substituted (CRA2)mheterocycloalkyl, -ORd, -SRd, -S(O)Re, -S(O)2Re, -S(O)2NRfRg, -C(O)NRfRg, -C(O)ORh, -C(O)Re, -N(Rb)C(O)Re, -N(Rb)C(O)NRfRg, -N(Rb)S(O)2Re, -N(Rb)S(O)2NRfRg, and -NRfRg. R5 = OH, (un)substituted OC1-C6 alkyl, -OC(O)Re, -OC(O)ORh, -F, -NHC(O)Re, -NHS(O)Re, -NHS(O)2Re, -NHC(S)NH(Rh), and -NHC(O)NH(Rh); X is P(O)(YR11)(Y'R11); Y and Y' = O-, and -NRV-; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, >60 example preps. are included. For example, II was prepared in 2 steps (64 and 95 %) starting from 3,5-dimethyl-4-(4-methoxymethoxy-3-isopropylbenzyl)phenol and di-Et p-tosyloxymethylphosphonate to give di-Et [[3,5-dimethyl-4-(4-methoxymethoxy-3-isopropylbenzyl)phenoxy]methyl]phosphonate, which was conversion to the acid. Thyroid hormone receptor $\alpha 1$ and $\beta 1$ binding affinities for many examples of I and prodrugs are tabulated; the I exhibited good to excellent affinity whereas the prodrugs has poor affinity. Both II and [3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]acetic acid (III) were comparable to T3 with regard to their thyromimetic effect in the liver; however T3 and II did not produce a significant effect in the heart unlike the other 2 compds. Other tests on examples of I or prodrugs showed: improved therapeutic index, serum cholesterol-lowering activity without undesirable effects on heart weight or endogenous thyroid axis, prodrug activation in rat liver microsomes and good affinity for the microsomal enzyme(s) catalyzing their activation, prodrug activation by human liver S9 and in fresh rat hepatocytes, adequate systemic exposure of II maintained over 8 h after oral administration of prodrug to rats, liver distribution following oral administration, enhancement of oxygen consumption in rats, tissue distribution and pharmacokinetics of III vs. II, decrease in hepatic fat content, glucose-lowering activity, lack of mediated induction of α -MHC hnRNA and repression of β -MHC hnRNA compared to T3 and non-selective mimetics like III, lack of significant chronotropic and inotropic effects in a normal SD rat.


IT 211110-63-3, [3,5-Dimethyl-4-(4-hydroxy-3-isopropylbenzyl)phenoxy]acetic acid

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL (Biological study)

(comparison compound; preparation of phosphonic acid-containing liver-selective thyromimetics effective against metabolic diseases)

RN 211110-63-3 CAPLUS


CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




L8 ANSWER 9 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1310610 CAPLUS
 DN 144:36660
 TI Trisphenoltrioxymethylcarboxylic acids and their tertiary cyclopentyl esters
 IN Nishikawa, Atsushi; Yoshitomo, Akira; Morita, Hitoshi
 PA Honshu Chemical Industry Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 12 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2005343797	A2	20051215	JP 2004-161951 JP 2004-161951	20040531 20040531


OS MARPAT 144:36660
 AB Title acids and esters, useful for photoresists for semiconductor device fabrication, etc., are I (R = H; R1 = H, C1-3 alkyl) and I (R = II; R1 = same as above; R2 = C1-3 alkyl), resp. Thus, 1,1-di(2-methyl-4-hydroxy-5-cyclohexylphenyl)-1-(2-hydroxyphenyl)methane was substituted with tert-Bu chloroacetate, hydrolyzed, and esterified with 1-methylcyclopentan-1-ol to give a corresponding cyclopentyl ester II.
 IT 740839-96-7P
 RL: IMF (Industrial manufacture); PREP (Preparation)
 (preparation of trisphenoltrioxymethylcarboxylic acids and their tertiary cyclopentyl esters for photoresists)
 RN 740839-96-7 CAPLUS
 CN Acetic acid, 2,2'-[[[2-[2-[(1-methylcyclopentyl)oxy]-2-oxoethoxy]phenyl]methylene]bis[(2-cyclohexyl-5-methyl-4,1-phenylene)oxy]]bis-, bis(1-methylcyclopentyl) ester (9CI) (CA INDEX NAME)



IT 262285-37-0P 870480-91-4P
 RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of trisphenoltrioxymethylcarboxylic acids and their tertiary cyclopentyl esters for photoresists)
 RN 262285-37-0 CAPLUS
 CN Acetic acid, 2,2'-[[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]methylene]bis[(2-cyclohexyl-5-methyl-4,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 870480-91-4 CAPLUS
 CN Acetic acid, 2,2'-[[[2-(carboxymethoxy)phenyl]methylene]bis[(2-cyclohexyl-5-methyl-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



L8 ANSWER 10 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1265236 CAPLUS
 DN 144:29764
 TI Positive resist composition and compound used therein
 IN Nitta, Kazuyuki
 PA Japan
 SO U.S. Pat. Appl. Publ., 17 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005266340	A1	20051201	US 2005-137164	20050525
				JP 2004-161983	20040531
				JP 2004-161983	20040531
	JP 2005345538	A2	20051215	JP 2004-161983	20040531
	CN 1704846	A	20051207	CN 2005-10074388	20050526

EP 1602977 A1 20051207 JP 2004-161983 A 20040531
 EP 2005-104527 20050526
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
 BA, HR, IS, YU

JP 2004-161983 A 20040531

OS MARPAT 144:29764

AB A pos. resist composition includes a resin component (A) which contains an acid dissociable dissoln. inhibiting group and displays increased alkali solubility under the action of acid, an acid generator component (B) that generates acid on exposure, and a compound (C) represented by a general formula I (wherein, each R1 group and each R3 group represents, independently, a hydrogen atom, an alkyl group of 1 to 3 carbon atoms, or a cycloalkyl group of 4 to 6 carbon atoms, provided at least one of the R1 and R3 groups is a cycloalkyl group of 4 to 6 carbon atoms, n represents an integer from 1 to 3, R2 represents an alkyl group of 1 to 3 carbon atoms, and X represents an alkylene group of either 4 or 5 carbon atoms).


IT 262285-37-0P 870480-91-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(invention's compound for pos. resist composition)


RN 262285-37-0 CAPLUS

CN Acetic acid, 2,2'-[[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]methylene]bis[(2-cyclohexyl-5-methyl-4,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 870480-91-4 CAPLUS

CN Acetic acid, 2,2'-[[[2-(carboxymethoxy)phenyl]methylene]bis[(2-cyclohexyl-5-methyl-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




IT 740839-96-7P 870480-92-5P

RL: SPN (Synthetic preparation); TEM (Technical or engineered material)

use); PREP (Preparation); USES (Uses)
(invention's compound for pos. resist composition)


RN 740839-96-7 CAPLUS

CN Acetic acid, 2,2'-[[[2-[2-[(1-methylcyclopentyl)oxy]-2-oxoethoxy]phenyl]methylene]bis[(2-cyclohexyl-5-methyl-4,1-phenylene)oxy]]bis-, bis(1-methylcyclopentyl) ester (9CI) (CA INDEX NAME)



RN 870480-92-5 CAPLUS

CN Acetic acid, 2,2'-[[[2-[2-[(1-ethylcyclohexyl)oxy]-2-oxoethoxy]phenyl]methylene]bis[(2-cyclohexyl-5-methyl-4,1-phenylene)oxy]]bis-, bis(1-ethylcyclohexyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 11 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1260415 CAPLUS

DN 144:64451

TI Molecular dynamics simulations of ligand dissociation from thyroid hormone receptors: evidence of the likeliest escape pathway and its implications for the design of novel ligands

AU Martinez, Leandro; Webb, Paul; Polikarpov, Igor; Skaf, Munir S.

CS Instituto de Quimica, Universidade Estadual de Campinas - UNICAMP, Campinas, 13084-862, Brazil

SO Journal of Medicinal Chemistry (2006), 49(1), 23-26


CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal
 LA English
 AB Steered mol. dynamics simulations of ligand dissociation from Thyroid hormone receptors indicate that dissociation is favored via rearrangements in a mobile part of the LBD comprising H3, the loop between H1 and H2, and nearby β -sheets, contrary to current models in which the H12 is mostly involved. Dissociation is facilitated in this path by the interaction of the hydrophilic part of the ligand with external water mols., suggesting strategies to enhance ligand binding affinity.

IT 211110-63-3, GC1
 RL: BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); BIOL (Biological study); PROC (Process)
 (mol. dynamics simulations of ligand dissociation from thyroid hormone receptors in relation to likeliest escape pathway and implications for design of novel ligands)

RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1159836 CAPLUS
 DN 143:416553
 TI Different configurations of specific thyroid hormone response elements mediate opposite effects of thyroid hormone and GC-1 on gene expression
 AU Gloss, Bernd; Giannocco, Gisele; Swanson, Eric A.; Moriscot, Anselmo S.; Chiellini, Grazia; Scanlan, Thomas; Baxter, John D.; Dillmann, Wolfgang H.
 CS Division of Endocrinology and Metabolism, University of California, San Diego, La Jolla, CA, 92093, USA
 SO Endocrinology (2005), 146(11), 4926-4933
 CODEN: ENDOAO; ISSN: 0013-7227
 PB Endocrine Society
 DT Journal
 LA English
 AB T3 regulates transcription of the rat sarcoendoplasmic reticulum calcium ATPase in the heart. The T3 effect is mediated by three differently configured T3 response elements (TREs). Here the authors report the mutation of each individual TRE in the promoter and the contribution of each TRE on gene expression. Mutation of TRE1, a direct repeat element, exerted the strongest T3 response, compared with TRE2 and TRE3, which are inverted palindromes. The isolated TRE2 and TRE3, which showed no response (TRE2) or were weakly pos. with T3 (TRE3), became strong neg. regulatory elements with the T3 analog GC-1. The authors found that TRE1 recruits corepressor complexes containing nuclear receptor corepressor and histone deacetylase 3 in the absence of ligand, and steroid receptor coactivator-1-containing coactivator complexes with both T3 and GC-1. TRE3 bound the same corepressor complexes without ligand but showed only a weak


association with steroid receptor coactivator-1 with T3 and a strong association with corepressor complexes with GC-1. Thus, GC-1 appears to control cofactor association differentially on these two sarcoendoplasmic reticulum calcium ATPase TREs, which could be the mechanism of ligand-dependent transcriptional activation and repression observed with the isolated TRE1 and TRE3 elements. Because the x-ray crystal structures of GC-1 and T3 complexed with the TR ligand binding domain are superimposable, the results imply that GC-1 and T3 induce differential effects on the receptor that are not evident in the static structures but must occur in the dynamic setting of receptor function. These results have implications for selective modulation of receptor function by agonist ligands.

IT 211110-63-3, GC-1

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(different configurations of specific thyroid hormone response elements of sarcoendoplasmic reticulum calcium ATPase mediate opposite effects of thyroid hormone and GC-1 on gene expression)

RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1155548 CAPLUS

DN 143:416204

TI Use of phenylacetamides as non-nucleoside reverse transcriptase inhibitors for treating retroviral infections

PA Roche Palo Alto LLC, USA

SO U.S. Pat. Appl. Publ., 67 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005239880	A1	20051027	US 2005-112590	20050422
				US 2004-565116P	P 20040423
	WO 2005102989	A1	20051103	WO 2005-EP4048	20050415
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,				

RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

US 2004-565116P P 20040423
US 2004-565117P P 20040423

PATENT FAMILY INFORMATION:

FAN 2005:1155549

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005239881	A1	20051027	US 2005-112591	20050422
WO 2005102989	A1	20051103	US 2004-565117P	P 20040423
			WO 2005-EP4048	20050415
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2004-565116P P 20040423
US 2004-565117P P 20040423

OS MARPAT 143:416204

AB Title compds. I [X1 = O, S, CH₂, C(O); R1 and R2 independently = H, alkyl, haloalkyl, etc. or together R1 and R2 are -O-CH:CH- or -O-CH₂CH₂- with provisions; R3 and R4 independently = H, alkoxy, alkylthio, etc.; R5 = alkyl, haloalkyl, cycloalkyl aryl or heteroaryl; Ar = (un)substituted aryl or heteroaryl; R6 = H, alkyl; addnl. details are given in the claims] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of non-nucleoside reverse transcriptase for use in treating or preventing an HIV infection, or treating AIDS or ARC. Although the methods of preparation are not claimed, .apprx.60 example preps. are included. For example, II was prepared by hydrolysis of III followed by chlorination and subsequent amidation using 4-aminobenzenesulfonamide. The inhibitory activity of I towards HIV1-RT was evaluated using radioactivity assay and it was revealed that selected compds. of the invention possessed IC₅₀ values = 0.0045-0.027.


IT 868070-55-7P, 2-[4-Chloro-3-(2,5-dichlorobenzyl)phenyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; use of phenylacetamides as non-nucleoside reverse transcriptase inhibitors for treating retroviral infections)

RN 868070-55-7 CAPLUS

CN Benzeneacetamide, N-[4-(aminosulfonyl)-2-chlorophenyl]-4-chloro-3-[(2,5-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




L8 ANSWER 14 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1021730 CAPLUS
 DN 143:326089
 TI Preparation of bisphenyl compounds useful as vitamin D3 receptor agonists
 IN Wallace, David; Arrhenius, Thomas; Russell, Anna; Liu, Dingguo; Xing, Amy;
 Tith, Sovouthy; Hou, Zheng; Takahashi, Tadakatsu; Ono, Yoshiyuki;
 Kashiwagi, Hirotaka; Shimizu, Kazuki; Ikura, Hitoshi
 PA Chugai Seiyaku Kabushiki Kaisha, Japan; et al.
 SO PCT Int. Appl., 645 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005087700	A2	20050922	WO 2005-US7747	20050308
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2004-551193P	P 20040308
	US 2006025474	A1	20060202	US 2005-76584	20050308
				US 2004-551193P	P 20040308


OS MARPAT 143:326089
 AB Title compds. I [X = (un)substituted methylene, ethylene, vinylene, NH, etc.; Y = CO₂R₈; CONH₂ and derivs., S-alkyl, etc.; W = OH, CO₂H, O-SO₂-CF₃, etc.; R₁, R₂ = independently (un)substituted cyclo/alkyl, alkenyl, alkynyl, etc.; R₃, R₄, R₅, R₆ = independently H, halo, (un)substituted cyclo/alkyl; with provisos; and their pharmaceutically acceptable salts and prodrugs] were prepared as vitamin D receptor modulators, particularly vitamin D₃ agonists. Thus, O-alkylation of phenol II (preparation given) with 4-bromomethylbenzoic acid Me ester and saponification gave bisphenyl (E)-III. Bisphenyl compds. I show similar properties of 1,25(OH)₂D₃, but with reduced serum calcium level, and may be used to treat psoriasis, secondary hyperparathyroidism, etc.
 IT 865239-02-7P, N-tert-Butyl-2-[4-[1-[4-[(S)-2,3-dihydroxypropyl]oxy]-3-methylphenyl]-1-ethylpropyl]-2-methylphenyl]acetamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of bisphenyl compds. useful as vitamin D₃ receptor agonists)
 RN 865239-02-7 CAPLUS
 CN Benzeneacetamide, 4-[1-[4-[(2S)-2,3-dihydroxypropoxy]-3-methylphenyl]-1-ethylpropyl]-N-(1,1-dimethylethyl)-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 865239-08-3P, N-tert-Butyl-2-[4-[1-[4-[(R)-2,2-dimethyl-
[1,3]dioxolan-4-yl]methoxy]-3-methylphenyl]-1-ethylpropyl]-2-
methylphenyl]acetamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of bisphenyl compds. useful as vitamin D3
receptor agonists)
RN 865239-08-3 CAPLUS
CN Benzeneacetamide, 4-[1-[4-[[4(R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]-3-
methylphenyl]-1-ethylpropyl]-N-(1,1-dimethylethyl)-2-methyl- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



L8 ANSWER 15 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:997778 CAPLUS
DN 144:143127
TI Clinical prospects for new thyroid hormone analogues
AU Ocasio, Cory A.; Scanlan, Thomas S.
CS Chemistry and Chemical Biology Graduate Program and the Departments of
Pharmaceutical Chemistry and Cellular and Molecular Pharmacology,
University of California-San Francisco, San Francisco, CA, USA
SO Current Opinion in Endocrinology & Diabetes (2005), 12(5), 363-370
CODEN: CENDES; ISSN: 1068-3097
PB Lippincott Williams & Wilkins
DT Journal; General Review
LA English
AB A review. Purpose of review: Scientists have been studying
liver-selective thyroid hormone analogs developed between the late 1980s
through the late 1990s to validate their utility in treating
hypercholesterolemia, diabetes, atherosclerosis, and obesity. Several
thyromimetics with agonistic or antagonist properties have recently been
developed and their clin. utility is being explored. This review presents
the progress of several thyromimetics with potential clin. utility and
provides an assessment of the potential of second-generation thyromimetics
with varying pharmacol. profiles. Recent findings: GC-1 exhibits
cholesterol-lowering effects in hypothyroid mice, cholesterol-fed rats,
and cynomolgus monkeys. DITPA (3,5-diiodothyropropionic acid) is

currently being investigated for use in treating congestive heart failure. In rat and rabbit postinfarction models, DITPA administration in combination with captopril or as monotherapy caused an increase in cardiac output and a decrease in left ventricular end-diastolic pressure without chronotropic or significant metabolic effects. DITPA treatment induces arteriolar growth and improves maximal perfusion potential of hypertrophied myocardium surviving a myocardial infarction. Thyroid hormone receptor- β -selective agonists, GC-24, KB-141, and KAT-681, as well as the thyroid hormone receptor- α -selective and thyroid hormone receptor- β -selective antagonists dronedarone and NH-3 show promise in treating hypercholesterolemia, hyperlipidemia, hepatocarcinogenesis, heart failure, and hyperthyroidism. Summary: Thyroid hormone receptors orchestrate a diverse array of physiologic activities in an isoform-specific manner. These activities include fetal and postnatal development, regulation of lipid inventory, and effects on cardiac performance. As a result, thyroid hormone analogs that selectively modulate thyroid hormone receptor isoforms serve as potential therapeutics in treating several metabolic and cardiac-related diseases.

IT	211110-63-3, GC-1 RL: BSU (Biological study, unclassified); BIOL (Biological study) (GC-1 exhibited cholesterol-lowering effect in hypothyroid mice, cholesterol-fed rat and cynomolgus monkey)
RN	211110-63-3 CAPLUS
CN	Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5- dimethylphenoxy]- (9CI) (CA INDEX NAME)




RE.CNT 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8	ANSWER 16 OF 168	CAPLUS	COPYRIGHT 2006 ACS on STN
AN	2005:886863	CAPLUS	
DN	143:360328		
TI	The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin		
AU	Mousa, Shaker A.; O'Connor, Laura J.; Bergh, Joel J.; Davis, Faith B.; Scanlan, Thomas S.; Davis, Paul J.		
CS	Pharmaceutical Research Institute at Albany, Albany College of Pharmacy, Albany, NY, USA		
SO	Journal of Cardiovascular Pharmacology (2005), 46(3), 356-360		
	CODEN: JPCPDT; ISSN: 0160-2446		
PB	Lippincott Williams & Wilkins		
DT	Journal		
LA	English		
AB	Our early reported investigations have demonstrated potent proangiogenic effects of L-thyroxine (T4) and 3,5,3'-triiodo-L-thyronine (T3) in the chick chorioallantoic membrane (CAM) model. Tetraiodothyroacetic acid (tetrac) blocks T4 binding to plasma membranes and its pro-angiogenic effect. T4/T3 stimulates expression of fibroblast growth factor 2 (FGF2) in endothelial cells. Thyroid hormone (T4/T3) is principally responsible for transcriptional activation mediated by nuclear thyroid hormone		

receptors TR β and TR α . In contrast, the hormone analog GC-1 also stimulates transcriptional activation via TR β 1. In the present study, we have defined the effect of GC-1, compared with T4 and T4-agarose, on angiogenesis in the CAM assay. GC-1 demonstrated a proangiogenic effect similar to that of T4 and T4-agarose. Tetrac inhibited GC-1- and T4-induced angiogenesis, indicating dependence on T4 and GC-1 binding to plasma membranes. The effects of GC-1, T4-agarose, and FGF2 were blocked by PD 98059, a mitogen-activated protein kinase (MAPK) pathway inhibitor. Addnl., the α v β 3 integrin antagonist XT199 inhibited angiogenesis induced by T4-agarose, GC-1, or FGF2. Thus, the proangiogenic effects of GC-1 and T4 are initiated at the plasma membrane, require interaction with α v β 3 integrin receptor, and are dependent on MAPK activation.

IT 211110-63-3, GC-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (proangiogenic effects of GC-1 and T4 initiated at plasma membrane, required interaction with α v β 3 integrin receptor, and dependent on MAPK activation)
 RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 17 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:683712 CAPLUS
 DN 143:206190
 TI Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice
 AU Johansson, Lisen; Rudling, Mats; Scanlan, Thomas S.; Lundasen, Thomas; Webb, Paul; Baxter, John; Angelin, Bo; Parini, Paolo
 CS Metabolism Unit, Center for Metabolism and Endocrinology, Department of Medicine, NOVUM, Karolinska Institute at Karolinska University Hospital-Huddinge, Stockholm, SE-141 86, Swed.
 SO Proceedings of the National Academy of Sciences of the United States of America (2005), 102(29), 10297-10302
 CODEN: PNASA6; ISSN: 0027-8424
 PB National Academy of Sciences
 DT Journal
 LA English
 AB Thyroid hormones [predominantly 3,5,3'-triiodo-L-thyronine (T3)] regulate cholesterol and lipoprotein metabolism, but cardiac effects restrict their use as hypolipidemic drugs. T3 binds to thyroid hormone receptors (TRs) α and β . TR β is the predominant isoform in liver, whereas T3 effects on heart rate are mediated mostly by TR α . Drugs that target TR β or exhibit tissue-selective uptake may improve plasma lipid levels while sparing the heart. Here, the authors asked how the TR β - and liver uptake-selective agonist GC-1 influences cholesterol and triglyceride metabolism in euthyroid mice. GC-1 treatment reduced serum

cholesterol levels by 25% and serum triglycerides by 75% in chow-fed mice and also attenuated diet-induced hypercholesterolemia. GC-1 reduced plasma high-d. lipoprotein cholesterol levels; increased expression of the hepatic high-d. lipoprotein receptor, SR-BI; stimulated activity of cholesterol 7 α -hydroxylase; and increased fecal excretion of bile acids. Collectively, these results suggest that GC-1 stimulates important steps in reverse cholesterol transport. Use of TR β and uptake selective agonists such as GC-1 should be further explored as a strategy to improve lipid metabolism in dyslipoproteinemia.

IT 211110-63-3, GC-1
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (thyroid receptor modulation by liver uptake-selective agonist GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice)
 RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 18 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:493577 CAPLUS
 DN 143:43688
 TI Preparation of non-steroidal vitamin D receptor modulators
 IN Bunel, Emilio Enrique; Gajewski, Robert Peter; Jones, Charles David; Lu, Jianliang; Nagpal, Sunil; Ma, Tianwei; Yee, Ying Kwong
 PA Eli Lilly and Company, USA
 SO PCT Int. Appl., 164 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051893	A2	20050609	WO 2004-US37182	20041116
WO 2005051893	A3	20050714		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 2003-523301P P 20031120

CA 2544501 AA 20050609 CA 2004-2544501 20041116
 US 2003-523301P P 20031120
 WO 2004-US37182 W 20041116
 EP 1687258 A2 20060809 EP 2004-800873 20041116
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
 US 2003-523301P P 20031120
 WO 2004-US37182 W 20041116

OS MARPAT 143:43688

AB Non-steroidal compds., such as I [R, R1 = H, alkyl; RR1 = cycloalkyl; R2, R3 = H, alkyl; -X-Y- = linking group, such as -C.tplbond.C-, -CH:CH-, -(CH2)2-, -CH(Me)CH2-, -CH2CO-, -CH2O-, -CH(Me)CO-, etc.], were prepared for use in pharmaceutical compns. with vitamin D receptor (VDR) modulating activity for treatment of disease states characterized by abnormal calcium regulation, abnormal cell proliferation, abnormal cell differentiation, abnormal immune response, dermatol. conditions, neurodegeneration, inflammation, and vitamin D sensitivity, and particularly for use in the treatment of bone disease and psoriasis. These VDR modulators are claimed for use in the treatment of specific disease states which include, but are not limited to, acne, actinic keratosis, alopecia, Alzheimer's disease, benign prostatic hyperplasia, bladder cancer, bone maintenance in zero gravity, bone fracture, cancers of the breast, colon, skin and prostate, Crohn's disease, type I diabetes, host-graft rejection, hypercalcemia, type II diabetes, leukemia, multiple sclerosis, myelodysplastic syndrome, insufficient sebum secretion, osteomalacia, osteoporosis, insufficient dermal firmness, insufficient dermal hydration, psoriatic arthritis, renal osteodystrophy, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, skin cell damage from mustard vesicants, ulcerative colitis, vitiligo and wrinkles. Thus, II was prepared via a multistep synthesis starting from 4-HO-3-MeC6H3C(OH)(CH2Me)2, Me-2-C6H4OH, Me3SiC.tplbond.CH, cyclopentanone and α -aminoisobutyric acid Me ester hydrochloride. The prepared compds. were tested for their effect on VDR activity.


IT 853247-96-8P 853248-05-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of non-steroidal vitamin D receptor modulators)


RN 853247-96-8 CAPLUS

CN Acetic acid, [4-[1-ethyl-1-[3-methyl-4-(phenylmethoxy)phenyl]propyl]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 853248-05-2 CAPLUS

CN Acetic acid, [4-[1-ethyl-1-[3-methyl-4-(phenylmethoxy)phenyl]propyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



L8 ANSWER 19 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:490263 CAPLUS
 DN 143:43967
 TI Preparation of phosphonic acid-containing liver-selective thyromimetics
 effective against metabolic diseases
 IN Erion, Mark D.; Jiang, Hongjian; Boyer, Serge H.
 PA Metabasis Therapeutics, Inc., USA
 SO PCT Int. Appl., 532 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005051298	A2	20050609	WO 2004-US39024	20041119
	WO 2005051298	A3	20050811		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				US 2003-523830P	P 20031119
				US 2004-598524P	P 20040803
AU	2004293013	A1	20050609	AU 2004-293013	20041119
				US 2003-523830P	P 20031119
				US 2004-598524P	P 20040803
CA	2546601	AA	20050609	WO 2004-US39024	W 20041119
				CA 2004-2546601	20041119
				US 2003-523830P	P 20031119
				US 2004-598524P	P 20040803
				WO 2004-US39024	W 20041119
EP	1689383	A2	20060816	EP 2004-811701	20041119
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU			
				US 2003-523830P	P 20031119
				US 2004-598524P	P 20040803
US	2006046980	A1	20060302	WO 2004-US39024	W 20041119
				US 2005-137773	20050526
				US 2003-523830P	P 20031119
				US 2004-598524P	P 20040803
				WO 2004-US39024	A2 20041119

PATENT FAMILY INFORMATION:

FAN 2006:192211

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	US 2006046980	A1	20060302	US 2005-137773	20050526
				US 2003-523830P	P 20031119
				US 2004-598524P	P 20040803
				WO 2004-US39024	A2 20041119
				WO 2004-US39024	20041119
	WO 2005051298	A2	20050609		
	WO 2005051298	A3	20050811		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				US 2003-523830P	P 20031119
				US 2004-598524P	P 20040803
OS	MARPAT 143:43967				
AB	<p>The present invention relates to phosphonic acid-containing T3 mimetics (shown as I; variables defined below; e.g. [[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]methyl]phosphonic acid (shown as II)), stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes. For I: G = O-, -S-, -S(O)-, -S(O)₂-, -CH₂-, -CF₂-, -CHF-, -C(O)-, -CH(OH)-, -NH-, and -N(C₁-C₄ alkyl)-; T = -(C_{Ra2})_k-, -C_{Rb}:C_{Rb}(C_{Ra2})_n-, -(C_{Ra2})_nC_{Rb}:C_{Rb}-, -(C_{Ra2})C_{Rb}:C_{Rb}(C_{Ra2})-, -O(C_{Rb2})(C_{Ra2})_n-, -S(C_{Rb2})(C_{Ra2})_n-, -N(R_c)(C_{Rb2})(C_{Ra2})_n-, -N(R_b)C(O)(C_{Ra2})_n-, -(C_{Ra2})_nCH(NR_bR_c)-, -C(O)(C_{Ra2})_m-, -(C_{Ra2})_mC(O)-, (C_{Ra2})C(O)(C_{Ra2})_n-, -(C_{Ra2})_nC(O)(C_{Ra2})-, and -C(O)NH(C_{Rb2})(C_{Ra2})_p-; k = 0-4; m = 0-3; n = 0-2; p = 0-1. Each R_a = H, (un)substituted -C₁-C₄ alkyl, halogen, -OH, (un)substituted -OC₁-C₄ alkyl, -OCF₃, (un)substituted -SC₁-C₄ alkyl, -NR_bR_c, (un)substituted C₂-C₄ alkenyl, and (un)substituted C₂-C₄ alkynyl; each R_b = H and (un)substituted C₁-C₄ alkyl; each R_c = H and (un)substituted C₁-C₄ alkyl, (un)substituted C(O)C₁-C₄ alkyl, and -C(O)H; R₁ and R₂ = halogen, (un)substituted C₁-C₄ alkyl, (un)substituted S-C₁-C₃ alkyl, (un)substituted C₂-C₄ alkenyl, (un)substituted C₂-C₄ alkynyl, -CF₃, -OCF₃, (un)substituted OC₁-C₃ alkyl, and cyano; R₃ and R₄ = H, halogen, -CF₃, -OCF₃, cyano, (un)substituted C₁-C₁₂ alkyl, (un)substituted C₂-C₁₂ alkenyl, (un)substituted C₂-C₁₂ alkynyl, (un)substituted (C_{Ra2})_maryl, (un)substituted (C_{Ra2})_mcycloalkyl, (un)substituted (C_{Ra2})_mheterocycloalkyl, -OR_d, -SR_d, -S(O)R_e, -S(O)₂R_e, -S(O)₂NR_fR_g, -C(O)NR_fR_g, -C(O)OR_h, -C(O)R_e, -N(R_b)C(O)R_e, -N(R_b)C(O)NR_fR_g, -N(R_b)S(O)₂R_e, -N(R_b)S(O)₂NR_fR_g, and -NR_fR_g. R₅ = OH, (un)substituted OC₁-C₆ alkyl, -OC(O)R_e, -OC(O)OR_h, -F, -NHC(O)R_e, -NHS(O)R_e, -HS(O)₂R_e, -NHC(S)NH(R_h), and -NHC(O)NH(R_h); X is P(O)(YR₁₁)(Y'R₁₁); Y and Y' = O-, and -NRV-; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, >60 example preps. are included. For example, II was prepared in 2 steps (64 and 95 %) starting from 3,5-dimethyl-4-(4-methoxymethoxy-3-isopropylbenzyl)phenol and di-Et p-tosyloxymethylphosphonate to give di-Et [[3,5-dimethyl-4-(4-methoxymethoxy-3-isopropylbenzyl)phenoxy]methyl]phosphonate, which was conversion to the acid. Thyroid hormone receptor α₁ and β₁ binding affinities for many examples of I and prodrugs are tabulated; the I exhibited good to excellent affinity whereas the prodrugs has poor</p>				

affinity. Both II and [3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy]acetic acid (III) were comparable to T3 with regard to their thyromimetic effect in the liver; however T3 and II did not produce a significant effect in the heart unlike the other 2 compds. Other tests on examples of I or prodrugs showed: improved therapeutic index, serum cholesterol-lowering activity without undesirable effects on heart weight or endogenous thyroid axis, prodrug activation in rat liver microsomes and good affinity for the microsomal enzyme(s) catalyzing their activation, prodrug activation by human liver S9 and in fresh rat hepatocytes, adequate systemic exposure of II maintained over 8 h after oral administration of prodrug to rats, liver distribution following oral administration, enhancement of oxygen consumption in rats, tissue distribution and pharmacokinetics of III vs. II, decrease in hepatic fat content, glucose-lowering activity, lack of mediated induction of α -MHC hnRNA and repression of β -MHC hnRNA compared to T3 and non-selective mimetics like III, lack of significant chronotropic and inotropic effects in a normal SD rat.

IT 211110-63-3, [3,5-Dimethyl-4-(4-hydroxy-3-isopropylbenzyl)phenoxy]acetic acid


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL (Biological study)

(comparison compound; preparation of phosphonic acid-containing

liver-selective thyromimetics)

RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



L8 ANSWER 20 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:283330 CAPLUS

DN 142:330277

TI Thyroid hormone analogs and their polymeric conjugates, alone or in combination with other drugs, as modifiers of angiogenesis

IN Mousa, Shaker A.; Davis, Faith B.; Davis, Paul J.

PA Ordway Research Institute, USA

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005027895	A2	20050331	WO 2004-US30583	20040915
	WO 2005027895	A3	20050506		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,			


TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

AU 2004273986 A1 20050331 US 2003-502721P P 20030915
 AU 2004-273986 20040915
 US 2003-502721P P 20030915
 WO 2004-US30583 W 20040915
 CA 2539288 AA 20050331 CA 2004-2539288 20040915
 US 2003-502721P P 20030915
 WO 2004-US30583 W 20040915
 EP 1670449 A2 20060621 EP 2004-784443 20040915
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 US 2003-502721P P 20030915
 WO 2004-US30583 W 20040915

AB Disclosed are methods of treating subjects having conditions related to
 angiogenesis including administering an effective amount of a polymeric form
 of thyroid hormone, or an antagonist thereof, to promote or inhibit
 angiogenesis in the subject. Compns. of the polymeric forms of thyroid
 hormone, or thyroid hormone analogs, are also disclosed.
 IT 211110-63-3, GC-1 211110-63-3D, GC-1, polyvinyl alc.
 conjugates
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (thyroid hormone analogs and their polymeric conjugates, alone or in
 combination with other drugs, as modifiers of angiogenesis)
 RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-
 dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-
 dimethylphenoxy]- (9CI) (CA INDEX NAME)




L8 ANSWER 21 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN


AN 2005:226829 CAPLUS
 DN 142:441282
 TI Hammett Analysis of Selective Thyroid Hormone Receptor Modulators Reveals Structural and Electronic Requirements for Hormone Antagonists
 AU Nguyen, Ngoc-Ha; Apriletti, James W.; Baxter, John D.; Scanlan, Thomas S.
 CS Program in Chemistry and Chemical Biology, Departments of Pharmaceutical Chemistry and Cellular and Molecular Pharmacology, University of California, San Francisco, CA, 94143-0446, USA
 SO Journal of the American Chemical Society (2005), 127(13), 4599-4608
 CODEN: JACSAT; ISSN: 0002-7863
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 142:441282
 AB Selective thyroid hormone modulators that function as isoform-selective agonists or antagonists of the thyroid hormone receptors (TRs) might be therapeutically useful in diseases associated with aberrant hormone signaling. The most potent thyroid hormone antagonist reported to date is NH-3. To explore the significance of the 5'-p-nitroaryl moiety of NH-3 and understand what chemical features are important to confer antagonism, we sought to expand the structure-activity relationship data for the class of 5'-phenylethynyl GC-1 derivs. Herein, we describe an improved synthetic route utilizing palladium-catalyzed chemical for efficient access to a series of 5'-phenylethynyl compds. with varying size and electronic properties. We prepared and tested sixteen analogs for TR binding and transactivation activity. Substitution at the 5'-position decreased binding affinity, but retained TR β -selectivity. In transactivation assays, the analogs displayed a spectrum of agonist, antagonist, and mixed agonist/antagonist activity that correlated with electronic character in a Hammett anal. between σ substituent value and TR modulation. Analogs NH-5, NH-7, NH-9, NH-11, and NH-23 displayed full antagonist activity with reduced potency compared to NH-3, indicating the nitro group is not required for antagonism. However, para-substitution with strong electron withdrawing properties on the 5'-aryl extension is important for antagonist activity, and antagonist potency-but not ligand receptor binding-was found to correlate linearly with the sigma values for the electron withdrawing substituents.
 IT 447415-19-2 447415-22-7 447415-26-1 447415-29-4
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (Hammett anal. of selective thyroid hormone receptor modulators reveals structural and electronic requirements for hormone antagonists)
 RN 447415-19-2 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-(phenylethynyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 447415-22-7 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-pentylphenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 447415-26-1 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-nitrophenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RN 447415-29-4 CAPLUS
 CN Acetic acid, [4-[[3-[(4-aminophenyl)ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




IT 446312-37-4P 851227-29-7P 851227-34-4P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (Hammett anal. of selective thyroid hormone receptor modulators reveals structural and electronic requirements for hormone antagonists)
 RN 446312-37-4 CAPLUS
 CN Acetic acid, [4-[[3-[(4-aminophenyl)ethynyl]-4-(methoxymethoxy)-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 851227-29-7 CAPLUS

CN Acetic acid, [4-[[3-[[4-(dimethylamino)phenyl]ethynyl]-4-(methoxymethoxy)-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 851227-34-4 CAPLUS

CN Acetic acid, [4-[[3-[(4-bromophenyl)ethynyl]-4-(methoxymethoxy)-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




IT 851227-23-1P 851227-24-2P 851227-25-3P
 851227-26-4P 851227-27-5P 851227-28-6P
 851227-30-0P 851227-31-1P 851227-32-2P
 851227-33-3P 851227-35-5P 851227-36-6P
 851227-37-7P 851227-38-8P 851227-39-9P
 851227-40-2P 851227-41-3P 851227-42-4P
 851227-43-5P 851227-44-6P 851227-45-7P
 851227-46-8P 851227-48-0P 851227-50-4P
 851227-51-5P 851227-52-6P 851227-53-7P
 851227-54-8P 851227-55-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(Hammett anal. of selective thyroid hormone receptor modulators reveals structural and electronic requirements for hormone antagonists)

RN 851227-23-1 CAPLUS


CN Acetic acid, [4-[[4-(methoxymethoxy)-3-(1-methylethyl)-5-[[4-(trifluoromethyl)phenyl]ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 851227-24-2 CAPLUS
CN Acetic acid, [4-[[4-(methoxymethoxy)-3-[(4-methoxyphenyl)ethynyl]-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 851227-25-3 CAPLUS
CN Acetic acid, [4-[[3-[(4-cyanophenyl)ethynyl]-4-(methoxymethoxy)-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 851227-26-4 CAPLUS
CN Acetic acid, [4-[[3-[(4-fluorophenyl)ethynyl]-4-(methoxymethoxy)-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 851227-27-5 CAPLUS
CN Benzoic acid, 4-[[2-(methoxymethoxy)-5-[[4-(2-methoxy-2-oxoethoxy)-2,6-


dimethylphenyl]methyl]-3-(1-methylethyl)phenyl]ethynyl]-, methyl ester
(9CI) (CA INDEX NAME)




RN 851227-28-6 CAPLUS
CN Acetic acid, [4-[[3-[[4-(aminocarbonyl)phenyl]ethynyl]-4-(methoxymethoxy)-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI)
(CA INDEX NAME)




RN 851227-30-0 CAPLUS
CN Acetic acid, [4-[[4-(methoxymethoxy)-3-(1-methylethyl)-5-[[3-(trifluoromethyl)phenyl]ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 851227-31-1 CAPLUS
CN Acetic acid, [4-[[4-(methoxymethoxy)-3-(1-methylethyl)-5-[[2-(trifluoromethyl)phenyl]ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 851227-32-2 CAPLUS
 CN Acetic acid, [4-[[3-[(3-aminophenyl)ethynyl]-4-(methoxymethoxy)-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 851227-33-3 CAPLUS
 CN Acetic acid, [4-[[3-[(2-aminophenyl)ethynyl]-4-(methoxymethoxy)-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 851227-35-5 CAPLUS
 CN Acetic acid, [4-[[4-(methoxymethoxy)-3-(1-methylethyl)-5-[[4-[[[tris(1-methylethyl)silyl]oxy]methyl]phenyl]ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




RN 851227-36-6 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[[4-(trifluoromethyl)phenyl]ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]- (9CI)
 (CA INDEX NAME)




RN 851227-37-7 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-[(4-methoxyphenyl)ethynyl]-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 851227-38-8 CAPLUS
 CN Acetic acid, [4-[[3-[(4-cyanophenyl)ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 851227-39-9 CAPLUS
 CN Acetic acid, [4-[[3-[(4-fluorophenyl)ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RN 851227-40-2 CAPLUS
 CN Benzoic acid, 4-[[5-[[4-(carboxymethoxy)-2,6-dimethylphenyl]methyl]-2-hydroxy-3-(1-methylethyl)phenyl]ethynyl]-, 1-methyl ester (9CI) (CA INDEX NAME)




RN 851227-41-3 CAPLUS
 CN Acetic acid, [4-[[3-[[4-(aminocarbonyl)phenyl]ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 851227-42-4 CAPLUS


CN Acetic acid, [4-[[3-[[4-(dimethylamino)phenyl]ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 851227-43-5 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[[3-(trifluoromethyl)phenyl]ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 851227-44-6 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[[2-(trifluoromethyl)phenyl]ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 851227-45-7 CAPLUS
CN Acetic acid, [4-[[3-[(3-aminophenyl)ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RN 851227-46-8 CAPLUS
 CN Acetic acid, [4-[[3-[(2-aminophenyl)ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 851227-48-0 CAPLUS
 CN Acetic acid, [4-[[3-[(4-azidophenyl)ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RN 851227-50-4 CAPLUS
 CN Benzenaminium, 4-[[[5-[[4-(carboxymethoxy)-2,6-dimethylphenyl]methyl]-2-hydroxy-3-(1-methylethyl)phenyl]ethynyl]-N,N,N-trimethyl-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 851227-49-1
 CMF C31 H36 N 04




CM 2


CRN 37181-39-8
 CMF C F3 O3 S




RN 851227-51-5 CAPLUS
 CN Acetic acid, [4-[[3-[(3-aminophenyl)ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 851227-52-6 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(3-nitrophenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 851227-53-7 CAPLUS
 CN Acetic acid, [4-[[3-[(4-acetylphenyl)ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 851227-54-8 CAPLUS
 CN Acetic acid, [4-[[3-[[4-(azidomethyl)phenyl]ethynyl]-4-(methoxymethoxy)-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 851227-55-9 CAPLUS
 CN Acetic acid, [4-[[3-[[4-(azidomethyl)phenyl]ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




IT 446312-35-2P 851227-20-8P 851227-21-9P
 851227-47-9P 863639-45-6P 863639-82-1P
 863640-00-0P 863640-01-1P 863640-02-2P
 863640-03-3P 863640-04-4P 863640-05-5P
 863640-08-8P 863640-10-2P 863640-11-3P
 863640-39-5P 863640-46-4P 863640-48-6P
 863640-99-7P 863641-31-0P 863642-22-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (Hammett anal. of selective thyroid hormone receptor modulators reveals
 structural and electronic requirements for hormone antagonists)
 RN 446312-35-2 CAPLUS
 CN Acetic acid, [4-[[3-iodo-4-(methoxymethoxy)-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 851227-20-8 CAPLUS
 CN Acetic acid, [4-[[4-(methoxymethoxy)-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 851227-21-9 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-iodo-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 851227-47-9 CAPLUS
CN Acetic acid, [4-[[4-(methoxymethoxy)-3-(1-methylethyl)-5-[[4-(1-nitroethyl)phenyl]ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 863639-45-6 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 863639-82-1 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[[4-(trifluoromethyl)phenyl]ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)


methyl ester (9CI) (CA INDEX NAME)




RN 863640-00-0 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-[(4-methoxyphenyl)ethynyl]-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 863640-01-1 CAPLUS
CN Acetic acid, [4-[[3-[(4-cyanophenyl)ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 863640-02-2 CAPLUS
CN Acetic acid, [4-[[3-[(4-fluorophenyl)ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 863640-03-3 CAPLUS
 CN Benzoic acid, 4-[[2-hydroxy-5-[[4-(2-methoxy-2-oxoethoxy)-2,6-dimethylphenyl]methyl]-3-(1-methylethyl)phenyl]ethynyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 863640-04-4 CAPLUS
 CN Acetic acid, [4-[[3-[[4-(aminocarbonyl)phenyl]ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 863640-05-5 CAPLUS
 CN Acetic acid, [4-[[3-[[4-(dimethylamino)phenyl]ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 863640-08-8 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[[3-(trifluoromethyl)phenyl]ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 863640-10-2 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[[2-(trifluoromethyl)phenyl]ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 863640-11-3 CAPLUS
CN Acetic acid, [4-[[3-[(2-aminophenyl)ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 863640-39-5 CAPLUS
CN Acetic acid, [4-[[3-[(4-azidophenyl)ethynyl]-4-(methoxymethoxy)-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 863640-46-4 CAPLUS
 CN Acetic acid, [4-[[3-[(4-azidophenyl)ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 863640-48-6 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[[4-(1-nitroethyl)phenyl]ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 863640-99-7 CAPLUS
 CN Acetic acid, [4-[[3-[[4-(hydroxymethyl)phenyl]ethynyl]-4-(methoxymethoxy)-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 863641-31-0 CAPLUS
 CN Acetic acid, [4-[[3-[[4-(azidomethyl)phenyl]ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 863642-22-2 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(3-nitrophenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:205091 CAPLUS
 DN 142:329982
 TI Mutant-Selective Thyromimetics for the Chemical Rescue of Thyroid Hormone Receptor Mutants Associated with Resistance to Thyroid Hormone
 AU Shi, Youheng; Ye, Haifen; Link, Kristian H.; Putnam, Marc C.; Hubner, Isaac; Dowdell, Sarah; Koh, John T.
 CS Department of Chemistry and Biochemistry, University of Delaware, Newark, DE, 19716, USA
 SO Biochemistry (2005), 44(12), 4612-4626
 CODEN: BICHAW; ISSN: 0006-2960
 PB American Chemical Society
 DT Journal
 LA English
 AB The thyroid hormone receptors (TRs) are ligand-dependent transcription factors that control the expression of multiple genes involved in development and homeostasis in response to thyroid hormone (triiodothyronine, T3). Mutations to TRβ that reduce or abolish ligand-dependent transactivation function are associated with resistance to thyroid hormone (RTH), an autosomal dominant human genetic disease. A series of neutral alc.-based compds., based on the halogen-free thyromimetic GC-1, have been designed, synthesized, and evaluated in

cell-based assays for their ability to selectively rescue three of the most common RTH-associated mutations (i.e., Arg 320 → Cys, Arg 320 → His, and Arg 316 → His) that affect the basic carboxylate-binding arginine cluster of TR β . Several analogs show improved potency and activity in the mutant receptors relative to the parent compound GC-1. Most significantly, two of these mutant-complementing thyromimetics show high potency and activity with a strong preference for the mutant receptors over wild-type TR α (wt), that is associated with the cardiotoxic actions of T3. The compds. were evaluated in reporter gene assays using the four common thyroid hormone response elements, DR4, PAL, F2 (LAP), and TSH, and show activities and selectivities consistent with their unique potential as agents to selectively rescue thyroid function to these RTH-associated mutants.


IT 211110-63-3

RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)

(preparation and structure-activity of mutant-selective thyromimetics for chemical rescue of thyroid hormone receptor mutants associated with resistance to thyroid hormone)

RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 23 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:152810 CAPLUS

DN 142:330121

TI The thyroid hormone receptor β -specific agonist GC-1 selectively affects the bone development of hypothyroid rats

AU Freitas, Fatima R. S.; Capelo, Luciane P.; O'Shea, Patrick J.; Jorgetti, Vanda; Moriscot, Anselmo S.; Scanlan, Thomas S.; Williams, Graham R.; Zorn, Telma M. T.; Gouveia, Cecilia H. A.

CS Department of Anatomy, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil

SO Journal of Bone and Mineral Research (2005), 20(2), 294-304

CODEN: JBMREJ; ISSN: 0884-0431

PB American Society for Bone and Mineral Research

DT Journal

LA English

AB We investigated the effects of GC-1, a TR β -selective agonist, on bone development of hypothyroid rats. Whereas T3 reverted the IGF-I deficiency and the skeletal defects caused by hypothyroidism, GC-1 had no effect on serum IGF-I or on IGF-I protein expression in the epiphyseal growth plate of the femur, but induced selective effects on bone development. Our findings indicate that T3 exerts some essential effects on bone development that are mediated by TR β 1. Introduction: We investigated the role of the thyroid hormone receptor β 1 (TR β 1) on skeletal development of rats using the TR β -selective agonist GC-1. Materials


and Methods: Twenty-one-day-old female rats (n = 6/group) were rendered hypothyroid (Hypo) and treated for 5 wk with 0.3 ug/100 g BW/day of T3 (1xT3), 5xT3, or equimolar doses of GC-1 (1xGC-1 and 5xGC-1). Serum triiodothyronine (T3), thyroxine (T4), TSH, and insulin-like growth factor (IGF)-I concns. were determined by RIA. BMD and longitudinal bone growth were determined by DXA. Trabecular bone histomorphometry and epiphyseal growth plate (EGP) morphometry were performed in the distal femur. Expressions of IGF-I protein and of collagen II and X mRNA were evaluated by immunohistochem. and in situ hybridization, resp. To determine hormonal effects on ossification, skeletal preps. of hypothyroid-, 5xGC-1-, and 5xT3-treated neonatal rats were compared. Results: Hypothyroidism impaired longitudinal body growth and BMD gain, delayed ossification, reduced the number of hypertrophic chondrocytes (HCs; 72% vs. Euthyroid [Eut] rats; $p < 0.001$), and resulted in disorganized columns of EGP chondrocytes. Serum IGF-I was 67% reduced vs. Eut rats ($p < 0.001$), and the expression of IGF-I protein and collagen II and X mRNA were undetectable in the EGP of Hypo rats. T3 completely or partially normalized all these parameters. In contrast, GC-1 did not influence serum concns. or EGP expression of IGF-I, failed to reverse the disorganization of proliferating chondrocyte columns, and barely affected longitudinal growth. Nevertheless, GC-1 induced ossification, HC differentiation, and collagen II and X mRNA expression and increased EGP thickness to Eut values. GC-1-treated rats had higher BMD gain in the total tibia, total femur, and in the femoral diaphysis than Hypo animals ($p < 0.05$). These changes were associated with increased trabecular volume (48%, $p < 0.01$), mineralization apposition rate (2.3-fold, $p < 0.05$), mineralizing surface (4.3-fold, $p < 0.01$), and bone formation rate (10-fold, $p < 0.01$). Conclusions: Treatment of hypothyroid rats with the TR β -specific agonist GC-1 partially reverts the skeletal development and maturation defects resultant of hypothyroidism. This finding suggests that TR β 1 has an important role in bone development.

IT 211110-63-3, GC-1

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(thyroid hormone receptor β -specific agonist GC-1 and T3
selectively affects bone development of hypothyroid rats)

RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 24 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:71624 CAPLUS



DN 142:335975

TI Hydrogen Bonded Dimers of Triurea Derivatives of Triphenylmethanes


AU Rudzevich, Yuliya; Rudzevich, Valentyn; Schollmeyer, Dieter; Thondorf, Iris; Boehmer, Volker

CS Abteilung Lehramt Chemie, Fachbereich Chemie und Pharmazie, Johannes Gutenberg-Universitaet Mainz, Mainz, D-55099, Germany

SO Organic Letters (2005), 7(4), 613-616
 CODEN: ORLEF7; ISSN: 1523-7060
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 142:335975
 AB Tri-(2-alkoxy-5-ureido-phenyl)methanes represent a novel self-complementary motif forming hydrogen bonded homo- and heterodimers in nonpolar, aprotic solvents as evidenced by ¹H NMR and ESI-mass spectra and by the formation of heterodimers. MD simulations suggest the formation of hydrogen bonds of different strength in agreement with NMR data. The dimerization does not interfere with that of tetraurea calix[4]arenes. A combination of both motifs may be used therefore to build up larger structures via self-assembly processes.
 IT 848415-85-0P 848415-86-1P 848415-88-3P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (hydrogen bonded dimers of triurea derivs. of triphenylmethanes)
 RN 848415-85-0 CAPLUS
 CN Acetic acid, 2,2',2''-[methylidynetris[(4-amino-2,1-phenylene)oxy]]tris-, triethyl ester (9CI) (CA INDEX NAME)




RN 848415-86-1 CAPLUS
 CN Acetic acid, 2,2',2''-[methylidynetris[[4-[[[(4-methylphenyl)amino]carbonyl]amino]-2,1-phenylene]oxy]]tris-, triethyl ester (9CI) (CA INDEX NAME)



RN 848415-88-3 CAPLUS
 CN Acetic acid, 2,2',2'''-[methylidynetris[[4-[[[(4-methylphenyl)amino]carbonyl]amino]-2,1-phenylene]oxy]]tris-, triethyl ester, compd. with N,N'',N''''-[methylidynetris(4-propoxy-3,1-phenylene)]tris[N'-(4-methylphenyl)urea] (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 848415-87-2
 CMF C52 H58 N6 O6



CM 2

CRN 848415-86-1

CMF C55 H58 N6 O12




IT 862251-45-4P 862251-64-7P

RL: SPN (Synthetic preparation); PREP (Preparation)


(hydrogen bonded dimers of triurea derivs. of triphenylmethanes)

RN 862251-45-4 CAPLUS

CN Acetic acid, 2,2',2''-[methylidynetris[[4-[[[(4-methylphenyl)sulfonyl]amino]carbonyl]amino]-2,1-phenylene]oxy]]tris-, triethyl ester (9CI) (CA INDEX NAME)



RN 862251-64-7 CAPLUS
 CN Acetic acid, 2,2',2''-[methylidynetris[[4-[[[(pentylamino)carbonyl]amino]-2,1-phenylene]oxy]]tris-, triethyl ester (9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 25 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:1080620 CAPLUS
 DN 142:32908
 TI A method for creating nuclear receptor activity-modulating pharmaceuticals
 IN Fletterick, Robert J.; Borngraeber, Sabine; Baxter, John D.; Scanlan, Thomas S.; Chiellini, Grazia; Webb, Paul
 PA The Regents of the University of California, USA
 SO U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Ser. No. 317,034.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004253648	A1	20041216	US 2003-732901	20031209
				US 2002-317034	A2 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
	US 2004110154	A1	20040610	US 2002-317034	20021210

PATENT FAMILY INFORMATION:


FAN 2004:473214

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004110154	A1	20040610	US 2002-317034	20021210
	WO 2004052302	A2	20040624	WO 2003-US39257	20031209
	WO 2004052302	A3	20040902		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,

		ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
			US 2002-317034	A	20021210
			US 2003-453608P	P	20030310
			US 2003-526931P	P	20031203
WO 2004052303	A2	20040624	WO 2003-US39258		20031209
WO 2004052303	A3	20050506			
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-317034	A	20021210
			US 2003-453608P	P	20030310
			US 2003-526931P	P	20031203
AU 2003300852	A1	20040630	AU 2003-300852		20031209
			US 2002-317034	A	20021210
			US 2003-453608P	P	20030310
			US 2003-526931P	P	20031203
AU 2003302741	A1	20040630	WO 2003-US39257	W	20031209
			AU 2003-302741		20031209
			US 2002-317034	A	20021210
			US 2003-453608P	P	20030310
			US 2003-526931P	P	20031203
US 2004253648	A1	20041216	WO 2003-US39258	W	20031209
			US 2003-732901		20031209
			US 2002-317034	A2	20021210
			US 2003-453608P	P	20030310
			US 2003-526931P	P	20031203
FAN 2004:513495					
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
-----	----	-----	-----	-----	
PI WO 2004052302	A2	20040624	WO 2003-US39257	20031209	
WO 2004052302	A3	20040902			
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-317034	A	20021210
			US 2003-453608P	P	20030310
			US 2003-526931P	P	20031203
US 2004110154	A1	20040610	US 2002-317034		20021210
AU 2003300852	A1	20040630	AU 2003-300852		20031209
			US 2002-317034	A	20021210
			US 2003-453608P	P	20030310
			US 2003-526931P	P	20031203
FAN 2004:513496			WO 2003-US39257	W	20031209
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
-----	----	-----	-----	-----	

PI WO 2004052303 A2 20040624 WO 2003-US39258 20031209
 WO 2004052303 A3 20050506
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2002-317034 A 20021210
 US 2003-453608P P 20030310
 US 2003-526931P P 20031203
 US 2004110154 A1 20040610 US 2002-317034 20021210
 AU 2003302741 A1 20040630 AU 2003-302741 20031209
 US 2002-317034 A 20021210
 US 2003-453608P P 20030310
 US 2003-526931P P 20031203
 WO 2003-US39258 W 20031209
 AB Methods for screening, identifying and/or designing agents that modulate
 nuclear receptors are provided. These agents contact a site on a nuclear
 receptor involved in dimer/heterodimer formation, cofactor mol.
 interactions, and/or folding, which is termed the nuclear receptor
 dimer/heterodimer regulatory site (DHRS). Methods employing the DHRS are
 included, along with nuclear receptor:agent complexes and libraries of
 agents.
 IT 211110-63-3, GC-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (method for creating nuclear receptor activity-modulating
 pharmaceuticals)
 RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-
 dimethylphenoxy]- (9CI) (CA INDEX NAME)




L8 ANSWER 26 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:891818 CAPLUS
 DN 142:32381
 TI Photo-caged agonists of the nuclear receptors RAR γ and TR β
 provide unique time-dependent gene expression profiles for light-activated
 gene patterning
 AU Link, Kristian H.; Cruz, Federico G.; Ye, Hai-Fen; O'Reilly, Kathryn E.;
 Dowdell, Sarah; Koh, John T.
 CS Department of Chemistry and Biochemistry, University of Delaware, Newark,
 DE, 19176, USA
 SO Bioorganic & Medicinal Chemistry (2004), 12(22), 5949-5959
 CODEN: BMECEP; ISSN: 0968-0896
 PB Elsevier Ltd.

DT Journal
 LA English
 OS CASREACT 142:32381
 AB Light-activated gene expression systems hold promise as new tools for studying spatial and temporal gene patterning in multicellular systems. Photo-caged forms of nuclear receptor agonists have recently been shown to mediate photo-dependent transcription in mammalian cells, however, because intracellularly released agonists can rapidly diffuse out of cells, the photo-initiated transcription response is only transient and limited to only a few hours in reported examples. Herein the authors describe a photo-caged thyroid hormone receptor agonist that provides a robust 36 h transcription response to a single irradiation event. These findings are in contrast to a closely related system, which uses a caged retinoic acid receptor agonist, which provides only a short transcription response. Comparison of the two systems, show that the duration of transcription response is not controlled by the rate of diffusion of free ligand out of the cell, but perhaps by the duration of ligand-induced transcription/stability of the active transcription complex.


IT 807380-39-8P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (photo-caged agonists of nuclear receptors RAR γ and TR β provide unique time-dependent gene expression profiles for light-activated gene patterning)

RN 807380-39-8 CAPLUS
 CN Acetic acid, [4-[[4-[(4,5-dimethoxy-2-nitrophenyl)methoxy]-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




IT 807380-89-8P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (photo-caged agonists of nuclear receptors RAR γ and TR β provide unique time-dependent gene expression profiles for light-activated gene patterning)

RN 807380-89-8 CAPLUS
 CN Acetic acid, [4-[[4-[(4,5-dimethoxy-2-nitrophenyl)methoxy]-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 218431-09-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (photo-caged agonists of nuclear receptors RAR γ and TR β
 provide unique time-dependent gene expression profiles for
 light-activated gene patterning)
 RN 218431-09-5 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-
 dimethylphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 27 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:646815 CAPLUS
 DN 141:408883
 TI Thyroid hormone-dependent seasonality in American tree sparrows (*Spizella arborea*): effects of GC-1, a thyroid receptor β -selective agonist, and of iopanoic acid, a deiodinase inhibitor
 AU Mishra, M. K.; Wilson, F. E.; Scanlan, T. S.; Chiellini, G.
 CS Division of Biology, Kansas State University, Manhattan, KS, 66506, USA
 SO Journal of Comparative Physiology, B: Biochemical, Systemic, and Environmental Physiology (2004), 174(6), 471-479
 CODEN: JPBPDJ; ISSN: 0174-1578
 PB Springer GmbH
 DT Journal
 LA English
 AB To explore the role of TH in the control of seasonality [i.e., photoperiodic testicular growth, photorefractoriness, and postnuptial (prebasic) molt] in American tree sparrows (*Spizella arborea*), the authors performed expts. in which THX males were simultaneously photostimulated and given TH replacement therapy. In the first experiment, equimolar concns. (1X = 1.3 nmol) of T4, T3, or GC-1, an iodine-free TR β agonist, were administered s.c. daily during the first 21 days of photostimulation. Two addnl. THX groups received GC-1 at 0.1X or 10X, and THX and THI control groups received vehicle. In the second experiment, T4 or T3, alone or in combination with the deiodinase inhibitor IOP, was injected i.m. twice daily during the first 14 days of photostimulation. In both expts., end points were testis length and molt score. In the first experiment, THI birds given vehicle and THX birds given T4 replacement therapy exhibited all three components of seasonality. THX birds given T3 or GC-1 (1X or 10X) showed a subdued photoperiodic testicular response, but they did not become photorefractory or initiate molt. THX birds that received 0.1X GC-1 or vehicle exhibited none of the components of seasonality. These data are consistent with the hypothesis that photoperiodic testicular growth, a vernal component of seasonality, is a TR β -mediated response and suggest that T4 may activate TR β more efficiently than does T3 or GC-1. By contrast, the failure both of T3 and of GC-1, but not of T4, to program photostimulated THX males for photorefractoriness and postnuptial molt suggests that autumnal components of seasonality may be TR α -mediated responses solely to T4. In the second experiment, IOP

administered alone had no significant impact on seasonality. THX birds that received T4 with or without IOP showed all components of seasonality, whereas birds that received T3 with or without IOP showed only photoperiodic testicular growth. These results challenge the widely held view that T4 is merely a prohormone for T3 and support the emerging view that T4 has intrinsic hormonal activity. Because IOP augmented the photoperiodic testicular response in T3-treated THX birds, T3 may act either independently or co-dependently with T4 in programming vernal seasonal events.

IT 211110-63-3, GC-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (thyroid hormone receptor β -selective agonist GC-1 effect on seasonality in American tree sparrows *Spizella arborea*)
 RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 28 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:610156 CAPLUS
 DN 141:156925
 TI Preparation of diphenylmethane derivatives as vitamin D receptor modulators for use in vesicant treatment
 IN Nagpal, Sunil; Yee, Ying Kwong
 PA Eli Lilly and Company, USA
 SO PCT Int. Appl., 347 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004063345	A2	20040729	WO 2004-US5	20040107
	WO 2004063345	A3	20060112		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
				US 2003-439580P	P 20030110
	EP 1587906	A2	20051026	EP 2004-700550	20040107
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			

			US 2003-439580P	P	20030110
			WO 2004-US5	W	20040107
US 2006094778	A1	20060504	US 2005-538142		20050608
			US 2003-439580P	P	20030110
			WO 2004-US5	W	20040107

OS MARPAT 141:156925


AB Title compds. I [R and R3 independently = alkyl, fluoroalkyl, or together form a (un)substituted (un)saturated carbocyclic ring; R1 and R2 independently = H, halo, alkyl, fluoroalkyl, alkoxy, etc.; Z1 = alkyl group linked via hydroxyalkyl, alkyloxy, thioalkyl, alkylcarbonyl, etc.; Z2 = CO₂H, CO₂Me, CO₂Et, CH₂CO₂H, etc.], their pharmaceutically acceptable salts and compns. thereof, are prepared and disclosed as vitamin D receptor modulators. Thus, e.g., II was prepared by reaction of two equivalent of o-cresol with 3-pentanone, followed by mono O-alkylation with 3,3-dimethyl-1-bromo-2-butanone, O-sulfonation with triflic anhydride, carbonyl reduction and desulfonation/carbonylation. In assays to determine vitamin D receptor (VDR) modulating activity, compds. of the invention possessed EC₅₀ values (nm) from 1-562. The present invention relates to a method of treating or preventing damage to human skin cells by chemical vesicants by administering a non-secosteroidal, di-Ph compound with VDR modulating activity.

IT 700821-49-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of diphenylmethane derivs. with vitamin D receptor modulator activity for vesicant treatment)

RN 700821-49-4 CAPLUS

CN Benzenepropanamide, 4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)



IT 700820-77-5P 700820-78-6P 700820-79-7P
 700820-80-0P 700820-81-1P 700820-82-2P
 700820-83-3P 700820-84-4P 700820-85-5P
 700820-86-6P 700820-87-7P 700820-88-8P
 700821-13-2P 700821-14-3P 700821-15-4P
 700821-16-5P 700821-17-6P 700821-18-7P
 700821-19-8P 700821-20-1P 700821-21-2P
 700821-22-3P 700821-23-4P 700821-24-5P
 700821-25-6P 700821-26-7P 700821-27-8P
 700821-28-9P 700821-29-0P 700821-30-3P
 700821-31-4P 700821-32-5P 700821-33-6P
 700821-34-7P 700821-35-8P 700821-36-9P
 700821-43-8P 700821-44-9P 700821-45-0P
 700821-46-1P 700821-47-2P 700821-48-3P
 700821-50-7P 700821-51-8P 700821-52-9P
 700821-53-0P 700821-54-1P 731801-87-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diphenylmethane derivs. with vitamin D receptor modulator activity for vesicant treatment)

activity for vesicant treatment)


RN 700820-77-5 CAPLUS

CN Benzeneacetamide, 4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700820-78-6 CAPLUS

CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700820-79-7 CAPLUS

CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-2,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700820-80-0 CAPLUS


CN Benzeneacetamide, 4-[1-ethyl-1-[3-methyl-4-(1,3,3-trimethyl-2-oxobutoxy)phenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700820-81-1 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700820-82-2 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,2,3,3-tetramethylbutoxy)-3-methylphenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 700820-83-3 CAPLUS
 CN Benzeneacetamide, 4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700820-84-4 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700820-85-5 CAPLUS

CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-2,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700820-86-6 CAPLUS

CN Benzeneacetamide, 4-[1-ethyl-1-[3-methyl-4-(1,3,3-trimethyl-2-oxobutoxy)phenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700820-87-7 CAPLUS

CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)



RN 700820-88-8 CAPLUS


CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,2,3,3-tetramethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-13-2 CAPLUS

CN Benzeneacetamide, 4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-


ethylpropyl]-2-methyl- α -oxo- (9CI) (CA INDEX NAME)




RN 700821-14-3 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-2-methyl- α -oxo- (9CI) (CA INDEX NAME)




RN 700821-15-4 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-2,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-2-methyl- α -oxo- (9CI) (CA INDEX NAME)




RN 700821-16-5 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[3-methyl-4-(1,3,3-trimethyl-2-oxobutoxy)phenyl]propyl]-2-methyl- α -oxo- (9CI) (CA INDEX NAME)




RN 700821-17-6 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-2-methyl- α -oxo- (9CI) (CA INDEX NAME)




RN 700821-18-7 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,2,3,3-tetramethylbutoxy)-3-methylphenyl]propyl]-2-methyl-α-oxo- (9CI) (CA INDEX NAME)




RN 700821-19-8 CAPLUS
 CN Benzeneacetamide, 4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-α-hydroxy-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-20-1 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-α-hydroxy-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-21-2 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-2,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-α-hydroxy-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-22-3 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[3-methyl-4-(1,3,3-trimethyl-2-oxobutoxy)phenyl]propyl]-α-hydroxy-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-23-4 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-α-hydroxy-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-24-5 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,2,3,3-tetramethylbutoxy)-3-methylphenyl]propyl]-α-hydroxy-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-25-6 CAPLUS
 CN Benzeneacetamide, 4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-N,N,2-trimethyl-α-oxo- (9CI) (CA INDEX NAME)




RN 700821-26-7 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl-α-oxo- (9CI) (CA INDEX NAME)




RN 700821-27-8 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-2,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl-α-oxo- (9CI) (CA INDEX NAME)




RN 700821-28-9 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[3-methyl-4-(1,3,3-trimethyl-2-oxobutoxy)phenyl]propyl]-N,N,2-trimethyl-α-oxo- (9CI) (CA INDEX NAME)




RN 700821-29-0 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl-α-oxo- (9CI) (CA INDEX NAME)




RN 700821-30-3 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,2,3,3-tetramethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl-α-oxo- (9CI) (CA INDEX NAME)




RN 700821-31-4 CAPLUS
 CN Benzeneacetamide, 4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-α-hydroxy-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-32-5 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-α-hydroxy-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-33-6 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-2,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-α-hydroxy-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-34-7 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[3-methyl-4-(1,3,3-trimethyl-2-oxobutoxy)phenyl]propyl]-α-hydroxy-N,N,2-trimethyl- (9CI) (CA INDEX NAME)



RN 700821-35-8 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-α-hydroxy-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-36-9 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,2,3,3-tetramethylbutoxy)-3-methylphenyl]propyl]-α-hydroxy-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-43-8 CAPLUS
 CN Benzenepropanamide, 4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethyl-1-(2-hydroxy-3-methyl-4-(2-oxo-2-(tert-butyl)-1-methylpropoxy)phenyl)propyl]-α-hydroxy-N,N,2-trimethyl- (9CI) (CA INDEX NAME)


ethylpropyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-44-9 CAPLUS
CN Benzenepropanamide, 4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-45-0 CAPLUS
CN Benzenepropanamide, 4-[1-ethyl-1-[4-(2-hydroxy-2,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-46-1 CAPLUS
CN Benzenepropanamide, 4-[1-ethyl-1-[3-methyl-4-(1,3,3-trimethyl-2-oxobutoxy)phenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-47-2 CAPLUS
CN Benzenepropanamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-48-3 CAPLUS
 CN Benzenepropanamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,2,3,3-tetramethylbutoxy)-3-methylphenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-50-7 CAPLUS
 CN Benzenepropanamide, 4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-51-8 CAPLUS
 CN Benzenepropanamide, 4-[1-ethyl-1-[4-(2-hydroxy-2,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-52-9 CAPLUS
 CN Benzenepropanamide, 4-[1-ethyl-1-[3-methyl-4-(1,3,3-trimethyl-2-oxobutoxy)phenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-53-0 CAPLUS
 CN Benzenepropanamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)



RN 700821-54-1 CAPLUS
 CN Benzenepropanamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,2,3,3-tetramethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)



RN 731801-87-9 CAPLUS
 CN 2-Propenamide, 3-[4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-2-methylphenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



L8 ANSWER 29 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:568609 CAPLUS
 DN 141:117169
 TI Human SGLT1 inhibitors containing benzylphenyl glucopyranoside or

galactopyranoside derivatives

IN Yonekubo, Shigeru; Shimizu, Kazuo; Shibazaki, Toshihide; Tomae, Masaki; Isaji, Masayuki

PA Kissei Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 90 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2004196788	A2	20040715	JP 2003-404247 JP 2002-352251	20031203 A 20021204

OS MARPAT 141:117169

AB The invention provides human glucose-sodium cotransporter (SGLT1) inhibitors containing benzylphenol derivative represented by the following general


formula I [R1 = OH, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, hydroxy(C1-6 alkyl), etc.; R2 = H, C1-6 alkyl, C1-6 alkoxy, phenoxy, phenylthio, phenylamino, halogen; R3, R4, R5 = H, C1-6 alkyl, C1-6 alkoxy, halogen; R6 = H, C1-6 alkyl; R7 = H, OH, amino, mono/di(C1-6 alkyl)amino, C1-6 alkyl, C1-6 alkoxy, hydroxy(C1-6 alkyl), carbamoyl(C1-6 alkyl); G = β -D-glucopyranosyl, β -D-galactopyranosyl] and pharmacol. acceptable salts or prodrugs thereof. A compound 5-hydroxy-3-methyl-2-[4-[(E)-2-[2-(sulfamoylamino)ethylcarbamoyl]vinyl]benzyl]phenyl β -D-glucopyranoside was prepared, and tested for its effect on human SGLT1 activity in vitro, and on blood glucose level in rats.

IT 721969-29-5P 721969-31-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(human SGLT1 inhibitors containing benzylphenyl glucopyranoside or galactopyranoside derivs.)

RN 721969-29-5 CAPLUS

CN Alanine, N-[4-[4-[[4-hydroxy-2-methyl-6-[(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyl)oxy]phenyl]methyl]-3-phenoxyphenyl]-1-oxobutyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 721969-31-9 CAPLUS

CN Alanine, N-[4-[4-[[4-hydroxy-2-[(2,3,4,6-tetra-O-acetyl- β -D-

glucopyranosyl)oxy]phenyl]methyl]-3-methylphenyl]-1-oxobutyl]-2-methyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 721969-30-8P 721969-33-1P 721969-34-2P
721969-35-3P 721969-36-4P 721969-37-5P
721969-38-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(human SGLT1 inhibitors containing benzylphenyl glucopyranoside or
galactopyranoside derivs.)

RN 721969-30-8 CAPLUS

CN Alanine, N-[4-[4-[[4-hydroxy-2-methyl-6-[(2,3,4,6-tetra-O-acetyl-beta-D-
glucopyranosyl)oxy]phenyl]methyl]-3-methylphenyl]-1-oxobutyl]-2-methyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 721969-33-1 CAPLUS

CN Benzenebutanamide, 4-[[2-(beta-D-glucopyranosyloxy)-4-hydroxy-6-
methylphenyl]methyl]-N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-1,1-dimethyl-
2-oxoethyl]-3-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 721969-34-2 CAPLUS
 CN Benzenebutanamide, 4-[[2-(β-D-glucopyranosyloxy)-4-hydroxy-6-methylphenyl]methyl]-N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 721969-35-3 CAPLUS
 CN Benzenebutanamide, 4-[[2-(β-D-glucopyranosyloxy)-4-hydroxyphenyl]methyl]-N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 721969-36-4 CAPLUS
 CN Benzenebutanamide, N-[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-4-[[2-(β -D-glucopyranosyloxy)-4-hydroxy-6-methylphenyl]methyl]-3-phenoxy-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 721969-37-5 CAPLUS

CN Benzenebutanamide, N-[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-4-[[2-(β -D-glucopyranosyloxy)-4-hydroxy-6-methylphenyl]methyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 721969-38-6 CAPLUS

CN Benzenebutanamide, N-[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-4-[[2-(β -D-glucopyranosyloxy)-4-hydroxyphenyl]methyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 721969-90-0P 721969-91-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of human SGLT1 inhibitors containing benzylphenyl
 glucopyranoside
 or galactopyranoside derivs.)
 RN 721969-90-0 CAPLUS
 CN Benzenebutanamide, N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-1,1-dimethyl-2-
 oxoethyl]-4-[[4-hydroxy-2-methyl-6-[(2,3,4,6-tetra-O-acetyl-β-D-
 glucopyranosyl)oxy]phenyl]methyl]-3-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A





RN 721969-91-1 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-[[4-[4-[[4-hydroxy-2-methyl-6-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]phenyl]methyl]-3-phenoxyphenyl]-1-oxobutyl]amino]-2-methyl-1-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 30 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:513496 CAPLUS
 DN 141:47278
 TI A method for creating nuclear receptor activity-modulating pharmaceuticals
 IN Fletterick, Robert J.; Borngraeber, Sabine; Baxter, John D.; Scanlan,
 Thomas S.; Chiellini, Grazia; Webb, Paul
 PA The Regents of the University of California, USA
 SO PCT Int. Appl., 144 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052303	A2	20040624	WO 2003-US39258	20031209
	WO 2004052303	A3	20050506		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				US 2002-317034	A 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
	US 2004110154	A1	20040610	US 2002-317034	20021210
	AU 2003302741	A1	20040630	AU 2003-302741	20031209
				US 2002-317034	A 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
				WO 2003-US39258	W 20031209

PATENT FAMILY INFORMATION:


FAN 2004:473214

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004110154	A1	20040610	US 2002-317034	20021210
	WO 2004052302	A2	20040624	WO 2003-US39257	20031209
	WO 2004052302	A3	20040902		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				US 2002-317034	A 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
	WO 2004052303	A2	20040624	WO 2003-US39258	20031209
	WO 2004052303	A3	20050506		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,			

	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003300852	A1	20040630	US 2002-317034	A	20021210
			US 2003-453608P	P	20030310
			US 2003-526931P	P	20031203
			AU 2003-300852		20031209
			US 2002-317034	A	20021210
			US 2003-453608P	P	20030310
			US 2003-526931P	P	20031203
			WO 2003-US39257	W	20031209
AU 2003302741	A1	20040630	AU 2003-302741		20031209
			US 2002-317034	A	20021210
			US 2003-453608P	P	20030310
			US 2003-526931P	P	20031203
			WO 2003-US39258	W	20031209
US 2004253648	A1	20041216	US 2003-732901		20031209
			US 2002-317034	A2	20021210
			US 2003-453608P	P	20030310
			US 2003-526931P	P	20031203
FAN 2004:513495					
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
-----	----	-----	-----	-----	
PI WO 2004052302	A2	20040624	WO 2003-US39257		20031209
WO 2004052302	A3	20040902			
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-317034	A	20021210
			US 2003-453608P	P	20030310
			US 2003-526931P	P	20031203
US 2004110154	A1	20040610	US 2002-317034		20021210
AU 2003300852	A1	20040630	AU 2003-300852		20031209
			US 2002-317034	A	20021210
			US 2003-453608P	P	20030310
			US 2003-526931P	P	20031203
			WO 2003-US39257	W	20031209
FAN 2004:1080620					
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
-----	----	-----	-----	-----	
PI US 2004253648	A1	20041216	US 2003-732901		20031209
			US 2002-317034	A2	20021210
			US 2003-453608P	P	20030310
			US 2003-526931P	P	20031203
US 2004110154	A1	20040610	US 2002-317034		20021210
AB					
Methods for screening, identifying and/or designing agents that modulate nuclear receptors are provided. These agents contact a site on a nuclear receptor involved in dimer/heterodimer formation, cofactor mol. interactions, and/or folding, which is termed the nuclear receptor dimer/heterodimer regulatory site (DHRS). Methods employing the DHRS are					

included, along with nuclear receptor:agent complexes and libraries of agents.

IT 211110-63-3, GC-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (method for creating nuclear receptor activity-modulating
 pharmaceuticals)
 RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-
 dimethylphenoxy]- (9CI) (CA INDEX NAME)



L8 ANSWER 31 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:513495 CAPLUS
 DN 141:47277
 TI Method for creating specific, high affinity nuclear receptor
 pharmaceuticals
 IN Baxter, John D.; Scanlan, Thomas S.; Fetterick, Robert J.; Borngraeber,
 Sabine; Webb, Paul; Chiellini, Grazia
 PA The Regents of the University of California, USA
 SO PCT Int. Appl., 164 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052302	A2	20040624	WO 2003-US39257	20031209
WO 2004052302	A3	20040902		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004110154	A1	20040610	US 2002-317034	A 20021210
AU 2003300852	A1	20040630	US 2003-453608P	P 20030310
			US 2003-526931P	P 20031203
			US 2002-317034	20021210
			AU 2003-300852	20031209
			US 2002-317034	A 20021210
			US 2003-453608P	P 20030310
			US 2003-526931P	P 20031203
			WO 2003-US39257	W 20031209

PATENT FAMILY INFORMATION:

FAN 2004:473214

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	US 2004110154	A1	20040610	US 2002-317034	20021210
	WO 2004052302	A2	20040624	WO 2003-US39257	20031209
	WO 2004052302	A3	20040902		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
	PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,				
	TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,				
	TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-317034	A 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
	WO 2004052303	A2	20040624	WO 2003-US39258	20031209
	WO 2004052303	A3	20050506		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
	PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,				
	TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,				
	TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-317034	A 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
	AU 2003300852	A1	20040630	AU 2003-300852	20031209
				US 2002-317034	A 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
				WO 2003-US39257	W 20031209
	AU 2003302741	A1	20040630	AU 2003-302741	20031209
				US 2002-317034	A 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
				WO 2003-US39258	W 20031209
	US 2004253648	A1	20041216	US 2003-732901	20031209
				US 2002-317034	A2 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
FAN	2004:513496				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052303	A2	20040624	WO 2003-US39258	20031209
	WO 2004052303	A3	20050506		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
	PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,				
	TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,				
	TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

				US 2002-317034	A	20021210
				US 2003-453608P	P	20030310
				US 2003-526931P	P	20031203
	US 2004110154	A1	20040610	US 2002-317034		20021210
	AU 2003302741	A1	20040630	AU 2003-302741		20031209
				US 2002-317034	A	20021210
				US 2003-453608P	P	20030310
				US 2003-526931P	P	20031203
				WO 2003-US39258	W	20031209

FAN 2004:1080620


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2004253648	A1	20041216	US 2003-732901	20031209
				US 2002-317034	A2 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
	US 2004110154	A1	20040610	US 2002-317034	20021210

AB The invention pertains to agonists that activate nuclear receptors. These agonists include an extension that contacts a region of the nuclear receptor outside the native ligand binding pocket. Methods for producing, identifying and designing such agonists are included along with nuclear receptor agonist complexes and libraries of agonists.

IT 211110-63-3, GC-1
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (method for creating specific high affinity nuclear receptor pharmaceuticals)

RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



L8 ANSWER 32 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:495475 CAPLUS

DN 141:100205

TI Quantitative Proteomics of the Thyroid Hormone Receptor-Coregulator Interactions

AU Moore, Jamie M. R.; Galicia, Sarah J.; McReynolds, Andrea C.; Nguyen, Ngoc-Ha; Scanlan, Thomas S.; Guy, R. Kiplin

CS Departments of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, CA, 94143-2280, USA

SO Journal of Biological Chemistry (2004), 279(26), 27584-27590
 CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology


DT Journal

LA English


AB The thyroid hormone receptor regulates a diverse set of genes that control processes from embryonic development to adult homeostasis. Upon binding of thyroid hormone, the thyroid receptor releases corepressor proteins and undergoes a conformational change that allows for the interaction of

coactivating proteins necessary for gene transcription. This interaction is mediated by a conserved motif, termed the NR box, found in many coregulators. Recent work has demonstrated that differentially assembled coregulator complexes can elicit specific biol. responses. However, the mechanism for the selective assembly of these coregulator complexes has yet to be elucidated. To further understand the principles underlying thyroid receptor-coregulator selectivity, we designed a high-throughput in vitro binding assay to measure the equilibrium affinity of thyroid receptor to a library of potential coregulators in the presence of different ligands including the endogenous thyroid hormone T3, synthetic thyroid receptor β -selective agonist GC-1, and antagonist NH-3. Using this homogenous method several coregulator NR boxes capable of associating with thyroid receptor at physiol. relevant concns. were identified including ones found in traditional coactivating proteins such as SRC1, SRC2, TRAP220, TRBP, p300, and ARA70; and those in coregulators known to repress gene activation including RIP140 and DAX-1. In addition, it was discovered that the thyroid receptor-coregulator binding patterns vary with ligand and that this differential binding can be used to predict biol. responses. Finally, it is demonstrated that this is a general method that can be applied to other nuclear receptors and can be used to establish rules for nuclear receptor-coregulator selectivity.

IT 211110-63-3, GC-1 447415-26-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (quant. proteomics of thyroid hormone receptor-coregulator interactions
 in the presence of different ligands)
 RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 447415-26-1 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-nitrophenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 33 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:481350 CAPLUS

DN 141:137293
 TI Induction of Larval Tissue Resorption in *Xenopus laevis* Tadpoles by the
 Thyroid Hormone Receptor Agonist GC-1
 AU Furlow, J. David; Yang, Ha Yung; Hsu, Mei; Lim, Wayland; Ermio, Davy J.;
 Chiellini, Grazia; Scanlan, Thomas S.
 CS Section of Neurobiology, Physiology, and Behavior, University of
 California, Davis, CA, 95616-8519, USA
 SO Journal of Biological Chemistry (2004), 279(25), 26555-26562
 CODEN: JBCHA3; ISSN: 0021-9258
 PB American Society for Biochemistry and Molecular Biology
 DT Journal
 LA English
 AB A major challenge in understanding nuclear hormone receptor function is to
 determine how the same ligand can cause very different tissue-specific
 responses. Tissue specificity may result from the presence of more than
 one receptor subtype arising from multiple receptor genes or alternative
 splicing. Recently, high affinity analogs of nuclear receptor ligands
 have been synthesized that show subtype selectivity. These analogs can
 greatly facilitate the study of receptor subtype-specific functions in
 organisms where mutational anal. is problematic or where it is desirable
 for receptors to be expressed in their normal physiol. contexts. The
 authors describe here the effects of the synthetic thyroid hormone analog
 GC-1 on the metamorphosis of the frog *Xenopus laevis*. The most potent
 natural thyroid hormone, 3,5,3'-triiodothyronine or T3, shows similar
 binding affinity and transactivation dose-response curves for both thyroid
 hormone receptor isotypes, designated TR α and TR β . GC-1,
 however, binds to and activates TR β at least an order of magnitude
 better than it does TR α . GC-1 efficiently induces death and
 resorption of premetamorphic tadpole tissues such as the gills and the
 tail, two tissues that strongly induce thyroid hormone receptor β
 during metamorphosis. GC-1 has less effect on the growth of adult tissues
 such as the hindlimbs, which express high TR α levels. The
 effectiveness of GC-1 in inducing tail resorption and tail gene expression
 correlates with increasing TR β levels. These results illustrate the
 utility of subtype selective ligands as probes of nuclear receptor
 function in vivo.
 IT 211110-63-3, GC-1
 RL: BSU (Biological study, unclassified); BUU (Biological use,
 unclassified); BIOL (Biological study); USES (Uses)
 (induction of larval tissue resorption in *Xenopus laevis* tadpoles by
 the thyroid hormone receptor agonist GC-1)
 RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-
 dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 34 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:473214 CAPLUS

DN 141:33740
 TI Method for creating specific, high affinity nuclear receptor
 pharmaceuticals
 IN Baxter, John D.; Scanlan, Thomas S.; Fetterick, Robert J.; Borngraeber,
 Sabine; Webb, Paul
 PA The Regents of the University of California, USA
 SO U.S. Pat. Appl. Publ., 37 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004110154	A1	20040610	US 2002-317034	20021210
	WO 2004052302	A2	20040624	WO 2003-US39257	20031209
	WO 2004052302	A3	20040902		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-317034	A 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
	WO 2004052303	A2	20040624	WO 2003-US39258	20031209
	WO 2004052303	A3	20050506		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-317034	A 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
	AU 2003300852	A1	20040630	AU 2003-300852	20031209
				US 2002-317034	A 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
				WO 2003-US39257	W 20031209
	AU 2003302741	A1	20040630	AU 2003-302741	20031209
				US 2002-317034	A 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
				WO 2003-US39258	W 20031209
	US 2004253648	A1	20041216	US 2003-732901	20031209
				US 2002-317034	A2 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203

PATENT FAMILY INFORMATION:


FAN 2004:513495

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	WO 2004052302	A2	20040624	WO 2003-US39257	20031209
	WO 2004052302	A3	20040902		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004110154	A1	20040610	US 2002-317034	A 20021210
	AU 2003300852	A1	20040630	US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
				US 2002-317034	20021210
				AU 2003-300852	20031209
				US 2002-317034	A 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
				WO 2003-US39257	W 20031209
FAN	2004:513496				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052303	A2	20040624	WO 2003-US39258	20031209
	WO 2004052303	A3	20050506		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004110154	A1	20040610	US 2002-317034	A 20021210
	AU 2003302741	A1	20040630	US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
				US 2002-317034	20021210
				AU 2003-302741	20031209
				US 2002-317034	A 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
				WO 2003-US39258	W 20031209
FAN	2004:1080620				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004253648	A1	20041216	US 2003-732901	20031209
				US 2002-317034	A2 20021210
				US 2003-453608P	P 20030310
				US 2003-526931P	P 20031203
	US 2004110154	A1	20040610	US 2002-317034	20021210
AB	The invention pertains to agonists that activate nuclear receptors. These agonists include an extension that contacts a region of the nuclear receptor outside the native ligand binding pocket. Methods for producing, identifying and designing such agonists are included along with nuclear receptor agonist complexes and libraries of agonists.				
IT	211110-63-3, GC-1				
	RL: BSU (Biological study, unclassified); PRP (Properties); BIOL				

(Biological study)
(method for creating specific, high affinity nuclear receptor
pharmaceuticals)

RN 211110-63-3 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-
dimethylphenoxy]- (9CI) (CA INDEX NAME)



L8 ANSWER 35 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:467841 CAPLUS
DN 141:38355
TI Preparation of non-secosteroidal diaryl compounds as vitamin D receptor
modulators for the treatment of bone disease, psoriasis, and other related
diseases
IN Bunel, Emilio Enrique; Gajewski, Robert Peter; Jones, Charles David; Lu,
Jianliang; Ma, Tianwei; Nagpal, Sunil; Yee, Ying Kwong
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 355 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004048309	A1	20040610	WO 2003-US35055	20031120
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2506891	AA	20040610	US 2002-429041P	P 20021122
				CA 2003-2506891	20031120
				US 2002-429041P	P 20021122
	AU 2003287500	A1	20040618	WO 2003-US35055	W 20031120
				AU 2003-287500	20031120
				US 2002-429041P	P 20021122
	EP 1565422	A1	20050824	WO 2003-US35055	W 20031120
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, BG, CZ, EE, HU, SK			EP 2003-781741	20031120
				US 2002-429041P	P 20021122
	CN 1714070	A	20051228	WO 2003-US35055	W 20031120
				CN 2003-80103892	20031120
				US 2002-429041P	P 20021122
	BR 2003016401	A	20060221	BR 2003-16401	20031120

JP 2006507344	T2	20060302	US 2002-429041P	P	20021122
			WO 2003-US35055	W	20031120
			JP 2004-555373		20031120
			US 2002-429041P	P	20021122
			WO 2003-US35055	W	20031120

OS MARPAT 141:38355

AB The present invention relates to the preparation of novel, non-secosteroidal, diaryl compds. I (R1 and R2 are independently H, F, Cl, CF3, CH2F, CHF2, OMe, OEt, vinyl, Me, Et, Pr, 1-methylethyl, 1,1-dimethylethyl, Bu, 1-methylpropyl, 2-methylpropyl or cyclopropyl; R3 = 1-methylethyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl or substituted pentyls; R4 and R5 are independently Me, Et, Pr, or 1-methylethyl; L1 = O, CH2, C(O), CHOH, CH(Me), or C(Me)OH; L2 = CH2, C(O), CHOH, CH(Me), or C(Me)OH; or L1 and L2 as a group = CH2-CH2, CH:CH, or C:C; L3 = CH2, C(O), CHOH, CH(Me), or C(Me)OH; R6 = substituted carboxylic acids, esters and amide) as vitamin D receptor modulators for the treatment of bone disease, psoriasis, and other related diseases. Thus, o-cresol, 3-pentanone, and methanesulfonic acid were reacted to give 3',3'-Bis[4-hydroxy-3-methylphenyl]pentane which was treated with 3,3-dimethyl-1-bromo-2-butanone to give II. II was treated with Tf2O to give the corresponding triflate, followed by reduction of the ketone to the alc. using NaBH4. The alc. was treated with Pd(OAc)2, Dppf, MeOH, Et3N, DMF, and pressurized carbon monoxide (1,000 psi) for 48 h to give III which had an EC50 of 21 nm in an OCN promoter assay.


IT	700820-77-5P	700820-78-6P	700820-79-7P
	700820-80-0P	700820-81-1P	700820-82-2P
	700820-83-3P	700820-84-4P	700820-85-5P
	700820-86-6P	700820-87-7P	700820-88-8P
	700821-13-2P	700821-14-3P	700821-15-4P
	700821-16-5P	700821-17-6P	700821-18-7P
	700821-19-8P	700821-20-1P	700821-21-2P
	700821-22-3P	700821-23-4P	700821-24-5P
	700821-25-6P	700821-26-7P	700821-27-8P
	700821-28-9P	700821-29-0P	700821-30-3P
	700821-31-4P	700821-32-5P	700821-33-6P
	700821-34-7P	700821-35-8P	700821-36-9P
	700821-43-8P	700821-44-9P	700821-45-0P
	700821-46-1P	700821-47-2P	700821-48-3P
	700821-49-4P	700821-50-7P	700821-51-8P
	700821-52-9P	700821-53-0P	700821-54-1P
	700833-12-1P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of diaryl vitamin D receptor modulators for treatment of bone disease, psoriasis and other implicated diseases)

RN 700820-77-5 CAPLUS


CN Benzeneacetamide, 4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700820-78-6 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700820-79-7 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-2,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 700820-80-0 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[3-methyl-4-(1,3,3-trimethyl-2-oxobutoxy)phenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700820-81-1 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700820-82-2 CAPLUS


CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,2,3,3-tetramethylbutoxy)-3-methylphenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700820-83-3 CAPLUS
CN Benzeneacetamide, 4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)



RN 700820-84-4 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700820-85-5 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-2,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700820-86-6 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[3-methyl-4-(1,3,3-trimethyl-2-

oxobutoxy)phenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700820-87-7 CAPLUS

CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700820-88-8 CAPLUS

CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,2,3,3-tetramethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-13-2 CAPLUS

CN Benzeneacetamide, 4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-2-methyl- α -oxo- (9CI) (CA INDEX NAME)




RN 700821-14-3 CAPLUS


CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-2-methyl- α -oxo- (9CI) (CA INDEX NAME)




RN 700821-15-4 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-2,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-2-methyl- α -oxo- (9CI) (CA INDEX NAME)




RN 700821-16-5 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[3-methyl-4-(1,3,3-trimethyl-2-oxobutoxy)phenyl]propyl]-2-methyl- α -oxo- (9CI) (CA INDEX NAME)




RN 700821-17-6 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-2-methyl- α -oxo- (9CI) (CA INDEX NAME)




RN 700821-18-7 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,2,3,3-tetramethylbutoxy)-3-methylphenyl]propyl]-2-methyl- α -oxo- (9CI) (CA INDEX NAME)




RN 700821-19-8 CAPLUS
 CN Benzeneacetamide, 4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-α-hydroxy-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-20-1 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-α-hydroxy-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-21-2 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-2,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-α-hydroxy-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-22-3 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[3-methyl-4-(1,3,3-trimethyl-2-oxobutoxy)phenyl]propyl]-α-hydroxy-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-23-4 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-α-hydroxy-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-24-5 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,2,3,3-tetramethylbutoxy)-3-methylphenyl]propyl]-α-hydroxy-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-25-6 CAPLUS
CN Benzeneacetamide, 4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-N,N,2-trimethyl-α-oxo- (9CI) (CA INDEX NAME)




RN 700821-26-7 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl-α-oxo- (9CI) (CA INDEX NAME)




RN 700821-27-8 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-2,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- α -oxo- (9CI) (CA INDEX NAME)




RN 700821-28-9 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[3-methyl-4-(1,3,3-trimethyl-2-oxobutoxy)phenyl]propyl]-N,N,2-trimethyl- α -oxo- (9CI) (CA INDEX NAME)




RN 700821-29-0 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- α -oxo- (9CI) (CA INDEX NAME)




RN 700821-30-3 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,2,3,3-tetramethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- α -oxo- (9CI) (CA INDEX NAME)




RN 700821-31-4 CAPLUS
 CN Benzeneacetamide, 4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-α-hydroxy-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-32-5 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-α-hydroxy-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-33-6 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-2,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-α-hydroxy-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-34-7 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[3-methyl-4-(1,3,3-trimethyl-2-oxobutoxy)phenyl]propyl]-α-hydroxy-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-35-8 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-α-hydroxy-N,N,2-trimethyl- (9CI) (CA INDEX NAME)



RN 700821-36-9 CAPLUS
 CN Benzeneacetamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,2,3,3-tetramethylbutoxy)-3-methylphenyl]propyl]-α-hydroxy-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-43-8 CAPLUS
 CN Benzenepropanamide, 4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-44-9 CAPLUS
 CN Benzenepropanamide, 4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-


methylphenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-45-0 CAPLUS
CN Benzenepropanamide, 4-[1-ethyl-1-[4-(2-hydroxy-2,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-46-1 CAPLUS
CN Benzenepropanamide, 4-[1-ethyl-1-[3-methyl-4-(1,3,3-trimethyl-2-oxobutoxy)phenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-47-2 CAPLUS
CN Benzenepropanamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-48-3 CAPLUS
CN Benzenepropanamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,2,3,3-tetramethylbutoxy)-3-methylphenyl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 700821-49-4 CAPLUS
 CN Benzenepropanamide, 4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-50-7 CAPLUS
 CN Benzenepropanamide, 4-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-51-8 CAPLUS
 CN Benzenepropanamide, 4-[1-ethyl-1-[4-(2-hydroxy-2,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-52-9 CAPLUS
 CN Benzenepropanamide, 4-[1-ethyl-1-[3-methyl-4-(1,3,3-trimethyl-2-oxobutoxy)phenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700821-53-0 CAPLUS
 CN Benzenepropanamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,3,3-trimethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)



RN 700821-54-1 CAPLUS
 CN Benzenepropanamide, 4-[1-ethyl-1-[4-(2-hydroxy-1,2,3,3-tetramethylbutoxy)-3-methylphenyl]propyl]-N,N,2-trimethyl- (9CI) (CA INDEX NAME)




RN 700833-12-1 CAPLUS
 CN 2-Propenamide, 3-[4-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-2-methylphenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 36 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:349011 CAPLUS

DN 140:400483
 TI Both thyroid hormone receptor (TR) β 1 and TR β 2 isoforms
 contribute to the regulation of hypothalamic thyrotropin-releasing hormone
 AU Dupre, Sandrine M.; Guissouma, Hajer; Flamant, Frederic; Seugnet,
 Isabelle; Scanlan, Thomas S.; Baxter, John D.; Samarut, Jacques; Demeneix,
 Barbara A.; Becker, Nathalie
 CS Museum National d'Histoire Naturelle, Unite Scientifique du Museum 501
 Departement Regulation, Developpement et Diversite Moleculaire, Centre
 National de la Recherche Scientifique (CNRS), Unite Mixte de Recherche
 (UMR) 5166, Paris, 75231, Fr.
 SO Endocrinology (2004), 145(5), 2337-2345
 CODEN: ENDOAO; ISSN: 0013-7227
 PB Endocrine Society
 DT Journal
 LA English
 AB Thyroid hormones (TH) are essential regulators of vertebrate development
 and metabolism Central mechanisms governing their production have evolved,
 with
 the β -TH receptor (TR β) playing a key regulatory role in the
 neg. feedback effects of circulating TH levels on production of hypothalamic
 TRH and hypophyseal TSH. Both TR β -isoforms (TR β 1 and TR β 2)
 are expressed in the hypothalamus and pituitary. However, their resp.
 roles in TH-dependent transcriptional regulation of TRH are undefined. We
 confirmed the preferential role of TR β vs. TR α isoforms in TRH
 regulation in wild-type mice in vivo by using the TR β preferential
 agonist GC-1. We next determined the effects of tissue-specific rescue of
 TR β 1 and TR β 2 isoforms by somatic gene transfer in hypothalami
 of TR β null (TR β -/-) mice. TH-dependent TRH transcriptional
 repression was impaired in TR β -/- mice, but was restored by
 cotransfection of either TR β 1 or TR β 2 into the hypothalamus.
 TR β 1, but not TR β 2, displayed a role in ligand-independent
 activation. In situ hybridization was used to examine endogenous TRH
 expression in the paraventricular nucleus of the hypothalamus of
 TR β -/- or TR α null (TR α o/o) mice under different thyroid
 states. In contrast to published data on TR β 2-/- mice, we found that
 both ligand-independent TRH activation and ligand-dependent TRH repression
 were severely impaired in TR β -/- mice. This study thus provides
 functional in vivo data showing that both TR β 1 and TR β 2 isoforms
 have specific roles in regulating TRH transcription.
 IT 211110-63-3, GC-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (thyroid hormone receptor β 1 and β 2 isoforms in regulation of
 hypothalamic TRH transcription)
 RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-
 dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 37 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:343382 CAPLUS
 DN 141:47420
 TI Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight
 AU Baxter, John D.; Webb, Paul; Grover, Gary; Scanlan, Tom S.
 CS Diabetes Center and Department of Medicine, University of California, San Francisco, CA, 94143-0540, USA
 SO Trends in Endocrinology and Metabolism (2004), 15(4), 154-157
 CODEN: TENME4; ISSN: 1043-2760
 PB Elsevier
 DT Journal; General Review
 LA English
 AB A review. The current report describes progress in development of a selective thyroid hormone receptor modulator, GC-1. This compound binds selectively to the β -isoform of the thyroid hormone receptor, and its uptake into the heart is relatively low. Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approx. two- to threefold more efficacy than Atorvastatin, a compound that blocks HMG-CoA reductase. GC-1 also decreases plasma levels of triglyceride and lipoprotein (a), and induces loss of fat. These effects can be observed under conditions where there is either no or minimal effect on heart rate, and no detectable loss of muscle. Although more study is required, compds. of this class deserve further investigation for treating lipid disorders and obesity.
 IT 211110-63-3, GC-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (selective activation of thyroid hormone signaling pathways by GC-1 for controlling cholesterol and body weight)
 RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 38 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:260097 CAPLUS
 DN 140:350954
 TI Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine
 AU Grover, Gary J.; Egan, Donald M.; Sleph, Paul G.; Beehler, Blake C.; Chiellini, Grazia; Nguyen, Ngoc-Ha; Baxter, John D.; Scanlan, Thomas S.
 CS Metabolic and Cardiovascular Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Pennington, NJ, 08534, USA
 SO Endocrinology (2004), 145(4), 1656-1661
 CODEN: ENDOAO; ISSN: 0013-7227
 PB Endocrine Society
 DT Journal

LA English

AB Current drug therapies for obesity are ineffective, and existing treatments for lipid disorders can be further improved. Thyroid hormones affect both conditions, although currently available nonselective thyromimetics are not clin. useful for such treatment due to cardiac side effects. Recent studies suggest that thyroid hormone receptor subtype β (TR β) selective agonists have a profile in which cholesterol can be reduced with minimal tachycardia. The purpose of this study was to determine whether modest (5-10%) increases in metabolic rate could also be observed with minimal tachycardia after TR β stimulation. For these studies, the TR β selective agonist, GC-1, was used to assess selectivity for lipid-lowering and metabolic rate changes relative to tachycardia. Studies in cholesterol-fed rats (7 d treatment) showed that GC-1 reduced cholesterol (ED₅₀ = 190 nmol/kg·d) approx. 30 times more potently than it induced tachycardia (ED₁₅ = 5451 nmol/kg·d). T₃ showed no potency difference between cholesterol lowering and tachycardia. GC-1 showed approx. 10-fold selectivity for increasing metabolic rate (ED₅ = 477 nmol/kg·d) relative to tachycardia compared with T₃, which showed no selectivity. In cynomolgus monkeys treated for 7 d, significant cholesterol-lowering and lipoprotein (a) reduction was noted for both T₃ and GC-1, whereas no tachycardia was observed


for GC-1, unlike T₃. T₃ and GC-1 caused a significant (.apprx.4%) reduction in body weight in these animals. Therefore, selective TR β activation may be a potentially usefully treatment for obesity and reduction of low d. lipoprotein cholesterol and reduction of the atherogenic risk factor lipoprotein (a).

IT 211110-63-3, GC-1

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effects of thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates and selective actions relative to 3,5,3'-triiodo-L-thyronine)

RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 39 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:166736 CAPLUS

DN 140:386301

TI Studies of antagonists and selective agonists of the thyroid hormone receptors

AU Yoshihara, Hikari Ananda Infinity


CS Univ. of California, San Francisco, CA, USA

SO (2003) 137 pp. Avail.: UMI, Order No. DA3088651

From: Diss. Abstr. Int., B 2003, 64(4), 1631


DT Dissertation

LA English
 AB Unavailable
 IT 211110-63-3, GC-1
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (analogs; studies of antagonists and selective agonists of the thyroid hormone receptors)
 RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



L8 ANSWER 40 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:161155 CAPLUS
 DN 140:297878
 TI Aberrant maturation of astrocytes in thyroid hormone receptor $\alpha 1$ knockout mice reveals an interplay between thyroid hormone receptor isoforms
 AU Morte, Beatriz; Manzano, Jimena; Scanlan, Thomas S.; Vennstroem, Bjoern; Bernal, Juan
 CS Instituto de Investigaciones Biomedicas Alberto Sols, Consejo Superior de Investigaciones Cientificas y Universidad Autonoma de Madrid, Madrid, 28029, Spain
 SO Endocrinology (2004), 145(3), 1386-1391
 CODEN: ENDOAO; ISSN: 0013-7227
 PB Endocrine Society
 DT Journal
 LA English
 AB Although the effects of thyroid hormones on the development of neurons and oligodendrocytes are well documented, less is known about the hormonal effects on astrocytes. The authors' analyses of cerebellar slices from 2-mo-old T3 receptor protein (TR) $\alpha 1$ -deficient mice show that mature astrocytes, Golgi epithelial cells, and their Bergmann processes had strongly reduced glial fibrillary acidic protein (GFAP) and nestin immunoreactivity, in contrast to wild-type mice. Furthermore, the Bergmann processes exhibited an irregular GFAP staining. A similar expression of nestin and GFAP was observed in 11-d-old (P11) mutant pups. Surprisingly, however, hypothyroidism normalized the appearance of these markers in the P11 mutants, suggesting that liganded TR β is detrimental to astroglial cell differentiation in the absence of TR $\alpha 1$. To test this hypothesis, hypothyroid mice were treated from birth until P11 with the TR β -selective ligand GC-1. This treatment was devastating in the TR $\alpha 1$ -/- mice, causing little if any nestin or GFAP immunoreactivity, whereas the wild-type mice were normal. The results thus indicate an important interplay between thyroid hormone receptor isoforms in astroglial cell maturation.
 IT 211110-63-3, GC-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (aberrant maturation of astrocytes in thyroid hormone receptor $\alpha 1$ knockout mice reveals an interplay between thyroid hormone receptor isoforms)

RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 41 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:147517 CAPLUS

DN 140:418430

TI The Y1 receptor subtype mediates the cardiovascular changes evoked by NPY administered into the posterior hypothalamic nucleus of conscious rat

AU Martin, John R.

CS Kirksville College of Osteopathic Medicine, Department of Pharmacology, A.T. Still University of Health Sciences, Kirksville, MO, 63501, USA

SO Brain Research (2004), 1002(1,2), 11-20

CODEN: BRREAP; ISSN: 0006-8993

PB Elsevier Science B.V.

DT Journal

LA English

AB An earlier study showed that the neuropeptide Y (NPY) receptor antagonist PYX-2 blocks the enhancement of a carbachol (CCh)-evoked pressor response produced by prior NPY administration into the posterior hypothalamic nucleus (PHN). The Y receptor subtype that mediates this response, and an increase in mean arterial pressure (MAP) and heart rate, remained unknown due to the lack of selectivity of PYX-2 for the Y receptor subtypes. Thus, the present study was undertaken to elucidate the Y receptor subtype responsible for mediating the NPY-evoked cardiovascular responses from the PHN by determining the rank order of potency of several NPY-related peptides

for

increasing MAP, and by correlating the pressor response evoked by these peptides to reported K_i 's and IC_{50} 's for the Y1, Y2, Y4 and Y5 receptor subtypes. The pharmacol. profile ($PYY \geq NPY \geq [Leu31,Pro34]NPY$. $gtoreq.NPY13-36 \geq hPP$) and correlations suggest that the Y1 and/or Y5 receptor subtypes mediate these cardiovascular changes. Administration of the relatively non-selective Y receptor antagonist PYX-2 or the selective Y1 receptor antagonist BIBP 3226 into the PHN prior to NPY completely blocked the cardiovascular responses. BIBP 3226 also blocked the cardiovascular changes evoked by $[Leu31,Pro34]NPY$, $NPY13-36$ and human pancreatic polypeptide (hPP). In contrast, neither BIBP 3226 nor PYX-2 inhibited the cardiovascular changes induced by peptide YY (PYY) or CCh microinjection into the PHN. These results show that NPY and PYY act on different receptors to mediate their resp. cardiovascular changes from the PHN with NPY stimulating the Y1 receptor.

IT 146999-93-1, PYX-2

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)


(NPY Y1 receptor subtype mediates cardiovascular changes evoked by NPY administered into posterior hypothalamic nucleus of conscious rat)

RN 146999-93-1 CAPLUS


CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutamyl-L-arginyl-3-[(2,6-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 42 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:10381 CAPLUS
DN 140:157625
TI Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor
AU Borngraeber, Sabine; Budny, Mary-jane; Chiellini, Grazia; Cunha-lima, Suzana T.; Togashi, Marie; Webb, Paul; Baxter, John D.; Scanlan, Thomas S.; Fletterick, Robert J.
CS Department of Biochemistry/Biophysics, University of California, San Francisco, CA, 94143-2240, USA
SO Proceedings of the National Academy of Sciences of the United States of America (2003), 100(26), 15358-15363
CODEN: PNAS6; ISSN: 0027-8424
PB National Academy of Sciences

DT Journal
 LA English
 AB Selective therapeutics for nuclear receptors would revolutionize treatment for endocrine disease. Specific control of nuclear receptor activity is challenging because the internal cavities that bind hormones can be virtually identical. Only one highly selective hormone analog is known for the thyroid receptor, GC-24, an agonist for human thyroid hormone receptor β . The compound differs from natural hormone in benzyl, substituting for an iodine atom in the 3' position. The benzyl is too large to fit into the enclosed pocket of the receptor. The crystal structure of human thyroid hormone receptor β at 2.8-Å resolution with GC-24 bound explains its agonist activity and unique isoform specificity. The benzyl of GC-24 is accommodated through shifts of 3-4 Å in two helices. These helices are required for binding hormone and positioning the critical helix 12 at the C terminus. Despite these changes, the complex assoc. with coactivator as tightly as human thyroid hormone receptor bound to thyroid hormone and is fully active. The authors' data suggest that increased specificity of ligand recognition derives from creating a new hydrophobic cluster with ligand and protein components.

IT 211110-63-3
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (crystal structure of thyroid receptor- β ligand binding domain/GC-24 complex in relation to ligand selectivity by seeking hydrophobicity in thyroid hormone receptor)

RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 43 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:971723 CAPLUS
 DN 140:23272
 TI Treatments for age-related macular degeneration (AMD) that increase reverse cholesterol transport using a hormone receptor ligand or a lipid transporter
 IN Schwartz, Daniel M.; Duncan, Keith G.; Bailey, Kathy R.; Kane, John P.; Ishida, Brian Y.
 PA The Regents of the University of California, USA
 SO U.S. Pat. Appl. Publ., 64 pp., Cont.-in-part of U.S. Pat. Appl. 2003 162,758.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2003229062	A1	20031211	US 2003-428551	20030502


US 2003162758	A1	20030828	US 2001-340498P	P	20011207
			US 2002-415864P	P	20021003
			US 2002-313641	A2	20021206
			US 2002-313641		20021206
US 2004266663	A1	20041230	US 2001-340498P	P	20011207
			US 2002-415864P	P	20021003
			US 2004-794198		20040305
			US 2001-340498P	P	20011207
WO 2004098506	A2	20041118	US 2002-415864P	P	20021003
			US 2002-313641	A2	20021206
			US 2003-428551	A2	20030502
			WO 2004-US13332		20040430
WO 2004098506	A3	20060112			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2005282750	A1	20051222	US 2003-428551	A	20030502
			US 2005-55309		20050210
			US 2001-340498P	P	20011207
			US 2002-415864P	P	20021003
			US 2002-313641	A2	20021206
			US 2003-428551	A2	20030502
			US 2004-794198	A3	20040305

PATENT FAMILY INFORMATION:


FAN 2003:472342

	PATENT NO.				KIND	DATE	APPLICATION NO.								DATE				
	-----				----	-----	-----								-----				
PI	WO	2003049685				A2	20030619	WO 2002-US38856								20021206			
	WO	2003049685				A3	20040708												
	W:		AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN	
			CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,	
			PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,	
			UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW							
	RW:		GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,	
			KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	
		FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	SI,	SK,	TR,	BF,	BJ,		
		CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG				
								US 2001-340498P								P	20011207		
								US 2002-415864P								P	20021003		
CA		2468989				AA	20030619	CA 2002-2468989									20021206		
								US 2001-340498P								P	20011207		
								US 2002-415864P								P	20021003		
								WO 2002-US38856								W	20021206		
AU		2002360489				A1	20030623	AU 2002-360489									20021206		
								US 2001-340498P								P	20011207		
								US 2002-415864P								P	20021003		
								WO 2002-US38856								W	20021206		
EP		1461028				A2	20040929	EP 2002-795748									20021206		
		R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
			IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	SK			
								US 2001-340498P								P	20011207		

				US 2002-415864P	P	20021003
				WO 2002-US38856	W	20021206
	JP 2005511713	T2	20050428	JP 2003-550736		20021206
				US 2001-340498P	P	20011207
				US 2002-415864P	P	20021003
				WO 2002-US38856	W	20021206
FAN	2005:2158					
	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
	-----	---	-----	-----		-----
PI	US 2004266663	A1	20041230	US 2004-794198		20040305
				US 2001-340498P	P	20011207
				US 2002-415864P	P	20021003
				US 2002-313641	A2	20021206
				US 2003-428551	A2	20030502
	US 2003162758	A1	20030828	US 2002-313641		20021206
				US 2001-340498P	P	20011207
				US 2002-415864P	P	20021003
	US 2003229062	A1	20031211	US 2003-428551		20030502
				US 2001-340498P	P	20011207
				US 2002-415864P	P	20021003
				US 2002-313641	A2	20021206
	US 2005282750	A1	20051222	US 2005-55309		20050210
				US 2001-340498P	P	20011207
				US 2002-415864P	P	20021003
				US 2002-313641	A2	20021206
				US 2003-428551	A2	20030502
				US 2004-794198	A3	20040305
	WO 2005091909	A2	20051006	WO 2005-US6554		20050301
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,					
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,					
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,					
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,					
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,					
	SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,					
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,					
	EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,					
	RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,					
	MR, NE, SN, TD, TG					
				US 2004-794198	A	20040305
AB	The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced. A kit for the prevention or treatment of macular degeneration containing a lipid transporter is also claimed.					
IT	211110-63-3, GC-1					
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)					
	(treatments for age-related macular degeneration (AMD) that increase reverse cholesterol transport using a hormone receptor ligand or a lipid transporter)					
RN	211110-63-3 CAPLUS					
CN	Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)					




L8 ANSWER 44 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:949395 CAPLUS
 DN 140:87962
 TI Differential effects of triiodothyronine and the thyroid hormone receptor β -specific agonist GC-1 on thyroid hormone target genes in the brain
 AU Manzano, Jimena; Morte, Beatriz; Scanlan, Thomas S.; Bernal, Juan
 CS Instituto de Investigaciones Biomedicas Alberto Sols, Consejo Superior de Investigaciones Cientificas y Universidad Autonoma de Madrid, Madrid, Spain
 SO Endocrinology (2003), 144(12), 5480-5487
 CODEN: ENDOAO; ISSN: 0013-7227
 PB Endocrine Society
 DT Journal
 LA English
 AB The availability of synthetic thyroid hormone receptor agonists provides a valuable tool to analyze whether specific receptor isoforms mediate specific physiol. responses to thyroid hormone. GC-1 is a thyroid hormone analog displaying selectivity for thyroid hormone receptor β . The authors have analyzed the effect of GC-1 on expression of thyroid hormone target genes in the cerebrum and cerebellum. Congenitally hypothyroid rats were treated with single daily doses of either T3 or GC-1. Both compds. similarly induced Purkinje cell protein-2 (PCP-2) in the cerebellum. Expression of RC3 and Rhes in the caudate, and hairless, neurotrophin-3, Reelin, and Rev-ErbA α in the cerebellum, was analyzed by in situ hybridization on postnatal d 16. Hypothyroidism strongly decreased expression of RC3 and Rhes in the caudate, and hairless, RevErbA α , and neurotrophin-3 in the cerebellum, and increased Reelin. T3 treatment normalized the expression of all genes. However, GC-1 effectively normalized expression of Rhes and Reelin only. The lack of a GC-1 effect on most cerebellar genes can be explained by the known distribution of thyroid hormone receptor α and β isoforms. However, in the caudate, RC3 and Rhes are expressed in the same cells, and therefore, they may represent specific gene responses linked to specific thyroid hormone receptor isoforms.
 IT 211110-63-3, GC-1
 RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); BIOL (Biological study); USES (Uses)
 (triiodothyronine and thyroid hormone receptor β -specific agonist GC-1 differential effects on thyroid hormone target genes in brain)
 RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 45 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:926095 CAPLUS
DN 140:87961
TI Spared bone mass in rats treated with thyroid hormone receptor
TRβ-selective compound GC-1
AU Freitas, Fatima R. S.; Moriscot, Anselmo S.; Jorgetti, Vanda; Soares,
Antonio G.; Passarelli, Marisa; Scanlan, Thomas S.; Brent, Gregory A.;
Bianco, Antonio C.; Gouveia, Cecilia H. A.
CS Department of Anatomy, Institute of Biomedical Sciences, University of Sao
Paulo, Sao Paulo, 05508-900, Brazil
SO American Journal of Physiology (2003), 285(5, Pt. 1), E1135-E1141
CODEN: AJPHAP; ISSN: 0002-9513
PB American Physiological Society
DT Journal
LA English
AB Thyrotoxicosis is frequently associated with increased bone turnover and
decreased bone mass. To investigate the role of thyroid hormone
receptor-β (TRβ) in mediating the osteopenic effects of
triiodothyronine (T3), female adult rats were treated daily (64 days) with
GC-1 (1.5 μg/100 g body weight), a TRβ-selective thyromimetic compound
Bone mass was studied by dual-energy x-ray absorptiometry of several
skeletal sites and histomorphometry of distal femur, and the results were
compared with T3-treated (3 μg/100 g body weight) or control animals. As
expected, treatment with T3 significantly reduced bone mineral d. (BMD) in
the lumbar vertebrae (L2-L5), femur, and tibia by 10-15%. In contrast,
GC-1 treatment did not affect the BMD in any of the skeletal sites
studied. The efficacy of GC-1 treatment was verified by a reduction in serum
TSH (-52% vs. control, P < 0.05) and cholesterol (-21% vs. control, P <
0.05). The histomorphometric anal. of the distal femur indicated that T3
but not GC-1 treatment reduced the trabecular volume, thickness, and number
The authors conclude that chronic, selective activation of the TRβ
isoform does not result in bone loss typical of T3-induced thyrotoxicosis,
suggesting that the TRβ isoform is not critical in this process. In
addition, the authors' findings suggest that the development of TR-selective
T3 analogs that spare bone mass represents a significant improvement
toward long-term TSH-suppressive therapy.
IT 211110-63-3, GC-1
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
BIOL (Biological study)
(spared bone mass in rats treated with thyroid hormone receptor
TRβ-selective compound GC-1)
RN 211110-63-3 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-
dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 46 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:472342 CAPLUS
DN 139:47197
TI Treatment for age-related macular degeneration
IN Schwartz, Daniel M.; Duncan, Keith; Bailey, Kathy; Kane, John; Ishida, Brian
PA Regents of the University of California, USA
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003049685	A2	20030619	WO 2002-US38856	20021206
WO 2003049685	A3	20040708		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2468989	AA	20030619	US 2001-340498P	P 20011207
			US 2002-415864P	P 20021003
			CA 2002-2468989	20021206
			US 2001-340498P	P 20011207
			US 2002-415864P	P 20021003
AU 2002360489	A1	20030623	WO 2002-US38856	W 20021206
			AU 2002-360489	20021206
			US 2001-340498P	P 20011207
			US 2002-415864P	P 20021003
			WO 2002-US38856	W 20021206
EP 1461028	A2	20040929	EP 2002-795748	20021206
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
			US 2001-340498P	P 20011207
			US 2002-415864P	P 20021003
JP 2005511713	T2	20050428	WO 2002-US38856	W 20021206
			JP 2003-550736	20021206
			US 2001-340498P	P 20011207
			US 2002-415864P	P 20021003
			WO 2002-US38856	W 20021206

PATENT FAMILY INFORMATION:
FAN 2003:971723

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 2003229062	A1	20031211	US 2003-428551	20030502
				US 2001-340498P	P 20011207
				US 2002-415864P	P 20021003
				US 2002-313641	A2 20021206
	US 2003162758	A1	20030828	US 2002-313641	20021206
				US 2001-340498P	P 20011207
				US 2002-415864P	P 20021003
	US 2004266663	A1	20041230	US 2004-794198	20040305
				US 2001-340498P	P 20011207
				US 2002-415864P	P 20021003
				US 2002-313641	A2 20021206
				US 2003-428551	A2 20030502
	WO 2004098506	A2	20041118	WO 2004-US13332	20040430
	WO 2004098506	A3	20060112		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				
				US 2003-428551	A 20030502
	US 2005282750	A1	20051222	US 2005-55309	20050210
				US 2001-340498P	P 20011207
				US 2002-415864P	P 20021003
				US 2002-313641	A2 20021206
				US 2003-428551	A2 20030502
				US 2004-794198	A3 20040305
FAN	2005:2158				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 2004266663	A1	20041230	US 2004-794198	20040305
				US 2001-340498P	P 20011207
				US 2002-415864P	P 20021003
				US 2002-313641	A2 20021206
				US 2003-428551	A2 20030502
	US 2003162758	A1	20030828	US 2002-313641	20021206
				US 2001-340498P	P 20011207
				US 2002-415864P	P 20021003
	US 2003229062	A1	20031211	US 2003-428551	20030502
				US 2001-340498P	P 20011207
				US 2002-415864P	P 20021003
				US 2002-313641	A2 20021206
	US 2005282750	A1	20051222	US 2005-55309	20050210
				US 2001-340498P	P 20011207
				US 2002-415864P	P 20021003
				US 2002-313641	A2 20021206
				US 2003-428551	A2 20030502
				US 2004-794198	A3 20040305
	WO 2005091909	A2	20051006	WO 2005-US6554	20050301
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,				

SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG


US 2004-794198 A 20040305

AB The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.

IT 211110-63-3, GC 1
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment for age-related macular degeneration)

RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



L8 ANSWER 47 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:421336 CAPLUS

DN 139:127969

TI Nuclear Hormone Receptor Targeted Virtual Screening

AU Schapira, Matthieu; Abagyan, Ruben; Totrov, Maxim

CS Molsoft LLC, La Jolla, CA, 92037, USA

SO Journal of Medicinal Chemistry (2003), 46(14), 3045-3059

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB Virtual library screening (VLS) is emerging as a valuable drug lead discovery tool. ICM-VLS implementation of this technol. was evaluated on a benchmark set of nuclear hormone receptors (NRs), an important therapeutic target family. Over 5000 structurally diverse compds., including 78 known NR ligands, were screened against 18 crystal structures and one computer model of 10 NR ligand binding domains in their active or inactive states. The results confirm the ability of the VLS method to generate highly focused subsets of the input chemical library, enriched 33- to 100-fold for all but one receptor studied. However, receptor flexibility remains to be fully addressed, and the choice of the specific conformation used for screening may determine the success of the exercise. The authors observe that for a particular ligand, VLS can often identify the correct target within the receptor family, although the technol. is unable to reliably discriminate between the closely related receptor isoforms. Addnl., the results suggest that VLS may be applied successfully without an exptl. structure of the receptor by using a homol. model. These data


represent a realistic snapshot of the state-of-the-art of NR-targeted VLS and define the recent progress and the remaining limitations of the technol.

IT 211110-63-3, GC1
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)

(nuclear hormone receptor targeted virtual screening)

RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 48 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:406967 CAPLUS

DN 139:128169

TI Structural Determinants of Selective Thyromimetics

AU Yoshihara, Hikari A. I.; Apriletti, James W.; Baxter, John D.; Scanlan, Thomas S.

CS Departments of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology, University of California, San Francisco, CA, 94143-2280, USA

SO Journal of Medicinal Chemistry (2003), 46(14), 3152-3161

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 139:128169

AB The thyromimetic GC-1 shows a preference for binding the β form of the thyroid hormone receptor (TR). GC-1 was designed as an analog of the thyromimetic DIMIT, which has a lower affinity for TR and is not selective. GC-1 has a methylene group linking its two aromatic rings and an oxyacetic acid polar side chain, while DIMIT has an ether oxygen linking its aromatic rings and an L-alanine polar side chain. The structural features of GC-1 that confer its greater affinity and selectivity compared to DIMIT were analyzed with the preparation of analogs that bear only one of their two different structural features. The analog of GC-1 with a biaryl ether has selectivity comparable to that of GC-1, while the analog of DIMIT with a methylene group linking its aromatic rings is only slightly selective. These results demonstrate that the oxyacetic acid side chain of GC-1 is critical in conferring TR- β selectivity.


IT 211110-63-3, GC-1

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(structural determinants of selective thyromimetics)

RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 49 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:312259 CAPLUS
DN 138:288120
TI Manufacture of flame retardant polyester
IN Sharma, Naresh Dutta; Chaturvedi, Sarita; Rao, Bommu Venkateswara
PA The Principal Scientist & Head, Sir Padampt Research Centre, A Division of
J.K. Synthetics Ltd., India
SO Indian, 19 pp.
CODEN: INXXAP
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	IN 176560	A	19960713	IN 1989-DE1176	19890112
				IN 1989-DE1176	19890112

AB A title polyester was manufactured from monomer obtained by condensation of tetrabromobisphenol A Na salt with ClCH₂CO₂Na in polar medium at ambient temperature in the presence of Na₂CO₃, acidifying the intermediate product and esterifying the resulting bis(carboxymethyl) ether of tetrabromobisphenol A with MeOH in the presence of acid catalyst to give the corresponding bis(methoxycarbonylmethoxy)tetrabromobisphenol A derivative This was used as monomer for the manufacture of flame retardant polyesters using customary polycondensation procedures. For example, a polyester fabric with limiting oxygen index (LOI) value 27 was knitted from yarn filament spun from di-Me terephthalate-ethylene glycol-4,4'-di(methoxycarbonylmethoxy)-3,3',5,5'-tetrabromobisphenol A copolymer (preparation given).

IT 57502-25-7P 504394-84-7P
RL: IMF (Industrial manufacture); PREP (Preparation)
(fiber; manufacture of flame retardant polyester)


RN 57502-25-7 CAPLUS

CN 1,4-Benzenedicarboxylic acid, dimethyl ester, polymer with dimethyl 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis[acetate] and 1,2-ethanediol (9CI) (CA INDEX NAME)

CM 1


CRN 19947-84-3

CMF C21 H20 Br4 O6



CM 2

CRN 120-61-6
CMF C10 H10 O4



CM 3


CRN 107-21-1
CMF C2 H6 O2



RN 504394-84-7 CAPLUS
CN 1,4-Benzenedicarboxylic acid, dimethyl ester, polymer with 1,2-ethanediol and 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis[acetic acid] (9CI) (CA INDEX NAME)


CM 1

CRN 47612-39-5
CMF C19 H16 Br4 O6



CM 2

CRN 120-61-6
CMF C10 H10 O4



CM 3

CRN 107-21-1

CMF C2 H6 O2




IT 74886-28-5P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(manufacture and conversion to acid form; manufacture of flame retardant polyester)

RN 74886-28-5 CAPLUS

CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis-, disodium salt (9CI) (CA INDEX NAME)




●2 Na

IT 47612-39-5P


RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(manufacture and esterification with methanol; manufacture of flame retardant polyester)

RN 47612-39-5 CAPLUS

CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



IT 19947-84-3P
 RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
 (manufacture and polymerization; manufacture of flame retardant polyester)
 RN 19947-84-3 CAPLUS
 CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis-, dimethyl ester (9CI) (CA INDEX NAME)




L8 ANSWER 50 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:242123 CAPLUS
 DN 138:271379
 TI Preparation of linked biaryl compounds useful for treatment of metabolic disorders, inflammatory diseases and cancer
 IN Abe, Hiroyuki; Houze, Jonathan; Kawasaki, Hisashi; Kayser, Frank; Sharma, Rajiv; Sperry, Samuel
 PA Tularik Inc., USA; Japan Tobacco, Inc.
 SO PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024395	A2	20030327	WO 2002-US29232	20020913
WO 2003024395	A3	20031211		
WO 2003024395	C1	20040122		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-322556P	P 20010914
			US 2001-335434P	P 20011130
			US 2002-378627P	P 20020507
			US 2002-386833P	P 20020606
CA 2460313	AA	20030327	CA 2002-2460313	20020913

			US 2001-322556P	P	20010914
			US 2001-335434P	P	20011130
			US 2002-378627P	P	20020507
			US 2002-386833P	P	20020606
			WO 2002-US29232	W	20020913
US 2003149108	A1	20030807	US 2002-244063		20020913
US 6869975	B2	20050322			
			US 2001-322556P	P	20010914
			US 2001-335434P	P	20011130
			US 2002-378627P	P	20020507
			US 2002-386833P	P	20020606
EP 1435946	A2	20040714	EP 2002-773386		20020913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
			US 2001-322556P	P	20010914
			US 2001-335434P	P	20011130
			US 2002-378627P	P	20020507
			US 2002-386833P	P	20020606
			WO 2002-US29232	W	20020913
BR 2002012512	A	20041026	BR 2002-12512		20020913
			US 2001-322556P	P	20010914
			US 2001-335434P	P	20011130
			US 2002-378627P	P	20020507
			US 2002-386833P	P	20020606
			WO 2002-US29232	W	20020913
CN 1585638	A	20050223	CN 2002-822324		20020913
			US 2001-322556P	P	20010914
			US 2001-335434P	P	20011130
			US 2002-378627P	P	20020507
			US 2002-386833P	P	20020606
JP 2005508318	T2	20050331	JP 2003-528493		20020913
			US 2001-322556P	P	20010914
			US 2001-335434P	P	20011130
			US 2002-378627P	P	20020507
			US 2002-386833P	P	20020606
			WO 2002-US29232	W	20020913
ZA 2004002021	A	20050314	ZA 2004-2021		20040312
			US 2001-322556P	P	20010914
OS	MARPAT 138:271379				
AB	<p>Title compds. I [X = O, S(O)m, CR₂R₃ and SO₂NR₃; Y = O or CR₂R₃; Z₁ and Z₂ independently equal O, S(O)m, (CR₂R₃)_n, N(R₃), C(O)NR₃, and CR₂R₃C(O)NR₄, or alternatively Z₁ and Z₂ may be combined to form alkenyl; Ar₁ and Ar₂ independently equal an aromatic group; Ar₃ = aryl; R₁ = H, alkyl, arylalkyl; Ra, Rb, R₂, R₃ and R₄ independently equal H, alkyl, aryl and arylalkyl; m = 0-2; n = 1-2] are prepared and disclosed as being useful for the treatment of metabolic disorders, inflammatory diseases and cancer are provided herein. Thus, II was prepared via esterification of bis(4-hydroxy-3-methylphenyl)sulfide with tert-butylbromoacetate and subsequent O-alkylation with 4-(trifluoromethyl)benzyl bromide and hydrolysis. I were analyzed for their ability to increase serum HDL cholesterol levels with several compds. of the invention, e.g., II, providing greater than 100% increases at 30mg/kg dosage levels. In particular, the invention provides compds. which modulate the expression and/or function of proteins involved in lipid metabolism, inflammation and cell proliferation.</p>				
IT	<p>503002-70-8P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of linked biaryl compound useful for treatment of metabolic disorders, inflammatory diseases and cancer)</p>				
RN	503002-70-8 CAPLUS				


CN Acetic acid, [2-methyl-4-[[3-methyl-4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]phenoxy]- (9CI) (CA INDEX NAME)



L8 ANSWER 51 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:212204 CAPLUS
 DN 139:173854
 TI Design of thyroid hormone receptor antagonists from first principles
 AU Webb, Paul; Nguyen, Ngoc-Ha; Chiellini, Grazia; Yoshihara, Hikari A. I.;
 Cunha Lima, Suzana T.; Apriletti, James W.; Ribeiro, Ralff C. J.;
 Marimuthu, Adhirai; West, Brian L.; Goede, Patrick; Mellstrom, Karin;
 Nilsson, Stefan; Kushner, Peter J.; Fletterick, Robert J.; Scanlan, Thomas
 S.; Baxter, John D.
 CS Diabetes Center and Metabolic Research Unit, University of California, San
 Francisco, CA, 94143, USA
 SO Journal of Steroid Biochemistry and Molecular Biology (2003), Volume Date
 2002, 83(1-5), 59-73
 CODEN: JSBBEZ; ISSN: 0960-0760
 PB Elsevier Science Ltd.
 DT Journal; General Review
 LA English
 AB A review. It is desirable to obtain TR antagonists for treatment of
 hyperthyroidism and other conditions. We have designed TR antagonists
 from first principles based on TR crystal structures. Since agonist
 ligands are buried in the fold of the TR ligand binding domain (LBD), we
 reasoned that ligands that resemble agonists with large extensions should
 bind the LBD, but would prevent its folding into an active conformation.
 In particular, we predicted that extensions at the 5' aryl position of
 ligand should reposition helix (H) 12, which forms part of the
 co-activator binding surface, and thereby inhibit TR activity. We have
 found that some synthetic ligands with 5' aryl ring extensions behave as
 antagonists (DIBRT, NH-3), or partial antagonists (GC-14, NH-4).
 Moreover, one compound (NH-3) represents the first potent TR antagonist with
 nanomolar affinity that also inhibits TR action in an animal model.
 However, the properties of the ligands also reveal unexpected aspects of
 TR behavior. While nuclear receptor antagonists generally promote binding
 of co-repressors, NH-3 blocks co-activator binding and also prevents
 co-repressor binding. More surprisingly, many compds. with extensions
 behave as full or partial agonists. We present hypotheses to explain both
 behaviors in terms of dynamic equilibrium of H12 position.
 IT 447415-26-1 447415-34-1, GC 14
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (design of thyroid hormone receptor antagonists)
 RN 447415-26-1 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-
 nitrophenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX
 NAME)




RN 447415-34-1 CAPLUS
 CN Acetic acid, [4-[[6-hydroxy-5-(1-methylethyl)-4'-nitro[1,1'-biphenyl]-3-yl]methyl]-3,5-dimethoxyphenyl]- (9CI) (CA INDEX NAME)




RE.CNT 100 THERE ARE 100 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 52 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:4476 CAPLUS
 DN 138:353724
 TI Facile preparation of O-substituted acyclic phenol-formaldehyde oligomers
 AU Ito, Kazuaki; Takasawa, Toshiro; Ohba, Yoshihiro
 CS Department of Chemistry and Chemical Engineering, Faculty of Engineering,
 Yamagata University, Yonezawa, 992-8510, Japan
 SO Synthetic Communications (2002), 32(24), 3839-3849
 CODEN: SYNCAV; ISSN: 0039-7911
 PB Marcel Dekker, Inc.
 DT Journal
 LA English
 OS CASREACT 138:353724
 AB Acyclic p-cresol-formaldehyde oligomers (dimer, trimer, and tetramer)
 having ester, carboxylic acid, amide groups on the phenolic OH groups were
 prepared in good yields.
 IT 518361-66-5P 518361-67-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (amination of; facile preparation of O-substituted acyclic
 phenol-formaldehyde di-, tri- and tetramers via multi-step synthetic
 routes)
 RN 518361-66-5 CAPLUS
 CN Acetic acid, 2,2'-[[5-methyl-2-[2-oxo-2-(pentafluorophenoxy)ethoxy]-1,3-
 phenylene]bis[methylene(4-methyl-2,1-phenylene)oxy]]bis-,
 bis(pentafluorophenyl) ester (9CI) (CA INDEX NAME)



RN 518361-67-6 CAPLUS
 CN Acetic acid, 2,2'-[methylenebis[[5-methyl-2-[2-oxo-2-(pentafluorophenoxy)ethoxy]-3,1-phenylene]methylene(4-methyl-2,1-phenylene)oxy]]bis-, bis(pentafluorophenyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




— F


— F

— Me


IT 518361-59-6P 518361-60-9P 518361-61-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (chlorination of; facile preparation of o-substituted acyclic
 phenol-formaldehyde di-, tri- and tetramers via multi-step synthetic
 routes)
 RN 518361-59-6 CAPLUS
 CN Acetic acid, 2,2'-[methylenebis[(4-methyl-2,1-phenylene)oxy]]bis- (9CI)
 (CA INDEX NAME)



RN 518361-60-9 CAPLUS
 CN Acetic acid, 2,2'-[[2-(carboxymethoxy)-5-methyl-1,3-
 phenylene]bis[methylene(4-methyl-2,1-phenylene)oxy]]bis- (9CI) (CA INDEX
 NAME)




RN 518361-61-0 CAPLUS
 CN Acetic acid, 2,2'-[methylenebis[[2-(carboxymethoxy)-5-methyl-3,1-phenylene]methylene(4-methyl-2,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




IT 518361-57-4P 518361-58-5P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (hydrolysis of; facile preparation and sodium cation affinity of o-substituted acyclic phenol-formaldehyde tri- and tetramers)


RN 518361-57-4 CAPLUS
 CN Acetic acid, 2,2'-[[2-(2-ethoxy-2-oxoethoxy)-5-methyl-1,3-phenylene]bis[methylene(4-methyl-2,1-phenylene)oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 518361-58-5 CAPLUS
 CN Acetic acid, 2,2'-[methylenebis[[2-(2-ethoxy-2-oxoethoxy)-5-methyl-3,1-phenylene]methylene(4-methyl-2,1-phenylene)oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A



IT 518361-56-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (hydrolysis of; facile preparation of O-substituted acyclic phenol-formaldehyde di-, tri- and tetramers via multi-step synthetic routes)
 RN 518361-56-3 CAPLUS
 CN Acetic acid, 2,2'-[methylenebis[(4-methyl-2,1-phenylene)oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 53 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:721656 CAPLUS
 DN 138:280956
 TI A thyroid hormone antagonist that inhibits thyroid hormone action in vivo
 AU Lim, Wayland; Nguyen, Ngoc-Ha; Yang, Ha Yung; Scanlan, Thomas S.; Furlow, J. David
 CS Sect. Neurobiol., Physiol, Behavior, University of California, Davis, CA, 95616-8519, USA
 SO Journal of Biological Chemistry (2002), 277(38), 35664-35670
 CODEN: JBCHA3; ISSN: 0021-9258
 PB American Society for Biochemistry and Molecular Biology
 DT Journal
 LA English
 AB We have characterized the newly developed thyroid hormone antagonist NH-3 in both cell culture and in vivo model systems. NH-3 binds Xenopus laevis thyroid hormone receptors directly in vitro and induces a conformation distinct from agonist-bound receptors. Transcriptional activation of a thyroid hormone response element-containing reporter gene is strongly inhibited by NH-3 in a dose-dependent manner. In addition, NH-3 prevents X. laevis thyroid hormone receptors from binding to the p160 family of co-activators GRIP-1 and SRC-1 in a two-hybrid assay. To assess the potency of the compound in vivo, we used induced and spontaneous X. laevis

tadpole metamorphosis, a thyroid hormone-dependent developmental process. NH-3 inhibits thyroid hormone-induced morphol. changes in a dose-dependent manner and inhibits the up-regulation of endogenous thyroid hormone-responsive genes. Spontaneous metamorphosis is efficiently and reversibly arrested by NH-3 with at least the same effectiveness as the thyroid hormone synthesis inhibitor methimazole. Therefore, NH-3 is the first thyroid hormone antagonist to demonstrate potent inhibition of thyroid hormone action in both cell culture- and whole animal-based assays.

IT 211110-63-3, GC-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (comparison ligand; thyroid hormone antagonist that inhibits thyroid hormone action in vivo)

RN 211110-63-3 CAPLUS


CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



IT 447415-26-1
 RL: BSU (Biological study, unclassified); DMA (Drug mechanism of action);
 PAC (Pharmacological activity); BIOL (Biological study)
 (thyroid hormone antagonist that inhibits thyroid hormone action in vivo)

RN 447415-26-1 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-nitrophenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 54 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:716241 CAPLUS

DN 137:232450

TI Preparation of biphenyl derivatives as thyroid hormone analogs

IN Haning, Helmut; Woltering, Michael; Schmidt, Gunter; Faeste, Christiane;
 Bischoff, Hilmar; Kretschmer, Axel; Voehringer, Verena; Ellinghaus, Peter

PA Bayer Aktiengesellschaft, Germany

SO PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002072539	A1	20020919	WO 2002-EP2065	20020227
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DE 2001-10111651	A 20010312
				DE 2001-10130835	A 20010627
	DE 10130835	A1	20020919	DE 2001-10130835	20010627
				DE 2001-10111651	A1 20010312
	US 2003105078	A1	20030605	US 2002-82022	20020226
	US 6777442	B2	20040817		
				DE 2001-10111651	A 20010312
				DE 2001-10130835	A 20010627
	CA 2440282	AA	20020919	CA 2002-2440282	20020227
				DE 2001-10111651	A 20010312
				DE 2001-10130835	A 20010627
				WO 2002-EP2065	W 20020227
	EP 1370523	A1	20031217	EP 2002-719938	20020227
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				DE 2001-10111651	A 20010312
				DE 2001-10130835	A 20010627
				WO 2002-EP2065	W 20020227

OS MARPAT 137:232450

AB Title compds. [I; X = O, S, SO₂, CH₂, CHF, CF₂, NR₈; R₈ = H, alkyl; R₁, R₂ = H, alkyl; R₃, R₄ = H, halo, cyano, alkyl, CF₃, CHF₂, CH₂F, vinyl, cycloalkyl; R₅ = H, alkyl, halo; R₆ = SR₉, S(O)_nR₁₀, NR₁₁C(O)R₁₂, CH₂, etc.; R₉ = alkyl, cycloalkyl, alkenyl, aryl, arylmethyl, etc.; n = 1, 2; R₁₀ = OR₁₅, NR₁₆R₁₇, alkyl, cycloalkyl, etc.; R₁₅ = H, Ph, benzyl, alkyl, etc.; R₁₆, R₁₇ = H, (branched) (substituted) alkyl, etc.; R₁₁ = H, (branched) (substituted) alkyl, etc.; R₁₂ = (branched) (substituted) alkyl, etc.; R₇ = H, alkyl, alkanoyl; Z = YmWCOR₃₆; Y = O, S; m = 0, 1; W = (substituted) alkylene; R₃₆ = OR₃₇, NR₃₈R₃₉; R₃₇-R₃₉ = H, Ph, benzyl, alkyl, etc.], were prepared as thyroid hormone analogs (no data). Thus, Et [4-(4-[benzyloxy]-3-[(4-fluorophenyl)sulfonyl]benzyl)-3,5-dimethylphenoxy]acetate (preparation given) in EtOH was hydrogenated in the presence of Pd/activated C for 2 h at room temperature and 1013 mbar to give

86%

Et [4-(3-[(4-fluorophenyl)sulfonyl]-4-hydroxybenzyl)-3,5-dimethylphenoxy]acetate which was saponified with 1 N NaOH in EtOH to give 90% [4-(3-[(4-fluorophenyl)sulfonyl]-4-hydroxybenzyl)-3,5-dimethylphenoxy]acetic acid. The compds. I are especially suitable for use in any indications that may be treated with natural thyroid hormones such as depression or thyroid tumor. The inventive compds. I are preferably used to treat arteriosclerosis, hypercholesterolemia, dyslipidemia as well as obesity.


IT 459431-01-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of biphenyl derivs. as thyroid hormone analogs)

RN 459431-01-7 CAPLUS

CN Acetic acid, [4-[[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenyl]methyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




IT 459431-02-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biphenyl derivs. as thyroid hormone analogs)

RN 459431-02-8 CAPLUS

CN Acetic acid, [4-[[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




IT 459430-99-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of biphenyl derivs. as thyroid hormone analogs)

RN 459430-99-0 CAPLUS

CN Acetic acid, [4-[[3-[(4-fluorophenyl)sulfonyl]-4-(phenylmethoxy)phenyl]methyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMATL8 ANSWER 55 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:464499 CAPLUS

DN 137:54610
 TI Positive resist composition sensitive to electron beam or X-ray
 IN Aogo, Toshiaki
 PA Fuji Photo Film Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 62 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002174894	A2	20020621	JP 2000-372986	20001207
				JP 2000-372986	20001207


AB The resist composition contains (A) polymers having a repeating unit $-\text{CH}_2\text{CR}_1(\text{A1SO}_2\text{SO}_2\text{R}_2)-$ [$\text{R}_1 = \text{H}$, halo, cyano, (substituted) alkyl or haloalkyl; $\text{R}_2 =$ (substituted) alkyl, cycloalkyl, aryl, or aralkyl; $\text{A1} =$ none, (substituted) alkylene, alkenylene, cycloalkylene, arylene, $-\text{OCOX1}-$, $-\text{COOX2}-$, $-\text{CONX3X4}-$; X1-2 , $\text{X4} =$ (substituted) alkylene, alkenylene, cycloalkylene, arylene; X1-2 and/or X4 may contain CO, COO, amido, urethane, or ureido structure; $\text{X3} = \text{H}$, (substituted) alkyl, cycloalkyl, aralkyl, aryl] and (B) acid-decomposable dissoln.-inhibiting compound with mol. weight ≤ 3000 . The resist composition has high sensitivity and resolution, and shows good patterning profiles. The resist composition is useful for microprocessing of semiconductor devices.

IT 177983-92-5
 RL: TEM (Technical or engineered material use); USES (Uses)
 (dissoln.-inhibiting compound; electron beam- or X-ray-sensitive pos.
 resist composition with high resolution and sensitivity)

RN 177983-92-5 CAPLUS


CN Acetic acid, 2,2',2'',2'''-[1,4-phenylenebis[methyldynebis[(2,5-dimethyl-4,1-phenylene)oxy]]]tetrakis-, tetrakis(1,1-dimethylethyl) ester (9CI)
 (CA INDEX NAME)

PAGE 1-A




— OBU-t

L8 ANSWER 56 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:457917 CAPLUS
 DN 137:169293
 TI Rational Design and Synthesis of a Novel Thyroid Hormone Antagonist That Blocks Coactivator Recruitment
 AU Nguyen, Ngoc-Ha; Apriletti, James W.; Lima, Suzana T. Cunha; Webb, Paul; Baxter, John D.; Scanlan, Thomas S.
 CS Program in Chemistry and Chemical Biology, Departments of Pharmaceutical Chemistry and Cellular and Molecular Pharmacology, University of California, San Francisco, CA, 94143-0446, USA
 SO Journal of Medicinal Chemistry (2002), 45(15), 3310-3320
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 137:169293
 AB The authors report the design and synthesis of a novel series of phenylethynyl derivs. I [R = H, (CH₂)₄Me, NO₂, NH₂] sharing the halogen-free thyronine scaffold of GC-1 (II). I (R = NO₂) is a T₃ antagonist with negligible TR agonist activity and improved TR binding affinity and potency that allow for further characterization of its observed activity. Its ability to block TR-coactivator interactions appears to be the mechanism for antagonism. It will be a useful pharmacol. tool for further study of T₃ signaling and TR function.
 IT 211110-63-3, GC-1 447415-34-1, GC 14
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of phenylethynyl derivs. of GC-1 as thyroid hormone analogs and their binding activity towards thyroid hormone receptors)
 RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RN 447415-34-1 CAPLUS
 CN Acetic acid, [4-[[6-hydroxy-5-(1-methylethyl)-4'-nitro[1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




IT 447415-19-2P 447415-22-7P 447415-26-1P
447415-29-4P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
BIOL (Biological study); PREP (Preparation)

(preparation of phenylethynyl derivs. of GC-1 as thyroid hormone analogs and
their binding activity towards thyroid hormone receptors)


RN 447415-19-2 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-(phenylethynyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 447415-22-7 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-pentylphenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 447415-26-1 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-nitrophenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 447415-29-4 CAPLUS
 CN Acetic acid, [4-[[3-[(4-aminophenyl)ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




IT 446312-33-0P 446312-34-1P 446312-35-2P
 446312-36-3P 446312-37-4P 446312-38-5P
 446312-39-6P 446312-40-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of phenylethynyl derivs. of GC-1 as thyroid hormone analogs and their binding activity towards thyroid hormone receptors)


RN 446312-33-0 CAPLUS
 CN Acetic acid, [4-[[4-(methoxymethoxy)-3-(1-methylethyl)-5-(phenylethynyl)phenyl]methyl]-3,5-dimethylphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 446312-34-1 CAPLUS
 CN Acetic acid, [4-[[4-(methoxymethoxy)-3-(1-methylethyl)-5-[(4-pentylphenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 446312-35-2 CAPLUS
 CN Acetic acid, [4-[[3-iodo-4-(methoxymethoxy)-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 446312-36-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-pentylphenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 446312-37-4 CAPLUS
 CN Acetic acid, [4-[[3-[(4-aminophenyl)ethynyl]-4-(methoxymethoxy)-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 446312-38-5 CAPLUS
 CN Acetic acid, [4-[[4-(methoxymethoxy)-3-(1-methylethyl)-5-[(4-nitrophenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 446312-39-6 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-nitrophenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 446312-40-9 CAPLUS
 CN Acetic acid, [4-[[3-[(4-aminophenyl)ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 57 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:409259 CAPLUS
 DN 136:406884
 TI Ibuprofen-aspirin and hydroxymethylacylfulvene analogs
 IN Guttag, Alvin
 PA USA
 SO U.S. Pat. Appl. Publ., 7 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002065254	A1	20020530	US 2001-954853	20010918
	US 6436916	B2	20020820		
	US 2003008833	A1	20030109	US 2000-239255P	P 20001012
	US 7015247	B2	20060321	US 2002-219960	20020815
				US 2000-239255P	P 20001012
				US 2001-954853	A2 20010918
				US 2001-327282P	P 20011005

PATENT FAMILY INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003008833	A1	20030109	US 2002-219960	20020815

US 7015247 B2 20060321

US 2000-239255P P 20001012

US 2001-954853 A2 20010918

US 2001-327282P P 20011005

US 2002065254 A1 20020530

US 2001-954853 20010918

US 6436916 B2 20020820

US 2000-239255P P 20001012


OS MARPAT 136:406884

AB Ibuprofen-aspirin compds. useful in treating aspirin or ibuprofen-treatable conditions and hydroxymethylacylfulvene analogs useful as antitumor drugs are described. Thus, p-isobutylhydratropic acid ester with salicylic acid was prepared by the reaction of p-isobutylhydratropoyl chloride with salicylic acid in anhydrous ether. A typical formulation for a tablet was prepared from microcryst. cellulose 130, modified starch 20, Mg stearate 5.5, polyvinylpyrrolidone 22, stearic acid 30, and p-iso-Bu hydratropic acid ester of salicylic acid 500 mg.

IT 429681-38-9D, hydroxymethylfulvene compds. esters with
 429681-39-0D, hydroxymethylfulvene compds. esters with
 429681-40-3D, hydroxymethylfulvene compds. esters with
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ibuprofen-aspirin derivs. and hydroxymethylacylfulvene analogs for pharmaceuticals)


RN 429681-38-9 CAPLUS

CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(3,5-dichloro-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 429681-39-0 CAPLUS

CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(3,5-dibromo-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



RN 429681-40-3 CAPLUS

CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(3,5-difluoro-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



L8 ANSWER 58 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:294153 CAPLUS
 DN 136:316938
 TI Positive resist composition and process for forming resist pattern using
 photosensitive laminate
 IN Okubo, Waki; Sato, Kazufumi; Nitta, Kazuyuki; Ogata, Toshiyuki
 PA Tokyo Ohka Kogyo Co., Ltd., Japan
 SO U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U.S. Ser. No. 651,099.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002045123	A1	20020418	US 2001-799549	20010307
	US 6638684	B2	20031028		
				JP 1999-245684	A 19990831
				US 2000-651099	A2 20000830
				JP 2000-263211	A 20000831
	JP 2001142217	A2	20010525	JP 2000-263211	20000831
				JP 1999-245684	A 19990831

PATENT FAMILY INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001142217	A2	20010525	JP 2000-263211	20000831
				JP 1999-245684	A 19990831
	US 2002045123	A1	20020418	US 2001-799549	20010307
	US 6638684	B2	20031028		
				JP 1999-245684	A 19990831
				US 2000-651099	A2 20000830
				JP 2000-263211	A 20000831

OS MARPAT 136:316938


AB The present invention relates to a photosensitive laminate including a
 substrate and a 500-5800 angstroms thick photoresist layer formed on the
 substrate. A composition for the resist layer includes (A) a compound which
 generates an acid upon irradiation with radioactive ray; (B) an alkali-soluble
 novolak resin; and (C) a compound having at least one acid-decomposable
 dissoln.-inhibiting group, and the dissoln.-inhibiting group is
 decomposable by action of an acid generated from the ingredient (A) to
 yield an organic carboxylic acid. This photosensitive laminate is
 sequentially subjected to selective exposure to KrF excimer laser light or
 to light having a short wavelength equal to or less than that of F2 laser,
 post-exposure baking, and developing with an alkali to yield a resist
 pattern.

IT 340755-42-2


RL: TEM (Technical or engineered material use); USES (Uses)
 (pos. resist composition and process for forming resist pattern using
 photosensitive laminate containing)

RN 340755-42-2 CAPLUS

CN Acetic acid, 2,2'-[methylenebis[[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-
 2,5-dimethyl-3,1-phenylene]methylenes(2,5-dimethyl-3,1-phenylene)oxy]]bis-,
 bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 59 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:266689 CAPLUS
 DN 136:380441
 TI Deletion of the thyroid hormone receptor $\alpha 1$ prevents the structural alterations of the cerebellum induced by hypothyroidism
 AU Morte, Beatriz; Manzano, Jimena; Scanlan, Thomas; Vennstrom, Bjorn; Bernal, Juan
 CS Instituto de Investigaciones Biomedicas Alberto Sols, Consejo Superior de Investigaciones Cientificas-Universidad Autonoma de Madrid, Madrid, 28029, Spain
 SO Proceedings of the National Academy of Sciences of the United States of America (2002), 99(6), 3985-3989
 CODEN: PNASA6; ISSN: 0027-8424
 PB National Academy of Sciences
 DT Journal
 LA English
 AB Thyroid hormone (T3) controls critical aspects of cerebellar development, such as migration of postmitotic granule cells and terminal differentiation of Purkinje cells. T3 acts through nuclear receptors (TR) of two types, TR $\alpha 1$ and TR β , that either repress or activate gene expression. We have analyzed the cerebellar structure of developing mice lacking the TR $\alpha 1$ isoform, which normally accounts for about 80% of T3 receptors in the cerebellum. Contrary to what was expected, granule cell migration and Purkinje cell differentiation were normal in the mutant mice. Even more striking was the fact that when neonatal hypothyroidism was induced, no alterations in cerebellar structure were observed in the mutant mice, whereas the wild-type mice showed delayed granule cell migration and arrested Purkinje cell growth. The results support the idea that repression by the TR $\alpha 1$ aporeceptor, and not the lack of thyroid hormone, is responsible for the hypothyroid phenotype. This conclusion was supported by expts. with the TR β -selective compound GC-1. Treatment of hypothyroid animals with T3, which binds to TR $\alpha 1$ and TR β , prevents any defect in cerebellar structure. In contrast, treatment with GC-1, which binds to TR β but not TR $\alpha 1$, partially corrects Purkinje cell differentiation but has no effect on granule cell migration. Our data indicate that thyroid hormone has a permissive effect on cerebellar granule cell migration through derepression by the TR $\alpha 1$ isoform.
 IT 211110-63-3, GC-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (thyroid hormone receptor $\alpha 1$ deletion prevents structural alterations of cerebellum induced by hypothyroidism in developing mice)
 RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 60 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:131262 CAPLUS
DN 136:207677
TI Positive-working photoresist compositions and substrates equipped with
photoresist layers
IN Ogata, Toshiyuki; Endo, Kotaro; Komano, Hiroshi
PA Tokyo Ohka Kogyo Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002055452	A2	20020220	JP 2000-240871	20000809
	US 2002025495	A1	20020228	US 2001-922723	20010807
	US 6787284	B2	20040907		
	US 2004152860	A1	20040805	JP 2000-240871	A 20000809
				US 2003-748190	20031231
				JP 2000-240871	A 20000809
				US 2001-922723	A3 20010807
	US 2005123854	A1	20050609	US 2005-35965	20050118
				JP 2000-240871	A 20000809
				US 2001-922723	A3 20010807
				US 2003-748190	A3 20031231
	JP 2005330488	A2	20051202	JP 2005-146860	20050519
				JP 2000-240871	A3 20000809

OS MARPAT 136:207677
AB The compns. contain (A) alkaline-soluble polysiloxanes, (B) radiation-activated photoacid generators, and (C) compds. with their H on phenolic OH or carboxyl groups substituted with ≥ 1 acid dissociative groups. Preferable compds. for component (C) is given in Markush I (Z = OH, carboxyl; R1-3 = H, OH, halogen, C1-5 alkoxy, C1-6 linear, branched, or cyclic alkyl; A = direct bond, (carboxyl-substituted) C1-5 alkylene or C2-5 alkylidene, carbonyl, Q, Q1, Q2; R4 = H, C1-5 alkyl; R5-6 = H, halogen, OH, C1-5 alkyl or alkoxy; R7-8 = C1-5 alkyl; R9-10 = H, OH, C1-5 alkyl; m = integer of 1-6) with its H on Z substituted with tertiary alkyloxycarbonylalkyl, tertiary alkyloxycarbonyl, tertiary alkyl, cyclic ether, and/or alkoxyalkyl. Substrates with a 1st resist layer consisting of an organic polymer and a 2nd 50-200 nm-thick resist layer comprising the claimed compns. are also claimed. Resist patterns with high resolution and excellent profiles are formed by irradiation with excimer lasers or extreme UV beams.
IT 303108-81-8 340755-42-2
RL: TEM (Technical or engineered material use); USES (Uses)
(alkaline-soluble polysiloxane-based pos. photoresist compns. containing photoacid

generators and acid-dissociative compds.)


RN 303108-81-8 CAPLUS

CN Acetic acid, 2,2'-[[[(2-hydroxyphenyl)methylene]bis[(2-cyclohexyl-5-methyl-4,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 340755-42-2 CAPLUS

CN Acetic acid, 2,2'-[methylenebis[[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2,5-dimethyl-3,1-phenylene]methylene(2,5-dimethyl-3,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 61 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:900234 CAPLUS

DN 136:340462

TI Synthesis and biological activity of novel thyroid hormone analogues: 5'-aryl substituted GC-1 derivatives

AU Chiellini, Grazia; Nguyen, Ngoc-Ha; Apriletti, James W.; Baxter, John D.; Scanlan, Thomas S.

CS Departments of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology, University of California, San Francisco, CA, 94143-0446, USA

SO Bioorganic & Medicinal Chemistry (2001), volume Date 2002, 10(2), 333-346 CODEN: BMECEP; ISSN: 0968-0896

PB Elsevier Science Ltd.

DT Journal

LA English

OS CASREACT 136:340462

AB Biphenylmethylphenoxyacetic acids I [R = 4-NO₂, 4-NHCH₂CO₂H, 4-NHCONHPh, 4-NHCH₂C.tplbond.CMe, 4-NH₂, 3-NO₂, 2-NO₂, 4-CO₂H, 4-CONH₂, 4-NHC(:NH)NH₂] were prepared via arylation of the diphenylmethaneboronic acid. Substitution at the 5'-position decreased binding affinity, but retained TRβ-selectivity for most of the compds. Transactivation assays


reveal that most of these compds. function as thyroid hormone agonists, but I [R = 4-NO₂] antagonizes the response to thyroid hormone.

IT 417871-97-7P 417872-05-0P 417872-10-7P
417872-14-1P 417872-18-5P 417872-30-1P
417872-38-9P 417872-45-8P 417872-54-9P
417872-67-4P 447415-34-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of biphenylmethylphenoxyacetic acids as thyroid hormone analogs)


RN 417871-97-7 CAPLUS

CN Acetic acid, [4-[[6-hydroxy-5-(1-methylethyl)[1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 417872-05-0 CAPLUS

CN Acetic acid, [4-[[6-hydroxy-5-(1-methylethyl)-3'-nitro[1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 417872-10-7 CAPLUS

CN Acetic acid, [4-[[6-hydroxy-5-(1-methylethyl)-2'-nitro[1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 417872-14-1 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid, 5'--[[4-(carboxymethoxy)-2,6-dimethylphenyl]methyl]-2'-hydroxy-3'-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 417872-18-5 CAPLUS
 CN Acetic acid, [4-[[4'-(aminocarbonyl)-6-hydroxy-5-(1-methylethyl)[1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]-(9CI) (CA INDEX NAME)




RN 417872-30-1 CAPLUS
 CN Glycine, N-[5'-[[4-(carboxymethoxy)-2,6-dimethylphenyl]methyl]-2'-hydroxy-3'-(1-methylethyl)[1,1'-biphenyl]-4-yl]-(9CI) (CA INDEX NAME)




RN 417872-38-9 CAPLUS
 CN Acetic acid, [4-[[6-hydroxy-5-(1-methylethyl)-4'-[[[(phenylamino)carbonyl]amino][1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]-(9CI) (CA INDEX NAME)




RN 417872-45-8 CAPLUS
 CN Acetic acid, [4-[[4'-(2-butynylamino)-6-hydroxy-5-(1-methylethyl)[1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 417872-54-9 CAPLUS
 CN Acetic acid, [4-[[4'-amino-6-hydroxy-5-(1-methylethyl)[1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RN 417872-67-4 CAPLUS
 CN Acetic acid, [4-[[4'-[(aminoiminomethyl)amino]-6-hydroxy-5-(1-methylethyl)[1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 447415-34-1 CAPLUS
 CN Acetic acid, [4-[[6-hydroxy-5-(1-methylethyl)-4'-nitro[1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




IT 417871-72-8P 417871-76-2P 417871-80-8P
 417871-84-2P 417871-88-6P 417871-93-3P
 417872-26-5P 417872-49-2P 417872-64-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of biphenylmethylphenoxyacetic acids as thyroid hormone
 analogs)


RN 417871-72-8 CAPLUS
 CN Acetic acid, [4-[[6-(methoxymethoxy)-5-(1-methylethyl)[1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 417871-76-2 CAPLUS
 CN Acetic acid, [4-[[6-(methoxymethoxy)-5-(1-methylethyl)-4'-nitro[1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 417871-80-8 CAPLUS
 CN Acetic acid, [4-[[6-(methoxymethoxy)-5-(1-methylethyl)-3'-nitro[1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 417871-84-2 CAPLUS
 CN Acetic acid, [4-[[6-(methoxymethoxy)-5-(1-methylethyl)-2'-nitro[1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


NAME)




RN 417871-88-6 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxylic acid, 5'-[[4-(2-ethoxy-2-oxoethoxy)-2,6-dimethylphenyl]methyl]-2'-(methoxymethoxy)-3'-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 417871-93-3 CAPLUS
 CN Acetic acid, [4-[[4'-(aminocarbonyl)-6-(methoxymethoxy)-5-(1-methylethyl)][1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 417872-26-5 CAPLUS
 CN Glycine, N-[5'-[[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2,6-dimethylphenyl]methyl]-2'-(methoxymethoxy)-3'-(1-methylethyl)][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN	417872-49-2	CAPLUS
CN	Acetic acid, [4-[[4'-amino-6-(methoxymethoxy)-5-(1-methylethyl)][1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)	



RN	417872-64-1	CAPLUS
CN	Acetic acid, [4-[[[4'-[[[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]amino]-6-(methoxymethoxy)-5-(1-methylethyl)[1,1'-biphenyl]-3-yl]methyl]-3,5-dimethylphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)	


PAGE 1-A






RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 62 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:746604 CAPLUS
DN 136:145158
TI A designed antagonist of the thyroid hormone receptor
AU Yoshihara, H. A. I.; Apriletti, J. W.; Baxter, J. D.; Scanlan, T. S.
CS Departments of Pharmaceutical Chemistry and Cellular & Molecular
Pharmacology, University of California, San Francisco, CA, 94143-0446, USA
SO Bioorganic & Medicinal Chemistry Letters (2001), 11(21), 2821-2825
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
AB An analog of the thyromimetic GC-1 bearing the same hydrophobic appendage
as the estrogen receptor antagonist ICI-164,384 was prepared while having
reduced affinity for the thyroid hormone receptors compared to GC-1, it
behaves in a manner consistent with a competitive antagonist in a
transactivation assay.
IT 211110-63-3D, GC 1, analogs
RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation and structure activity relations of GC-1 analogs as antagonists
of thyroid hormone receptor)
RN 211110-63-3 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-
dimethylphenoxy]- (9CI) (CA INDEX NAME)




IT 253329-29-2P 253329-32-7P 253329-33-8P
253329-34-9P 393836-17-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(preparation and structure activity relations of GC-1 analogs as antagonists
of thyroid hormone receptor)
RN 253329-29-2 CAPLUS
CN Acetic acid, [4-[12-(butylmethylamino)-1-[4-hydroxy-3-(1-
methylethyl)phenyl]-12-oxododecyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX
NAME)




RN 253329-32-7 CAPLUS

CN Acetic acid, [4-[1-[4-hydroxy-3-(1-methylethyl)phenyl]-3-butenyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 253329-33-8 CAPLUS

CN Acetic acid, [4-[4-hydroxy-1-[4-hydroxy-3-(1-methylethyl)phenyl]butyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 253329-34-9 CAPLUS



CN Acetic acid, [4-[(2,4-dimethoxyphenyl)[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 393836-17-4 CAPLUS
 CN Acetic acid, [4-[12-(butylmethylamino)-1-[4-hydroxy-3-(1-methylethyl)phenyl]-12-oxo-4-dodecenyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




IT 253329-15-6P 253329-20-3P 253329-21-4P
 253329-23-6P 253329-31-6P 393836-15-2P
 393836-16-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and structure activity relations of GC-1 analogs as antagonists of thyroid hormone receptor)
 RN 253329-15-6 CAPLUS
 CN Acetic acid, [3,5-dimethyl-4-[1-[3-(1-methylethyl)-4-[[tris(1-methylethyl)silyl]oxy]phenyl]-4-oxobutyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 253329-20-3 CAPLUS
 CN Acetic acid, [3,5-dimethyl-4-[1-[3-(1-methylethyl)-4-[[tris(1-methylethyl)silyl]oxy]phenyl]-3-butenyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 253329-21-4 CAPLUS
 CN Acetic acid, [4-[4-hydroxy-1-[3-(1-methylethyl)-4-[[tris(1-methylethyl)silyl]oxy]phenyl]butyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 253329-23-6 CAPLUS
 CN Acetic acid, [4-[methoxy[3-(1-methylethyl)-4-[[tris(1-methylethyl)silyl]oxy]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 253329-31-6 CAPLUS
 CN Acetic acid, [4-[methoxy[3-(1-methylethyl)-4-[[tris(1-methylethyl)silyl]oxy]phenyl]methyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 393836-15-2 CAPLUS
 CN Acetic acid, [4-[(2,4-dimethoxyphenyl)[3-(1-methylethyl)-4-[[tris(1-methylethyl)silyl]oxy]phenyl]methyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 393836-16-3 CAPLUS
 CN Acetic acid, [4-[(12-(butylmethylamino)-1-[3-(1-methylethyl)-4-[[tris(1-methylethyl)silyl]oxy]phenyl]-12-oxo-4-dodecenyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 63 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:482817 CAPLUS
 DN 135:205767
 TI Thyroid hormone-sympathetic interaction and adaptive thermogenesis are thyroid hormone receptor isoform-specific
 AU Ribeiro, Miriam O.; Carvalho, Suzy D.; Schultz, James J.; Chiellini, Grazia; Scanlan, Thomas S.; Bianco, Antonio C.; Brent, Gregory A.

CS Molecular Endocrinology Laboratory, Veterans Affairs Greater Los Angeles Healthcare System and Departments of Medicine and Physiology, UCLA School of Medicine, Los Angeles, CA, USA

SO Journal of Clinical Investigation (2001), 108(1), 97-105
CODEN: JCINAO; ISSN: 0021-9738

PB American Society for Clinical Investigation

DT Journal


LA English

AB In newborns and small mammals, cold-induced adaptive (or nonshivering) thermogenesis is produced primarily in brown adipose tissue (BAT). Heat production is stimulated by the sympathetic nervous system, but it has an absolute requirement for thyroid hormone. The authors used the thyroid hormone receptor- β -selective (TR- β -selective) ligand, GC-1, to determine by a pharmacol. approach whether adaptive thermogenesis was TR isoform-specific. Hypothyroid mice were treated for 10 days with varying doses of T3 or GC-1. The level of uncoupling protein 1 (UCP1), the key thermogenic protein in BAT, was restored by either T3 or GC-1 treatment. However, whereas interscapular BAT in T3-treated mice showed a 3.0 °C elevation upon infusion of norepinephrine, indicating normal thermogenesis, the temperature did not increase (<0.5 °C) in GC-1-treated mice. When exposed to cold (4 °C), GC-1-treated mice also failed to maintain core body temperature and had reduced stimulation of BAT UCP1 mRNA, indicating impaired adrenergic responsiveness. Brown adipocytes isolated from hypothyroid mice replaced with T3, but not from those replaced with GC-1, had normal cAMP production in response to adrenergic stimulation in vitro. The authors conclude that two distinct thyroid-dependent pathways, stimulation of UCP1 and augmentation of adrenergic responsiveness, are mediated by different TR isoforms in the same tissue.

IT 211110-63-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(thyroid hormone-sympathetic interaction and adaptive thermogenesis are thyroid hormone receptor isoform-specific)

RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 64 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:379722 CAPLUS

DN 134:374053

TI Photosensitive substrate, formation of resist pattern, and positive-working resist composition

IN Okubo, Kazuyoshi; Sato, Kazushi; Nitta, Kazuyuki; Ogata, Toshiyuki

PA Tokyo Ohka Kogyo Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF

DT Patent
LA Japanese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001142217	A2	20010525	JP 2000-263211	20000831
				JP 1999-245684	A 19990831
	US 2002045123	A1	20020418	US 2001-799549	20010307
	US 6638684	B2	20031028		
				JP 1999-245684	A 19990831
				US 2000-651099	A2 20000830
			JP 2000-263211	A 20000831	

PATENT FAMILY INFORMATION:

FAN 2002:294153

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002045123	A1	20020418	US 2001-799549	20010307
	US 6638684	B2	20031028		
				JP 1999-245684	A 19990831
				US 2000-651099	A2 20000830
				JP 2000-263211	A 20000831
				JP 2000-263211	20000831
	JP 2001142217	A2	20010525	JP 2000-263211	20000831
				JP 1999-245684	A 19990831

AB The photosensitive substrate has a 500-5,800 Å-thick resist layer on a support, wherein resist composition comprises (A) a photoacid, (B) an alkaline soluble

novolak resin, and (C) a compound which contains ≥ 1 acid-decomposable solubility-suppressing group and releases an organic carboxylic acid upon reaction


with an acid generated from the photoacid. The photosensitive substrate is exposed by a KrF excimer laser, a F2 laser, or a laser having a lower wavelength. This photosensitive substrate showed excellent dry etching resistance and high sensitivity.

IT 340755-42-2

RL: TEM (Technical or engineered material use); USES (Uses)
(pos.-working photoresist composition from)

RN 340755-42-2 CAPLUS

CN Acetic acid, 2,2'-[methylenebis[[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2,5-dimethyl-3,1-phenylene]methylene(2,5-dimethyl-3,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




L8 ANSWER 65 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:184292 CAPLUS
DN 134:231960
TI Hormone selectivity in thyroid hormone receptors

AU Wagner, Richard L.; Huber, B. Russell; Shiau, Andrew K.; Kelly, Alex; Lima, Suzana T. Cunha; Scanlan, Thomas S.; Apriletti, James W.; Baxter, John D.; West, Brian L.; Fletterick, Robert J.
 CS Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, 94143, USA
 SO Molecular Endocrinology (2001), 15(3), 398-410
 CODEN: MOENEN; ISSN: 0888-8809
 PB Endocrine Society
 DT Journal
 LA English
 AB Sep. genes encode thyroid hormone receptor subtypes TR α (NR1A1) and TR β (NR1A2). Products from each of these contribute to hormone action, but the subtypes differ in tissue distribution and physiolo. response. Compds. that discriminate between these subtypes in vivo may be useful in treating important medical problems such as obesity and hypercholesterolemia. We previously determined the crystal structure of the rat (r) TR α ligand-binding domain (LBD). In the present study, we determined the crystal structure of the rTR α LBD in a complex with an addnl. ligand, Triac (3,5, 3'-triiodothyroacetic acid), and two crystal structures of the human (h) TR β receptor LBD in a complex with either Triac or a TR β -selective compound, GC-1. The rTR α and hTR β LBDs show close structural similarity. However, the hTR β structures extend into the DNA-binding domain and allow definition of a structural "hinge" region of only three amino acids. The two TR subtypes differ in the loop between helices 1 and 3, which could affect both ligand recognition and the effects of ligand in binding coactivators and corepressors. The two subtypes also differ in a single amino acid residue in the hormone-binding pocket, Asn (TR β) for Ser (TR α). Studies here with TRs in which the subtype-specific residue is exchanged suggest that most of the selectivity in binding derives from this amino acid difference. The flexibility of the polar region in the TR β receptor, combined with differential recognition of the chemical group at the 1-carbon position, seems to stabilize the complex with GC-1 and contribute to its β -selectivity. These results suggest a strategy for development of subtype-specific compds. involving modifications of the ligand at the 1-position.

IT 211110-63-3
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
 (hormone selectivity in thyroid hormone receptors)

RN 211110-63-3 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 66 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:137023 CAPLUS
 DN 134:178552

TI 3(5)-Acylaminopyrazole derivatives, process for their preparation and
 their use as antitumor agents
 IN Pevarello, Paolo; Orsini, Paolo; Traquandi, Gabriella; Varasi, Mario;
 Fritzen, Edward L.; Warpehoski, Martha A.; Pierce, Betsy S.; Brasca, Maria
 Grabriella
 PA Pharmacia & Upjohn S.p.A., Italy; Pharmacia & Upjohn Company
 SO PCT Int. Appl., 123 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012189	A1	20010222	WO 2000-US6699	20000505
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2383555	AA	20010222	US 1999-372831	A 19990812
				CA 2000-2383555	20000505
				US 1999-372831	A 19990812
	AU 2000049714	A5	20010313	WO 2000-US6699	W 20000505
				AU 2000-49714	20000505
				US 1999-372831	A 19990812
	EP 1202733	A1	20020508	WO 2000-US6699	W 20000505
	EP 1202733	B1	20051005	EP 2000-931906	20000505
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
				US 1999-372831	A 19990812
	BR 2000013143	A	20020611	WO 2000-US6699	W 20000505
				BR 2000-13143	20000505
				US 1999-372831	A 19990812
	JP 2003507329	T2	20030225	WO 2000-US6699	W 20000505
				JP 2001-516535	20000505
				US 1999-372831	A 19990812
	EE 200200065	A	20030415	WO 2000-US6699	W 20000505
				EE 2002-65	20000505
				US 1999-372831	A 19990812
	NZ 517237	A	20040227	WO 2000-US6699	W 20000505
				NZ 2000-517237	20000505
				US 1999-372831	A 19990812
	AT 305782	E	20051015	WO 2000-US6699	W 20000505
				AT 2000-931906	20000505
				US 1999-372831	A 19990812
	ES 2249270	T3	20060401	WO 2000-US6699	W 20000505
				ES 2000-931906	20000505
	US 6218418	B1	20010417	US 1999-372831	A 19990812
				US 2000-667603	20000922
				US 1999-372831	A1 19990812
				US 2000-560400	A1 20000428
	NO 2002000684	A	20020403	NO 2002-684	20020211
				US 1999-372831	A 19990812
	HR 2002000128	A1	20030430	WO 2000-US6699	W 20000505
				HR 2002-128	20020212
				US 1999-372831	A 19990812
				WO 2000-US6699	W 20000505

ZA 2002001511	A	20030311	ZA 2002-1511	20020222
BG 106480	A	20020930	US 1999-372831	A 19990812
			BG 2002-106480	20020305
			US 1999-372831	A 19990812
US 7034049	B1	20060425	WO 2000-US6699	W 20000505
			US 2002-48486	20020501
			US 1999-372831	B2 19990812
			WO 2000-US6699	W 20000505

PATENT FAMILY INFORMATION:

FAN 2006:374223

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 7034049	B1	20060425	US 2002-48486	20020501
				US 1999-372831	B2 19990812
				WO 2000-US6699	W 20000505
	WO 2001012189	A1	20010222	WO 2000-US6699	20000505
	W:			AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZW	
	RW:			GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
	US 6218418	B1	20010417	US 1999-372831	A 19990812
				US 2000-667603	20000922
				US 1999-372831	A1 19990812
				US 2000-560400	A1 20000428


OS MARPAT 134:178552

AB Compds. which are 3-acylaminopyrazole derivs. (I; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-2,2-diphenylacetamide) wherein R is C3-C6 cycloalkyl group optionally substituted by a straight or branched C1-C6 alkyl or arylalkyl group; R1 is a straight or branched C1-C6 alkyl, C2-C4 alkenyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, arylalkyl, arylcarbonyl, aryloxyalkyl or arylalkenyl group, each of which may be optionally further substituted as indicated in the description; or a pharmaceutically acceptable salt thereof, processes for their preparation and their therapeutic uses. The compds. are useful for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases, but no quant. test results are presented. The cancer is selected from carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer and Kaposi's sarcoma. The cell proliferative disorder is selected from benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis. The method of treatment provides tumor angiogenesis and metastasis inhibition, cell cycle inhibition or cdk/cyclin dependent inhibition, and treatment or prevention of radiotherapy-induced or chemotherapy-induced alopecia. A process for preparing the 3-aminopyrazole derivative or the pharmaceutically acceptable salt thereof, comprising: (a) reacting RCO₂R₂ (R₂ = alkyl), with MeCN in the presence of a basic agent, to obtain RC(O)CH₂CN; (b) reacting RC(O)CH₂CN with hydrazine hydrate to obtain an 3-amino-5-R-1H-pyrazole; (c) oxidizing the 3-amino-5-R-1H-pyrazole to obtain the nitro analog; (d) reacting the nitro compound with tert-butoxycarbonyl anhydride (Boc₂O) to obtain the N-Boc derivative; (e) reducing this BOC derivative to obtain the amino analog;

(f)

reacting this amino compound with $R1C(O)X$ ($X = OH$ or a suitable leaving group) to obtain the N1-Boc-protected I; and (g) hydrolyzing this intermediate in an acidic medium to obtain I. Other methods of preparation are also claimed.

IT 326822-92-8P, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-2-[5-(2,6-difluorobenzyl)-2-methoxyphenyl]acetamide
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (acylamino pyrazole derivs., process for preparation and use as antitumor agents)
 RN 326822-92-8 CAPLUS
 CN Benzeneacetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-5-[(2,6-difluorophenyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 67 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:67039 CAPLUS
 DN 134:126317
 TI A subtype-selective thyromimetic designed to bind a mutant thyroid hormone receptor implicated in resistance to thyroid hormone
 AU Ye, Hai Fen; O'Reilly, Kathryn E.; Koh, John T.
 CS Department of Chemistry and Biochemistry, University of Delaware, Newark, DE, 19716, USA
 SO Journal of the American Chemical Society (2001), 123(7), 1521-1522
 CODEN: JACSAT; ISSN: 0002-7863
 PB American Chemical Society
 DT Journal
 LA English
 AB The authors demonstrate that by using a known receptor agonists as a structural scaffold, potent (nanomolar active) hormone analogs can be rationally designed to complement a mutant form of the human thyroid hormone receptor beta (hTR β) implicated in the genetic disease resistance to thyroid hormone (RTH). The RTH-associated mutation, TR β (R320C) exhibits a reduced affinity for triiodothyronine (T3). Furthermore, concns. of T3 required to significantly activate the mutant TR β (R320C), impart an undesirable saturating response to TR α -mediated transactivation ($EC_{50} = 0.14 \pm 0.24$ nM). Therefore, compds. having high affinity and selectivity for mutant forms of TR β over the α -subtype are sought for RTH therapy. The potent nonhalogenated thyromimetic GC1 shows a significantly reduced activity toward the mutant receptor TR β (R320C) ($EC_{50} = 37.7 \pm 10.8$ nM) than to the TR β (Wt) ($EC_{50} 3.67 \pm 1.1$ nM) in cultured cells and is therefore no longer selective for the mutant β -subtype over TR α (Wt) ($EC_{50} = 6.6 \pm 1.0$ nM). On the basis of site-models generated from the coordinates of the T3/TR β crystal structure, the authors designed the neutral alc. HY1 as a potential subtype-selective ligand for the mutant receptor hTR β (R320C). Assays of

transactivation function show that HY1 ($EC_{50} = 7.01 \pm 3.0$ nM) is 5-times more potent an agonist toward TR β (R320C) than the parent compound GC1, indicating that the authors' designed ligand was indeed more potent than GC1. Importantly, HY1 is also capable of eliciting substantial transactivation response from the mutant TR β at concns. that show only partial activation of TR α ($EC_{50} = 37.69 \pm 10.4$ nM) and TR β ($EC_{50} = 32.05 \pm 8.7$ nM). Although even greater levels of subtype-selectivity may be desirable, these data suggest that HY1 may have unique potential as a therapeutic capable of recovering activity from the mutant form of TR β while potentially avoiding the undesirable side effects associated with TR α over stimulation. This work demonstrates that by making compensatory modifications to known hormone agonists, new, highly potent ligands can be made which are selective for mutant receptors implicated in human disease. Although in principle this general strategy may require a unique drug to be designed for each mutation associated with a particular disease, as demonstrated by this work on hTR β , similar design strategies may be used to complement structurally similar mutations in related receptors.


IT 211110-63-3

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(subtype-selective thyromimetic designed to bind mutant thyroid hormone receptor implicated in resistance to thyroid hormone)

RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 68 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:861461 CAPLUS

DN 134:32764

TI Method of treating hair loss using diphenylmethane derivatives

IN Zhang, Lixin Lilly; Youngquist, Robert Scott

PA Procter and Gamble Company, USA

SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000072813	A1	20001207	WO 2000-US5254	20000301
	W: AU, BR, CA, CN, JP, KR, MX, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2374266	AA	20001207	US 1999-137024P CA 2000-2374266	P 19990601 20000301

			US 1999-137024P	P	19990601
			WO 2000-US5254	W	20000301
AU 2000035078	A5	20001218	AU 2000-35078		20000301
			US 1999-137024P	P	19990601
			WO 2000-US5254	W	20000301
EP 1185231	A1	20020313	EP 2000-913678		20000301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
			US 1999-137024P	P	19990601
			WO 2000-US5254	W	20000301
JP 2003500433	T2	20030107	JP 2000-620925		20000301
			US 1999-137024P	P	19990601
			WO 2000-US5254	W	20000301
US 6680344	B1	20040120	US 2002-980407		20020329
			US 1999-137024P	P	19990601
			WO 2000-US5254	W	20000301

OS MARPAT 134:32764


AB The present disclosure describes methods for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth. The methods comprise administering a cardiac-sparing diphenylmethane derivative and a pharmaceutically-acceptable carrier. A topical composition contained (3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy)acetic acid 5, EtOH 97, propylene glycol 19, and di-Me isosorbide 19%. A human male subject suffering from male pattern baldness was treated by the above formulation.

IT 211110-63-3

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diphenylmethane derivs. for treating hair loss)

RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 69 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:832454 CAPLUS

DN 134:207586

TI Improved synthesis of the iodine-free thyromimetic GC-1

AU Chiellini, G.; Nguyen, N.-H.; Yoshihara, H. A. I.; Scanlan, T. S.

CS Departments of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology, University of California, San Francisco, CA, 94143-0446, USA

SO Bioorganic & Medicinal Chemistry Letters (2000), 10(23), 2607-2611

CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English

OS CASREACT 134:207586

AB Synthesis of the thyroid hormone receptor β -selective thyromimetic


GC-1, [3,5-dimethyl-4-(4-hydroxy-3-isopropylbenzyl)phenoxy]acetate, was improved using methoxymethyl (MOM) and triisopropylsilyl (TIPS) substituents as phenolic protecting groups. The new synthetic route is adaptable to analog design.

IT 328236-48-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thyromimetic GC-1)

RN 328236-48-2 CAPLUS

CN Acetic acid, [4-[[4-(methoxymethoxy)-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 211110-63-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of thyromimetic GC-1)

RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 70 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:780898 CAPLUS

DN 133:321704

TI Preparation of partially protective trisphenols for dissolution inhibitors of photoresists

IN Shiomi, Yasukazu; Miyagi, Sachiko

PA Honshu Chemical Industry Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 14 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000309561	A2	20001107	JP 1999-247755	19990901
				JP 1999-49016	A 19990225
	WO 2004103950	A1	20041202	WO 2000-JP1079	20000224

W: US

			JP 1999-49016	A	19990225
			JP 1999-247755	A	19990901
US 6603029	B1	20030805	US 2000-673886		20001218
			JP 1999-49016	A	19990225
			JP 1999-247755	A	19990901
			WO 2000-JP1079	W	20000224

OS CASREACT 133:321704; MARPAT 133:321704


AB Title compds. I (R1 = C1-4 alkyl, alkoxy; R2 = C1-6 alkyl, C5-6 cycloalkyl; X = (C1-4 alkoxy)carbonylmethyl, (C1-4 alkoxy)carbonyl, tetrahydropyranyl; m = 0-2; n = 0-3), useful for dissoln. inhibitors of chemical amplification photoresists (no data), are prepared by reaction of aldehydes II (R1, m = same as I) with benzyl halides in the presence of alkalies, reaction of resulting benzyloxybenzaldehydes with phenols III (R2, n = same as I) in the presence of acid catalysts, protection of two OH groups of resulting monobenzylated trisphenols with protecting agents selected from C1-4 alkyl haloacetates, di(C1-4 alkyl) carbonates, and 2,3-dihydro-4-H-pyran, and hydrogenolysis of protected trisphenols in the presence of catalysts. Salicylaldehyde was etherified with benzyl chloride in DMF in the presence of K₂CO₃ at 70° for 2 h, condensed with 2-cyclohexyl-5-methylphenol in MeOH in the presence of HCl at 60° for 3 h, protected with tert-Bu chloroacetate in DMF in the presence of K₂CO₃ at 70-100° for 28 h, and hydrogenated in the presence of Pd/C in THF at 40° for 8 h to give 4,4'-bis(1-tert-butoxycarbonylmethoxy-2-cyclohexyl-5-methylphenyl)methyl-2-hydroxybenzene in 77.2% total yield.

IT 303108-83-0P 303108-91-0P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of partially protective trisphenols by condensation of benzyloxybenzaldehydes with phenols and protection)


RN 303108-83-0 CAPLUS

CN Acetic acid, 2,2'-[[[2-(phenylmethoxy)phenyl]methylene]bis[(2-cyclohexyl-5-methyl-4,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 303108-91-0 CAPLUS


CN Acetic acid, 2,2'-[[[3-methoxy-4-(phenylmethoxy)phenyl]methylene]bis[(3,5-dimethyl-2,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



IT 303108-81-8P 303108-89-6P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); TEM
 (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (preparation of partially protective trisphenols by condensation of
 benzyloxybenzaldehydes with phenols and protection)
 RN 303108-81-8 CAPLUS
 CN Acetic acid, 2,2'-[[[(2-hydroxyphenyl)methylene]bis[(2-cyclohexyl-5-methyl-
 4,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX
 NAME)




RN 303108-89-6 CAPLUS
 CN Acetic acid, 2,2'-[[[(4-hydroxy-3-methoxyphenyl)methylene]bis[(3,5-dimethyl-
 2,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX
 NAME)



L8 ANSWER 71 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:603809 CAPLUS
 DN 133:233130
 TI The thyroid hormone receptor- β -selective agonist GC-1 differentially affects plasma lipids and cardiac activity
 AU Trost, Susanne U.; Swanson, Eric; Gloss, Bernd; Wang-Iverson, David B.; Zhang, Hongjiang; Volodarsky, Tanya; Grover, Gary J.; Baxter, John D.; Chiellini, Grazia; Scanlan, Thomas S.; Dillmann, Wolfgang H.
 CS Department of Medicine, University of California, San Diego, CA, 92093-0618, USA
 SO Endocrinology (2000), 141(9), 3057-3064
 CODEN: ENDOAO; ISSN: 0013-7227
 PB Endocrine Society
 DT Journal
 LA English
 AB Thyroid hormones influence the function of many organs and mediate their diverse actions through two types of thyroid hormone receptors, TR α and TR β . Little is known about effects of ligands that preferentially interact with the two different TR subtypes. In the current study the comparison of the effects of the novel synthetic TR β -selective compound GC-1 with T3 at equimolar doses in hypothyroid mice revealed that GC-1 had better triglyceride-lowering and similar cholesterol-lowering effects than T3. T3, but not GC-1, increased heart rate and elevated mRNA levels coding for the If channel (HCN2), a cardiac pacemaker that was decreased in hypothyroid mice. T3 had a larger pos. inotropic effect than GC-1. T3, but not GC-1, normalized heart and body wts. and mRNAs of myosin heavy chain α and β and the sarcoplasmic reticulum ATPase (Serca2). Addnl. dose-response studies in hypercholesteremic rats confirmed the preferential effect of GC-1 on TR β -mediated parameters by showing a much higher potency to influence cholesterol and TSH than heart rate. The preferred accumulation of GC-1 in the liver vs. the heart probably also contributes to its marked lipid-lowering effect vs. the absent effect on heart rate. These data indicate that GC-1 could represent a prototype for new drugs for the treatment of high lipid levels or obesity.
 IT 211110-63-3
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (thyroid hormone receptor- β -selective agonist GC-1 differentially affects plasma lipids and cardiac activity)
 RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 72 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:573897 CAPLUS
DN 133:174260
TI Luminescent metal-ligand complexes
IN Terpetschnig, Ewald A.; Yang, Dan-hui; Owicki, John C.
PA Ljl Biosystems, Inc., USA
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 26

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047693	A1	20000817	WO 2000-US3589	20000211
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 1999-119884P	P 19990212
			US 1999-165813P	P 19991116
US 2001021514	A1	20010913	US 2001-767583	20010122
			US 1999-119884P	P 19990212
			US 1999-165813P	P 19991116
			WO 2000-US3589	A1 20000211

PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004364	A2	20000127	WO 1999-US16057	19990715
WO 2000004364	A3	20000908		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			WO 1998-US14575	W 19980715
			US 1998-93838P	P 19980722

EP 1032813	A2	20000906	US 1998-160533	A	19980924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			EP 1998-959374		19980709
			US 1997-63811P	P	19971031
			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75414P	P	19980220
			US 1998-75806P	P	19980224
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-84167P	P	19980504
			US 1998-85335P	P	19980513
			US 1998-85500P	P	19980514
			US 1998-89848P	P	19980619
			US 1998-92203P	P	19980709
			US 1998-94275P	P	19980709
			US 1998-94276P	P	19980727
			US 1998-100817P	P	19980918
			US 1998-100951P	P	19980918
			US 1998-156318	A	19980918
			US 1998-160533	A	19980924
			US 1998-104964P	P	19981020
			WO 1998-US23095	W	19981030
WO 9904228	A2	19990128	WO 1998-US14575		19980715
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
			US 1997-52876P	P	19970716
			US 1997-59639P	P	19970920
			US 1997-63811P	P	19971031
			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75414P	P	19980220
			US 1998-75806P	P	19980224
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-84167P	P	19980504
			US 1998-85335P	P	19980513
			US 1998-85500P	P	19980514
			US 1998-89848P	P	19980619
EP 1012579	A2	20000628	EP 1998-935657		19980715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
			US 1997-52876P	P	19970716
			US 1997-59639P	P	19970920
			US 1997-63811P	P	19971031
			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75414P	P	19980220
			US 1998-75806P	P	19980224
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-84167P	P	19980504
			US 1998-85335P	P	19980513
			US 1998-85500P	P	19980514

JP 2002509235	T2	20020326	US 1998-89848P	P	19980619
			WO 1998-US14575	W	19980715
			JP 2000-503394		19980715
			US 1997-52876P	P	19970716
			US 1997-59639P	P	19970920
			US 1997-63811P	P	19971031
			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75414P	P	19980220
			US 1998-75806P	P	19980224
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-84167P	P	19980504
			US 1998-85335P	P	19980513
			US 1998-85500P	P	19980514
			US 1998-89848P	P	19980619
			WO 1998-US14575	W	19980715
			AU 1999-15184		19981029
			US 1997-63811P	P	19971031
			US 1998-72499P	P	19980126
AU 9915184	A1	19990524	US 1998-72780P	P	19980127
			US 1998-75414P	P	19980220
			US 1998-75806P	P	19980224
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-84167P	P	19980504
			US 1998-85335P	P	19980513
			US 1998-85500P	P	19980514
			US 1998-89848P	P	19980619
			US 1998-92203P	P	19980709
			US 1998-94275P	P	19980727
			US 1998-94276P	P	19980727
			US 1998-100817P	P	19980918
			US 1998-100951P	P	19980918
			US 1998-156318	A	19980918
			US 1998-160533	A	19980924
			US 1998-104964P	P	19981020
			WO 1998-US23095	W	19981030
			JP 2000-519281		19981030
			US 1997-63811P	P	19971031
JP 2003521670	T2	20030715	US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75414P	P	19980220
			US 1998-75806P	P	19980224
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-84167P	P	19980504
			US 1998-85335P	P	19980513
			US 1998-85500P	P	19980514
			US 1998-89848P	P	19980619
			US 1998-92203P	P	19980709
			US 1998-94275P	P	19980727
			US 1998-94276P	P	19980727
			US 1998-100817P	P	19980918
			US 1998-100951P	P	19980918
			US 1998-156318	A	19980918
			US 1998-160533	A	19980924
			US 1998-104964P	P	19981020
			WO 1998-US23095	W	19981030
			AU 1999-23448		19990125
AU 9923448	A1	19990809	US 1998-72499P	P	19980126

			US 1998-72780P	P	19980127
			US 1998-75806P	P	19980224
			US 1998-62472	A	19980417
			US 1998-84167P	P	19980504
			US 1998-160533	A	19980924
			WO 1998-US23095	A	19981030
			WO 1999-US1656	W	19990125
JP 2003526077	T2	20030902	JP 2000-528201		19990125
			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75806P	P	19980224
			US 1998-62472	A	19980417
			US 1998-84167P	P	19980504
			US 1998-160533	A	19980924
			WO 1998-US23095	A	19981030
			WO 1999-US1656	W	19990125
EP 1060384	A1	20001220	EP 1999-908291		19990219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
			US 1998-75414P	P	19980220
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-100951P	P	19980918
			US 1998-160533	A	19980924
			WO 1998-US23095	W	19981030
			WO 1999-US1656	W	19990125
			WO 1999-US3678	W	19990219
JP 2003526767	T2	20030909	JP 2000-532708		19990219
			US 1998-75414P	P	19980220
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-100951P	P	19980918
			US 1998-160533	A	19980924
			WO 1998-US23095	A	19981030
			WO 1999-US1656	A	19990125
			WO 1999-US3678	W	19990219
AU 9949990	A1	20000207	AU 1999-49990		19990715
			WO 1998-US14575	A	19980715
			US 1998-93838P	P	19980722
			US 1998-160533	A	19980924
			WO 1999-US16057	W	19990715
US 2004239922	A1	20041202	US 2003-445292		20030522
US 6992761	B2	20060131			
			US 1998-144578	A2	19980831
			US 1998-146081	A3	19980902
			US 1998-156318	A1	19980918
			US 1998-160533	A1	19980924
			WO 1998-US23095	A1	19981030
			WO 1999-US1656	A1	19990125
			WO 1999-US3678	A1	19990219
			WO 1999-US8410	A1	19990416
			US 1999-302158	A2	19990429
			US 1999-349733	B2	19990708
			WO 1999-US16057	A1	19990715
			WO 1999-US16453	A1	19990721
			WO 1999-US16621	A1	19990723
			WO 1999-US16286	A1	19990726
			WO 1999-US16287	A1	19990726
			US 2000-478819	A2	20000105
			WO 2000-US895	A1	20000114
			US 2000-494407	A2	20000128

WO 2000-US4543	A1 20000222
WO 2000-US6841	A1 20000315
WO 2000-US12277	A1 20000503
WO 2000-US18547	A1 20000707
US 2000-626208	B2 20000726
US 2000-629599	A2 20000731
US 2000-643221	A1 20000818
US 2000-710061	A2 20001110
US 2000-722247	B2 20001124
US 2000-733370	B2 20001208
US 2001-759711	A2 20010112
US 2001-765869	A2 20010119
US 2001-765874	A2 20010119
US 2001-766131	B2 20010119
US 2001-767316	A2 20010122
US 2001-767434	A2 20010122
US 2001-767579	A2 20010122
US 2001-770720	B2 20010125
US 2001-777343	A1 20010205
US 2001-778224	A2 20010206
US 2001-836575	B2 20010416
US 2001-12255	A2 20011112
US 2001-4647	A2 20011203
US 2002-41532	B2 20020107
US 2002-218897	A2 20020813

FAN	2000:84945				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2000005336	A2	20000203	WO 1999-US16453	19990721
	WO 2000005336	A3	20000427		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2001006417	A1	20010705	US 1998-93768P	P 19980722
	US 6486947	B2	20021126	US 2001-767434	20010122
				US 1998-93768P	P 19980722
				US 1998-94275P	P 19980727
				US 1998-94276P	P 19980727
				US 1998-94306P	P 19980727
				US 1998-100817P	P 19980918
				US 1998-100951P	P 19980918
				US 1998-104964P	P 19981020
				US 1998-114209P	P 19981229
				US 1999-116113P	P 19990115
				US 1999-117278P	P 19990126
				US 1999-119884P	P 19990212
				US 1999-121229P	P 19990223
				US 1999-124686P	P 19990316
				US 1999-125346P	P 19990319
				US 1999-126661P	P 19990329
				US 1999-130149P	P 19990420
				US 1999-132262P	P 19990503
				US 1999-132263P	P 19990503
				US 1999-135284P	P 19990521
				US 1999-136566P	P 19990528

US 2002006671	A1	20020117	US 1999-138311P	P	19990609
			US 1999-138438P	P	19990610
			US 1999-138737P	P	19990611
			US 1999-138893P	P	19990611
			US 1999-142721P	P	19990707
			US 1999-143185P	P	19990709
			WO 1999-US16453	A1	19990721
			US 2001-770724		20010125
			US 1997-840553	A	19970414
			US 1997-929095	A	19970915
			US 1998-144578	A	19980831
			US 1999-302158	A	19990429
			US 1999-138311P	P	19990609
			US 1999-143185P	P	19990709
			WO 1999-US16453	A	19990721
US 2004239922 US 6992761	A1 B2	20041202 20060131	US 2000-478819	A	20000105
			US 2000-556030	A	20000420
			US 2000-202087P	P	20000504
			WO 2000-US15774	A1	20000609
			US 2003-445292		20030522
			US 1998-144578	A2	19980831
			US 1998-146081	A3	19980902
			US 1998-156318	A1	19980918
			US 1998-160533	A1	19980924
			WO 1998-US23095	A1	19981030
			WO 1999-US1656	A1	19990125
			WO 1999-US3678	A1	19990219
			WO 1999-US8410	A1	19990416
			US 1999-302158	A2	19990429
			US 1999-349733	B2	19990708
			WO 1999-US16057	A1	19990715
			WO 1999-US16453	A1	19990721
			WO 1999-US16621	A1	19990723
			WO 1999-US16286	A1	19990726
			WO 1999-US16287	A1	19990726
			US 2000-478819	A2	20000105
			WO 2000-US895	A1	20000114
			US 2000-494407	A2	20000128
			WO 2000-US4543	A1	20000222
			WO 2000-US6841	A1	20000315
			WO 2000-US12277	A1	20000503
			WO 2000-US18547	A1	20000707
			US 2000-626208	B2	20000726
			US 2000-629599	A2	20000731
			US 2000-643221	A1	20000818
			US 2000-710061	A2	20001110
			US 2000-722247	B2	20001124
			US 2000-733370	B2	20001208
			US 2001-759711	A2	20010112
			US 2001-765869	A2	20010119
			US 2001-765874	A2	20010119
			US 2001-766131	B2	20010119
			US 2001-767316	A2	20010122
			US 2001-767434	A2	20010122
			US 2001-767579	A2	20010122
			US 2001-770720	B2	20010125
			US 2001-777343	A1	20010205
			US 2001-778224	A2	20010206
			US 2001-836575	B2	20010416
			US 2001-12255	A2	20011112

				US 2001-4647	A2 20011203
				US 2002-41532	B2 20020107
				US 2002-218897	A2 20020813
FAN	2000:98889				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2000006989	A2	20000210	WO 1999-US16286	19990726
	WO 2000006989	A3	20000323		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9956674	A1	20000221	US 1998-94306P	P 19980727
				AU 1999-56674	19990726
				US 1998-94306P	P 19980727
	US 2001016330	A1	20010823	WO 1999-US16286	W 19990726
				US 2001-766131	20010119
				US 1998-94306P	P 19980727
	US 2004239922	A1	20041202	WO 1999-US16286	A1 19990726
	US 6992761	B2	20060131	US 2003-445292	20030522
				US 1998-144578	A2 19980831
				US 1998-146081	A3 19980902
				US 1998-156318	A1 19980918
				US 1998-160533	A1 19980924
				WO 1998-US23095	A1 19981030
				WO 1999-US1656	A1 19990125
				WO 1999-US3678	A1 19990219
				WO 1999-US8410	A1 19990416
				US 1999-302158	A2 19990429
				US 1999-349733	B2 19990708
				WO 1999-US16057	A1 19990715
				WO 1999-US16453	A1 19990721
				WO 1999-US16621	A1 19990723
				WO 1999-US16286	A1 19990726
				WO 1999-US16287	A1 19990726
				US 2000-478819	A2 20000105
				WO 2000-US895	A1 20000114
				US 2000-494407	A2 20000128
				WO 2000-US4543	A1 20000222
				WO 2000-US6841	A1 20000315
				WO 2000-US12277	A1 20000503
				WO 2000-US18547	A1 20000707
				US 2000-626208	B2 20000726
				US 2000-629599	A2 20000731
				US 2000-643221	A1 20000818
				US 2000-710061	A2 20001110
				US 2000-722247	B2 20001124
				US 2000-733370	B2 20001208
				US 2001-759711	A2 20010112
				US 2001-765869	A2 20010119
				US 2001-765874	A2 20010119
				US 2001-766131	B2 20010119
				US 2001-767316	A2 20010122
				US 2001-767434	A2 20010122
				US 2001-767579	A2 20010122
				US 2001-770720	B2 20010125

				US 2001-777343	A1 20010205
				US 2001-778224	A2 20010206
				US 2001-836575	B2 20010416
				US 2001-12255	A2 20011112
				US 2001-4647	A2 20011203
				US 2002-41532	B2 20020107
				US 2002-218897	A2 20020813
FAN	2000:98891				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2000006990	A2	20000210	WO 1999-US16287	19990726
	WO 2000006990	A3	20000518		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1032813	A2	20000906	US 1998-94276P	P 19980727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			EP 1998-959374	19980709
				US 1997-63811P	P 19971031
				US 1998-72499P	P 19980126
				US 1998-72780P	P 19980127
				US 1998-75414P	P 19980220
				US 1998-75806P	P 19980224
				US 1998-62472	A 19980417
				US 1998-82253P	P 19980417
				US 1998-84167P	P 19980504
				US 1998-85335P	P 19980513
				US 1998-85500P	P 19980514
				US 1998-89848P	P 19980619
				US 1998-92203P	P 19980709
				US 1998-94275P	P 19980709
				US 1998-94276P	P 19980727
				US 1998-100817P	P 19980918
				US 1998-100951P	P 19980918
				US 1998-156318	A 19980918
				US 1998-160533	A 19980924
				US 1998-104964P	P 19981020
				WO 1998-US23095	W 19981030
AU 9915184		A1	19990524	AU 1999-15184	19981029
				US 1997-63811P	P 19971031
				US 1998-72499P	P 19980126
				US 1998-72780P	P 19980127
				US 1998-75414P	P 19980220
				US 1998-75806P	P 19980224
				US 1998-62472	A 19980417
				US 1998-82253P	P 19980417
				US 1998-84167P	P 19980504
				US 1998-85335P	P 19980513
				US 1998-85500P	P 19980514
				US 1998-89848P	P 19980619
				US 1998-92203P	P 19980709
				US 1998-94275P	P 19980727
				US 1998-94276P	P 19980727
				US 1998-100817P	P 19980918
				US 1998-100951P	P 19980918

JP 2003521670	T2	20030715	US 1998-156318	A	19980918
			US 1998-160533	A	19980924
			US 1998-104964P	P	19981020
			WO 1998-US23095	W	19981030
			JP 2000-519281		19981030
			US 1997-63811P	P	19971031
			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75414P	P	19980220
			US 1998-75806P	P	19980224
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-84167P	P	19980504
			US 1998-85335P	P	19980513
			US 1998-85500P	P	19980514
			US 1998-89848P	P	19980619
			US 1998-92203P	P	19980709
			US 1998-94275P	P	19980727
			US 1998-94276P	P	19980727
			US 1998-100817P	P	19980918
			US 1998-100951P	P	19980918
			US 1998-156318	A	19980918
			US 1998-160533	A	19980924
			US 1998-104964P	P	19981020
			WO 1998-US23095	W	19981030
AU 9956675	A1	20000221	AU 1999-56675		19990726
			US 1998-94276P	P	19980727
US 2001003044	A1	20010607	WO 1999-US16287	W	19990726
US 6483582	B2	20021119	US 2001-765874		20010119
			US 1998-94276P	P	19980727
			WO 1999-US16287	A1	19990726
US 2004239922	A1	20041202	US 2003-445292		20030522
US 6992761	B2	20060131			
			US 1998-144578	A2	19980831
			US 1998-146081	A3	19980902
			US 1998-156318	A1	19980918
			US 1998-160533	A1	19980924
			WO 1998-US23095	A1	19981030
			WO 1999-US1656	A1	19990125
			WO 1999-US3678	A1	19990219
			WO 1999-US8410	A1	19990416
			US 1999-302158	A2	19990429
			US 1999-349733	B2	19990708
			WO 1999-US16057	A1	19990715
			WO 1999-US16453	A1	19990721
			WO 1999-US16621	A1	19990723
			WO 1999-US16286	A1	19990726
			WO 1999-US16287	A1	19990726
			US 2000-478819	A2	20000105
			WO 2000-US895	A1	20000114
			US 2000-494407	A2	20000128
			WO 2000-US4543	A1	20000222
			WO 2000-US6841	A1	20000315
			WO 2000-US12277	A1	20000503
			WO 2000-US18547	A1	20000707
			US 2000-626208	B2	20000726
			US 2000-629599	A2	20000731
			US 2000-643221	A1	20000818
			US 2000-710061	A2	20001110
			US 2000-722247	B2	20001124

				US 2000-733370	B2 20001208
				US 2001-759711	A2 20010112
				US 2001-765869	A2 20010119
				US 2001-765874	A2 20010119
				US 2001-766131	B2 20010119
				US 2001-767316	A2 20010122
				US 2001-767434	A2 20010122
				US 2001-767579	A2 20010122
				US 2001-770720	B2 20010125
				US 2001-777343	A1 20010205
				US 2001-778224	A2 20010206
				US 2001-836575	B2 20010416
				US 2001-12255	A2 20011112
				US 2001-4647	A2 20011203
				US 2002-41532	B2 20020107
				US 2002-218897	A2 20020813
FAN	2000:98892				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2000006991	A2	20000210	WO 1999-US16621	19990723
	WO 2000006991	A3	20000504		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				
	DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,				
	JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
	MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
	TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,				
	ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,				
	CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1998-94275P	P 19980727
				US 1999-117278P	P 19990126
				US 1999-136566P	P 19990528
				EP 1998-959374	19980709
EP 1032813		A2	20000906		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, FI				
				US 1997-63811P	P 19971031
				US 1998-72499P	P 19980126
				US 1998-72780P	P 19980127
				US 1998-75414P	P 19980220
				US 1998-75806P	P 19980224
				US 1998-62472	A 19980417
				US 1998-82253P	P 19980417
				US 1998-84167P	P 19980504
				US 1998-85335P	P 19980513
				US 1998-85500P	P 19980514
				US 1998-89848P	P 19980619
				US 1998-92203P	P 19980709
				US 1998-94275P	P 19980709
				US 1998-94276P	P 19980727
				US 1998-100817P	P 19980918
				US 1998-100951P	P 19980918
				US 1998-156318	A 19980918
				US 1998-160533	A 19980924
				US 1998-104964P	P 19981020
				WO 1998-US23095	W 19981030
AU 9915184		A1	19990524	AU 1999-15184	19981029
				US 1997-63811P	P 19971031
				US 1998-72499P	P 19980126
				US 1998-72780P	P 19980127
				US 1998-75414P	P 19980220
				US 1998-75806P	P 19980224

JP 2003521670	T2	20030715	US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-84167P	P	19980504
			US 1998-85335P	P	19980513
			US 1998-85500P	P	19980514
			US 1998-89848P	P	19980619
			US 1998-92203P	P	19980709
			US 1998-94275P	P	19980727
			US 1998-94276P	P	19980727
			US 1998-100817P	P	19980918
			US 1998-100951P	P	19980918
			US 1998-156318	A	19980918
			US 1998-160533	A	19980924
			US 1998-104964P	P	19981020
			WO 1998-US23095	W	19981030
			JP 2000-519281		19981030
			US 1997-63811P	P	19971031
			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75414P	P	19980220
			US 1998-75806P	P	19980224
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-84167P	P	19980504
			US 1998-85335P	P	19980513
			US 1998-85500P	P	19980514
			US 1998-89848P	P	19980619
			US 1998-92203P	P	19980709
			US 1998-94275P	P	19980727
			US 1998-94276P	P	19980727
			US 1998-100817P	P	19980918
			US 1998-100951P	P	19980918
			US 1998-156318	A	19980918
			US 1998-160533	A	19980924
			US 1998-104964P	P	19981020
			WO 1998-US23095	W	19981030
AU 9952238	A1	20000221	AU 1999-52238		19990723
			US 1998-94275P	P	19980727
			US 1999-117278P	P	19990126
			US 1999-136566P	P	19990528
US 2001007496 US 6466316	A1	20010712	WO 1999-US16621	W	19990723
	B2	20021015	US 2001-765869		20010119
			US 1998-94275P	P	19980727
			US 1999-117278P	P	19990126
			US 1999-136566P	P	19990528
			WO 1999-US16621	W	19990723
			US 2003-445292		20030522
US 2004239922 US 6992761	A1	20041202	US 1998-144578	A2	19980831
	B2	20060131	US 1998-146081	A3	19980902
			US 1998-156318	A1	19980918
			US 1998-160533	A1	19980924
			WO 1998-US23095	A1	19981030
			WO 1999-US1656	A1	19990125
			WO 1999-US3678	A1	19990219
			WO 1999-US8410	A1	19990416
			US 1999-302158	A2	19990429
			US 1999-349733	B2	19990708
			WO 1999-US16057	A1	19990715
			WO 1999-US16453	A1	19990721

WO 1999-US16621	A1 19990723
WO 1999-US16286	A1 19990726
WO 1999-US16287	A1 19990726
US 2000-478819	A2 20000105
WO 2000-US895	A1 20000114
US 2000-494407	A2 20000128
WO 2000-US4543	A1 20000222
WO 2000-US6841	A1 20000315
WO 2000-US12277	A1 20000503
WO 2000-US18547	A1 20000707
US 2000-626208	B2 20000726
US 2000-629599	A2 20000731
US 2000-643221	A1 20000818
US 2000-710061	A2 20001110
US 2000-722247	B2 20001124
US 2000-733370	B2 20001208
US 2001-759711	A2 20010112
US 2001-765869	A2 20010119
US 2001-765874	A2 20010119
US 2001-766131	B2 20010119
US 2001-767316	A2 20010122
US 2001-767434	A2 20010122
US 2001-767579	A2 20010122
US 2001-770720	B2 20010125
US 2001-777343	A1 20010205
US 2001-778224	A2 20010206
US 2001-836575	B2 20010416
US 2001-12255	A2 20011112
US 2001-4647	A2 20011203
US 2002-41532	B2 20020107
US 2002-218897	A2 20020813

FAN	2000:123385				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 981043	A1	20000223	EP 1999-116048	19990816
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				US 1998-96999P	P 19980818
				US 1999-274753	A 19990323
				US 1999-337623	A 19990621
	US 6232608	B1	20010515	US 1999-274796	19990323
				US 1998-96999P	P 19980818
	US 6313471	B1	20011106	US 1999-274791	19990323
				US 1998-96999P	P 19980818
	US 6316774	B1	20011113	US 1999-274753	19990323
				US 1998-96999P	P 19980818
	US 6236456	B1	20010522	US 1999-337623	19990621
				US 1998-96999P	P 19980818
				US 1999-274753	A2 19990323

FAN	2000:278167				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2000023785	A2	20000427	WO 1999-US24707	19991019
	WO 2000023785	A3	20000803		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				

CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG						
EP 1032813	A2	20000906	US 1998-104964P	P	19981020	
			US 1999-126661P	P	19990329	
			EP 1998-959374		19980709	
			R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
AU 9915184	A1	19990524	US 1997-63811P	P	19971031	
			US 1998-72499P	P	19980126	
			US 1998-72780P	P	19980127	
			US 1998-75414P	P	19980220	
			US 1998-75806P	P	19980224	
			US 1998-62472	A	19980417	
			US 1998-82253P	P	19980417	
			US 1998-84167P	P	19980504	
			US 1998-85335P	P	19980513	
			US 1998-85500P	P	19980514	
			US 1998-89848P	P	19980619	
			US 1998-92203P	P	19980709	
			US 1998-94275P	P	19980709	
			US 1998-94276P	P	19980727	
			US 1998-100817P	P	19980918	
			US 1998-100951P	P	19980918	
			US 1998-156318	A	19980918	
			US 1998-160533	A	19980924	
			US 1998-104964P	P	19981020	
			WO 1998-US23095	W	19981030	
			AU 1999-15184		19981029	
			US 1997-63811P	P	19971031	
			US 1998-72499P	P	19980126	
			US 1998-72780P	P	19980127	
			US 1998-75414P	P	19980220	
			US 1998-75806P	P	19980224	
			US 1998-62472	A	19980417	
			US 1998-82253P	P	19980417	
			US 1998-84167P	P	19980504	
			US 1998-85335P	P	19980513	
			US 1998-85500P	P	19980514	
			US 1998-89848P	P	19980619	
			US 1998-92203P	P	19980709	
			US 1998-94275P	P	19980727	
			US 1998-94276P	P	19980727	
			US 1998-100817P	P	19980918	
			US 1998-100951P	P	19980918	
			US 1998-156318	A	19980918	
			US 1998-160533	A	19980924	
			US 1998-104964P	P	19981020	
			WO 1998-US23095	W	19981030	
JP 2003521670	T2	20030715	JP 2000-519281		19981030	
			US 1997-63811P	P	19971031	
			US 1998-72499P	P	19980126	
			US 1998-72780P	P	19980127	
			US 1998-75414P	P	19980220	
			US 1998-75806P	P	19980224	
			US 1998-62472	A	19980417	
			US 1998-82253P	P	19980417	
			US 1998-84167P	P	19980504	
			US 1998-85335P	P	19980513	
			US 1998-85500P	P	19980514	
			US 1998-89848P	P	19980619	
			US 1998-92203P	P	19980709	
			US 1998-94275P	P	19980727	

				US 1998-94276P	P	19980727
				US 1998-100817P	P	19980918
				US 1998-100951P	P	19980918
				US 1998-156318	A	19980918
				US 1998-160533	A	19980924
				US 1998-104964P	P	19981020
AU 2000012198	A5	20000508		WO 1998-US23095	W	19981030
				AU 2000-12198		19991019
				US 1998-104964P	P	19981020
				US 1999-126661P	P	19990329
US 2001018194	A1	20010830		WO 1999-US24707	W	19991019
				US 2001-768742		20010123
				US 1998-104964P	P	19981020
				US 1998-114209P	P	19981229
				US 1999-116113P	P	19990115
				US 1999-117278P	P	19990126
				US 1999-119884P	P	19990212
				US 1999-121229P	P	19990223
				US 1999-124686P	P	19990316
				US 1999-125346P	P	19990319
				US 1999-126661P	P	19990329
				US 1999-130149P	P	19990420
				US 1999-132262P	P	19990503
				US 1999-132263P	P	19990503
				US 1999-135284P	P	19990521
				US 1999-138311P	P	19990609
				US 1999-138438P	P	19990610
				US 1999-138737P	P	19990611
				US 1999-138893P	P	19990611
				US 1999-142721P	P	19990707
				US 1999-153251P	P	19990910
				WO 1999-US24707	A1	19991019
FAN 2000:493700						
PATENT NO.	KIND	DATE		APPLICATION NO.		DATE
-----	----	-----		-----		-----
PI WO 2000042209	A1	20000720		WO 2000-US895		20000114
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,					
	DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,					
	JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,					
	MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,					
	TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,					
	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,					
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
				US 1999-116113P	P	19990115
				WO 1999-US1656	A	19990125
				WO 1999-US8410	A	19990416
				US 1999-135284P	P	19990521
				US 1999-167463P	P	19991124
AU 9923448	A1	19990809		AU 1999-23448		19990125
				US 1998-72499P	P	19980126
				US 1998-72780P	P	19980127
				US 1998-75806P	P	19980224
				US 1998-62472	A	19980417
				US 1998-84167P	P	19980504
				US 1998-160533	A	19980924
				WO 1998-US23095	A	19981030
				WO 1999-US1656	W	19990125
JP 2003526077	T2	20030902		JP 2000-528201		19990125
				US 1998-72499P	P	19980126
				US 1998-72780P	P	19980127

EP 1060384	A1	20001220	US 1998-75806P	P	19980224
			US 1998-62472	A	19980417
			US 1998-84167P	P	19980504
			US 1998-160533	A	19980924
			WO 1998-US23095	A	19981030
			WO 1999-US1656	W	19990125
			EP 1999-908291		19990219
JP 2003526767	T2	20030909	US 1998-75414P	P	19980220
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-100951P	P	19980918
			US 1998-160533	A	19980924
			WO 1998-US23095	W	19981030
			WO 1999-US1656	W	19990125
			WO 1999-US3678	W	19990219
			JP 2000-532708		19990219
			US 1998-75414P	P	19980220
US 6297018	B1	20011002	US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-100951P	P	19980918
			US 1998-160533	A	19980924
			WO 1998-US23095	A	19981030
			WO 1999-US1656	A	19990125
			WO 1999-US3678	W	19990219
			US 2000-494407		20000128
			US 1998-62472	A2	19980417
			US 1998-96999P	P	19980818
WO 2000055372	A1	20000921	US 1998-160533	A2	19980924
			WO 1999-US1656	A2	19990125
			US 1999-124686P	P	19990316
			US 1999-125346P	P	19990319
			WO 1999-US8410	A2	19990416
			US 1999-135284P	P	19990521
			US 1999-349733	A2	19990708
			US 1999-167463P	P	19991124
			US 1999-468440	A2	19991221
			WO 2000-US895	A2	20000114
			WO 2000-US6841		20000315
			W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,		
			CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,		
			IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,		
			MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,		
			SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW		
			RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,		
			DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,		
			CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
			US 1999-124686P	P	19990316
US 2001034025	A1	20011025	US 1999-125346P	P	19990319
			WO 1999-US8410	W	19990416
			US 1999-135284P	P	19990521
			US 1999-349733	A	19990708
			WO 2000-US895	W	20000114
			US 2000-494407	A	20000128
			US 2000-184719P	P	20000224
			US 2000-184924P	P	20000225
			US 2001-767316		20010122
US 6503719	B2	20030107	US 1999-116113P	P	19990115
			WO 1999-US1656	A	19990125

US 2001046673	A1	20011129	WO 1999-US8410	A 19990416
			US 1999-135284P	P 19990521
			US 1999-167463P	P 19991124
			WO 2000-US895	A1 20000114
			US 2001-770720	20010125
			US 1999-124686P	P 19990316
			US 1999-125346P	P 19990319
			WO 1999-US8410	A2 19990416
			US 1999-130149P	P 19990420
			US 1999-132262P	P 19990503
			US 1999-138311P	P 19990503
			US 1999-135284P	P 19990521
			US 1999-132263P	P 19990609
			US 1999-138438P	P 19990610
			US 1999-138737P	P 19990611
			US 1999-138893P	P 19990611
			US 1999-142721P	P 19990707
			US 1999-349733	A2 19990708
			US 1999-153251P	P 19990910
			US 1999-164633P	P 19991110
			WO 2000-US895	A2 20000114
			US 2000-494407	A2 20000128
			US 2000-184719P	P 20000224
			US 2000-184924P	P 20000225
US 2004239922	A1	20041202	WO 2000-US6841	A2 20000315
			US 2003-445292	20030522
US 6992761	B2	20060131	US 1998-144578	A2 19980831
			US 1998-146081	A3 19980902
			US 1998-156318	A1 19980918
			US 1998-160533	A1 19980924
			WO 1998-US23095	A1 19981030
			WO 1999-US1656	A1 19990125
			WO 1999-US3678	A1 19990219
			WO 1999-US8410	A1 19990416
			US 1999-302158	A2 19990429
			US 1999-349733	B2 19990708
			WO 1999-US16057	A1 19990715
			WO 1999-US16453	A1 19990721
			WO 1999-US16621	A1 19990723
			WO 1999-US16286	A1 19990726
			WO 1999-US16287	A1 19990726
			US 2000-478819	A2 20000105
			WO 2000-US895	A1 20000114
			US 2000-494407	A2 20000128
			WO 2000-US4543	A1 20000222
			WO 2000-US6841	A1 20000315
			WO 2000-US12277	A1 20000503
			WO 2000-US18547	A1 20000707
			US 2000-626208	B2 20000726
			US 2000-629599	A2 20000731
			US 2000-643221	A1 20000818
			US 2000-710061	A2 20001110
			US 2000-722247	B2 20001124
			US 2000-733370	B2 20001208
			US 2001-759711	A2 20010112
			US 2001-765869	A2 20010119
			US 2001-765874	A2 20010119
			US 2001-766131	B2 20010119
			US 2001-767316	A2 20010122
			US 2001-767434	A2 20010122

				US 2001-767579	A2 20010122
				US 2001-770720	B2 20010125
				US 2001-777343	A1 20010205
				US 2001-778224	A2 20010206
				US 2001-836575	B2 20010416
				US 2001-12255	A2 20011112
				US 2001-4647	A2 20011203
				US 2002-41532	B2 20020107
				US 2002-218897	A2 20020813
FAN	2000:608994				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000050877	A1	20000831	WO 2000-US4543	20000222
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				
	CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,				
	IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				
	MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,				
	SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2001019409	A1	20010906	US 1999-121229P	P 19990223
	US 6317207	B2	20011113	US 2001-767579	20010122
				US 1999-121229P	P 19990223
	US 2004239922	A1	20041202	WO 2000-US4543	A1 20000222
	US 6992761	B2	20060131	US 2003-445292	20030522
				US 1998-144578	A2 19980831
				US 1998-146081	A3 19980902
				US 1998-156318	A1 19980918
				US 1998-160533	A1 19980924
				WO 1998-US23095	A1 19981030
				WO 1999-US1656	A1 19990125
				WO 1999-US3678	A1 19990219
				WO 1999-US8410	A1 19990416
				US 1999-302158	A2 19990429
				US 1999-349733	B2 19990708
				WO 1999-US16057	A1 19990715
				WO 1999-US16453	A1 19990721
				WO 1999-US16621	A1 19990723
				WO 1999-US16286	A1 19990726
				WO 1999-US16287	A1 19990726
				US 2000-478819	A2 20000105
				WO 2000-US895	A1 20000114
				US 2000-494407	A2 20000128
				WO 2000-US4543	A1 20000222
				WO 2000-US6841	A1 20000315
				WO 2000-US12277	A1 20000503
				WO 2000-US18547	A1 20000707
				US 2000-626208	B2 20000726
				US 2000-629599	A2 20000731
				US 2000-643221	A1 20000818
				US 2000-710061	A2 20001110
				US 2000-722247	B2 20001124
				US 2000-733370	B2 20001208
				US 2001-759711	A2 20010112
				US 2001-765869	A2 20010119
				US 2001-765874	A2 20010119
				US 2001-766131	B2 20010119
				US 2001-767316	A2 20010122

					US 2001-767434	A2 20010122
					US 2001-767579	A2 20010122
					US 2001-770720	B2 20010125
					US 2001-777343	A1 20010205
					US 2001-778224	A2 20010206
					US 2001-836575	B2 20010416
					US 2001-12255	A2 20011112
					US 2001-4647	A2 20011203
					US 2002-41532	B2 20020107
					US 2002-218897	A2 20020813
FAN	2000:666923					
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
	-----	----	-----	-----	-----	
PI	WO 2000055372	A1	20000921	WO 2000-US6841	20000315	
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,					
	CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,					
	IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,					
	MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,					
	SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,					
	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,					
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
				US 1999-124686P	P 19990316	
				US 1999-125346P	P 19990319	
				WO 1999-US8410	W 19990416	
				US 1999-135284P	P 19990521	
				US 1999-349733	A 19990708	
				WO 2000-US895	W 20000114	
				US 2000-494407	A 20000128	
				US 2000-184719P	P 20000224	
				US 2000-184924P	P 20000225	
	WO 2000042209	A1	20000720	WO 2000-US895	20000114	
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,					
	DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,					
	JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,					
	MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,					
	TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,					
	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,					
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
				US 1999-116113P	P 19990115	
				WO 1999-US1656	A 19990125	
				WO 1999-US8410	A 19990416	
				US 1999-135284P	P 19990521	
				US 1999-167463P	P 19991124	
	US 6297018	B1	20011002	US 2000-494407	20000128	
				US 1998-62472	A2 19980417	
				US 1998-96999P	P 19980818	
				US 1998-160533	A2 19980924	
				WO 1999-US1656	A2 19990125	
				US 1999-124686P	P 19990316	
				US 1999-125346P	P 19990319	
				WO 1999-US8410	A2 19990416	
				US 1999-135284P	P 19990521	
				US 1999-349733	A2 19990708	
				US 1999-167463P	P 19991124	
				US 1999-468440	A2 19991221	
				WO 2000-US895	A2 20000114	
	US 2001046673	A1	20011129	US 2001-770720	20010125	
				US 1999-124686P	P 19990316	
				US 1999-125346P	P 19990319	

			WO 1999-US8410	A2 19990416
			US 1999-130149P	P 19990420
			US 1999-132262P	P 19990503
			US 1999-138311P	P 19990503
			US 1999-135284P	P 19990521
			US 1999-132263P	P 19990609
			US 1999-138438P	P 19990610
			US 1999-138737P	P 19990611
			US 1999-138893P	P 19990611
			US 1999-142721P	P 19990707
			US 1999-349733	A2 19990708
			US 1999-153251P	P 19990910
			US 1999-164633P	P 19991110
			WO 2000-US895	A2 20000114
			US 2000-494407	A2 20000128
			US 2000-184719P	P 20000224
			US 2000-184924P	P 20000225
			WO 2000-US6841	A2 20000315
US 2004239922	A1	20041202	US 2003-445292	20030522
US 6992761	B2	20060131		
			US 1998-144578	A2 19980831
			US 1998-146081	A3 19980902
			US 1998-156318	A1 19980918
			US 1998-160533	A1 19980924
			WO 1998-US23095	A1 19981030
			WO 1999-US1656	A1 19990125
			WO 1999-US3678	A1 19990219
			WO 1999-US8410	A1 19990416
			US 1999-302158	A2 19990429
			US 1999-349733	B2 19990708
			WO 1999-US16057	A1 19990715
			WO 1999-US16453	A1 19990721
			WO 1999-US16621	A1 19990723
			WO 1999-US16286	A1 19990726
			WO 1999-US16287	A1 19990726
			US 2000-478819	A2 20000105
			WO 2000-US895	A1 20000114
			US 2000-494407	A2 20000128
			WO 2000-US4543	A1 20000222
			WO 2000-US6841	A1 20000315
			WO 2000-US12277	A1 20000503
			WO 2000-US18547	A1 20000707
			US 2000-626208	B2 20000726
			US 2000-629599	A2 20000731
			US 2000-643221	A1 20000818
			US 2000-710061	A2 20001110
			US 2000-722247	B2 20001124
			US 2000-733370	B2 20001208
			US 2001-759711	A2 20010112
			US 2001-765869	A2 20010119
			US 2001-765874	A2 20010119
			US 2001-766131	B2 20010119
			US 2001-767316	A2 20010122
			US 2001-767434	A2 20010122
			US 2001-767579	A2 20010122
			US 2001-770720	B2 20010125
			US 2001-777343	A1 20010205
			US 2001-778224	A2 20010206
			US 2001-836575	B2 20010416
			US 2001-12255	A2 20011112
			US 2001-4647	A2 20011203

				US 2002-41532	B2 20020107
				US 2002-218897	A2 20020813
FAN	2000:790397				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000066269	A1	20001109	WO 2000-US12277	20000503
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-132262P	P 19990503
				US 1999-132263P	P 19990503
				US 1999-138737P	P 19990611
				US 1999-138893P	P 19990611
				US 1999-153251P	P 19990910
				US 1999-167301P	P 19991124
EP 1181100		A1	20020227	EP 2000-935868	20000503
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				US 1999-132262P	P 19990503
				US 1999-132263P	P 19990503
				US 1999-138737P	P 19990611
				US 1999-138893P	P 19990611
				US 1999-153251P	P 19990910
				US 1999-167301P	P 19991124
US 2001048899		A1	20011206	WO 2000-US12277	W 20000503
US 6902703		B2	20050607	US 2001-777343	20010205
				US 1999-132262P	P 19990503
				US 1999-132263P	P 19990503
				US 1999-138311P	P 19990609
				US 1999-138438P	P 19990610
				US 1999-138737P	P 19990611
				US 1999-138893P	P 19990611
				US 1999-142721P	P 19990707
				US 1999-153251P	P 19990910
				US 1999-164633P	P 19991110
				US 1999-165813P	P 19991116
				US 1999-167301P	P 19991124
				US 1999-167463P	P 19991124
				US 2000-178026P	P 20000126
				US 2000-182036P	P 20000211
				US 2000-182419P	P 20000214
				US 2000-190265P	P 20000317
				US 2000-191890P	P 20000323
				US 2000-193586P	P 20000330
				US 2000-197324P	P 20000414
				US 2000-200530P	P 20000427
				US 2000-200594P	P 20000428
US 2004239922		A1	20041202	WO 2000-US12277	A1 20000503
US 6992761		B2	20060131	US 2003-445292	20030522
				US 1998-144578	A2 19980831
				US 1998-146081	A3 19980902
				US 1998-156318	A1 19980918
				US 1998-160533	A1 19980924
				WO 1998-US23095	A1 19981030

WO 1999-US1656	A1 19990125
WO 1999-US3678	A1 19990219
WO 1999-US8410	A1 19990416
US 1999-302158	A2 19990429
US 1999-349733	B2 19990708
WO 1999-US16057	A1 19990715
WO 1999-US16453	A1 19990721
WO 1999-US16621	A1 19990723
WO 1999-US16286	A1 19990726
WO 1999-US16287	A1 19990726
US 2000-478819	A2 20000105
WO 2000-US895	A1 20000114
US 2000-494407	A2 20000128
WO 2000-US4543	A1 20000222
WO 2000-US6841	A1 20000315
WO 2000-US12277	A1 20000503
WO 2000-US18547	A1 20000707
US 2000-626208	B2 20000726
US 2000-629599	A2 20000731
US 2000-643221	A1 20000818
US 2000-710061	A2 20001110
US 2000-722247	B2 20001124
US 2000-733370	B2 20001208
US 2001-759711	A2 20010112
US 2001-765869	A2 20010119
US 2001-765874	A2 20010119
US 2001-766131	B2 20010119
US 2001-767316	A2 20010122
US 2001-767434	A2 20010122
US 2001-767579	A2 20010122
US 2001-770720	B2 20010125
US 2001-777343	A1 20010205
US 2001-778224	A2 20010206
US 2001-836575	B2 20010416
US 2001-12255	A2 20011112
US 2001-4647	A2 20011203
US 2002-41532	B2 20020107
US 2002-218897	A2 20020813

FAN	2000:881177				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2000075167	A2	20001214	WO 2000-US16025	20000609
	WO 2000075167	A3	20020912		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				US 1999-138311P	P 19990609
				US 1999-138438P	P 19990610
				US 1999-349733	A 19990708
				US 2000-200594P	P 20000428
EP 1261621		A2	20021204	EP 2000-941332	20000609
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, FI, CY				
				US 1999-138311P	P 19990609
				US 1999-138438P	P 19990610

US 2002034766	A1	20020321	US 1999-349733	A	19990708
US 7070921	B2	20060704	US 2000-200594P	P	20000428
			WO 2000-US16025	W	20000609
			US 2001-844655		20010427
			US 2000-200594P	P	20000428
			WO 2000-US16025	A1	20000609
			US 2000-596444	A1	20000619
			US 2000-223642P	P	20000808
			US 2000-241032P	P	20001017
EP 1156329	A2	20011121	EP 2001-303960		20010430
EP 1156329	A3	20040303			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
			US 2000-200594P	P	20000428
			WO 2000-US16025	W	20000609
			US 2000-596444	A	20000619
			US 2000-223642P	P	20000808
			US 2000-241032P	P	20001017
			US 2001-844655	A	20010427
US 2005227294	A1	20051013	US 2005-146553		20050606
			US 1997-929095	B2	19970915
			US 2000-200594P	P	20000428
			WO 2000-US16025	A2	20000609
			US 2000-596444	A2	20000619
			US 2000-223642P	P	20000808
			US 2000-241032P	P	20001017
			US 2001-844655	A2	20010427
			US 2002-436725P	P	20021226
			US 2003-507006P	P	20030929
			US 2003-746797	A2	20031223
			US 2004-577079P	P	20040604
			US 2004-602712P	P	20040818
			US 2004-615308P	P	20040930
US 2006121544	A1	20060608	US 2005-241872		20050930
			US 1997-929095	B2	19970915
			US 1999-138311P	P	19990609
			US 1999-138438P	P	19990610
			US 1999-349733	B2	19990708
			US 2000-200594P	P	20000428
			WO 2000-US16025	A2	20000609
			US 2000-596444	A2	20000619
			US 2000-223642P	P	20000808
			US 2000-241032P	P	20001017
			US 2001-844655	A2	20010427
			US 2002-436725P	P	20021226
			US 2003-507006P	P	20030929
			US 2003-507569P	P	20030930
			US 2003-746797	A2	20031223
			US 2004-577079P	P	20040604
			US 2004-602712P	P	20040818
			US 2004-615308P	P	20040930
			US 2004-957332	A2	20040930
			US 2005-683377P	P	20050520
			US 2005-146553	A2	20050606
FAN 2000:881425					
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
-----	----	-----	-----	-----	
PI WO 2000075662	A1	20001214	WO 2000-US16012		20000609
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,					

	ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-138311P	P 19990609
				US 2000-182036P	P 20000211
				US 2000-200594P	P 20000428
EP 1101113	A1	20010523	EP 2000-944641		20000609
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, SI, LT, LV, FI, RO					
				US 1999-138311P	P 19990609
				US 2000-182036P	P 20000211
				US 2000-200594P	P 20000428
US 2004203000	A1	20041014	WO 2000-US16012	W	20000609
US 6806053	B2	20041019	US 2001-768661		20010123
				US 1999-138311P	P 19990609
				US 2000-182036P	P 20000211
				US 2000-200594P	P 20000428
				WO 2000-US16012	A1 20000609
US 2005136454	A1	20050623	US 2004-968869		20041018
				US 1999-138311P	P 19990609
				US 2000-182036P	P 20000211
				US 2000-200594P	P 20000428
				WO 2000-US16012	A1 20000609
				US 2001-768661	A1 20010123
FAN 2000:881427					
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
-----	----	-----	-----	-----	
PI WO 2000075664	A1	20001214	WO 2000-US15774		20000609
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 2002006671	A1	20020117	US 1999-138311P	P	19990609
			US 2001-770724		20010125
			US 1997-840553	A	19970414
			US 1997-929095	A	19970915
			US 1998-144578	A	19980831
			US 1999-302158	A	19990429
			US 1999-138311P	P	19990609
			US 1999-143185P	P	19990709
			WO 1999-US16453	A	19990721
			US 2000-478819	A	20000105
			US 2000-556030	A	20000420
			US 2000-202087P	P	20000504
			WO 2000-US15774	A1	20000609
FAN 2001:43551					
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
-----	----	-----	-----	-----	
PI WO 2001004608	A1	20010118	WO 2000-US18547		20000707
WO 2001004608	C2	20020725			
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,					

CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG						
US 6310687	B1	20011030	US 1999-142721P	P	19990707	
			US 2001-768765		20010123	
			US 1999-142721P	P	19990707	
			WO 2000-US18547	A1	20000707	
US 2004239922	A1	20041202	US 2003-445292		20030522	
US 6992761	B2	20060131				
			US 1998-144578	A2	19980831	
			US 1998-146081	A3	19980902	
			US 1998-156318	A1	19980918	
			US 1998-160533	A1	19980924	
			WO 1998-US23095	A1	19981030	
			WO 1999-US1656	A1	19990125	
			WO 1999-US3678	A1	19990219	
			WO 1999-US8410	A1	19990416	
			US 1999-302158	A2	19990429	
			US 1999-349733	B2	19990708	
			WO 1999-US16057	A1	19990715	
			WO 1999-US16453	A1	19990721	
			WO 1999-US16621	A1	19990723	
			WO 1999-US16286	A1	19990726	
			WO 1999-US16287	A1	19990726	
			US 2000-478819	A2	20000105	
			WO 2000-US895	A1	20000114	
			US 2000-494407	A2	20000128	
			WO 2000-US4543	A1	20000222	
			WO 2000-US6841	A1	20000315	
			WO 2000-US12277	A1	20000503	
			WO 2000-US18547	A1	20000707	
			US 2000-626208	B2	20000726	
			US 2000-629599	A2	20000731	
			US 2000-643221	A1	20000818	
			US 2000-710061	A2	20001110	
			US 2000-722247	B2	20001124	
			US 2000-733370	B2	20001208	
			US 2001-759711	A2	20010112	
			US 2001-765869	A2	20010119	
			US 2001-765874	A2	20010119	
			US 2001-766131	B2	20010119	
			US 2001-767316	A2	20010122	
			US 2001-767434	A2	20010122	
			US 2001-767579	A2	20010122	
			US 2001-770720	B2	20010125	
			US 2001-777343	A1	20010205	
			US 2001-778224	A2	20010206	
			US 2001-836575	B2	20010416	
			US 2001-12255	A2	20011112	
			US 2001-4647	A2	20011203	
			US 2002-41532	B2	20020107	
			US 2002-218897	A2	20020813	
FAN 2001:371718						
PATENT NO.						

PI US 6236456	B1	20010522	US 1999-337623		19990621	
			US 1998-96999P	P	19980818	

US 6232608	B1	20010515	US 1999-274753	A2	19990323
			US 1999-274796		19990323
US 6313471	B1	20011106	US 1998-96999P	P	19980818
			US 1999-274791		19990323
US 6316774	B1	20011113	US 1998-96999P	P	19980818
			US 1999-274753		19990323
EP 981043	A1	20000223	US 1998-96999P	P	19980818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			EP 1999-116048		19990816
			US 1998-96999P	P	19980818
			US 1999-274753	A	19990323
			US 1999-337623	A	19990621
FAN 2001:719017					
PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
-----	----	-----	-----		-----
PI US 6297018	B1	20011002	US 2000-494407		20000128
			US 1998-62472	A2	19980417
			US 1998-96999P	P	19980818
			US 1998-160533	A2	19980924
			WO 1999-US1656	A2	19990125
			US 1999-124686P	P	19990316
			US 1999-125346P	P	19990319
			WO 1999-US8410	A2	19990416
			US 1999-135284P	P	19990521
			US 1999-349733	A2	19990708
			US 1999-167463P	P	19991124
			US 1999-468440	A2	19991221
			WO 2000-US895	A2	20000114
US 6071748	A	20000606	US 1998-62472		19980417
			US 1997-52876P	P	19970716
			US 1997-59639P	P	19970920
			US 1997-63811P	P	19971031
			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75414P	P	19980220
			US 1998-75806P	P	19980224
			US 1998-82253P	P	19980417
EP 1032813	A2	20000906	EP 1998-959374		19980709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
			US 1997-63811P	P	19971031
			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75414P	P	19980220
			US 1998-75806P	P	19980224
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-84167P	P	19980504
			US 1998-85335P	P	19980513
			US 1998-85500P	P	19980514
			US 1998-89848P	P	19980619
			US 1998-92203P	P	19980709
			US 1998-94275P	P	19980709
			US 1998-94276P	P	19980727
			US 1998-100817P	P	19980918
			US 1998-100951P	P	19980918
			US 1998-156318	A	19980918
			US 1998-160533	A	19980924
			US 1998-104964P	P	19981020
			WO 1998-US23095	W	19981030

EP 1012579	A2	20000628	EP 1998-935657	19980715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
			US 1997-52876P	P 19970716
			US 1997-59639P	P 19970920
			US 1997-63811P	P 19971031
			US 1998-72499P	P 19980126
			US 1998-72780P	P 19980127
			US 1998-75414P	P 19980220
			US 1998-75806P	P 19980224
			US 1998-62472	A 19980417
			US 1998-82253P	P 19980417
			US 1998-84167P	P 19980504
			US 1998-85335P	P 19980513
			US 1998-85500P	P 19980514
			US 1998-89848P	P 19980619
			WO 1998-US14575	W 19980715
JP 2002509235	T2	20020326	JP 2000-503394	19980715
			US 1997-52876P	P 19970716
			US 1997-59639P	P 19970920
			US 1997-63811P	P 19971031
			US 1998-72499P	P 19980126
			US 1998-72780P	P 19980127
			US 1998-75414P	P 19980220
			US 1998-75806P	P 19980224
			US 1998-62472	A 19980417
			US 1998-82253P	P 19980417
			US 1998-84167P	P 19980504
			US 1998-85335P	P 19980513
			US 1998-85500P	P 19980514
			US 1998-89848P	P 19980619
			WO 1998-US14575	W 19980715
AU 9884853	A1	19990210	AU 1998-84853	19980720
			US 1997-52876P	P 19970716
			US 1997-59639P	P 19970920
			US 1997-63811P	P 19971031
			US 1998-72499P	P 19980126
			US 1998-72780P	P 19980127
			US 1998-75414P	P 19980220
			US 1998-75806P	P 19980224
			US 1998-62472	A 19980417
			US 1998-82253P	P 19980417
			US 1998-84167P	P 19980504
			US 1998-85335P	P 19980513
			US 1998-85500P	P 19980514
			US 1998-89848P	P 19980619
			AU 1999-15184	19981029
AU 9915184	A1	19990524	US 1997-63811P	P 19971031
			US 1998-72499P	P 19980126
			US 1998-72780P	P 19980127
			US 1998-75414P	P 19980220
			US 1998-75806P	P 19980224
			US 1998-62472	A 19980417
			US 1998-82253P	P 19980417
			US 1998-84167P	P 19980504
			US 1998-85335P	P 19980513
			US 1998-85500P	P 19980514
			US 1998-89848P	P 19980619
			US 1998-92203P	P 19980709
			US 1998-94275P	P 19980727
			US 1998-94276P	P 19980727

			US 1998-100817P	P	19980918
			US 1998-100951P	P	19980918
			US 1998-156318	A	19980918
			US 1998-160533	A	19980924
			US 1998-104964P	P	19981020
JP 2003521670	T2	20030715	WO 1998-US23095	W	19981030
			JP 2000-519281		19981030
			US 1997-63811P	P	19971031
			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75414P	P	19980220
			US 1998-75806P	P	19980224
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-84167P	P	19980504
			US 1998-85335P	P	19980513
			US 1998-85500P	P	19980514
			US 1998-89848P	P	19980619
			US 1998-92203P	P	19980709
			US 1998-94275P	P	19980727
			US 1998-94276P	P	19980727
			US 1998-100817P	P	19980918
			US 1998-100951P	P	19980918
			US 1998-156318	A	19980918
			US 1998-160533	A	19980924
			US 1998-104964P	P	19981020
AU 9923448	A1	19990809	WO 1998-US23095	W	19981030
			AU 1999-23448		19990125
			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75806P	P	19980224
			US 1998-62472	A	19980417
			US 1998-84167P	P	19980504
			US 1998-160533	A	19980924
			WO 1998-US23095	A	19981030
JP 2003526077	T2	20030902	WO 1999-US1656	W	19990125
			JP 2000-528201		19990125
			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75806P	P	19980224
			US 1998-62472	A	19980417
			US 1998-84167P	P	19980504
			US 1998-160533	A	19980924
			WO 1998-US23095	A	19981030
AU 9927758	A1	19990906	WO 1999-US1656	W	19990125
			AU 1999-27758		19990219
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-100951P	P	19980918
			US 1998-75414P	P	19980918
EP 1060384	A1	20001220	EP 1999-908291		19990219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
			US 1998-75414P	P	19980220
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-100951P	P	19980918
			US 1998-160533	A	19980924
			WO 1998-US23095	W	19981030
			WO 1999-US1656	W	19990125
			WO 1999-US3678	W	19990219

JP 2003526767	T2	20030909	JP 2000-532708	19990219
			US 1998-75414P	P 19980220
			US 1998-62472	A 19980417
			US 1998-82253P	P 19980417
			US 1998-100951P	P 19980918
			US 1998-160533	A 19980924
			WO 1998-US23095	A 19981030
			WO 1999-US1656	A 19990125
			WO 1999-US3678	W 19990219
US 6232608	B1	20010515	US 1999-274796	19990323
			US 1998-96999P	P 19980818
US 6313471	B1	20011106	US 1999-274791	19990323
			US 1998-96999P	P 19980818
WO 2000042209	A1	20000720	WO 2000-US895	20000114
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 1999-116113P	P 19990115
			WO 1999-US1656	A 19990125
			WO 1999-US8410	A 19990416
			US 1999-135284P	P 19990521
			US 1999-167463P	P 19991124
WO 2000055372	A1	20000921	WO 2000-US6841	20000315
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,				
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,				
MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,				
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 1999-124686P	P 19990316
			US 1999-125346P	P 19990319
			WO 1999-US8410	W 19990416
			US 1999-135284P	P 19990521
			US 1999-349733	A 19990708
			WO 2000-US895	W 20000114
			US 2000-494407	A 20000128
			US 2000-184719P	P 20000224
			US 2000-184924P	P 20000225
US 2001046673	A1	20011129	US 2001-770720	20010125
			US 1999-124686P	P 19990316
			US 1999-125346P	P 19990319
			WO 1999-US8410	A2 19990416
			US 1999-130149P	P 19990420
			US 1999-132262P	P 19990503
			US 1999-138311P	P 19990503
			US 1999-135284P	P 19990521
			US 1999-132263P	P 19990609
			US 1999-138438P	P 19990610
			US 1999-138737P	P 19990611
			US 1999-138893P	P 19990611
			US 1999-142721P	P 19990707
			US 1999-349733	A2 19990708
			US 1999-153251P	P 19990910
			US 1999-164633P	P 19991110

				WO 2000-US895	A2 20000114
				US 2000-494407	A2 20000128
				US 2000-184719P	P 20000224
				US 2000-184924P	P 20000225
				WO 2000-US6841	A2 20000315
US 2004239922	A1	20041202		US 2003-445292	20030522
US 6992761	B2	20060131			
				US 1998-144578	A2 19980831
				US 1998-146081	A3 19980902
				US 1998-156318	A1 19980918
				US 1998-160533	A1 19980924
				WO 1998-US23095	A1 19981030
				WO 1999-US1656	A1 19990125
				WO 1999-US3678	A1 19990219
				WO 1999-US8410	A1 19990416
				US 1999-302158	A2 19990429
				US 1999-349733	B2 19990708
				WO 1999-US16057	A1 19990715
				WO 1999-US16453	A1 19990721
				WO 1999-US16621	A1 19990723
				WO 1999-US16286	A1 19990726
				WO 1999-US16287	A1 19990726
				US 2000-478819	A2 20000105
				WO 2000-US895	A1 20000114
				US 2000-494407	A2 20000128
				WO 2000-US4543	A1 20000222
				WO 2000-US6841	A1 20000315
				WO 2000-US12277	A1 20000503
				WO 2000-US18547	A1 20000707
				US 2000-626208	B2 20000726
				US 2000-629599	A2 20000731
				US 2000-643221	A1 20000818
				US 2000-710061	A2 20001110
				US 2000-722247	B2 20001124
				US 2000-733370	B2 20001208
				US 2001-759711	A2 20010112
				US 2001-765869	A2 20010119
				US 2001-765874	A2 20010119
				US 2001-766131	B2 20010119
				US 2001-767316	A2 20010122
				US 2001-767434	A2 20010122
				US 2001-767579	A2 20010122
				US 2001-770720	B2 20010125
				US 2001-777343	A1 20010205
				US 2001-778224	A2 20010206
				US 2001-836575	B2 20010416
				US 2001-12255	A2 20011112
				US 2001-4647	A2 20011203
				US 2002-41532	B2 20020107
				US 2002-218897	A2 20020813
FAN	2002:610381				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 1231472	A1	20020814	EP 2002-250913	20020211
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2001-267639P	P 20010210
				US 2002-61416P	P 20020201
FAN	2002:906982				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----

PI	US 2002176801	A1	20021128	US 2002-61416		20020201
				US 1998-96999P	P	19980818
				US 1999-274792	B2	19990323
				US 2001-267639P	P	20010210
	US 6232608	B1	20010515	US 1999-274796		19990323
				US 1998-96999P	P	19980818
	US 6313471	B1	20011106	US 1999-274791		19990323
				US 1998-96999P	P	19980818
FAN	2003:532026					
	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
	-----	----	-----	-----		-----
PI	US 2003127609	A1	20030710	US 2002-218897		20020813
	US 6982431	B2	20060103			
				US 1998-144578	A2	19980831
				US 1999-302158	A2	19990429
				US 1999-349733	B2	19990708
				US 2000-478819	A2	20000105
				US 2000-629599	A2	20000731
				US 2000-710061	A2	20001110
				US 2000-733370	B2	20001208
				US 2001-759711	A2	20010112
				US 2001-765869	A2	20010119
				US 2001-767434	A2	20010122
				US 2001-778224	A2	20010206
				US 2001-836575	B2	20010416
				US 2001-12255	A2	20011112
				US 2001-4647	A2	20011203
				US 2002-41532	B2	20020107
	US 6499366	B1	20021231	US 1998-144578		19980831
				US 1997-52876P	P	19970716
				US 1997-59639P	P	19970920
				US 1997-63811P	P	19971031
				US 1998-72499P	P	19980126
				US 1998-72780P	P	19980127
				US 1998-75414P	P	19980220
				US 1998-75806P	P	19980224
				US 1998-62472	A1	19980417
				US 1998-82253P	P	19980417
				US 1998-84167P	P	19980504
				US 1998-85335P	P	19980513
				US 1998-85500P	P	19980514
				US 1998-89848P	P	19980619
				WO 1998-US14575	B1	19980715
				US 1998-118141	A1	19980716
				US 1998-118310	A1	19980716
				US 1998-118341	A1	19980716
				US 1998-94275P	P	19980727
				US 1998-94276P	P	19980727
				US 1998-94306P	P	19980727
	US 6488892	B1	20021203	US 2000-478819		20000105
				US 1998-62472	A1	19980417
				US 1998-85500P	P	19980514
				US 1998-89848P	P	19980619
				US 1998-156318	A1	19980918
				US 1998-160533	A1	19980924
				US 1998-114209P	P	19981229
				US 1999-119829P	P	19990212
				WO 1999-US8410	A1	19990416
	US 6469311	B1	20021022	US 2000-629599		20000731
				US 1997-52876P	P	19970716
				US 1997-59639P	P	19970920

			US 1997-63811P	P	19971031
			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75414P	P	19980220
			US 1998-75806P	P	19980224
			US 1998-62472	A1	19980417
			US 1998-82253P	P	19980417
			US 1998-84167P	P	19980504
			US 1998-85335P	P	19980513
			US 1998-85500P	P	19980514
			US 1998-89848P	P	19980619
			WO 1998-US14575	A1	19980715
			US 1998-118141	A1	19980716
			US 1998-118310	A1	19980716
			US 1998-118341	A1	19980716
			US 1998-94275P	P	19980727
			US 1998-94276P	P	19980727
			US 1998-94306P	P	19980727
			US 1998-144575	A1	19980831
			US 1998-144578	A1	19980831
			US 1998-146081	A1	19980902
			US 1998-100817P	P	19980918
			US 1998-156318	A1	19980918
			US 1998-160533	A1	19980924
			US 2000-478819	A1	20000105
US 6825921	B1	20041130	US 2000-710061		20001110
US 2001007496	A1	20010712	US 1999-164633P	P	19991110
US 6466316	B2	20021015	US 2001-765869		20010119
			US 1998-94275P	P	19980727
			US 1999-117278P	P	19990126
			US 1999-136566P	P	19990528
			WO 1999-US16621	W	19990723
US 2001006417	A1	20010705	US 2001-767434		20010122
US 6486947	B2	20021126			
			US 1998-93768P	P	19980722
			US 1998-94275P	P	19980727
			US 1998-94276P	P	19980727
			US 1998-94306P	P	19980727
			US 1998-100817P	P	19980918
			US 1998-100951P	P	19980918
			US 1998-104964P	P	19981020
			US 1998-114209P	P	19981229
			US 1999-116113P	P	19990115
			US 1999-117278P	P	19990126
			US 1999-119884P	P	19990212
			US 1999-121229P	P	19990223
			US 1999-124686P	P	19990316
			US 1999-125346P	P	19990319
			US 1999-126661P	P	19990329
			US 1999-130149P	P	19990420
			US 1999-132262P	P	19990503
			US 1999-132263P	P	19990503
			US 1999-135284P	P	19990521
			US 1999-136566P	P	19990528
			US 1999-138311P	P	19990609
			US 1999-138438P	P	19990610
			US 1999-138737P	P	19990611
			US 1999-138893P	P	19990611
			US 1999-142721P	P	19990707
			US 1999-143185P	P	19990709

US 2002009391	A1	20020124	WO 1999-US16453	A1	19990721
US 6838051	B2	20050104	US 2001-778224		20010206
			US 1999-132262P	P	19990503
			US 1999-132263P	P	19990503
			US 1999-138737P	P	19990611
			US 1999-138893P	P	19990611
			US 1999-153251P	P	19990910
			US 1999-167301P	P	19991124
US 2004239922	A1	20041202	US 2003-445292		20030522
US 6992761	B2	20060131			
			US 1998-144578	A2	19980831
			US 1998-146081	A3	19980902
			US 1998-156318	A1	19980918
			US 1998-160533	A1	19980924
			WO 1998-US23095	A1	19981030
			WO 1999-US1656	A1	19990125
			WO 1999-US3678	A1	19990219
			WO 1999-US8410	A1	19990416
			US 1999-302158	A2	19990429
			US 1999-349733	B2	19990708
			WO 1999-US16057	A1	19990715
			WO 1999-US16453	A1	19990721
			WO 1999-US16621	A1	19990723
			WO 1999-US16286	A1	19990726
			WO 1999-US16287	A1	19990726
			US 2000-478819	A2	20000105
			WO 2000-US895	A1	20000114
			US 2000-494407	A2	20000128
			WO 2000-US4543	A1	20000222
			WO 2000-US6841	A1	20000315
			WO 2000-US12277	A1	20000503
			WO 2000-US18547	A1	20000707
			US 2000-626208	B2	20000726
			US 2000-629599	A2	20000731
			US 2000-643221	A1	20000818
			US 2000-710061	A2	20001110
			US 2000-722247	B2	20001124
			US 2000-733370	B2	20001208
			US 2001-759711	A2	20010112
			US 2001-765869	A2	20010119
			US 2001-765874	A2	20010119
			US 2001-766131	B2	20010119
			US 2001-767316	A2	20010122
			US 2001-767434	A2	20010122
			US 2001-767579	A2	20010122
			US 2001-770720	B2	20010125
			US 2001-777343	A1	20010205
			US 2001-778224	A2	20010206
			US 2001-836575	B2	20010416
			US 2001-12255	A2	20011112
			US 2001-4647	A2	20011203
			US 2002-41532	B2	20020107
			US 2002-218897	A2	20020813
FAN 2004:1036352					
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
-----	----	-----	-----	-----	
PI US 2004239922	A1	20041202	US 2003-445292		20030522
US 6992761	B2	20060131			
			US 1998-144578	A2	19980831
			US 1998-146081	A3	19980902

		US 1998-156318	A1 19980918
		US 1998-160533	A1 19980924
		WO 1998-US23095	A1 19981030
		WO 1999-US1656	A1 19990125
		WO 1999-US3678	A1 19990219
		WO 1999-US8410	A1 19990416
		US 1999-302158	A2 19990429
		US 1999-349733	B2 19990708
		WO 1999-US16057	A1 19990715
		WO 1999-US16453	A1 19990721
		WO 1999-US16621	A1 19990723
		WO 1999-US16286	A1 19990726
		WO 1999-US16287	A1 19990726
		US 2000-478819	A2 20000105
		WO 2000-US895	A1 20000114
		US 2000-494407	A2 20000128
		WO 2000-US4543	A1 20000222
		WO 2000-US6841	A1 20000315
		WO 2000-US12277	A1 20000503
		WO 2000-US18547	A1 20000707
		US 2000-626208	B2 20000726
		US 2000-629599	A2 20000731
		US 2000-643221	A1 20000818
		US 2000-710061	A2 20001110
		US 2000-722247	B2 20001124
		US 2000-733370	B2 20001208
		US 2001-759711	A2 20010112
		US 2001-765869	A2 20010119
		US 2001-765874	A2 20010119
		US 2001-766131	B2 20010119
		US 2001-767316	A2 20010122
		US 2001-767434	A2 20010122
		US 2001-767579	A2 20010122
		US 2001-770720	B2 20010125
		US 2001-777343	A1 20010205
		US 2001-778224	A2 20010206
		US 2001-836575	B2 20010416
		US 2001-12255	A2 20011112
		US 2001-4647	A2 20011203
		US 2002-41532	B2 20020107
		US 2002-218897	A2 20020813
EP 1032813	A2 20000906	EP 1998-959374	19980709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
		US 1997-63811P	P 19971031
		US 1998-72499P	P 19980126
		US 1998-72780P	P 19980127
		US 1998-75414P	P 19980220
		US 1998-75806P	P 19980224
		US 1998-62472	A 19980417
		US 1998-82253P	P 19980417
		US 1998-84167P	P 19980504
		US 1998-85335P	P 19980513
		US 1998-85500P	P 19980514
		US 1998-89848P	P 19980619
		US 1998-92203P	P 19980709
		US 1998-94275P	P 19980709
		US 1998-94276P	P 19980727
		US 1998-100817P	P 19980918
		US 1998-100951P	P 19980918
		US 1998-156318	A 19980918

US 6499366	B1	20021231	US 1998-160533	A	19980924
			US 1998-104964P	P	19981020
			WO 1998-US23095	W	19981030
			US 1998-144578		19980831
			US 1997-52876P	P	19970716
			US 1997-59639P	P	19970920
			US 1997-63811P	P	19971031
			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75414P	P	19980220
			US 1998-75806P	P	19980224
			US 1998-62472	A1	19980417
			US 1998-82253P	P	19980417
			US 1998-84167P	P	19980504
			US 1998-85335P	P	19980513
			US 1998-85500P	P	19980514
			US 1998-89848P	P	19980619
			WO 1998-US14575	B1	19980715
			US 1998-118141	A1	19980716
			US 1998-118310	A1	19980716
			US 1998-118341	A1	19980716
			US 1998-94275P	P	19980727
			US 1998-94276P	P	19980727
			US 1998-94306P	P	19980727
US 6187267	B1	20010213	US 1998-146081		19980902
			US 1997-52876P	P	19970716
			US 1997-59639P	P	19970920
			US 1997-63811P	P	19971031
			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75414P	P	19980220
			US 1998-75806P	P	19980224
			US 1998-82253P	P	19980417
			US 1998-84167P	P	19980504
			US 1998-85335P	P	19980513
			US 1998-85500P	P	19980514
			US 1998-89848P	P	19980619
			US 1998-94275P	P	19980727
			US 1998-94276P	P	19980727
US 6258326	B1	20010710	US 1998-94306P	P	19980727
			US 1998-156318		19980918
			US 1997-59640P	P	19970920
			US 1998-85500P	P	19980514
			US 1998-89848P	P	19980619
AU 9915184	A1	19990524	AU 1999-15184		19981029
			US 1997-63811P	P	19971031
			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75414P	P	19980220
			US 1998-75806P	P	19980224
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-84167P	P	19980504
			US 1998-85335P	P	19980513
			US 1998-85500P	P	19980514
			US 1998-89848P	P	19980619
			US 1998-92203P	P	19980709
			US 1998-94275P	P	19980727
			US 1998-94276P	P	19980727
			US 1998-100817P	P	19980918
			US 1998-100951P	P	19980918

[illegible]

JP 2003526077	T2	20030902	WO 1999-US1656	W	19990125
			JP 2000-528201		19990125
			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75806P	P	19980224
			US 1998-62472	A	19980417
			US 1998-84167P	P	19980504
			US 1998-160533	A	19980924
			WO 1998-US23095	A	19981030
			WO 1999-US1656	W	19990125
EP 1060384	A1	20001220	EP 1999-908291		19990219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
			US 1998-75414P	P	19980220
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-100951P	P	19980918
			US 1998-160533	A	19980924
			WO 1998-US23095	W	19981030
			WO 1999-US1656	W	19990125
			WO 1999-US3678	W	19990219
JP 2003526767	T2	20030909	JP 2000-532708		19990219
			US 1998-75414P	P	19980220
			US 1998-62472	A	19980417
			US 1998-82253P	P	19980417
			US 1998-100951P	P	19980918
			US 1998-160533	A	19980924
			WO 1998-US23095	A	19981030
			WO 1999-US1656	A	19990125
			WO 1999-US3678	W	19990219
			WO 1999-US16057		19990715
WO 2000004364	A2	20000127			
WO 2000004364	A3	20000908			
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
			WO 1998-US14575	W	19980715
			US 1998-93838P	P	19980722
			US 1998-160533	A	19980924
			WO 1999-US16453		19990721
WO 2000005336	A2	20000203			
WO 2000005336	A3	20000427			
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
			US 1998-93768P	P	19980722
WO 2000006991	A2	20000210	WO 1999-US16621		19990723
WO 2000006991	A3	20000504			
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW					

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 1998-94275P P 19980727
 US 1999-117278P P 19990126
 US 1999-136566P P 19990528
 WO 2000006989 A2 20000210 WO 1999-US16286 19990726
 WO 2000006989 A3 20000323
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
 DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
 JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 1998-94306P P 19980727
 WO 2000006990 A2 20000210 WO 1999-US16287 19990726
 WO 2000006990 A3 20000518
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
 DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
 JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 1998-94276P P 19980727
 US 2000-478819 20000105
 US 1998-62472 A1 19980417
 US 1998-85500P P 19980514
 US 1998-89848P P 19980619
 US 1998-156318 A1 19980918
 US 1998-160533 A1 19980924
 US 1998-114209P P 19981229
 US 1999-119829P P 19990212
 WO 1999-US8410 A1 19990416
 WO 2000-US895 20000114
 WO 2000042209 A1 20000720
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
 DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
 JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 1999-116113P P 19990115
 WO 1999-US1656 A 19990125
 WO 1999-US8410 A 19990416
 US 1999-135284P P 19990521
 US 1999-167463P P 19991124
 US 2000-494407 20000128
 US 1998-62472 A2 19980417
 US 1998-96999P P 19980818
 US 1998-160533 A2 19980924
 WO 1999-US1656 A2 19990125
 US 1999-124686P P 19990316
 US 1999-125346P P 19990319
 WO 1999-US8410 A2 19990416
 US 1999-135284P P 19990521
 US 1999-349733 A2 19990708

			US 1999-167463P	P 19991124
			US 1999-468440	A2 19991221
			WO 2000-US895	A2 20000114
WO 2000050877	A1	20000831	WO 2000-US4543	20000222
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
			US 1999-121229P	P 19990223
WO 2000055372	A1	20000921	WO 2000-US6841	20000315
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
			US 1999-124686P	P 19990316
			US 1999-125346P	P 19990319
			WO 1999-US8410	W 19990416
			US 1999-135284P	P 19990521
			US 1999-349733	A 19990708
			WO 2000-US895	W 20000114
			US 2000-494407	A 20000128
			US 2000-184719P	P 20000224
			US 2000-184924P	P 20000225
WO 2000066269	A1	20001109	WO 2000-US12277	20000503
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
			US 1999-132262P	P 19990503
			US 1999-132263P	P 19990503
			US 1999-138737P	P 19990611
			US 1999-138893P	P 19990611
			US 1999-153251P	P 19990910
			US 1999-167301P	P 19991124
WO 2001004608	A1	20010118	WO 2000-US18547	20000707
WO 2001004608	C2	20020725		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6469311	B1	20021022	US 1999-142721P	P 19990707
			US 2000-629599	20000731
			US 1997-52876P	P 19970716
			US 1997-59639P	P 19970920
			US 1997-63811P	P 19971031

			US 1998-72499P	P	19980126
			US 1998-72780P	P	19980127
			US 1998-75414P	P	19980220
			US 1998-75806P	P	19980224
			US 1998-62472	A1	19980417
			US 1998-82253P	P	19980417
			US 1998-84167P	P	19980504
			US 1998-85335P	P	19980513
			US 1998-85500P	P	19980514
			US 1998-89848P	P	19980619
			WO 1998-US14575	A1	19980715
			US 1998-118141	A1	19980716
			US 1998-118310	A1	19980716
			US 1998-118341	A1	19980716
			US 1998-94275P	P	19980727
			US 1998-94276P	P	19980727
			US 1998-94306P	P	19980727
			US 1998-144575	A1	19980831
			US 1998-144578	A1	19980831
			US 1998-146081	A1	19980902
			US 1998-100817P	P	19980918
			US 1998-156318	A1	19980918
			US 1998-160533	A1	19980924
			US 2000-478819	A1	20000105
US 6825921	B1	20041130	US 2000-710061		20001110
US 2001003044	A1	20010607	US 1999-164633P	P	19991110
US 6483582	B2	20021119	US 2001-765874		20010119
			US 1998-94276P	P	19980727
			WO 1999-US16287	A1	19990726
US 2001007496	A1	20010712	US 2001-765869		20010119
US 6466316	B2	20021015			
			US 1998-94275P	P	19980727
			US 1999-117278P	P	19990126
			US 1999-136566P	P	19990528
			WO 1999-US16621	W	19990723
US 2001016330	A1	20010823	US 2001-766131		20010119
			US 1998-94306P	P	19980727
			WO 1999-US16286	A1	19990726
US 2001006417	A1	20010705	US 2001-767434		20010122
US 6486947	B2	20021126			
			US 1998-93768P	P	19980722
			US 1998-94275P	P	19980727
			US 1998-94276P	P	19980727
			US 1998-94306P	P	19980727
			US 1998-100817P	P	19980918
			US 1998-100951P	P	19980918
			US 1998-104964P	P	19981020
			US 1998-114209P	P	19981229
			US 1999-116113P	P	19990115
			US 1999-117278P	P	19990126
			US 1999-119884P	P	19990212
			US 1999-121229P	P	19990223
			US 1999-124686P	P	19990316
			US 1999-125346P	P	19990319
			US 1999-126661P	P	19990329
			US 1999-130149P	P	19990420
			US 1999-132262P	P	19990503
			US 1999-132263P	P	19990503
			US 1999-135284P	P	19990521
			US 1999-136566P	P	19990528

			US 1999-138311P	P	19990609
			US 1999-138438P	P	19990610
			US 1999-138737P	P	19990611
			US 1999-138893P	P	19990611
			US 1999-142721P	P	19990707
			US 1999-143185P	P	19990709
			WO 1999-US16453	A1	19990721
			US 2001-767579		20010122
US 2001019409	A1	20010906			
US 6317207	B2	20011113			
			US 1999-121229P	P	19990223
			WO 2000-US4543	A1	20000222
			US 2001-767316		20010122
US 2001034025	A1	20011025			
US 6503719	B2	20030107			
			US 1999-116113P	P	19990115
			WO 1999-US1656	A	19990125
			WO 1999-US8410	A	19990416
			US 1999-135284P	P	19990521
			US 1999-167463P	P	19991124
			WO 2000-US895	A1	20000114
US 2001046673	A1	20011129	US 2001-770720		20010125
			US 1999-124686P	P	19990316
			US 1999-125346P	P	19990319
			WO 1999-US8410	A2	19990416
			US 1999-130149P	P	19990420
			US 1999-132262P	P	19990503
			US 1999-138311P	P	19990503
			US 1999-135284P	P	19990521
			US 1999-132263P	P	19990609
			US 1999-138438P	P	19990610
			US 1999-138737P	P	19990611
			US 1999-138893P	P	19990611
			US 1999-142721P	P	19990707
			US 1999-349733	A2	19990708
			US 1999-153251P	P	19990910
			US 1999-164633P	P	19991110
			WO 2000-US895	A2	20000114
			US 2000-494407	A2	20000128
			US 2000-184719P	P	20000224
			US 2000-184924P	P	20000225
			WO 2000-US6841	A2	20000315
US 2001048899	A1	20011206	US 2001-777343		20010205
US 6902703	B2	20050607			
			US 1999-132262P	P	19990503
			US 1999-132263P	P	19990503
			US 1999-138311P	P	19990609
			US 1999-138438P	P	19990610
			US 1999-138737P	P	19990611
			US 1999-138893P	P	19990611
			US 1999-142721P	P	19990707
			US 1999-153251P	P	19990910
			US 1999-164633P	P	19991110
			US 1999-165813P	P	19991116
			US 1999-167301P	P	19991124
			US 1999-167463P	P	19991124
			US 2000-178026P	P	20000126
			US 2000-182036P	P	20000211
			US 2000-182419P	P	20000214
			US 2000-190265P	P	20000317
			US 2000-191890P	P	20000323
			US 2000-193586P	P	20000330
			US 2000-197324P	P	20000414

US 2002009391	A1	20020124	US 2000-200530P	P	20000427
US 6838051	B2	20050104	US 2000-200594P	P	20000428
			WO 2000-US12277	A1	20000503
			US 2001-778224		20010206
			US 1999-132262P	P	19990503
			US 1999-132263P	P	19990503
			US 1999-138737P	P	19990611
			US 1999-138893P	P	19990611
			US 1999-153251P	P	19990910
US 2003127609	A1	20030710	US 1999-167301P	P	19991124
US 6982431	B2	20060103	US 2002-218897		20020813
			US 1998-144578	A2	19980831
			US 1999-302158	A2	19990429
			US 1999-349733	B2	19990708
			US 2000-478819	A2	20000105
			US 2000-629599	A2	20000731
			US 2000-710061	A2	20001110
			US 2000-733370	B2	20001208
			US 2001-759711	A2	20010112
			US 2001-765869	A2	20010119
			US 2001-767434	A2	20010122
			US 2001-778224	A2	20010206
			US 2001-836575	B2	20010416
			US 2001-12255	A2	20011112
			US 2001-4647	A2	20011203
			US 2002-41532	B2	20020107
FAN 2005:1103253					
PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
-----	----	-----	-----		-----
PI US 2005227294	A1	20051013	US 2005-146553		20050606
			US 1997-929095	B2	19970915
			US 2000-200594P	P	20000428
			WO 2000-US16025	A2	20000609
			US 2000-596444	A2	20000619
			US 2000-223642P	P	20000808
			US 2000-241032P	P	20001017
			US 2001-844655	A2	20010427
			US 2002-436725P	P	20021226
			US 2003-507006P	P	20030929
			US 2003-746797	A2	20031223
			US 2004-577079P	P	20040604
			US 2004-602712P	P	20040818
			US 2004-615308P	P	20040930
WO 2000075167	A2	20001214	WO 2000-US16025		20000609
WO 2000075167	A3	20020912			
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,				
	CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,				
	ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,				
	LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,				
	SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,				
	ZA, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,				
	CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 1999-138311P	P	19990609
			US 1999-138438P	P	19990610
			US 1999-349733	A	19990708
			US 2000-200594P	P	20000428
US 2002034766	A1	20020321	US 2001-844655		20010427

US 7070921		B2	20060704	US 2000-200594P	P	20000428
				WO 2000-US16025	A1	20000609
				US 2000-596444	A1	20000619
				US 2000-223642P	P	20000808
				US 2000-241032P	P	20001017
US 2006121544		A1	20060608	US 2005-241872		20050930
				US 1997-929095	B2	19970915
				US 1999-138311P	P	19990609
				US 1999-138438P	P	19990610
				US 1999-349733	B2	19990708
				US 2000-200594P	P	20000428
				WO 2000-US16025	A2	20000609
				US 2000-596444	A2	20000619
				US 2000-223642P	P	20000808
				US 2000-241032P	P	20001017
				US 2001-844655	A2	20010427
				US 2002-436725P	P	20021226
				US 2003-507006P	P	20030929
				US 2003-507569P	P	20030930
				US 2003-746797	A2	20031223
				US 2004-577079P	P	20040604
				US 2004-602712P	P	20040818
				US 2004-615308P	P	20040930
				US 2004-957332	A2	20040930
				US 2005-683377P	P	20050520
				US 2005-146553	A2	20050606
FAN	2005:1355610					
	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
	-----	----	-----	-----		-----
PI	US 2005285129	A1	20051229	US 2005-100320		20050405
				US 2000-244012P	P	20001027
				US 2001-3030	A2	20011029
	WO 2002035260	A2	20020502	WO 2001-US46411		20011029
	WO 2002035260	A3	20021024			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,					
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,					
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,					
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,					
	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,					
	UG, US, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,					
	KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,					
	IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,					
	GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2000-244012P	P	20001027
AU	2002030592	A5	20020506	AU 2002-30592		20011029
				US 2000-244012P	P	20001027
				WO 2001-US46411	W	20011029
	US 2002109100	A1	20020815	US 2001-3030		20011029
	US 6930314	B2	20050816			
				US 1998-96999P	P	19980818
				US 2000-244012P	P	20001027
FAN	2006:344049					
	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
	-----	----	-----	-----		-----
PI	WO 2006039505	A2	20060413	WO 2005-US35215		20050930
	WO 2006039505	A3	20060706			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,					
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,					
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,					

	LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
				US 2004-615308P	P 20040930
				US 2005-683377P	P 20050520
FAN	2006:544538				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2006121544	A1	20060608	US 2005-241872	20050930
				US 1997-929095	B2 19970915
				US 1999-138311P	P 19990609
				US 1999-138438P	P 19990610
				US 1999-349733	B2 19990708
				US 2000-200594P	P 20000428
				WO 2000-US16025	A2 20000609
				US 2000-596444	A2 20000619
				US 2000-223642P	P 20000808
				US 2000-241032P	P 20001017
				US 2001-844655	A2 20010427
				US 2002-436725P	P 20021226
				US 2003-507006P	P 20030929
				US 2003-507569P	P 20030930
				US 2003-746797	A2 20031223
				US 2004-577079P	P 20040604
				US 2004-602712P	P 20040818
				US 2004-615308P	P 20040930
				US 2004-957332	A2 20040930
				US 2005-683377P	P 20050520
				US 2005-146553	A2 20050606
WO 2000075167		A2	20001214	WO 2000-US16025	20000609
WO 2000075167		A3	20020912		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-138311P	P 19990609
				US 1999-138438P	P 19990610
				US 1999-349733	A 19990708
				US 2000-200594P	P 20000428
US 2002034766		A1	20020321	US 2001-844655	20010427
US 7070921		B2	20060704		
				US 2000-200594P	P 20000428
				WO 2000-US16025	A1 20000609
				US 2000-596444	A1 20000619
				US 2000-223642P	P 20000808
				US 2000-241032P	P 20001017
US 2005227294		A1	20051013	US 2005-146553	20050606
				US 1997-929095	B2 19970915
				US 2000-200594P	P 20000428
				WO 2000-US16025	A2 20000609

US 2000-596444	A2 20000619
US 2000-223642P	P 20000808
US 2000-241032P	P 20001017
US 2001-844655	A2 20010427
US 2002-436725P	P 20021226
US 2003-507006P	P 20030929
US 2003-746797	A2 20031223
US 2004-577079P	P 20040604
US 2004-602712P	P 20040818
US 2004-615308P	P 20040930

OS MARPAT 133:174260

AB Compns. are described which comprise photoluminescent metal-ligand complexes having a high intrinsic fundamental polarization which are described by the general formulas B-M-L-R1 or R2(R3)M(E1)E2 (M = a long-lifetime luminophor, especially Ru, Os, or Rh; L = independently selected -C(:O)-(O)m-Q1 groups; m = 0 or 1; Q = alkyl or aryl; R1 = -N:C:S or -NH-C(:S)-NH-P'; R2, R3 = -N:C:S, L-N:C:S, -NH-C(:S)-NH-P', or L-NH-C(:S)-NH-P' for which the L groups are selected independently; P' = proteins, polynucleotides, antibodies, beads, and solid supports; E1 = an electron-withdrawing group; and E2 = H or an electron-withdrawing group). Use in luminescence assays is indicated. The complexes and/or acceptors may be used in free, reactive, and/or conjugated form, alone or mixed with other compds. Preferred luminescence assays include luminescence polarization and luminescence resonance energy transfer assays, among others.


IT 288396-78-1P


RL: ARG (Analytical reagent use); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses)
(luminescent metal-ligand complexes)

RN 288396-78-1 CAPLUS


CN Benzenesulfonic acid, 5-[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethoxy]-2-[[4-[ethyl[(3-sulfophenyl)methyl]amino]-2-methylphenyl]][4-[ethyl[(3-sulfophenyl)methyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





IT 288396-76-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (luminescent metal-ligand complexes)
 RN 288396-76-9 CAPLUS
 CN Acetic acid, [4-[[4-[ethyl[(3-sulfophenyl)methyl]amino]-2-methylphenyl]][4-
 [ethyl[(3-sulfophenyl)methyl]amino]phenyl]methyl]-3-sulfophenoxy]-,
 1-ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 73 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:495227 CAPLUS
 DN 133:266557
 TI Extended structures built on a triphenoxymethane platform; C3-symmetric,
 conformational mimics of calix[n]arenes
 AU Dinger, Maarten B.; Scott, Michael J.
 CS Department of Chemistry, University of Florida, Gainesville, FL,
 32611-7200, USA
 SO European Journal of Organic Chemistry (2000), (13), 2467-2478
 CODEN: EJOCFK; ISSN: 1434-193X
 PB Wiley-VCH Verlag GmbH
 DT Journal
 LA English
 OS CASREACT 133:266557
 AB A series of C3-sym. tris(3,5-dialkyl-2-hydroxyphenyl)methanes (alkyl =
 CMe3, Me, CMe2Et) were synthesized in high yield from their resp. phenols

and fully characterized, including single crystal X-ray structures for 2 examples. The di-tert-butyl-substituted compound was derivatized to a tris-acid chloride, which was treated with a variety of amines (dimethylamine, benzylamine, glycine, alanine) from which the corresponding trisamides were formed. The absolute geometry and conformation of the dimethylamine-, glycine-, and alanine-derived systems were determined by x-ray anal., and in all cases, the 3 phenolate arms point up with respect to the central methyne. Alkali metal binding studies (Li, Na, K, Rb, Cs) were carried out for the dimethylamine, benzylamine, and glycine compds., and these compds. were found to have some selectivity for K+. NMR studies demonstrate that C3 symmetry is retained in all the compds. and the stoichiometry for Li+ complexation is 1:1, whereas two ligands are needed to complex Na+. Crystal structures of the dimethylamine derivative with Li picrate and the benzylamine and glycine derivs. with NaBPh4 were also determined

IT 297164-44-4P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(crystal structure)


RN 297164-44-4 CAPLUS

CN Acetic acid, 2,2',2''-[methylidynetris[[6-(1,1-dimethylethyl)-4-methyl-2,1-phenylene]oxy]]tris-, triethyl ester, compd. with methanol (3:4) (9CI)
(CA INDEX NAME)

CM 1

CRN 297164-36-4

CMF C46 H64 O9



CM 2

CRN 67-56-1


CMF C H4 O

H₃C—OH



IT 297164-35-3P 297164-37-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)


(preparation of extended structures built on triphenoxymethane platform)
 RN 297164-35-3 CAPLUS
 CN Acetic acid, 2,2',2''-[methylidynetris[[4,6-bis(1,1-dimethylethyl)-2,1-phenylene]oxy]]tris-, triethyl ester (9CI) (CA INDEX NAME)



RN 297164-37-5 CAPLUS
 CN Acetic acid, 2,2',2''-[methylidynetris[[4,6-bis(1,1-dimethylethyl)-2,1-phenylene]oxy]]tris- (9CI) (CA INDEX NAME)



IT 297164-36-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of extended structures built on triphenoxymethane platform)
 RN 297164-36-4 CAPLUS
 CN Acetic acid, 2,2',2''-[methylidynetris[[6-(1,1-dimethylethyl)-4-methyl-2,1-phenylene]oxy]]tris-, triethyl ester (9CI) (CA INDEX NAME)



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 74 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:324131 CAPLUS

DN 133:119863

TI Stereoselective Heck-type cross-coupling reactions of iodine heterocyclic compounds with olefins

AU Liang, Yongmin; Luo, Shengjun; Liu, Chaomin; Wu, Xiaoli; Ma, Yongxiang

CS National Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou, 730000, Peop. Rep. China

SO Tetrahedron (2000), 56(19), 2961-2965

CODEN: TETRAB; ISSN: 0040-4020

PB Elsevier Science Ltd.

DT Journal

LA English

AB Polyfunctional mols. are prepared by a modified stereoselective Heck-type cross-coupling reaction between iodine heterocyclic compds. and olefins in DMF using Pd(OAc)₂ as a catalyst in the presence of bases (Na₂CO₃ or K₂CO₃). The starting materials thus used were 3,7-bis(dimethylamino)-10H-dibenz[b,e]iodinium compds., 3,7-dinitro-10H-dibenz[b,e]iodinium and dibenziodolium. This coupling reaction proceeds smoothly at room temperature and gave coupling products in high yields. For example, the palladium diacetate-catalyzed coupling of 3,7-bis(dimethylamino)-10H-dibenz[b,e]iodinium iodide with 2-propenal in DMF gave (2E)-3-[2-[[4-(dimethylamino)-2-iodophenyl]methyl]phenyl]-2-propenal in 90% yield.


IT 284038-29-5P 284038-32-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 284038-29-5 CAPLUS


CN 2-Propenamide, 3-[5-(dimethylamino)-2-[[4-(dimethylamino)-2-iodophenyl]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 284038-32-0 CAPLUS
 CN 2-Propenamide, 3-[2-[(2-iodo-4-nitrophenyl)methyl]-5-nitrophenyl]-, (2E)-
 (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 75 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:198003 CAPLUS
 DN 132:236873
 TI Preparation of trisphenol ethers as dissolution inhibitors for
 photoresists
 IN Miyagi, Sachiko; Masuda, Toru
 PA Honshu Chemical Industry Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000086584	A2	20000328	JP 1999-43177	19990222
				JP 1998-200737	A 19980715

OS MARPAT 132:236873
 AB Title compds. I (R1 = CH2CO2CMe3, tetrahydropyranyl; R2 = C1-4 alkyl; R3 = C5-6 cycloalkyl; R4 = C1-4 alkyl, alkoxy; m = 0-3; n = 0-2; k = 0, 1; 0 ≤ m + n ≤ 3), useful as dissoln. inhibitors for chemical amplified photoresists (no data), are prepared Bis(5-cyclohexyl-4-hydroxy-2-methylphenyl)methyl-2-hydroxybenzene was treated with ClCH2CO2CMe3 and K2CO3 in DMF at 110° for 7 h to give 90.1% I bis(2-methyl-4-tert-butoxycarbonylmethyloxy-5-cyclohexylphenyl)methyl-2-tert-

IT butoxycarbonylmethyloxybenzene.
 262285-37-0P 262285-43-8P
 RL: SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (preparation of trisphenol ethers as dissoln. inhibitors for photoresists)
 RN 262285-37-0 CAPLUS
 CN Acetic acid, 2,2'-[[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]methylene]bis[(2-cyclohexyl-5-methyl-4,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 262285-43-8 CAPLUS
 CN Acetic acid, 2,2'-[[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-methoxyphenyl]methylene]bis[(3,5,6-trimethyl-2,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 76 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:130258 CAPLUS
 DN 132:264937
 TI Synthesis and antimicrobial screening of 1,1,1-trichloro-2-(4'-carboxymethoxy-3'-methylphenyl)-2-(carboxyaryl/carboxymethoxyaryl)ethanes
 AU Purohit, D. M.; Shah, V. H.
 CS Department of Chemistry, Saurashtra University, Rajkot, 360 005, India
 SO Journal of the Institution of Chemists (India) (1999), 71(2), 56-57
 CODEN: JOICA7; ISSN: 0020-3254
 PB Institution of Chemists (India)
 DT Journal
 LA English
 AB Title compds. such as I were prepared from 2-MeC₆H₄OCH₂CO₂H and chloral

hydrate via II. The products showed moderate to good antimicrobial activity as compared to known standard drugs, ampicillin, chloramphenicol, norfloxacin and griseofulvin.


IT 263141-67-9P 263141-71-5P 263141-72-6P
263141-73-7P 263141-74-8P 263141-75-9P
263141-76-0P 263141-77-1P 263141-78-2P
263141-79-3P 263141-80-6P 263141-81-7P
263141-82-8P 263141-83-9P 263141-84-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antimicrobial activity of)


RN 263141-67-9 CAPLUS

CN Benzoic acid, 3-[1-[4-(carboxymethoxy)-3-methylphenyl]-2,2,2-trichloroethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 263141-71-5 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 4-[1-[4-(carboxymethoxy)-3-methylphenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 263141-72-6 CAPLUS

CN 1,4-Benzenedicarboxylic acid, 2-[1-[4-(carboxymethoxy)-3-methylphenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 263141-73-7 CAPLUS


CN Benzoic acid, 5-[1-[4-(carboxymethoxy)-3-methylphenyl]-2,2,2-trichloroethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 263141-74-8 CAPLUS
CN Benzoic acid, 3-[1-[4-(carboxymethoxy)-3-methylphenyl]-2,2,2-trichloroethyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 263141-75-9 CAPLUS
CN Benzoic acid, 5-[1-[4-(carboxymethoxy)-3-methylphenyl]-2,2,2-trichloroethyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 263141-76-0 CAPLUS
CN Benzoic acid, 3-[1-[4-(carboxymethoxy)-3-methylphenyl]-2,2,2-trichloroethyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 263141-77-1 CAPLUS
CN Benzoic acid, 5-[1-[4-(carboxymethoxy)-3-methylphenyl]-2,2,2-trichloroethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 263141-78-2 CAPLUS
 CN Benzoic acid, 3-[1-[4-(carboxymethoxy)-3-methylphenyl]-2,2,2-trichloroethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 263141-79-3 CAPLUS
 CN Benzoic acid, 5-[1-[4-(carboxymethoxy)-3-methylphenyl]-2,2,2-trichloroethyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 263141-80-6 CAPLUS
 CN Acetic acid, [4-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 263141-81-7 CAPLUS
 CN Acetic acid, [4-[1-[5-(carboxymethoxy)-2-chlorophenyl]-2,2,2-trichloroethyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 263141-82-8 CAPLUS

CN Acetic acid, [5-[1-[4-(carboxymethoxy)-3-methylphenyl]]-2,2,2-trichloroethyl]-2-nitrophenoxy]- (9CI) (CA INDEX NAME)




RN 263141-83-9 CAPLUS

CN Acetic acid, [3-[1-[4-(carboxymethoxy)-3-methylphenyl]]-2,2,2-trichloroethyl]-4-nitrophenoxy]- (9CI) (CA INDEX NAME)



RN 263141-84-0 CAPLUS

CN Acetic acid, [4-[1-[4-(carboxymethoxy)-2-methylphenyl]]-2,2,2-trichloroethyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



L8 ANSWER 77 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:15170 CAPLUS

DN 132:64066

TI synthesis and pharmaceutical compositions of thyroid hormone analogues

IN Scanlan, Thomas S.; Yoshihara, Hikari A. I.; Chiellini, Grazia; Mitchison, Timothy J.

PA The Regents of the University of California, USA

SO PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.


KIND

DATE

APPLICATION NO.


DATE

PI WO 2000000468 A1 20000106 WO 1999-US14627 19990628
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
 DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
 JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2335551 AA 20000106 US 1998-91185P P 19980630
 CA 1999-2335551 19990628
 US 1998-91185P P 19980630
 WO 1999-US14627 W 19990628
 AU 9948401 A1 20000117 AU 1999-48401 19990628
 US 1998-91185P P 19980630
 EP 1089968 A1 20010411 EP 1999-932002 19990628
 EP 1089968 B1 20050420
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 US 1998-91185P P 19980630
 WO 1999-US14627 W 19990628
 JP 2002519340 T2 20020702 JP 2000-557229 19990628
 US 1998-91185P P 19980630
 WO 1999-US14627 W 19990628
 AT 293595 E 20050515 AT 1999-932002 19990628
 US 1998-91185P P 19980630
 WO 1999-US14627 W 19990628
 ES 2241294 T3 20051016 ES 1999-932002 19990628
 US 1998-91185P P 19980630
 EP 1598334 A1 20051123 EP 2005-8536 19990628
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI, CY
 US 1998-91185P P 19980630
 EP 1999-932002 A3 19990628
 US 1999-345673 19990630
 US 1998-91185P P 19980630
 US 6107517 A 20000822
 OS MARPAT 132:64066
 AB Synthesis of thyroid hormone analogs (I) [n = 1-3; R1 = alkyl, alkanol,
 alkenyl, alkenol, heterocyclo, (un)substituted aryl; R2 = H, alkyl,
 cycloalkyl; R3= H, alkyl, cycloalkyl; R4 = H, alkyl, cycloalkyl, acyl; R5,
 R6 = H, alkyl; R7, R8 = independently H, halogen, alkyl, (un)substituted
 Ph, (un)substituted benzyl, heteroaryl providing both are not H] and
 pharmaceutically acceptable salts are disclosed. Methods of using such
 analogs and pharmaceutical compns. containing them are also disclosed, as are
 novel procedures for their preparation
 IT 253329-29-2P 253329-30-5P 253329-32-7P
 253329-33-8P 253329-34-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis and pharmaceutical compns. of thyroid hormone analogs)
 RN 253329-29-2 CAPLUS
 CN Acetic acid, [4-[12-(butylmethylamino)-1-[4-hydroxy-3-(1-
 methylethyl)phenyl]-12-oxododecyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX
 NAME)




RN 253329-30-5 CAPLUS
 CN Acetic acid, [4-[(4Z)-12-(butylmethylamino)-1-[4-hydroxy-3-(1-methylethyl)phenyl]-12-oxo-4-dodecenyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 253329-32-7 CAPLUS
 CN Acetic acid, [4-[1-[4-hydroxy-3-(1-methylethyl)phenyl]-3-butenyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 253329-33-8 CAPLUS
 CN Acetic acid, [4-[4-hydroxy-1-[4-hydroxy-3-(1-methylethyl)phenyl]butyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)





RN 253329-34-9 CAPLUS
 CN Acetic acid, [4-[(2,4-dimethoxyphenyl)[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



IT 253329-14-5P 253329-15-6P 253329-16-7P
 253329-17-8P 253329-18-9P 253329-19-0P
 253329-20-3P 253329-21-4P 253329-22-5P
 253329-23-6P 253329-24-7P 253329-25-8P
 253329-31-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (synthesis and pharmaceutical compns. of thyroid hormone analogs)
 RN 253329-14-5 CAPLUS
 CN Acetic acid, [4-[(4-hydroxy-1-[3-(1-methylethyl)-4-[[tris(1-methylethyl)silyl]oxy]phenyl]butyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 253329-15-6 CAPLUS
 CN Acetic acid, [3,5-dimethyl-4-[1-[3-(1-methylethyl)-4-[[tris(1-methylethyl)silyl]oxy]phenyl]-4-oxobutyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 253329-16-7 CAPLUS
 CN Acetic acid, [4-[(4Z)-12-(butylmethylamino)-1-[3-(1-methylethyl)-4-[[tris(1-methylethyl)silyl]oxy]phenyl]-12-oxo-4-dodeceny]]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 253329-17-8 CAPLUS
 CN Acetic acid, [4-[12-(butylmethylamino)-1-[3-(1-methylethyl)-4-[[tris(1-methylethyl)silyl]oxy]phenyl]-12-oxododecyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 253329-18-9 CAPLUS
 CN Acetic acid, [4-[12-(butylmethylamino)-1-[4-hydroxy-3-(1-methylethyl)phenyl]-12-oxododecyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 253329-19-0 CAPLUS
 CN Acetic acid, [4-[(4Z)-12-(butylmethylamino)-1-[4-hydroxy-3-(1-methylethyl)phenyl]-12-oxo-4-dodecenyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 253329-20-3 CAPLUS
 CN Acetic acid, [3,5-dimethyl-4-[1-[3-(1-methylethyl)-4-[[tris(1-methylethyl)silyl]oxy]phenyl]-3-butenyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 253329-21-4 CAPLUS

CN Acetic acid, [4-[4-hydroxy-1-[3-(1-methylethyl)-4-[[tris(1-methylethyl)silyl]oxy]phenyl]butyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 253329-22-5 CAPLUS

CN Acetic acid, [4-[4-hydroxy-1-[4-hydroxy-3-(1-methylethyl)phenyl]butyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 253329-23-6 CAPLUS

CN Acetic acid, [4-[methoxy[3-(1-methylethyl)-4-[[tris(1-methylethyl)silyl]oxy]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 253329-24-7 CAPLUS


CN Acetic acid, [4-[(2,4-dimethoxyphenyl)[3-(1-methylethyl)-4-[[tris(1-methylethyl)silyl]oxy]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 253329-25-8 CAPLUS
 CN Acetic acid, [4-[(2,4-dimethoxyphenyl)(1-methylethyl)methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 253329-31-6 CAPLUS
 CN Acetic acid, [4-[methoxy[3-(1-methylethyl)-4-[[tris(1-methylethyl)silyl]oxy]phenyl]methyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 78 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1999:780157 CAPLUS
 DN 132:122347
 TI Synthesis and antimicrobial screening of 1,1,1-trichloro-2-[3-(carboxymethoxy)-4-chlorophenyl]-2-(carboxyaryl/carboxymethoxyaryl)ethanes
 AU Purohit, D. M.; Shah, V. H.
 CS Chemistry Department, Saurashtra University, Rajkot, 360005, India


SO Journal of the Institution of Chemists (India) (1999), 71(1), 37-39
 CODEN: JOICA7; ISSN: 0020-3254
 PB Institution of Chemists (India)
 DT Journal
 LA English
 AB Title compds. such as I were prepared from benzyl alc. derivative II and substituted benzenes in the presence of concentrated sulfuric acid. The products were active against Gram pos. and neg. bacteria and fungi.
 IT 256379-76-7P 256379-80-3P 256379-81-4P
 256379-82-5P 256379-83-6P 256379-84-7P
 256379-85-8P 256379-86-9P 256379-87-0P
 256379-88-1P 256379-89-2P 256379-90-5P
 256379-91-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antimicrobial activity of)
 RN 256379-76-7 CAPLUS
 CN Benzoic acid, 5-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 256379-80-3 CAPLUS
 CN Benzoic acid, 5-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 256379-81-4 CAPLUS
 CN 1,2-Benzenedicarboxylic acid, 4-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 256379-82-5 CAPLUS
 CN 1,4-Benzenedicarboxylic acid, 2-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 256379-83-6 CAPLUS
 CN Benzoic acid, 5-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 256379-84-7 CAPLUS
 CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 256379-85-8 CAPLUS
 CN Benzoic acid, 5-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 256379-86-9 CAPLUS
 CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 256379-87-0 CAPLUS
 CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 256379-88-1 CAPLUS
 CN Acetic acid, [3-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-4-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 256379-89-2 CAPLUS
 CN Acetic acid, [5-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-2-nitrophenoxy]- (9CI) (CA INDEX NAME)



RN 256379-90-5 CAPLUS
 CN Acetic acid, [4-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-3-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 256379-91-6 CAPLUS
 CN Acetic acid, [3-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-4-methylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 79 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1999:613860 CAPLUS
 DN 131:243084
 TI Preparation of naphthyl and indolyl acylsulfonamides for the treatment and prevention of prostaglandin mediated disease
 IN Gareau, Yves; Labelle, Marc; Juteau, Helene; Gallant, Michel; Lachance, Nicolas; Belley, Michel
 PA Merck Frosst Canada & Co., Can.
 SO PCT Int. Appl., 143 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9947497	A2	19990923	WO 1999-CA212	19990312
	WO 9947497	A3	19991028		
	W:	AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				US 1998-77990P	P 19980313
				GB 1998-15856	A 19980721
	US 6242493	B1	20010605	US 1999-266047	19990310
				US 1998-77990P	P 19980313
	CA 2322742	AA	19990923	CA 1999-2322742	19990312

			US 1998-77990P	P	19980313
			WO 1999-CA212	W	19990312
AU 9927086	A1	19991011	AU 1999-27086		19990312
AU 756333	B2	20030109			
			US 1998-77990P	P	19980313
			GB 1998-15856	A	19980721
			WO 1999-CA212	W	19990312
EP 1071648	A2	20010131	EP 1999-907214		19990312
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
			US 1998-77990P	P	19980313
			GB 1998-15856	A	19980721
			WO 1999-CA212	W	19990312
JP 2002506851	T2	20020305	JP 2000-536694		19990312
			US 1998-77990P	P	19980313
			WO 1999-CA212	W	19990312

OS MARPAT 131:243084

AB Naphthyl and indolyl acylsulfonamides (I) [where HET = 5-12 membered monocyclic or bicyclic aromatic ring with 1-3 O, S(O)_n, or N(O)_m heteroatoms; A = O, S(O)_n, (un)substituted NH, C(O), (un)substituted CH₂, CH₂-CH₂ or CH=CH, etc.; B = (un)substituted (CH₂)_p-Y-(CH₂)_q; X = (un)substituted 5-10 membered monocyclic or bicyclic (hetero)aryl with 1-3 O, S(O)_n, or N(O)_m heteroatoms; Y = O, S(O)_n, (un)substituted NH, a bond, or (un)substituted CH=CH; Z = OH or NH-SO₂R₄; R₁, R₂, and R₃ = independently H, halogen, alkyl, alkenyl, (heteroaryl)alkynyl, (un)substituted (CH₂)_pS(O)_nH, (CH₂)_pOH, or (CH₂)_pNH₂, CN, NO₂, CO₂H or ester, (un)substituted C(O)-NH₂; R₄ = (heteroaryl)alkyl, (heteroaryl)alkenyl, alkynyl, CF₃, heteroaryl; m = 0 or 1; n = 0-2; p and q = independently 0-3 and p + q = 0-6], as well as pharmaceutically acceptable salts, hydrates and esters thereof, were prepared as antagonists of the pain and inflammatory effects of E-type prostaglandins. For instance, Et (E)-3-[2-(bromomethyl)phenyl]-2-propenoate (preparation given) was treated with 2-naphthylboronic acid, followed by hydrolysis of the ester to give (E)-3-[2-(2-naphthylmethyl)phenyl]-2-propenoic acid. The acid was coupled with 2-thiophenesulfonamide to yield N-{(E)-3-[2-(2-naphthylmethyl)phenyl]-2-propenoyl}-2-thiophenesulfonamide (II). Compds. of the invention were reported to have demonstrated prostanoid antagonist or agonist activity and selectivity through a variety of in vitro and in vivo prostanoid receptor assays (no data). Testing against edema, pyrexia, inflammation, and arthritis was also discussed (no data). The compds. are claimed to be useful as analgesics, antipyretic agents, antiinflammatory agents, and antitumor agents for the treatment or prevention of prostaglandin mediated disease.

IT 244102-12-3P 244102-16-7P 244102-25-8P
244102-28-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of naphthyl and indolyl acylsulfonamides for the treatment and prevention of prostaglandin mediated disease)


RN 244102-12-3 CAPLUS

CN 2-Propenamide, N-[(5-bromo-2-methoxyphenyl)sulfonyl]-3-[5-chloro-2-[(3,4-dichlorophenyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 244102-16-7 CAPLUS
 CN 2-Propenamide, N-[(5-bromo-2-methoxyphenyl)sulfonyl]-3-[4-chloro-2-[(3,4-dichlorophenyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244102-25-8 CAPLUS
 CN 2-Propenamide, 3-[5-chloro-2-[(3,4-dichlorophenyl)methyl]phenyl]-N-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)




RN 244102-28-1 CAPLUS
 CN 2-Propenamide, 3-[4-chloro-2-[(3,4-dichlorophenyl)methyl]phenyl]-N-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)



IT 244103-67-1
 RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
 (treatment; preparation of naphthyl and indolyl acylsulfonamides for the treatment and prevention of prostaglandin mediated disease)
 RN 244103-67-1 CAPLUS
 CN 2-Propenamide, N-[(5-bromo-2-methoxyphenyl)sulfonyl]-3-[5-chloro-2-[(3,4-dichlorophenyl)methyl]phenyl]-, sodium salt, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● Na

L8 ANSWER 80 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1999:533606 CAPLUS
 DN 131:286234
 TI Synthesis of 1,1,1-trichloro-2,2-bis(carboxymethoxyaryl)ethanes as potential antimicrobial and insecticidal agents
 AU Purohit, D. M.; Shah, V. H.
 CS Department of Chemistry, Saurashtra University, Rajkot, 360 005, India
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1999), 38B(5), 618-622
 CODEN: IJSBDB; ISSN: 0376-4699
 PB National Institute of Science Communication, CSIR
 DT Journal
 LA English
 AB Some new 1,1,1-trichloro-2,2-bis(carboxymethoxyaryl)ethanes have been

synthesized by treating aryloxyacetic acids (2 mol) with chloral hydrate (1 mol) in the presence of a catalytic amount of concentrated sulfuric acid.

The

aryloxyacetic acids are prepared by reaction of phenols with chloroacetic acid in the presence of aqueous sodium hydroxide. The antimicrobial activities of these compds. have been assayed against Gram pos. and Gram neg. bacteria and fungi; insecticidal activities have been examined against the rice leaf hopper.


IT 246149-75-7P 246149-76-8P 246149-77-9P
246149-78-0P 246149-79-1P 246149-80-4P
246149-81-5P 246149-82-6P 246149-83-7P
246149-84-8P 246149-85-9P 246149-86-0P
246149-87-1P 246149-88-2P 246149-89-3P
246149-90-6P 246149-91-7P 246149-92-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antimicrobial and insecticidal activity of)


RN 246149-75-7 CAPLUS

CN Benzoic acid, 3,3'-(2,2,2-trichloroethylidene)bis[6-(carboxymethoxy)-
(9CI) (CA INDEX NAME)




RN 246149-76-8 CAPLUS

CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(2-chloro-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-77-9 CAPLUS

CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(3-chloro-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-78-0 CAPLUS


CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(5,6-dichloro-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-79-1 CAPLUS
CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(4,6-dichloro-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-80-4 CAPLUS
CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(4,6-dichloro-2,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-81-5 CAPLUS
CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(2,4,6-trichloro-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-82-6 CAPLUS
CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(2-methyl-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-83-7 CAPLUS
CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(3-methyl-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-84-8 CAPLUS
CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(4-methyl-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-85-9 CAPLUS
CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(4,6-dimethyl-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-86-0 CAPLUS
CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(2,5-dimethyl-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-87-1 CAPLUS
 CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(2-methyl-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



RN 246149-88-2 CAPLUS
 CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(5-nitro-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-89-3 CAPLUS
 CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(4-nitro-3,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 246149-90-6 CAPLUS
 CN Acetic acid, 2,2',2'',2'''-[(2,2,2-trichloroethylidene)bis[4,1,2-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)


benzenetriylbis(oxy)]]tetrakis- (9CI) (CA INDEX NAME)



RN 246149-91-7 CAPLUS
CN Acetic acid, 2,2',2'',2'''-[(2,2,2-trichloroethylidene)bis[1,2,4-benzenetriylbis(oxy)]]tetrakis- (9CI) (CA INDEX NAME)



RN 246149-92-8 CAPLUS
CN Acetic acid, 2,2',2'',2'''-[(2,2,2-trichloroethylidene)bis[2,1,4-benzenetriylbis(oxy)]]tetrakis- (9CI) (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 81 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:390409 CAPLUS
DN 131:45048
TI Preparation of disalicylate analog based sialyl Lewisx mimetics as
antiinflammatory agents and selectin receptors
IN Anderson, Mark B.; Levy, Daniel E.; Holme, Kevin R.
PA Glycomed Incorporated, USA; Sankyo Co., Ltd.
SO PCT Int. Appl., 104 pp.

CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9929706	A2	19990617	WO 1998-US25788	19981204
	WO 9929706	A3	19990812		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9919036	A1	19990628	US 1997-67877P	P 19971208
				AU 1999-19036	19981204
				US 1997-67877P	P 19971208
				WO 1998-US25788	W 19981204

OS MARPAT 131:45048


AB The present invention discloses medicaments that are selectin-ligand structural mimetics that bind to certain selectins wherein the mimetics may lack the sialic acid and/or fucose of the natural selecting ligand, sialyl Lewisx (sLex), but have a structure capable of mimicking the structural features necessary for selectin recognition. In particular, the invention compds. mimic the key structural features of the oligosaccharides responsible for selectin-mediated cell adhesion. These features consist of the charge-distance-coordination relationship between the carboxylic acid functionality of sialic acid at a distance of 8-12 angstroms of the L-fucose moiety. The invention compds. are disalicylate, its analogs, and disalicylate-based C-glycoside compds. I wherein R1-R12 are independently alkoxy, H, OH, aryl, aryloxy, aralkoxy, alkoxyaryl, amino, alkyl, sialic acid, quinic acid, sulfone, sulfonamide, phosphate, NO2, carboxylic acid, heterocycle; R2R3 and R9R10 are S, O, amine; R5R12 is CH2, CO, O, S, imino; R6R7 is O, CH2, imino, were prepared as selectin receptors. The present invention also discloses methods of treating selectin-mediated disorders comprising administering the compds. disclosed. Thus, C-glycoside II was prepared as P-selectin receptor (IC50 = 1039 μ M).

IT 227595-86-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of disalicylate analog based sialyl Lewisx mimetics as antiinflammatory agents and selectin receptors)

RN 227595-86-0 CAPLUS

CN Benzoic acid, 5-[[3-carboxy-4-(carboxymethoxy)phenyl]methyl]-2-hydroxy-(9CI) (CA INDEX NAME)



L8 ANSWER 82 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:355792 CAPLUS
 DN 131:14490
 TI Nuclear thyroid receptor ligand modeling based on three-dimensional structures of their ligand-binding domains
 IN Scanlan, Thomas S.; Baxter, John D.; Fletterick, Robert J.; Wagner, Richard L.; Kushner, Peter J.; Apriletti, James W.; West, Brian L.; Shiau, Andrew K.
 PA The Regents of the University of California, USA
 SO PCT Int. Appl., 447 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9926966	A2	19990603	WO 1998-US25296	19981125
	WO 9926966	A3	20000120		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1997-980115	A1 19971126
	US 6266622	B1	20010724	US 1997-980115	19971126
				US 1995-8540P	P 19951213
				US 1995-8543P	P 19951213
				US 1995-8606P	P 19951214
				US 1996-764870	A2 19961213
	CA 2314096	AA	19990603	CA 1998-2314096	19981125
				US 1997-980115	A 19971126
				WO 1998-US25296	W 19981125
	AU 9917999	A1	19990615	AU 1999-17999	19981125
	AU 763452	B2	20030724		
				US 1997-980115	A 19971126
				WO 1998-US25296	W 19981125
	EP 1034184	A2	20000913	EP 1998-962849	19981125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				US 1997-980115	A 19971126
				WO 1998-US25296	W 19981125
	BR 9815061	A	20011120	BR 1998-15061	19981125
				US 1997-980115	A 19971126
				WO 1998-US25296	W 19981125
	JP 2001524489	T2	20011204	JP 2000-522122	19981125
				US 1997-980115	A 19971126
				WO 1998-US25296	W 19981125

PATENT FAMILY INFORMATION:

FAN 1997:516262

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9721993	A2	19970619	WO 1996-US20778	19961213
	WO 9721993	A3	19970724		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,				

MR, NE, SN, TD, TG					
				US 1995-8540P	P 19951213
				US 1995-8543P	P 19951213
				US 1995-8606P	P 19951214
CA 2240024	AA	19970619		CA 1996-2240024	19961213
				US 1995-8540P	P 19951213
AU 9718216	A1	19970703		US 1995-8606P	P 19951214
AU 717743	B2	20000330		AU 1997-18216	19961213
				US 1995-8540P	P 19951213
				US 1995-8543P	P 19951213
				US 1995-8606P	P 19951214
EP 873361	A2	19981028		WO 1996-US20778	W 19961213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				EP 1996-945800	19961213
				US 1995-8540P	P 19951213
				US 1995-8606P	P 19951214
				WO 1996-US20778	W 19961213
JP 2000502086	T2	20000222		JP 1997-522303	19961213
				US 1995-8540P	P 19951213
				US 1995-8606P	P 19951214
				WO 1996-US20778	W 19961213
AU 2003220708	A1	20030814		AU 2003-220708	20030710
				US 1995-8540P	P 19951213
				AU 2000-34045	A3 20000511
FAN 2001:538255					
PATENT NO.	KIND	DATE		APPLICATION NO.	DATE
-----	----	-----		-----	-----
PI US 6266622	B1	20010724		US 1997-980115	19971126
				US 1995-8540P	P 19951213
				US 1995-8543P	P 19951213
				US 1995-8606P	P 19951214
				US 1996-764870	A2 19961213
CA 2240024	AA	19970619		CA 1996-2240024	19961213
				US 1995-8540P	P 19951213
				US 1995-8606P	P 19951214
US 6236946	B1	20010522		US 1996-764870	19961213
				US 1995-8540P	P 19951213
				US 1995-8543P	P 19951213
				US 1995-8606P	P 19951214
CA 2314096	AA	19990603		CA 1998-2314096	19981125
				US 1997-980115	A 19971126
				WO 1998-US25296	W 19981125
WO 9926966	A2	19990603		WO 1998-US25296	19981125
WO 9926966	A3	20000120			
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
				US 1997-980115	A1 19971126
AU 9917999	A1	19990615		AU 1999-17999	19981125
AU 763452	B2	20030724			
				US 1997-980115	A 19971126
				WO 1998-US25296	W 19981125
EP 1034184	A2	20000913		EP 1998-962849	19981125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,					

IE, FI

TR 200002257	T2	20001221	US 1997-980115	A	19971126
			WO 1998-US25296	W	19981125
			TR 2000-200002257		19981125
BR 9815061	A	20011120	US 1997-980115	A	19971126
			BR 1998-15061		19981125
			US 1997-980115	A	19971126
JP 2001524489	T2	20011204	WO 1998-US25296	W	19981125
			JP 2000-522122		19981125
			US 1997-980115	A	19971126
AU 2003220708	A1	20030814	WO 1998-US25296	W	19981125
			AU 2003-220708		20030710
			US 1995-8540P	P	19951213
			AU 2000-34045	A3	20000511


OS MARPAT 131:14490

AB The present invention provides new methods, particularly computational methods, and compns. for the generation of nuclear receptor synthetic ligands based on the three dimensional structure of nuclear receptors, particularly the thyroid receptor (herein referred to as "TR"). Also provided are crystals, nuclear receptor synthetic ligands, and related methods. Atomic coordinates are provided for crystals of rat TR α -isoform residues 122-410 (the ligand-binding domain or LBD) complexed with 3,5,3'-triiodothyronine (T3), 3,5-dibromo-3'-isopropylthyronine (IpBr2), 3,5-dimethyl-3'-isopropylthyronine (Dimit), and 3,5,3'-triiodothyroacetic acid (Triac), as well as crystals of human TR β -isoform residues 202-461 complexed with Triac or 3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxyacetic acid (GC1). The 3-dimensional model of TR LBD with a bound ligand reveals a previously unknown structure for nuclear receptors and shows that the ligand is bound in a water inaccessible binding cavity of the ligand-binding domain of the receptor. The present invention provides computational methods for designing nuclear receptor synthetic ligands using such crystal and 3-dimensional structural information to generate synthetic ligands that modulate the conformational changes of a nuclear receptor's LBD. Receptor selectivity for a TR-type receptor vs. other nuclear receptors is provided by selecting a compound that interacts with conformationally constrained residues of a TR LBD that are conserved among TR isoforms. The chemical synthesis and biol. activities of various agonists, especially those that bind selectively to one of the two TR isoforms, and antagonists, are also provided.

IT 211110-63-3D, complex with ligand-binding domain of thyroid hormone receptors α and β
 RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process); USES (Uses)
 (nuclear thyroid receptor ligand modeling based on three-dimensional structures of their ligand-binding domains)

RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



L8 ANSWER 83 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:285722 CAPLUS

DN 131:102065

TI synthesis of 1,1,1-trichloro-2-(2',4'-dichloro-5'-carboxymethoxyphenyl)-2-(carboxyaryl/carboxymethoxyaryl)ethanes as possible antimicrobial agents

AU Purohit, D. M.; Shah, V. H.

CS Department of Chemistry, Saurashtra University, Rajkot, 360 005, India

SO Indian Journal of Heterocyclic Chemistry (1999), 8(3), 209-212

CODEN: IJCHEI; ISSN: 0971-1627

PB Prof. R. S. Varma

DT Journal

LA English

AB The title compds. I (R = HO₂C, HO₂CCH:CH, HO₂CCH₂, HO₂CCH₂O; R₁ = H, HO₂C, Me, Cl, MeO, NO₂, HO₂CCH₂O) were prepared by reaction of 2,4-Cl₂C₆H₃OCH₂CO₂H with chloral hydrate in the presence of concentrated H₂SO₄ to afford the (trichloroethyl)phenoxyacetic acid II. II reacted with RR₁C₆H₄ in the presence of a catalytic amount of concentrated H₂SO₄ to give I. All products were

screened for antimicrobial activity. The mol. structures of the products were supported by IR, PMR, and mass spectroscopy and elemental anal.


IT 231628-61-8P 231628-62-9P 231628-63-0P
231628-64-1P 231628-65-2P 231628-66-3P
231628-67-4P 231628-68-5P 231628-69-6P
231628-70-9P 231628-71-0P 231628-72-1P
231628-73-2P 231628-74-3P 231628-75-4P
231628-76-5P 231628-77-6P 231628-78-7P
231628-79-8P 231628-80-1P 231628-81-2P
231628-82-3P 231628-83-4P 231628-84-5P
231628-85-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and bactericidal/fungicidal activities of [(carboxymethoxy)dichlorophenyl]trichloroethanes)


RN 231628-61-8 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 4-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 231628-62-9 CAPLUS


CN 1,3-Benzenedicarboxylic acid, 5-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 231628-63-0 CAPLUS
 CN 1,4-Benzenedicarboxylic acid, 2-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 231628-64-1 CAPLUS
 CN Benzoic acid, 5-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 231628-65-2 CAPLUS
 CN Benzoic acid, 3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 231628-66-3 CAPLUS
 CN Benzoic acid, 3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 231628-67-4 CAPLUS
 CN Benzoic acid, 5-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 231628-68-5 CAPLUS
 CN Benzoic acid, 3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-5-chloro- (9CI) (CA INDEX NAME)




RN 231628-69-6 CAPLUS
 CN Benzoic acid, 3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 231628-70-9 CAPLUS
 CN Benzoic acid, 5-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 231628-71-0 CAPLUS
CN Benzoic acid, 3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 231628-72-1 CAPLUS
CN Benzoic acid, 3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 231628-73-2 CAPLUS
CN Benzoic acid, 2-(carboxymethoxy)-5-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]- (9CI) (CA INDEX NAME)




RN 231628-74-3 CAPLUS
CN Acetic acid, [5-[1-[3-(carboxymethoxy)-4-chlorophenyl]-2,2,2-trichloroethyl]-2,4-dichlorophenoxy]- (9CI) (CA INDEX NAME)




RN 231628-75-4 CAPLUS
CN Acetic acid, [5-[1-[4-(carboxymethoxy)-2-chlorophenyl]]-2,2,2-trichloroethyl]-2,4-dichlorophenoxy- (9CI) (CA INDEX NAME)




RN 231628-76-5 CAPLUS
CN Acetic acid, [5-[1-[5-(carboxymethoxy)-2-chlorophenyl]]-2,2,2-trichloroethyl]-2,4-dichlorophenoxy- (9CI) (CA INDEX NAME)




RN 231628-77-6 CAPLUS
CN Acetic acid, [5-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]]-2,2,2-trichloroethyl]-2-nitrophenoxy- (9CI) (CA INDEX NAME)




RN 231628-78-7 CAPLUS
CN Acetic acid, [4-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]]-2,2,2-trichloroethyl]-3-nitrophenoxy- (9CI) (CA INDEX NAME)




RN 231628-79-8 CAPLUS
 CN Acetic acid, [3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-4-nitrophenoxy]- (9CI) (CA INDEX NAME)




RN 231628-80-1 CAPLUS
 CN Acetic acid, [5-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 231628-81-2 CAPLUS
 CN Acetic acid, [4-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-3-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 231628-82-3 CAPLUS
 CN Acetic acid, [3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-4-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 231628-83-4 CAPLUS
 CN Acetic acid, 2,2'-[[4-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-1,2-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)



RN 231628-84-5 CAPLUS
 CN Acetic acid, 2,2'-[[2-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-1,4-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)



RN 231628-85-6 CAPLUS
 CN Acetic acid, 2,2'-[[5-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloroethyl]-1,3-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 84 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1999:9803 CAPLUS
 DN 130:81287
 TI Preparation of phenoxyakanoates as thyroid hormone receptor β agonists
 IN Scanlan, Thomas S.; Chellini, Grazia; Yoshihara, Hikari; Apriletti, James; Baxter, John D.; Ribeiro, Ralf C. J.
 PA The Regents of the University of California, USA
 SO PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9857919	A1	19981223	WO 1998-US11758	19980608
	W: AU, CA, JP, KP, KR				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

US 5883294	A	19990316	US 1997-877792	A	19970618
CA 2290622	AA	19981223	US 1997-877792		19970618
			CA 1998-2290622		19980608
			US 1997-877792	A	19970618
AU 9878234	A1	19990104	WO 1998-US11758	W	19980608
AU 746991	B2	20020509	AU 1998-78234		19980608
			US 1997-877792	A	19970618
EP 991618	A1	20000412	WO 1998-US11758	W	19980608
EP 991618	B1	20031112	EP 1998-926384		19980608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
			US 1997-877792	A	19970618
			WO 1998-US11758	W	19980608
JP 2002511084	T2	20020409	JP 1999-504530		19980608
			US 1997-877792	A	19970618
			WO 1998-US11758	W	19980608
AT 254095	E	20031115	AT 1998-926384		19980608
			US 1997-877792	A	19970618
			WO 1998-US11758	W	19980608

OS MARPAT 130:81287


AB R3OZ1CR1R2Z2O(CH₂)_nCO₂R [I; R = H or (cyclo)alkyl; R₁,R₂ = H or alkyl; 1 of R₁,R₂ = H and the other = OH; R₁R₂ = O; R₃ = H, (cyclo)alkyl, acyl; Z₁ = (un)substituted 1,4-phenylene; Z₂ = (un)substituted 3,5-dimethyl-4,1-phenylene] were prepared. Thus, 4-bromo-2-isopropylanisole was condensed with 2,6-dimethyl-4-methoxybenzaldehyde (preparation each given) and the product converted in 4 steps to title compound II. Data for biol. activity of I were given.

IT 211110-63-3P 218431-15-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenoxyakanoates as thyroid hormone receptor β agonists)


RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 218431-15-3 CAPLUS


CN Acetic acid, [4-[1-[4-hydroxy-3-(1-methylethyl)phenyl]ethyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



IT 218431-09-5P 218431-14-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of phenoxyakanoates as thyroid hormone receptor β
 agonists)
 RN 218431-09-5 CAPLUS
 CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-
 dimethylphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 218431-14-2 CAPLUS
 CN Acetic acid, [4-[1-[4-hydroxy-3-(1-methylethyl)phenyl]ethyl]-3,5-
 dimethylphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 85 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1998:435316 CAPLUS
 DN 129:157050
 TI A high-affinity subtype-selective agonist ligand for the thyroid hormone
 receptor
 AU Chiellini, Grazia; Apriletti, James W.; Yoshihara, Hikari A.; Baxter, John
 D.; Ribeiro, Ralf C. J.; Scanlan, Thomas S.
 CS Department of Pharmaceutical Chemistry and Cellular & Molecular
 Pharmacology, University of California, San Francisco, CA, 94143-0446, USA
 SO Chemistry & Biology (1998), 5(6), 299-306
 CODEN: CBOLE2; ISSN: 1074-5521

PB Current Biology Ltd.

DT Journal

LA English

AB Thyroid hormones regulate many different physiol. processes in different tissues in vertebrates. Most of the actions of thyroid hormones are mediated by the thyroid hormone receptor (TR), which is a member of the nuclear receptor superfamily of ligand-activated transcription regulators. There are two different genes that encode two different TRs, TR α and TR β , and these two TRs are often co-expressed at different levels in different tissues. Most thyroid hormones do not discriminate between the two TRs and bind both with similar affinities. The authors have designed and synthesized a thyroid hormone analog that has high affinity for the TRs and is selective in both binding and activation functions for TR β over TR α . The compound, GC-1, was initially designed to solve synthetic problems that limit thyroid hormone analog preparation, and contains several structural changes with respect to the natural hormone 3,5,3'-triiodo-L-thyronine (T3). These changes include replacement of the three iodines with Me and iso-Pr groups, replacement of the biaryl ether linkage with a methylene linkage, and replacement of the amino-acid sidechain with an oxyacetic-acid sidechain. The result of this study show that GC-1 is a member of a new class of thyromimetic compds. that are more synthetically accessible than traditional thyromimetics and have potentially useful receptor binding and activation properties. The TR β selectivity of GC-1 is particularly interesting and suggests that GC-1 might be a useful in vivo probe for studying the physiol. roles of the different thyroid hormone receptor isoforms.


IT 211110-63-3P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)

(design and synthesis of high-affinity subtype-selective agonist ligand for thyroid hormone receptor)

RN 211110-63-3 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 86 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:296799 CAPLUS

DN 129:50028

TI A comparison of actions of neuropeptide Y (NPY) agonists and antagonists at NPY Y1 and Y2 receptors in anesthetized rats

AU Smith-White, M.; Moriarty, M. J.; Potter, E. K.

CS Prince of Wales Medical Research Institute, Sydney, 2031, Australia

SO Neuropeptides (Edinburgh) (1998), 32(2), 109-118

CODEN: NRPPDD; ISSN: 0143-4179

PB Churchill Livingstone


DT Journal
 LA English
 AB The pancreatic polypeptide family includes three members, neuropeptide Y (NPY), peptide YY (PYY) and pancreatic polypeptide (PP), with sequence homol. between members and species varying from approx. 50 to 80%. Some of these peptides were compared in the mammalian cardiovascular system for activity mediated by actions on pre- (Y2) and post-junctional (Y1) NPY receptors. NPY and PYY, with sequence homol. of 67% have similar actions on Y1 and Y2 receptors. Rat pancreatic polypeptide (rPP) with sequence homol. of approx. 50% is inactive at both. This study reports that the chimeric peptide, hPP1-11/NPY12-36 and the truncated peptide NPY2-36 show similar activity to NPY mediated through both receptor types in vivo, while salmon PYY (sPYY), with 81% homol. to NPY, has improved potency at both receptor subtypes. NPY3-36 has equal activity with NPY on actions mediated through Y2 receptors, but significantly reduced activity mediated through Y1 receptors. Two NPY antagonists were also examined: PYX2 was inactive in vivo and 1229U91 showed potent, long-lasting activity on Y1 receptor-mediated effects.


IT 146999-93-1, PYX-2
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (neuropeptide Y agonists and antagonists at neuropeptide Y1 and Y2 receptors in anesthetized rats)

RN 146999-93-1 CAPLUS
 CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutamyl-L-arginyl-3-[(2,6-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 87 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:723427 CAPLUS
DN 128:22689
TI 1,1,1-Trichloro-2-[2,4,6-trichloro-5-(carboxymethoxy)phenyl]-2-(carboxyaryl/carboxymethoxyaryl)ethanes
AU Purohit, D. M.; Shah, V. H.
CS Chemistry Department, Shri M and N Virani Science College, Rajkot, 5, India
SO Journal of the Institution of Chemists (India) (1997), 69(4), 120-122
CODEN: JOICA7; ISSN: 0020-3254
PB Institution of Chemists (India)
DT Journal
LA English
AB The preparation of the title compds., i.e., [[(carboxymethoxy)trichlorophenyl]trichlorohydroxyethyl]benzoic acid derivs., and their evaluation as antimicrobial agents (bactericides, fungicides) was reported.
IT 199337-62-7P 199337-65-0P 199337-68-3P
199337-69-4P 199337-71-8P 199337-72-9P
199337-74-1P 199337-75-2P 199337-77-4P
199337-87-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of [[(carboxymethoxy)trichlorophenyl]alkyl]benzoic acid derivs. as antimicrobial agents)
RN 199337-62-7 CAPLUS
CN Benzoic acid, 5-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 199337-65-0 CAPLUS


CN 1,4-Benzenedicarboxylic acid, 2-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]- (9CI) (CA INDEX NAME)




RN 199337-68-3 CAPLUS
CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 199337-69-4 CAPLUS
CN Benzoic acid, 5-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 199337-71-8 CAPLUS
CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 199337-72-9 CAPLUS
CN Benzoic acid, 5-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-

trichloro-1-hydroxyethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 199337-74-1 CAPLUS

CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 199337-75-2 CAPLUS

CN Acetic acid, [3-[1-[4-(carboxymethoxy)-3-chlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]- (9CI) (CA INDEX NAME)




RN 199337-77-4 CAPLUS


CN Acetic acid, [3-[1-[5-(carboxymethoxy)-2-chlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]- (9CI) (CA INDEX NAME)




RN 199337-87-6 CAPLUS
 CN Acetic acid, [3-[1-[5-(carboxymethoxy)-2,4-dichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]- (9CI) (CA INDEX NAME)




IT 199337-63-8P 199337-64-9P 199337-66-1P
 199337-67-2P 199337-70-7P 199337-73-0P
 199337-76-3P 199337-78-5P 199337-79-6P
 199337-80-9P 199337-81-0P 199337-82-1P
 199337-83-2P 199337-84-3P 199337-85-4P
 199337-86-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of [[(carboxymethoxy)trichlorophenyl]alkyl]benzoic acid derivs.
 as antimicrobial agents)
 RN 199337-63-8 CAPLUS
 CN 1,2-Benzenedicarboxylic acid, 4-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]- (9CI) (CA INDEX NAME)




RN 199337-64-9 CAPLUS
 CN 1,3-Benzenedicarboxylic acid, 5-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]- (9CI) (CA INDEX NAME)




RN 199337-66-1 CAPLUS
 CN Benzoic acid, 5-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199337-67-2 CAPLUS
 CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 199337-70-7 CAPLUS
 CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-5-chloro- (9CI) (CA INDEX NAME)




RN 199337-73-0 CAPLUS


CN Benzoic acid, 3-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 199337-76-3 CAPLUS
CN Acetic acid, [3-[1-[4-(carboxymethoxy)-2-chlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]- (9CI) (CA INDEX NAME)




RN 199337-78-5 CAPLUS
CN Acetic acid, [3-[1-[3-(carboxymethoxy)-4-nitrophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]- (9CI) (CA INDEX NAME)




RN 199337-79-6 CAPLUS
CN Acetic acid, [3-[1-[4-(carboxymethoxy)-2-nitrophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]- (9CI) (CA INDEX NAME)




RN 199337-80-9 CAPLUS
 CN Acetic acid, [3-[1-[5-(carboxymethoxy)-2-nitrophenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]- (9CI) (CA INDEX NAME)





RN 199337-81-0 CAPLUS
 CN Benzoic acid, 2-(carboxymethoxy)-5-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]- (9CI) (CA INDEX NAME)




RN 199337-82-1 CAPLUS
 CN Acetic acid, 2,2'-[[4-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-1,2-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)




RN 199337-83-2 CAPLUS
 CN Acetic acid, 2,2'-[[2-[1-[3-(carboxymethoxy)-2,4,6-trichlorophenyl]-2,2,2-trichloro-1-hydroxyethyl]-1,4-phenylene]bis(oxy)]bis- (9CI) (CA INDEX NAME)




RN 199337-84-3 CAPLUS
 CN Acetic acid, [3-[1-[4-(carboxymethoxy)-3-methylphenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]- (9CI) (CA INDEX NAME)



RN 199337-85-4 CAPLUS
 CN Acetic acid, [3-[1-[4-(carboxymethoxy)-2-methylphenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]- (9CI) (CA INDEX NAME)





RN 199337-86-5 CAPLUS
 CN Acetic acid, [3-[1-[5-(carboxymethoxy)-2-methylphenyl]-2,2,2-trichloro-1-hydroxyethyl]-2,4,6-trichlorophenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 88 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1997:631661 CAPLUS
 DN 127:242815
 TI Anionic- and Lipophilic-Mediated Surface Binding Inhibitors of Human Leukocyte Elastase
 AU Regan, John; McGarry, Daniel; Bruno, Joseph; Green, Daniel; Newman, Jack; Hsu, Chin-Yi; Kline, Jane; Barton, Jeffrey; Travis, Jeffrey; Choi, Yong Mi; Volz, Francis; Pauls, Henry; Harrison, Richard; Zilberstein, Asher; Ben-Sasson, Shmuel A.; Chang, Michael
 CS Departments of Medicinal Chemistry and Inflammation Biology, Rhone-Poulenc Rorer, Collegeville, PA, 19426, USA
 SO Journal of Medicinal Chemistry (1997), 40(21), 3408-3422
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 AB We report the synthesis of a series of diphenylmethane-based oligomers containing anionic and lipophilic functionalities that are potent inhibitors of human leukocyte elastase (HLE). The enzyme inhibition is regulated by the size of the oligomer, as well as, the number of charges. Lipophilicity is an important element in determining potency and specificity against other basic enzymes. Compds. whose scaffolds contain three phenoxyacetic acid groups and three alkyl ethers are competitive and specific inhibitors of HLE with $K_i = 20$ nM. The mechanism of action of this class of compds. is believed to involve multidendate interactions with the surface of HLE near the active site which prevents substrate access to the catalytic site.
 IT 147067-39-8P 147067-41-2P 195601-58-2P
 195601-59-3P 195601-60-6P 195601-61-7P
 195601-62-8P 195601-63-9P 195601-64-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis of diphenylmethane-based oligomers as selective inhibitors of human leukocyte elastase)
 RN 147067-39-8 CAPLUS



CN Acetic acid, [2-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-(hydroxymethyl)-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-4-hydroxyphenoxy]- (9CI) (CA INDEX NAME)




RN 147067-41-2 CAPLUS



CN Acetic acid, [2-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-(hydroxymethyl)-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-4-hydroxyphenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 195601-58-2 CAPLUS
CN Acetic acid, [2-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-(hydroxymethyl)-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-4-hydroxyphenoxy]- (9CI) (CA INDEX NAME)




RN 195601-59-3 CAPLUS
CN Acetic acid, [2-[[4-[[5-(carboxymethoxy)-4-[[4-[[5-(carboxymethoxy)-4-[(5-hydroxy-2-methoxy-4-methylphenyl)methyl]-2-methoxyphenyl]methyl]-5-hydroxy-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-5-hydroxy-2-methoxyphenyl]methyl]-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 195601-60-6 CAPLUS
 CN Acetic acid, [2-[[4-[[5-(carboxymethoxy)-4-[[4-[[5-(carboxymethoxy)-2-methoxy-4-[[2-methoxy-5-[(2-methoxyethoxy)methoxy]-4-methylphenyl]methyl]phenyl]methyl]-2-methoxy-5-[(2-methoxyethoxy)methoxy]phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-[(2-methoxyethoxy)methoxy]phenyl]methyl]-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 195601-61-7 CAPLUS

CN Acetic acid, [2-[[4-[[5-(carboxymethoxy)-4-[[4-[[5-(carboxymethoxy)-4-[[4-(hydroxymethyl)-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-4-hydroxyphenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 195601-62-8 CAPLUS

CN Acetic acid, [2-[[4-[[5-(carboxymethoxy)-4-[[4-[[5-(carboxymethoxy)-2-methoxy-4-[[2-methoxy-4-methyl-5-(3-phenylpropoxy)phenyl]methyl]phenyl]methyl]-2-methoxy-5-(3-phenylpropoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(3-phenylpropoxy)phenyl]methyl]-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B




RN 195601-63-9 CAPLUS
 CN Acetic acid, [2-[[4-[[5-(carboxymethoxy)-4-[[4-[[5-(carboxymethoxy)-4-[[5-(hexyloxy)-2-methoxy-4-methylphenyl]methyl]-2-methoxyphenyl]methyl]-5-(hexyloxy)-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-5-(hexyloxy)-2-methoxyphenyl]methyl]-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)


PAGE 1-A





RN 195601-64-0 CAPLUS
 CN Acetic acid, [2-[[4-[[5-(carboxymethoxy)-4-[[4-[[5-(carboxymethoxy)-4-[[5-(cyclohexylmethoxy)-2-methoxy-4-methylphenyl]methyl]-2-methoxyphenyl]methyl]-5-(cyclohexylmethoxy)-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-5-(cyclohexylmethoxy)-2-methoxyphenyl]methyl]-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)





RE.CNT 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 89 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:557773 CAPLUS
DN 127:255331
TI Positive-working photosensitive composition providing good profile pattern
IN Fujimori, Toru; Aoso, Toshiaki; Yamanaka, Hitoshi; Uenishi, Kazuya
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 63 pp.
CODEN: JKXXAF

DT Patent
LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 09211865	A2	19970815	JP 1996-19002	19960205
				JP 1996-19002	19960205

AB The title composition contains a resin insol. in water and soluble in alkaline aqueous

solns., a compound generating an acid upon irradiation, and an acid-decomposable


dissoln.-inhibiting compound with mol. weight ≤3000 which has basic N and acid-decomposable groups and of which the solubility in alkaline developing solns. is increased by the action of acid. The composition may also contain an acid-decomposable dissoln.inhibitor without N. The diffusion of the acid and the inactivation of the acid on the surface of the resist during the period from exposure to heat treatment are prevented and the dissoln.-inhibiting effect is improved, and hence high resolution patterns with high sensitivity and good profile are obtained. Thus, a resist comprised m-cresol-p-cresol-HCHO novolak resin, Ph₃S⁺.CF₃SO₃⁻, 2,2-bis(tert-butoxycarbonyloxyphenyl)propane, and I.

IT 195706-49-1P


RL: MOA (Modifier or additive use); PNU (Preparation, unclassified); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses) (pos.-working photoresist composition containing acid-decomposable dissoln.-inhibitor)

RN 195706-49-1 CAPLUS

CN Acetic acid, 2,2'-[methylenebis[[2-[(dimethylamino)methyl]-6-methyl-4,1-phenylene]oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




IT 195706-83-3
 RL: MOA (Modifier or additive use); TEM (Technical or engineered material use); USES (Uses)
 (pos.-working photoresist composition containing acid-decomposable dissoln.-inhibitor)
 RN 195706-83-3 CAPLUS
 CN Acetic acid, 2,2'-[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis[methylene[2-[(dimethylamino)methyl]-6-methyl-4,1-phenylene]oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




L8 ANSWER 90 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1997:480922 CAPLUS
 DN 127:121546
 TI Synthesis of Functionalized Aromatic Oligomers from a Versatile Diphenylmethane Template
 AU Bruno, J. G.; Chang, M. N.; Choi-Sledeski, Y. M.; Green, D. M.; McGarry, D. G.; Regan, J. R.; Volz, F. A.
 CS Department of Medicinal Chemistry, Rhone-Poulenc Rorer, Collegeville, PA, 19426-0995, USA
 SO Journal of Organic Chemistry (1997), 62(15), 5174-5190
 CODEN: JOCEAH; ISSN: 0022-3263
 PB American Chemical Society
 DT Journal
 LA English
 AB An efficient synthesis of the functionalized diphenylmethane system I [R = H, R1 = CH2OCH2CH2OMe, R2 = OSi(CMe3)Ph2] is described. Selective unmasking of the latent phenol groups allowed the introduction of various appendages onto the diphenylmethane scaffold via simple alkylation, Mitsunobu etherification, and transition-metal-mediated C-C bond formation. Conversion to iodide I [R = I, R1 = Me, R2 = OSi(CMe3)Ph2] and benzylic zinc reagent I (R = H, R1 = CH2OCH2CH2OMe, R2 = ZnBr), followed by palladium(0)-mediated coupling of these derivs., provided homolog II. Repetitive application of this homologation protocol was used to prepare oligomers of chain length up to 16. Several examples of functional group manipulations on these higher order oligomers are presented. I [R = H, R1 = CH2OCH2CH2OMe, R2 = OSi(CMe3)Ph2] was also employed as a key building

oxoethoxy]-3-[[3-(hydroxymethyl)-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-4-[(2-methoxyethoxy)methoxy]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 192698-70-7 CAPLUS
 CN Acetic acid, [3-[[3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[3-formyl-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-4-[(2-methoxyethoxy)methoxy]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 192698-83-2 CAPLUS
CN Benzoic acid, 5-[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-4-[[3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-5-(phenylmethoxy)phenyl]ethynyl]-2-[(2-methoxyethoxy)methoxy]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—OMe


RN 192698-84-3 CAPLUS
 CN Benzoic acid, 5-[2-[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-4-[[3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-5-(phenylmethoxy)phenyl]ethyl]-2-[(2-methoxyethoxy)methoxy]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—Ph



RN 192698-85-4 CAPLUS
 CN Benzoic acid, 5-[2-[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-4-[[3-(hydroxymethyl)-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-5-(phenylmethoxy)phenyl]ethyl]-2-[(2-methoxyethoxy)methoxy]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—Ph

RN 192698-86-5 CAPLUS
 CN Benzoic acid, 5-[2-[4-[[3-(bromomethyl)-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-(phenylmethoxy)phenyl]ethyl]-2-[(2-methoxyethoxy)methoxy]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—Ph


RN 192698-87-6 CAPLUS
 CN Benzoic acid, 3,3'-[1,2-ethanediylbis[[2-methoxy-5-(phenylmethoxy)-3,1-phenylene]methylene[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-(phenylmethoxy)-4,1-phenylene]-2,1-ethanediyl]]bis[6-[(2-

methoxyethoxy)methoxy]-, dimethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C

-CH₂-OMe


IT 192698-71-8P 192698-73-0P 192698-88-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (functionalized aromatic oligomers from versatile diphenylmethane template)

RN 192698-71-8 CAPLUS


CN Benzoic acid, 3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2-[(2-methoxyethoxy)methoxy]phenyl]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-

(phenylmethoxy)phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxy-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 192698-73-0 CAPLUS
 CN Acetic acid, [3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2-[(2-methoxyethoxy)methoxy]phenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-4-methoxy-5-methylphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




PAGE 1-C


—CH₂—OMe

RN 192698-88-7 CAPLUS
 CN Benzoic acid, 3,3'-[1,2-ethanediylbis[[2-methoxy-5-(phenylmethoxy)-3,1-phenylene]methylene[2-(carboxymethoxy)-5-(phenylmethoxy)-4,1-phenylene]-2,1-ethanediyl]]bis[6-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RE.CNT 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 91 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:480322 CAPLUS
DN 127:101713
TI Silver halide color photographic material containing magenta coupler
IN Yamada, Keiko; Sugita, Shuichi; Kaneko, Yutaka
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 30 pp.
CODEN: JKXXAF

DT Patent
LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 09146240	A2	19970606	JP 1995-307477	19951127
				JP 1995-307477	19951127


AB The title material, comprising a support coated with photog. constituting layers containing blue-, green-, and red-sensitive Ag halide emulsion layers, contains, in ≥ 1 of the green-sensitive layers, ≥ 1 coupler I or II [R1, R11 = H, substituent; R12, R13 = H, alkyl; R14 = substituent; L1, L11 = alkylene; L2 = O, S, carbonyl, sulfonyl, alkylene, NR2 (R2 = H, alkyl, aryl), divalent group composed of these atoms and groups; L12 = CO2, OCO, SO3, OSO2, CONR15, NR16CO, SO2NR17, NR18SO2 (R15-18 = H, alkyl); X1, X11 = H, group releasing upon reaction with oxidized developing agents; Y11 = alkylene, O, S, sulfonyl; Z1, Z11 = nonmetal atoms required to form a N-containing heterocycle; m = 0, 1; n = 0-3]. The materials shows good coloring properties and provides magenta images with excellent lightfastness.

IT 191273-39-9

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of pyrazolotriazole derivative photog. magenta coupler)

RN 191273-39-9 CAPLUS
 CN Acetic acid, 2,2'-[methylenebis[(4-chloro-2,1-phenylene)oxy]]bis- (9CI)
 (CA INDEX NAME)




IT 191273-33-3 191273-35-5
 RL: DEV (Device component use); MOA (Modifier or additive use); USES
 (Uses)
 (pyrazolotriazole derivative photog. magenta coupler)
 RN 191273-33-3 CAPLUS
 CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(4-methyl-2,1-phenylene)oxy]]bis-, bis[4-(7-chloro-6-pentadecyl-1H-pyrazolo[5,1-c]-1,2,4-triazol-3-yl)-4-methylpentyl] ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 191273-35-5 CAPLUS
 CN Acetic acid, 2,2'-[methylenebis[[4,6-bis(1,1-dimethylethyl)-2,1-phenylene]oxy]]bis-, bis[2-[2-[7-chloro-6-(1,1-dimethylethyl)-1H-pyrazolo[5,1-c]-1,2,4-triazol-3-yl]-2-methylpropoxy]ethyl] ester (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



IT 191273-22-0P
 RL: DEV (Device component use); MOA (Modifier or additive use); PNU
 (Preparation, unclassified); PREP (Preparation); USES (Uses)
 (pyrazolotriazole derivative photog. magenta coupler)
 RN 191273-22-0 CAPLUS
 CN Acetic acid, 2,2'-[methylenebis[(4-chloro-2,1-phenylene)oxy]]bis-,
 bis[2-[7-chloro-6-(1,1-dimethylethyl)-1H-pyrazolo[5,1-c]-1,2,4-triazol-3-yl]-2-methylpropyl] ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—Cl

—Bu-t

L8 ANSWER 92 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1997:376519 CAPLUS
 DN 127:90944
 TI Differential modulation of NMDA-stimulated [3H]dopamine release from rat striatum by neuropeptide Y and σ receptor ligands
 AU Ault, David T.; Werling, Linda L.
 CS Neuroscience Program and Department of Pharmacology, The George Washington University Medical Center, 2300 I Street, N.W., Washington, USA
 SO Brain Research (1997), 760(1,2), 210-217
 CODEN: BRREAP; ISSN: 0006-8993
 PB Elsevier
 DT Journal
 LA English
 AB Although the identity of the endogenous ligands for sigma (σ) receptors is unknown, neuropeptide Y (NPY) has been named as a possible candidate for a natural transmitter at these receptors. Using a superfusion system, the authors compared the effect of NPY on NMDA-stimulated [3H]dopamine release in rat striatum to that of the σ agonists (+)-pentazocine and BD737. In contrast to (+)-pentazocine- or BD737-mediated inhibition of release, NPY enhanced release. However, the same σ antagonists (BD1008, DuP734, haloperidol and DTG) that reverse (+)-pentazocine- or BD737-mediated inhibition, as well as a Y receptor antagonist, PYX-1, all reversed the

enhancement. PYX-1 also reversed the (+)-pentazocine- and BD737-mediated inhibition of release. Peptide YY (PYY) and [Leu31,Pro34]NPY did not mimic the effect of NPY. NPY13-36 enhanced release to the same extent as NPY but the effect was not reversed by σ antagonists. The authors' findings are consistent with the potential role of NPY as an endogenous ligand for a subtype of σ receptor with characteristics different from Y1, Y2 and Y3 receptors but sensitive to PYX-1.

IT 140842-17-7, PYX 1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)


(differential modulation of NMDA-stimulated [3H]dopamine release from rat striatum by neuropeptide Y and σ receptor ligands)

RN 140842-17-7 CAPLUS


CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutamyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 93 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1997:296965 CAPLUS
 DN 126:285346
 TI Resists containing polymer having sulfonyl groups as photoacid generator
 and patterning method
 IN Kihara, Naoko; Saito, Satoshi; Wakabayashi, Hiromitsu; Nakase, Makoto;
 Ooba, Masayuki
 PA Tokyo Shibaura Electric Co, Japan
 SO Jpn. Kokai Tokkyo Koho, 31 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 09050127	A2	19970218	JP 1996-55027	19960312
	JP 3382081	B2	20030304		
				JP 1995-134615	A 19950601
	US 5756254	A	19980526	US 1996-654215	19960528
				JP 1995-134615	A 19950601
				JP 1996-55027	A 19960312
	KR 191858	B1	19990615	KR 1996-19028	19960531
				JP 1995-134615	A 19950601
				JP 1996-55027	A 19960312

AB A resist containing [CR1(SO2R2)R3]_n [R1 = H, halo, NO2, cyano, nitrile group,
 monovalent organic group; R2 = halo, NO2, cyano, nitrile group, monovalent
 organic group; R3 = divalent organic group, preferably I (R21-26 = H, halo,
 NO2,
 cyano, nitrile group, monovalent organic group; Z = divalent organic group); n
 ≥2] are claimed. The resist preferably contains a compound having
 substituent(s) which forms alkali-soluble group after being decomposed by acids
 to make the resist pos.-working. The resist provides a resist film with
 high rigidity resulting in giving a superfine pattern with high aspect
 ratio.

IT 188778-62-3
 RL: TEM (Technical or engineered material use); USES (Uses)
 (alkali-soluble group-forming compound; resists containing polymers having
 sulfonyl groups as photoacid generators for improved rigidity)

RN 188778-62-3 CAPLUS
 CN Poly[(1,1',3,3'-tetrahydro-1,1',3,3'-tetraoxo[5,5'-bi-2H-isoindole]-2,2'-
 diyl)[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-1,3-phenylene][2,2,2-
 trifluoro-1-(trifluoromethyl)ethylidene][4-[2-(1,1-dimethylethoxy)-2-
 oxoethoxy]-1,3-phenylene]] (9CI) (CA INDEX NAME)



L8 ANSWER 94 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:751324 CAPLUS

DN 126:24864

TI 2,2-Bis(2,4-di-tert-butoxycarbonylmethoxyphenyl)propane and its derivative for dissolution-preventing agent of photoresist

IN Watanabe, Atsushi; Ishihara, Toshinobu; Yagihashi, Fujio

PA Shinetsu Chemical Industry Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08245515	A2	19960924	JP 1995-306557	19951031
				JP 1995-306557	A 19951031
				JP 1995-20956	19950113

OS MARPAT 126:24864

AB The 2,2-bis(2,4-di-tert-butoxycarbonylmethoxyphenyl)propane I (R = alkyl; m = 0-3) and its derivative are claimed. I showed high solubility for polymers.


IT 184294-77-7P

RL: PNU (Preparation, unclassified); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

(bis(di-tert-butoxycarbonylmethoxyphenyl)propanes for dissoln.-preventing agent of photoresist)

RN 184294-77-7 CAPLUS

CN Acetic acid, 2,2',2'',2'''-[(1-methylethylidene)bis[(3-methyl-1,2,4-benzenetriyl)bis(oxy)]]tetrakis-, tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 95 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:634665 CAPLUS

DN 125:261269

TI 2,6-Bis(2-tert-butoxycarbonylmethoxyphenylmethyl)-1-tert-butoxycarbonylmethoxy-4-methylbenzene derivative for dissolution inhibitor of three-component resist

IN Watanabe, Atsushi; Ishihara, Toshinobu; Yagihashi, Fujio

PA Shinetsu Chemical Industry Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08193055	A2	19960730	JP 1995-20957	19950113
				JP 1995-20957	19950113

OS MARPAT 125:261269

AB The derivative is I [R = alkyl; n = 0, 1; m = an integer of 0-(4-n)]. The derivative shows good solubility toward macromol. compound in a pos.-working resist,

and is useful for dissoln. inhibitor of the resist.


IT 182251-85-0P 182251-88-3P

RL: PNU (Preparation, unclassified); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)


(preparation of bisphenylmethylbenzene derivative for dissoln. inhibitor of three-component resist)

RN 182251-85-0 CAPLUS

CN Acetic acid, 2,2'-[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis[methylene(4-methyl-2,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 182251-88-3 CAPLUS
 CN Acetic acid, 2,2',2'',2'''-[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis[methylene(3-methyl-1,2,4-benzenetriyl)]]tetrakis-, tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 96 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:631702 CAPLUS
 DN 125:261267
 TI Bis(4-tert-butoxycarbonylmethyloxy-2,5-dimethylphenyl)methyl-4-tert-butoxycarbonylmethyloxybenzene derivative for dissolution inhibitor of three-component resist
 IN Watanabe, Atsushi; Ishihara, Toshinobu; Yagihashi, Fujio
 PA Shinetsu Chemical Industry Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 4 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE

PI JP 08193054 A2 19960730 JP 1995-20955 19950113
 JP 1995-20955 19950113
 OS MARPAT 125:261267
 AB The derivative is represented by I (R = alkyl; m = an integer of 0-4). The derivative shows good solubility toward macromol. compds. in a pos.-working three-component resist, and is useful for dissoln. inhibitor of the resist.
 IT 182252-62-6P
 RL: PNU (Preparation, unclassified); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (preparation of di-Ph methylbenzene derivative for dissoln. inhibitor of three-component pos.-working resist)
 RN 182252-62-6 CAPLUS
 CN Acetic acid, 2,2'-[[[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]methylene]bis[(2,5-dimethyl-4,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 97 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:629766 CAPLUS
 DN 125:261263
 TI Positive-working resists containing t-butoxycarbonylmethyloxybenzene dissolution inhibitor for suppressed alkaline impurity
 IN Watanabe, Atsushi; Ishihara, Toshinobu; Yagihashi, Fujio; Tanaka, Haruyori; Kawai, Yoshio; Nakamura, Jiro
 PA Shinetsu Chemical Industry Co., Ltd., Japan; Nippon Telegraph & Telephone
 SO Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF

DT Patent
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08194313	A2	19960730	JP 1995-20958	19950113
				JP 1995-20958	19950113

OS MARPAT 125:261263
 AB The pos. resists comprise 3 components of an acid generator, a polymer compound, and a dissoln. inhibitor selected from 1,4-bis[bis(4-t-butoxycarbonylmethyloxyphenyl)methyl]benzene, its derivative I (R1-2 = alkyl; k = 0-4; l = 0-2, k + l ≤ 4), 1,3-bis(4-t-butoxycarbonylmethyloxyphenylmethyl)-4,6-bis-t-butoxycarbonylmethyloxybenzene, its derivative II (R = H, alkyl),


bis(4-t-butoxycarbonylmethyloxy-2,5-dimethylphenyl)methyl-4-t-butoxycarbonylmethyloxybenzene, its derivative III (R = alkyl; m = 0-4), 2,2-bis(2,4-di-t-butoxycarbonylmethyloxyphenyl)propane, its derivative IV (R4 = alkyl; m = 0-3), 2,6-bis(2-t-butoxycarbonylmethyloxyphenylmethyl)-1-t-butoxycarbonylmethyloxy-4-methylbenzene, and its derivative V (R = alkyl; n = 0, 1; m = 0-(4-n)). The dissoln. inhibitor suppresses penetration of an alkaline impurity in the resist film and provides high-resolution images.

IT 182251-85-0 182251-88-3 182261-29-6

RL: TEM (Technical or engineered material use); USES (Uses)
(pos. resists containing t-butoxycarbonylmethyloxybenzene dissoln. inhibitor for suppressed alkaline impurity)


RN 182251-85-0 CAPLUS

CN Acetic acid, 2,2'-[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis[methylene(4-methyl-2,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 182251-88-3 CAPLUS

CN Acetic acid, 2,2',2'',2'''-[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis[methylene(3-methyl-1,2,4-benzenetriyl)]]tetrakis-, tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 182261-29-6 CAPLUS
 CN Acetic acid, 2,2',2'',2'''-[(1-methylethylidene)bis[1,2,4-benzenetriylbis(oxy)]]tetrakis-, tetrakis(1,1-dimethylethyl) ester (9CI)
 (CA INDEX NAME)



L8 ANSWER 98 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:628057 CAPLUS
 DN 125:261265
 TI 1,4-Bis[bis(4-tert-butoxycarbonylmethyloxyphenyl)methyl]benzene and its
 derivative for dissolution inhibitor of resist composition
 IN Watanabe, Atsushi; Ishihara, Toshinobu; Yagihashi, Fujio
 PA Shinetsu Chemical Industry Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 4 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08193052	A2	19960730	JP 1995-20953	19950113
				JP 1995-20953	19950113

OS MARPAT 125:261265
 AB The 1,4-bis[bis(4-tert-butoxycarbonylmethyloxyphenyl)methyl]benzene and
 its derivative are I (R1-2 = alkyl; k = an integer of 0-4, l = an integer of
 0-2, k + l ≤ 4). The claimed compound shows good solubility toward
 macromol. compds. in pos.-type resist, and is useful for dissoln.
 inhibitor.

IT 177983-92-5P 182216-34-8P
 RL: PNU (Preparation, unclassified); TEM (Technical or engineered material
 use); PREP (Preparation); USES (Uses)
 (preparation of 1,4-bis(bisphenylmethyl)benzene derivative for dissoln.
 inhibitor of pos. resist)

RN 177983-92-5 CAPLUS
 CN Acetic acid, 2,2',2'',2'''-[1,4-phenylenebis[methyldidynebis[(2,5-dimethyl-
 4,1-phenylene)oxy]]]tetrakis-, tetrakis(1,1-dimethylethyl) ester (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OBu-t



RN 182216-34-8 CAPLUS
 CN Acetic acid, 2,2',2'',2'''-[1,4-phenylenebis[methyldynebis[(3,5-dimethyl-4,1-phenylene)oxy]]]tetrakis-, tetrakis(1,1-dimethylethyl) ester (9CI)
 (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OBu-t



L8 ANSWER 99 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:448613 CAPLUS
 DN 125:133035
 TI Characterization of the peptide binding requirements for the cloned human
 pancreatic polypeptide-preferring receptor
 AU Gehlert, Donald R.; Schober, Douglas A.; Beavers, Lisa; Gadski, Robert;
 Hoffman, James A.; Smiley, David L.; Chance, Ronald E.; Lundell, Ingrid;
 Larhammar, Dan
 CS Lilly Res. Lab., Eli Lilly and Company, Indianapolis, IN, 46285, USA
 SO Molecular Pharmacology (1996), 50(1), 112-118
 CODEN: MOPMA3; ISSN: 0026-895X
 PB Williams & Wilkins
 DT Journal
 LA English
 AB Traditionally, neuropeptide Y (NPY) receptors have been divided into Y1
 and Y2 subtypes based on peptide pharmacol. and synaptic localization.
 Other receptor subtypes have been proposed based on preferences for NPY,
 peptide YY (PYY), or pancreatic polypeptide (PP). Recently, we discovered
 a novel human membrane of this receptor family exhibiting high affinity
 for PP and PYY. In the current study, we expressed a DNA clone encoding
 this human PP-preferring receptor [hPP1 (or Y4)] in Chinese hamster ovary
 cells and performed a peptide structure-activity study. [125I]pPYY bound
 to homogenates of hPP1-Chinese hamster ovary cells with a K_d of 0.064 nM
 and a B_{max} of 244 fmol/mg protein. Human PP inhibited binding with a K_i
 of 0.023 nM, whereas human PYY (K_i = 0.31 nM) and human NPY (K_i = 12 nM)
 were significantly less potent. Rat, porcine, and bovine PP inhibited
 binding with similar affinities to human PP, whereas avian PP was
 substantially less potent (K_i = 1 nM). Deletion of the first four amino
 acids reduced the affinity of bovine PP to 1 nM. Carboxyl-terminal
 fragments of NPY and PYY also had reduced potency compared with the native
 peptides. In addition, deletion of Tyr36-amide produced a substantial
 reduction

in affinity. Pro34-substituted NPY and PYY had modestly increased affinity compared with the native peptides, although Gln34-bPP had similar affinity compared with bovine PP. The carboxyl-terminally derived Y1 antagonist 1229U91 was a very potent ($K_i = 0.042$ nM) inhibitor of binding to hPP1. Thus, the carboxyl-terminal region of PP seems to be the most important part of the peptide for high affinity binding to hPP1. A few key residues (amino acids 2 and 3) in the amino-terminal region of PP contribute to the high affinity of the native peptide. Thus, features required for peptide recognition by the hPP1 receptor seem to be distinct from the Y1 and Y2 receptor.

IT 140842-17-7 146999-93-1


RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(peptide binding domain characterization in cloned human pancreatic polypeptide-preferring receptor)

RN 140842-17-7 CAPLUS


CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutamyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 146999-93-1 CAPLUS
 CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginy-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutaminy-L-arginyl-3-[(2,6-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L8 ANSWER 100 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:388353 CAPLUS
 DN 125:45136
 TI Resist composition
 IN Abe, Nobunori; Matsuno, Shugo; Tanaka, Hideyuki; Sugimoto, Tatsuya; Wada, Yasumasa
 PA Nippon Zeon Co., Ltd., Japan
 SO PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 9612216 W: KR, US RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE	A1	19960425	WO 1995-JP2114	19951013
				JP 1994-274457	A 19941013
				JP 1995-21250	A 19950113
				JP 1995-84729	A 19950316
	JP 08194308	A2	19960730	JP 1995-21250	19950113
	JP 08254828	A2	19961001	JP 1995-84729	19950316
	JP 08211613	A2	19960820	JP 1995-284583	19951005
				JP 1994-274457	A 19941013
	EP 786701 R: DE, GB	A1	19970730	EP 1995-934306	19951013
				JP 1994-274457	A 19941013
				JP 1995-21250	A 19950113
				JP 1995-84729	A 19950316
				WO 1995-JP2114	W 19951013
	US 6010826	A	20000104	US 1997-817358	19970411
				JP 1994-274457	A 19941013
				JP 1995-21250	A 19950113
				JP 1995-84729	A 19950316
				WO 1995-JP2114	W 19951013


AB A resist composition contains a polymer (a) having acid-cleavable groups and a compound (b) capable of yielding an acid when irradiated with active rays of light, wherein the polymer (a) has groups containing an allyloxy group having at least two substituents as the acid-cleavable group. Also claimed is another resist composition containing a resin binder (A), a compound (B) capable of yielding an acid when irradiated with active rays of light, and a compound (C) having an acid-cleavable group, wherein the compound (C) has a group containing an allyloxy group having at least one substituent as the acid-cleavable group. These comps. are excellent in sensitivity, resolution, heat resistance, and pattern formation.

IT 178177-76-9P
RL: PNU (Preparation, unclassified); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(resist composition from)

RN 178177-76-9 CAPLUS

CN Acetic acid, 2,2'-[[5-methyl-2-[2-[(3-methyl-2-butenyl)oxy]-2-oxoethoxy]-1,3-phenylene]bis[methylene(4-methyl-2,1-phenylene)oxy]]bis-, bis(3-methyl-2-butenyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



—CH₂—CH=CMe₂

L8 ANSWER 101 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:379720 CAPLUS

DN 125:45127

TI Positive chemically amplified resist composition and method for producing compounds used therein

IN Aoi, Toshiaki; Fujimori, Toru

PA Fuji Photo Film Co., Ltd., Japan

SO Eur. Pat. Appl., 78 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 709736	A1	19960501	EP 1995-116815	19951025
	EP 709736	B1	19990421		
	R: BE, DE				
	JP 08123031	A2	19960517	JP 1994-262790	A 19941026
	JP 3340864	B2	20021105	JP 1994-262790	19941026

OS MARPAT 125:45127

AB A pos. chemical amplified resist composition is disclosed, comprising (a) a compound

which generates an acid upon irradiation with active light or radiant ray, (b) a resin insol. in water but soluble in an aqueous alkali solution, and (c) a low-mol-weight acid-decomposable dissoln. inhibitor having a mol. weight of

3000

or less and containing an acid-decomposable alkyl ester group represented by the formula -(CR₁R₂)_nCO₂CR₃R₄R₅ (R₁, R₂ = H, alkyl, or aryl; R₃, R₄, R₅ = H, alkyl, cycloalkyl, alkoxy, alkenyl, aralkyl, or aryl, provided that two of R₃, R₄, and R₅ may be combined to form a ring; n = an integer of 1-10), which increases its solubility in an alkali developer by the action of an acid, and having a sodium content and a potassium content each of 30 ppb or less. Further disclosed are methods for producing the compds. (c).

IT 177983-92-5P 177983-96-9P


RL: SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

(preparation and use as acid-decomposable dissoln. inhibitor for pos photoresist)

RN 177983-92-5 CAPLUS

CN Acetic acid, 2,2',2'',2'''-[1,4-phenylenebis[methyldynebis[(2,5-dimethyl-4,1-phenylene)oxy]]]tetrakis-, tetrakis(1,1-dimethylethyl) ester (9CI)
(CA INDEX NAME)


PAGE 1-A



PAGE 1-B

—OBu-t

RN 177983-96-9 CAPLUS
 CN Acetic acid, 2,2',2''-[[1-(4-hydroxy-2,5-dimethylphenyl)-1-pentanyl-5-ylidene]tris[(2,5-dimethyl-4,1-phenylene)oxy]]tris-, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 102 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:367650 CAPLUS
 DN 125:45124
 TI Positive-working photosensitive composition
 IN Aoi, Toshiaki; Yamanaka, Tsukasa; Uenishi, Kazuya
 PA Fuji Photo Film Co., Ltd., Japan
 SO Eur. Pat. Appl., 78 pp.
 CODEN: EPXXDW

DT Patent
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 708368	A1	19960424	EP 1995-114054	19950907
	EP 708368	B1	19990630		
	R: BE, DE				
	JP 08123030	A2	19960517	JP 1994-252351	A 19941018
	JP 3317597	B2	20020826	JP 1994-252351	19941018

PATENT FAMILY INFORMATION:

FAN 1997:719619

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5683856	A	19971104	US 1996-634529	19960418
				JP 1994-252351	A 19941018
				US 1995-525157	B2 19950908
	JP 08123030	A2	19960517	JP 1994-252351	19941018
	JP 3317597	B2	20020826		

AB A pos.-working photosensitive composition for the production of lithog. plates comprises (a) a resin which is insol. in water but soluble in an alkaline aqueous

solution, (b) a compound which generates an acid upon irradiation with active light, (c) a low-mol.-weight acid-decomposable dissoln.-inhibitive compound having a mol. weight of 3000 or less, containing a group decomposable with an acid, and being capable of increasing its solubility in an alkaline developer

by the action of an acid, and (d) a resin containing a basic nitrogen atom and having a weight-average mol. weight of 2000 or more. The pos.-working photosensitive composition of the present invention can easily and properly inhibit acid diffusion and acid deactivation on the surface thereof with time between the exposure and the heat treatment, keep the dissoln. inhibiting effect exerted by a dissoln.-inhibitive compound, and exhibit a good profile, a high sensitivity, and a high resolving power.


IT 153698-59-0

RL: TEM (Technical or engineered material use); USES (Uses)

(lithog. plate manufacture and resist pattern formation using pos.-working photosensitive comps. containing)

RN 153698-59-0 CAPLUS

CN Acetic acid, 2,2',2'',2'''-[1,5-pentanediyldenetetrakis[(2,6-dimethyl-4,1-phenylene)oxy]]tetrakis-, tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 103 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:137212 CAPLUS

DN 124:207814

TI Metal cation extraction properties of linear all-ortho phenolic oligomers

AU Yamagishi, Tada-Aki; Tani, Kenji; Shirano, Keiko; Ishida, Shin-Ichiro; Nakamoto, Yoshiaki

CS Dep. Chemistry Chemical Engineering, Kanazawa Univ., Kanazawa, 920, Japan

SO Journal of Polymer Science, Part A: Polymer Chemistry (1996), 34(4), 687-93

CODEN: JPACEC; ISSN: 0887-624X

PB Wiley

DT Journal

LA English

AB A series of Et acetate (nBP-ES) and trioxyethylene ether (nBP-OE) derivs. of linear all-ortho methylene-linked oligomers of p-tert-butylphenol (n = 1-7) was prepared, and cation extraction properties were determined For alkali metal

cations, nBP-ES had an affinity, and especially 5BP-ES was selective for Na⁺. On the other hand, nBP-OE also showed sufficient affinity. However, the extraction behavior was completely different from that of nBP-ES, i.e., the affinity of even membered BP-OE was higher than that of the odd membered. The nBP-ES extracted cations by forming a cavity winding around them, while nBP-OE extracted with two trioxyethylene chain picking up cations. For

alkaline

earth metal cations, nBP-ES extracted more than that for alkali cations.

Particularly, 7BP-ES showed the highest affinity for the larger cations, Sr²⁺ and Ba²⁺, among phenolic oligomers and 18-crown-6 compound On the

other hand, nBP-OE showed a lower affinity than that for alkali metal

cations. The linear phenolic oligomers extracted alkali and alkaline earth

metal

cations, and the kind of ion ligand introduced influenced the affinity and selectivity.

IT 158730-76-8P 158730-77-9P 158730-78-0P


158730-79-1P 158730-80-4P 158730-81-5P

RL: PUR (Purification or recovery); PREP (Preparation)


(metal cation extraction by linear all-ortho phenolic oligomers)

RN 158730-76-8 CAPLUS

CN Acetic acid, 2,2'-[methylenebis[[4-(1,1-dimethylethyl)-2,1-phenylene]oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)





RN 158730-77-9 CAPLUS
 CN Acetic acid, 2,2'-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)-1,3-phenylene]bis[methylene[4-(1,1-dimethylethyl)-2,1-phenylene]oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)





RN 158730-78-0 CAPLUS
 CN Acetic acid, 2,2'-[methylenebis[[4-(1,1-dimethylethyl)-6-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)phenyl]methyl]-2,1-phenylene]oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






RN 158730-79-1 CAPLUS
 CN Acetic acid, 2,2'-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)-1,3-phenylene]bis[methylene[4-(1,1-dimethylethyl)-6-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)phenyl]methyl]-2,1-phenylene]oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 158730-80-4 CAPLUS
 CN Acetic acid, 2,2'-[methylenebis[[4-(1,1-dimethylethyl)-6-[[5-(1,1-dimethylethyl)-3-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)phenyl]methyl]-2-(2-ethoxy-2-oxoethoxy)phenyl]methyl]-2,1-phenylene]oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 158730-81-5 CAPLUS

CN Acetic acid, 2,2'-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)-1,3-phenylene]bis[methylene[4-(1,1-dimethylethyl)-6-[[5-(1,1-dimethylethyl)-3-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)phenyl]methyl]-2-(2-ethoxy-2-oxoethoxy)phenyl]methyl]-2,1-phenylene]oxy]]bis-, diethyl ester (9CI)
(CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L8 ANSWER 104 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:126694 CAPLUS
 DN 124:160416
 TI Positive photosensitive composition
 IN Aoi, Toshiaki; Yamanaka, Tsukasa
 PA Fuji Photo Film Co., Ltd., Japan
 SO Eur. Pat. Appl., 81 pp.
 CODEN: EPXXDW
 DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 691575	A2	19960110	EP 1995-110358	19950703
	EP 691575	A3	19960515		
	EP 691575	B1	20020320		
	R: BE, DE				
				JP 1994-152218	A 19940704
				JP 1994-157278	A 19940708
				JP 1994-160143	A 19940712
	JP 08015862	A2	19960119	JP 1994-152218	19940704
	JP 3290303	B2	20020610		
	JP 08022126	A2	19960123	JP 1994-157278	19940708
	JP 3290305	B2	20020610		
	JP 08029982	A2	19960202	JP 1994-160143	19940712
	JP 3337827	B2	20021028		
	US 5824451	A	19981020	US 1995-497795	19950703
				JP 1994-152218	A 19940704
				JP 1994-157278	A 19940708
				JP 1994-160143	A 19940712

AB A pos. photosensitive composition comprises (a) a resin soluble in an aqueous alkali solution containing a specific structure unit, (b) a compound which generates an acid with irradiation of an active ray or radiation, and (c) a low-mol.-weight acid-decomposable dissoln. inhibitor having a mol. weight of not more than 3000, which possesses a tertiary alkyl ester group and whose solubility in an aqueous alkali solution is increased by the action of an acid, wherein


compound (c) is a compound having at least two tertiary alkyl ester groups, in which the longest distance with respect to the distance between two tertiary ester groups selected arbitrarily comprises at least 10 bonding atoms except for the atoms contained in the ester groups or a compound having at least three tertiary alkyl ester groups, in which the longest distance with respect to the distance between two tertiary ester groups. The pos. photosensitive composition has a high sensitivity, high resolution and good profile and

excels in storage stability and heat resistance of the resist solution

IT 153698-59-0P 159293-89-7P 173786-60-2P
 RL: SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (preparation and use in pos. photosensitive compns. for lithog. plate manufacture)


RN 153698-59-0 CAPLUS

CN Acetic acid, 2,2',2'',2'''-[1,5-pentanediyldienetetakis[(2,6-dimethyl-4,1-phenylene)oxy]]tetakis-, tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 159293-89-7 CAPLUS

CN Acetic acid, 2,2',2'',2'''-[(1,4-phenylenedimethylidyne)tetrakis[(2,6-dimethyl-4,1-phenylene)oxy]]tetrakis-, tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 173786-60-2 CAPLUS

CN Acetic acid, 2,2'-[[[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-methoxyphenyl]methylene]bis[(2,6-dimethyl-4,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 105 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:50352 CAPLUS
 DN 124:101865
 TI Positive-working photoresist composition
 IN Yamanaka, Tsukasa; Sakaguchi, Shinji; Kokubo, Tadayoshi; Kawabe, Yasumasa
 PA Fuji Photo Film Co Ltd, Japan
 SO Jpn. Kokai Tokkyo Koho, 53 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07271037	A2	19951020	JP 1994-63862	19940331
				JP 1994-63862	19940331


AB The title composition comprises an alkali soluble resin, a photoacid generator, and ≥ 1 kinds of compds. selected from I and II (R1-41 = H, XRa1, CN, OD0; X1-10 = single bond, carbonyl, sulfido, sulfonyl, CRb1Rb2; x = single bond, O, S, CO, OCO, NRA1CO, NRA2; Ra1 = C1-10 alkyl, alkylene, cycloalkyl, haloalkyl, aryl, alkylaryl, aralkyl; Ra2 = H, Ra1; Rb1, Rb2 = H, Me, Et, C1-4 haloalkyl; D0-12 = H, Dinh; Dinh = XiRi; Xi = CRb1Rb2, CRb1Rb2O, CO, CS, COO, COS, CRb1Rb2CO, CRb1Rb2COO, CRb1ORi, CONRb1; Ri = H, C1-20 alkyl, alkenyl, C3-20 cycloalkyl, C6-20 aryl, cumyl, adamantyl, SiZiRb3ZiRb4ZiRb5, tetrahydro-pyranyl, pyranyl, 1,3-dithia-indane-2-yl; Rb3-b5 = C1-20 alkyl, cycloalkyl, alkenyl, C6-20 aryl; Zi = single bond, O; i, j, k, m, n = 0, 1).

IT 172651-17-1P 172651-19-3P 172651-22-8P
 172651-25-1P 172651-26-2P 172651-28-4P
 172651-31-9P 172651-32-0P

RL: DEV (Device component use); IMF (Industrial manufacture); PREP (Preparation); USES (Uses)
 (pos.-working photoresist composition comprising)


RN 172651-17-1 CAPLUS

CN Acetic acid, 2,2'-[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis[methylene(2,5-dimethyl-4,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 172651-19-3 CAPLUS
 CN Acetic acid, 2,2'-[methylenebis[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-3,1-phenylene]methyleno-4,1-phenyleneoxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 172651-22-8 CAPLUS
 CN Acetic acid, 2,2'-[methylenebis[[6-[[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2,5-dimethylphenyl]methyl]-4-methyl-2,1-phenylene]oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B




RN 172651-25-1 CAPLUS
 CN Acetic acid, 2,2'-[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis[methylene[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-3,1-phenylene]methylene-4,1-phenyleneoxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 172651-26-2 CAPLUS
 CN Acetic acid, 2,2'-[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis[methylene[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2,5-dimethyl-3,1-phenylene]methylene-4,1-phenyleneoxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 172651-28-4 CAPLUS

CN Acetic acid, 2,2'-[methylenebis[[6-[[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]methyl]-2,5-dimethylphenyl]methyl]-4-methyl-2,1-phenylene]oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 172651-31-9 CAPLUS


CN Acetic acid, 2,2'-[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis[methylene[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2,5-dimethyl-3,1-phenylene]methylene[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2,5-dimethyl-4,1-phenylene]methylene(2-methyl-4,1-phenylene)oxy]]bis-,

bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 172651-32-0 CAPLUS
 CN Acetic acid, 2,2'-[(2,5-dimethyl-1,3-phenylene)bis[methylene[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2,5-dimethyl-3,1-phenylene]methylene[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3,1-phenylene]methylene(2-methyl-4,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L8 ANSWER 106 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:994163 CAPLUS

DN 124:55584

TI Preparation of calixarene-based compounds having antibacterial, antifungal, anticancer, and anti-HIV activity

IN Harris, Stephen J.

PA Ire.

SO PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9519974	A2	19950727	WO 1995-IE8	19950124
	WO 9519974	A3	19950921		
	W:	AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, FI, GB, HU, JP, KP, LU, NO, RO, UA, US			
	RW:	AT, BE, CH, DE, ES, FR, GB, GR, IE, LU, NL, SE, GA, ML, NE, SN, TD, TG			
	AU 9515453	A1	19950808	IE 1994-57	A 19940124
				AU 1995-15453	19950124
				WO 1995-IE8	A 19950124

OS MARPAT 124:55584

AB Calixarene-based compds., which are calixarenes or oxacalixarenes, acyclic phenyl-formaldehyde oligomers, cyclotrimeratrylene derivs., cyclic tetrameric resorcinol-aldehyde derivs. known as Hogberg compds. and cyclic tetrameric pyrogallol-aldehyde derivs., are prepared For example, calixarenes or oxacalixarenes are represented by general formula [I; n + m


= 3-8; m = 0-3; n = 0-8; R1 = H, halo, hydrocarbyl, aryl, (un)substituted hydrocarbylaryl, NO2, SO3M1; wherein M1 = alkali metal, SO3H; R1 = OR2; wherein R2 = CH2CO2R3, CH2CO2Mp/p, CH2CONR4R5; wherein R3 = (un)substituted alkyl; M = metal, ammonium ion; p = the charge on the metal ion; R4 or R5 may be the same or different, or both may be part of amino acid ester of poly(amino acid ester) or one or more of the same or different amino acids or part of a cyclic polyene antibiotic/antifungal drug or part of a cyclic nitrogen heterocycle; X = halo, NO2, CO2H, cyano, other electron withdrawing group]. Thus, n-butyraldehyde and pyrogallol in a 1:4 mixture of 37% aqueous HCl and EtOH was refluxed under N for 90 min to give a cyclic tetramer (II; R = X = H), which was brominated with Br in CHCl3 to II (R = H, X = Br) and etherified with Et bromoacetate in the presence of K2CO3 in refluxing acetone to give II (R = CH2CO2Et, X = Br). The latter compound was saponified with KOH in refluxing EtOH, acidified with aqueous HCl, and treated with 25% aqueous NH4OH to give II (R = CH2CO2-NH4+, X

= Br). The latter compound in vitro inhibited the infection of C8166 cells with HIV-2, SIV (Simian immunodeficiency virus), and HIV-1 with EC50 of 10, 20, and 0.03 μ M.


IT 171798-86-0P 171798-87-1P 171798-88-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of calixarene-based compds. having antibacterial, antifungal, anticancer, and anti-HIV activity)

RN 171798-86-0 CAPLUS
 CN Acetic acid, 2,2',2'',2'''-[methylenebis[[5-bromo-2-(2-ethoxy-2-oxoethoxy)-3,1-phenylene]methylene(5-bromo-3,1,2-benzenetriyl)bis(methyleneoxy)]]tetraakis-, hexaethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B




RN 171798-87-1 CAPLUS
 CN Acetic acid, 2,2',2'',2'''-[methylenebis[[5-bromo-2-(carboxymethoxy)-3,1-phenylene]methylene(5-bromo-3,1,2-benzenetriyl)bis(methyleneoxy)]]tetrakis-, hexapotassium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 6 K

RN 171798-88-2 CAPLUS
 CN Acetic acid, 2,2',2'',2'''-[methylenebis[[5-bromo-2-(carboxymethoxy)-3,1-phenylene]methylene(5-bromo-3,1,2-benzenetriyl)bis(methyleneoxy)]]tetrakis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L8 ANSWER 107 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1995:933848 CAPLUS
 DN 124:1276
 TI Failure of the putative neuropeptide Y antagonists, benextramine and
 PYX-2, to inhibit Y₂ receptors in rat isolated prostatic vas deferens
 AU Palea, S.; Corsi, M.; Rimland, J. M.; Trist, D. G.; Ratti, E.
 CS Pharmacology Department, Glaxo Research Laboratories, Verona, 37135, Italy
 SO British Journal of Pharmacology (1995), 116(5), 2401-6
 CODEN: BJPCBM; ISSN: 0007-1188
 PB Stockton
 DT Journal
 LA English
 AB The pharmacol. activity of neuropeptide Y (NPY) and some analogs in
 inhibiting the twitch contractions induced by elec. stimulation (single
 pulses at 25 V, 0.15 Hz, 1 ms) in the prostatic portion of the rat
 isolated vas deferens was investigated. The rank order of agonist potency
 was: PYY > NPY₂₋₃₆ > NPY » NPY₁₃₋₃₆ » NPY₁₈₋₃₆ »
 [Leu³¹,Pro³⁴]NPY = hPP, which is consistent with the activation of a Y₂
 receptor. The putative Y₁ and Y₂ antagonist, benextramine (BXT),
 incubated at 100 μM for 10 or 60 min, was ineffective against
 PYY-induced inhibition of the twitch response. The putative NPY
 antagonist, PYX-2, incubated at 1 μM for 20 min, was completely
 ineffective in antagonizing PYY-induced inhibition of twitches. The
 twitch response was totally inhibited by suramin (100 μM) but was

little affected by prazosin (1 μ M). Furthermore, NPY was without effect on the dose-response curve to ATP in resting conditions. Taken together, these results suggest that in our paradigm, NPY inhibits the release of a purinergic neurotransmitter which mediates contraction of the prostatic portion of the rat vas deferens.

IT 146999-93-1, PYX 2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)


(failure of putative neuropeptide Y antagonists, benextramine and PYX-2, to inhibit Y2 receptors in prostatic vas deferens)

RN 146999-93-1 CAPLUS


CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutamyl-L-arginyl-3-[(2,6-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L8 ANSWER 108 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:621504 CAPLUS

DN 123:44372

TI Positive-working resist composition and patterning using same

IN Tanaka, Sachiko; Kumada, Teruhiko; Horibe, Hideo; Kubota, Shigeru; Hizuka, Juji

PA Mitsubishi Electric Corp, Japan

SO Jpn. Kokai Tokkyo Koho, 23 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06242607	A2	19940902	JP 1993-28880	19930218
				JP 1993-28880	19930218

OS MARPAT 123:44372

AB The title composition comprises (1) 40-90% polymer compound in which 5-50 mol% of

groups providing alkaline solubility is substituted with protective groups decomposable by an acid, (2) 10-55% compound which becomes alkaline soluble

upon decomposition by an acid, and (3) 0.03-15% compound forming an acid upon irradiation

of light. This composition provides a large solubility ratio of exposed and nonexposed regions of the resist film with a developer.


IT 163915-97-7

RL: POF (Polymer in formulation); TEM (Technical or engineered material use); USES (Uses)

(pos.-working resist composition and patterning using same)

RN 163915-97-7 CAPLUS

CN Acetic acid, 2,2'-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2-methyl-1,3-phenylene]bis[methylene(4-methyl-3,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 109 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:522641 CAPLUS

DN 122:278146

TI Positive-working photoresist composition with durability, high sensitivity, and high resolution

IN Aoso, Toshiaki; Yamanaka, Tsukasa; Kokubo, Tadayoshi

PA Fuji Photo Film Co Ltd, Japan

SO Jpn. Kokai Tokkyo Koho

CODEN: JKXXAF


DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI JP 06266109 A2 19940922 JP 1993-54121 19930315
 JP 1993-54121 19930315
 AB The title composition comprises a solvent with b.p. 130-155° and a
 dissoln. inhibitor having ≥ 2 groups capable of dissoln. upon
 reaction with an acid.
 IT 153698-51-2 153698-52-3
 RL: DEV (Device component use); USES (Uses)
 (pos.-working photoresist composition with durability, high sensitivity, and
 high resolution)
 RN 153698-51-2 CAPLUS
 CN Acetic acid, 2,2'-[[4-[bis[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3,5-
 dimethylphenyl]methyl]-1,2-phenylene]bis(oxy)]bis-, bis(1,1-dimethylethyl)
 ester (9CI) (CA INDEX NAME)



RN 153698-52-3 CAPLUS
 CN Acetic acid, 2,2'-[[[3-methoxy-4-[2-(1-methyl-1-phenylethoxy)-2-
 oxoethoxy]phenyl]methylene]bis[(2,6-dimethyl-4,1-phenylene)oxy]]bis-,
 bis(1-methyl-1-phenylethyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 110 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1995:478115 CAPLUS
 DN 122:226801
 TI Positive working photosensitive composition
 IN Yamanaka, Tsukasa; Aoai, Toshiaki; Kokubo, Tadayoshi
 PA Fuji Photo Film Co., Ltd., Japan

SO Ger. Offen., 39 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4410441	A1	19940929	DE 1994-4410441	19940325
				JP 1993-68630	A 19930326
	JP 06282073	A2	19941007	JP 1993-68630	19930326
	JP 3290234	B2	20020610		
	BE 1010516	A4	19981006	BE 1994-322	19940325
				JP 1993-68630	A 19930326


AB The title composition comprises: an alkaline developer-soluble resin containing acid-decomposable groups; a photoacid generator; and an acid-decomposable non-polymeric dissoln.-inhibitor containing an acid-decomposable group and having a mol. weight ≤ 3000 . The dissoln.-inhibitor contains ≥ 3 structural components per mol. each of which contains an acid-decomposable group and there are ≥ 9 atom-bonds between any 2 such acid-decomposable groups without counting the acid-decomposable groups.

IT 153698-59-0 159293-89-7 162130-33-8

RL: MOA (Modifier or additive use); USES (Uses)
(photosensitive composition component)

RN 153698-59-0 CAPLUS

CN Acetic acid, 2,2',2'',2'''-[1,5-pentanediyldenetetrakis[(2,6-dimethyl-4,1-phenylene)oxy]]tetrakis-, tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 159293-89-7 CAPLUS

CN Acetic acid, 2,2',2'',2'''-[(1,4-phenylenedimethyldiene)tetrakis[(2,6-dimethyl-4,1-phenylene)oxy]]tetrakis-, tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

JP 06242608 A2 19940902 JP 1993-111129 A 19930415
 JP 06301210 A2 19941028 JP 1993-51222 19930218
 JP 1993-111129 19930415


AB The title material comprises a binder resin, a photoacid generator, and low mol. weight acid-splittable dissoln. inhibitor where the dissoln. inhibitor is selected from: (1) a compound containing ≥ 2 acid-splittable groups with a distance of ≥ 10 atoms between 2 acid-splittable groups; and (2) a compound containing ≥ 3 acid-splittable groups with a distance of ≥ 9 atoms between 2 acid-splittable groups. The material has improved photosensitivity, solubility, storage stability, and thermal stability.

IT 161822-26-0 162181-27-3
 RL: MOA (Modifier or additive use); USES (Uses)
 (dissoln. inhibitor for photosensitive composition)


RN 161822-26-0 CAPLUS

CN Acetic acid, 2,2',2'',2'''-[1,4-phenylenebis[methyldynebis[(2,6-dimethyl-4,1-phenylene)oxy]]]tetrakis-, tetrakis(1-methyl-1-phenylethyl) ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B



RN 162181-27-3 CAPLUS
 CN Acetic acid, 2,2',2'',2'''-[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis(methylene-1,2,4-benzenetriyl)]tetrakis-, tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




L8 ANSWER 112 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1995:312613 CAPLUS
 DN 122:201259
 TI Positive-working photosensitive compositions
 IN Aoso, Toshiaki; Yamanaka, Tsukasa; Kokubo, Tadayoshi
 PA Fuji Photo Film Co Ltd, Japan
 SO Jpn. Kokai Tokkyo Koho, 25 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06266107	A2	19940922	JP 1993-49258	19930310
				JP 1993-49258	19930310


AB The title compns. contain a water-insol. and alkali-soluble resin, a compound generating an acid by irradiation with active rays or radiations, and a dissoln. inhibitor with mol. weight ≤ 3000 , whose solubility in developing solns. increases by acid, having ≤ 3 acid-decomposable groups branching from the same saturated C with ≥ 9 bonding atoms (except the decomposable group bonds) between the 2 decomposable groups in the farthest positions. A pos.-working resist comprising m-cresol-p-cresol-HCHO novolak resin, $\text{Ph}_2\text{I}^+\text{.AsF}_6^-$, and I gave high resolution patterns with good profile by using a KrF excimer laser.

IT 159293-89-7 161715-11-3
 RL: MOA (Modifier or additive use); TEM (Technical or engineered material use); USES (Uses)
 (dissoln. inhibitor; pos.-working photosensitive compns. containing alkali-soluble resins, acid generators, and acid-decomposing dissoln. inhibitors)


RN 159293-89-7 CAPLUS
 CN Acetic acid, 2,2',2'',2'''-[(1,4-phenylenedimethyldiyne)tetrakis[(2,6-dimethyl-4,1-phenylene)oxy]]tetrakis-, tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 161715-11-3 CAPLUS
 CN Acetic acid, 2,2',2'',2'''-[1,2-ethanediylidene]tetraakis(2,6-dimethyl-4,1-phenyleneoxy)]tetraakis-, tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 113 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1995:177456 CAPLUS
 DN 122:204915
 TI Putative neuropeptide Y antagonist failed to decrease overeating in obese Zucker rats
 AU Beck, Bernard; Stricker-Krongrad, Alain; Musse, Nadine; Nicolas, Jean-Pierre; Burlet, Claude
 CS INSERM U.308, Mecanismes de Regulation du Comportement Alimentaire, 38 rue Lionnois, Nancy, 54000, Fr.
 SO Neuroscience Letters (1994), 181(1-2), 126-8
 CODEN: NELED5; ISSN: 0304-3940



RN 162130-33-8 CAPLUS
 CN Acetic acid, 2,2'-[[[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]methylene]bis[(2,6-dimethyl-4,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 111 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1995:446446 CAPLUS
 DN 123:22183
 TI Positive working photosensitive composition
 IN Aoi, Toshiaki; Yamanaka, Tsukasa; Kokubo, Tadayoshi
 PA Fuji Photo Film Co., Ltd., Japan
 SO Ger. Offen., 71 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4405108	A1	19940825	DE 1994-4405108	19940217
				JP 1993-51222	A 19930218

PB Elsevier

DT Journal

LA English

AB A central dysregulation of several neuropeptides could be at the origin of the marked hyperphagia of the obese Zucker rat, a well-known animal model used for the study of obesity. Neuropeptide Y (NPY), which stimulates food intake and increases early in life in obese rats, plays a major role in the development of this hyperphagia. The aim of our experiment was to test a proposed NPY antagonist namely PYX-2 in obese hyperphagic Zucker rats to know if it could be an interesting drug for limiting their food intakes. Four doses of PYX-2 (50-1000 pmol) were injected in a counterbalanced order in the lateral brain ventricles of 10 adult male Zucker rats. Food intake was recorded 0.5, 1, 2, 3, 6, and 23 h after PYX-2 injection and compared either to the rat's spontaneous food intake or to the food intake following injection of artificial CSF (vehicle) only. It was not modified by any dose of PYX-2 whatever the time considered (1 h after injection: 4.3 (1000 pmol) vs. 4.6 g; 23 h period: 27.0 (1000 pmol) vs. 26.6 g; N.S.). Thus, PYX-2, the putative NPY antagonist, totally failed to inhibit food intake in the obese rats. The absence of effect of PYX-2 on food intake can be explained by the structure of PYX-2, a modified 27-36 amino acid sequence that may not be recognized by the Y1-type NPY receptors which are involved in the regulation of feeding behavior.

IT 146999-93-1, PYX-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)


(putative neuropeptide Y antagonist PYX-2 failed to decrease overeating in obese Zucker rats)


RN 146999-93-1 CAPLUS

CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutamyl-L-arginyl-3-[(2,6-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L8 ANSWER 114 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1994:712009 CAPLUS
 DN 121:312009
 TI Three-component chemical amplification-type positive-working resist
 composition for high resolution and high sensitivity
 IN Aoso, Toshiaki; Yamanaka, Tsukasa; Uenishi, Kazuya; Kokubo, Tadayoshi
 PA Fuji Photo Film Co Ltd, Japan
 SO Jpn. Kokai Tokkyo Koho, 59 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06095390	A2	19940408	JP 1992-286045	19921023
				JP 1992-199689	A1 19920727
	DE 4336009	A1	19940428	DE 1993-4336009	19931021
				JP 1992-305929	A 19921021
				JP 1992-286045	A 19921023

PATENT FAMILY INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4336009	A1	19940428	DE 1993-4336009	19931021
				JP 1992-305929	A 19921021
				JP 1992-286045	A 19921023
	JP 06130670	A2	19940513	JP 1992-305929	19921021
	JP 06095390	A2	19940408	JP 1992-286045	19921023
				JP 1992-199689	A1 19920727


AB In the title composition comprising an alkaline-soluble resin, a photosensitive acid-generating compound, a dissoln. retarding agent for in an acid, the dissoln. retarding agent is a polycyclic aromatic compound, ≥ 1 mol of which is a compound containing an alkaline-soluble group.

IT 153698-52-3 159293-89-7


RL: TEM (Technical or engineered material use); USES (Uses)
 (three-component chemical amplification-type pos.-working resist composition)

RN 153698-52-3 CAPLUS

CN Acetic acid, 2,2'-[[[3-methoxy-4-[2-(1-methyl-1-phenylethoxy)-2-oxoethoxy]phenyl]methylene]bis[(2,6-dimethyl-4,1-phenylene)oxy]]bis-, bis(1-methyl-1-phenylethyl) ester (9CI) (CA INDEX NAME)



RN 159293-89-7 CAPLUS
 CN Acetic acid, 2,2',2'',2'''-[(1,4-phenylenedimethylidyne)tetrakis[(2,6-dimethyl-4,1-phenylene)oxy]]tetrakis-, tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 115 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1994:657019 CAPLUS
 DN 121:257019
 TI Linear all-ortho oligomers of phenol-formaldehyde resins. II. Preparations and cation extraction properties of ester derivatives
 AU Yamagishi, Tada Aki; Tani, Kenji; Ishida, Shinichiro; Nakamoto, Yoshiaki
 CS Dep. Chem. and Chem. Engineering, Kanazawa Univ., Kanazawa, 920, Japan
 SO Polymer Bulletin (Berlin, Germany) (1994), 33(3), 281-7
 CODEN: POBUDR; ISSN: 0170-0839
 DT Journal
 LA English
 AB The Et acetate derivs. of all-ortho oligomers of p-tert-butylphenol-formaldehyde resins were prepared The cation extraction properties were determined

and were compared with those of the calixarene derivs. The derivs. of linear oligomers showed affinity toward alkali metal cations, arising from the cavity based on the pseudo-cyclic conformation. The same derivs. of p-tert-butylphenol resins also showed affinity toward alkali metal cations.


IT 158730-76-8 158730-77-9 158730-78-0

158730-79-1 158730-80-4 158730-81-5

RL: NUU (Other use, unclassified); PRP (Properties); USES (Uses)
(extraction of alkali metals via)


RN 158730-76-8 CAPLUS

CN Acetic acid, 2,2'-[methylenebis[[4-(1,1-dimethylethyl)-2,1-phenylene]oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 158730-77-9 CAPLUS


CN Acetic acid, 2,2'-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)-1,3-phenylene]bis[methylene[4-(1,1-dimethylethyl)-2,1-phenylene]oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 158730-78-0 CAPLUS

CN Acetic acid, 2,2'-[methylenebis[[4-(1,1-dimethylethyl)-6-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)phenyl]methyl]-2,1-phenylene]oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B





RN 158730-79-1 CAPLUS
 CN Acetic acid, 2,2'-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)-1,3-phenylene]bis[methylene[4-(1,1-dimethylethyl)-6-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)phenyl]methyl]-2,1-phenylene]oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






RN 158730-80-4 CAPLUS
 CN Acetic acid, 2,2'-[methylenebis[[4-(1,1-dimethylethyl)-6-[[5-(1,1-dimethylethyl)-3-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)phenyl]methyl]-2-(2-ethoxy-2-oxoethoxy)phenyl]methyl]-2,1-phenylene]oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 158730-81-5 CAPLUS
 CN Acetic acid, 2,2'-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)-1,3-phenylene]bis[methylene[4-(1,1-dimethylethyl)-6-[[5-(1,1-dimethylethyl)-3-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)phenyl]methyl]-2-(2-ethoxy-2-oxoethoxy)phenyl]methyl]-2,1-phenylene]oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L8 ANSWER 116 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1994:290690 CAPLUS
 DN 120:290690
 TI Inhibitory effect of neuropeptide Y and its analogs on inositol
 1,4,5-trisphosphate level in rat cardiomyocytes
 AU Xiang, Hong; Brown, John C.
 CS Dep. Physiol., Univ. British Columbia, Vancouver, BC, V6T 1Z3, Can.
 SO Receptors and Channels (1993), 1(4), 315-21
 CODEN: RCHAE4; ISSN: 1060-6823

DT Journal

LA English

AB A neg. inotropic effect of neuropeptide Y (NPY) in the mammalian heart has been reported. The mechanism(s) involved in the action of NPY in the heart is still unclear. Since D-myo-inositol 1,4,5-trisphosphate [Ins(1,4,5)P₃] is known to be an important second messenger in the regulation of cardiac function, the authors carried out a study to investigate the status of Ins(1,4,5)P₃ levels in response to NPY stimulation in rat cardiomyocytes. The authors also studied the possible involvement of NPY receptor subtypes in Ins(1,4,5)P₃ formation. [Leu³¹,Pro³⁴]NPY, NPY₁₃₋₃₆, NPY and peptide YY (PYY) induced a concentration-dependent decrease in Ins(1,4,5)P₃ levels [measured with an Ins(1,4,5)P₃ protein binding assay kit] in rat cardiomyocytes, which was blocked by NPY antagonists NPY₁₈₋₃₆ or PYX-2. There is no difference in the inhibitory effect of NPY and PYY on Ins(1,4,5)P₃ formation. Furthermore, effects of NPY and its analogs were insensitive to pertussis toxin pretreatment. Two new and more specific Y₂ receptor agonists, [Ahx⁵⁻²⁴]NPY and [Ahx⁵⁻²⁴,γ-Glu²-ε-Lys³⁰]NPY, produced similar effects as NPY₁₃₋₃₆ on Ins(1,4,5)P₃ formation. These observations indicate that Y₁ and Y₂ subtypes of NPY receptor in rat cardiomyocytes may be associated with Ins(1,4,5)P₃ formation through a pertussis-toxin-insensitive G_q protein. The decreased Ins(1,4,5)P₃ formation may be implicated in the neg. inotropic effect of NPY in the heart.

IT 146999-93-1, PYX-2

RL: BIOL (Biological study)


(neuropeptide Y-inhibited inositol triphosphate formation in response to, in heart)


RN 146999-93-1 CAPLUS

CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutamyl-L-arginyl-3-[(2,6-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







L8 ANSWER 117 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1994:226974 CAPLUS
 DN 120:226974
 TI Pharmaceutical compositions containing antihyperlipidemic or
 antiarteriosclerotic agents
 IN Aikawa, Kazuhiro; Aoki, Kozo
 PA Fuji Photo Film Co., Ltd., Japan
 SO Eur. Pat. Appl., 41 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 583665	A2	19940223	EP 1993-112181	19930729
	EP 583665	A3	19940518		
	EP 583665	B1	20030305		
	R: CH, DE, FR, GB, IT, LI				
	JP 06048942	A2	19940222	JP 1992-204122	A 19920730
	JP 2907646	B2	19990621	JP 1992-234767	A 19920902
	JP 06080563	A2	19940322	JP 1992-204122	19920730
	US 5387600	A	19950207	JP 1992-234767	19920902
				US 1993-94321	19930721
				JP 1992-204122	A 19920730
				JP 1992-234767	A 19920902

OS MARPAT 120:226974
 AB Pharmaceutical compns. containing antihyperlipidemic or antiarteriosclerotic agents such as certain benzimidazole or 2,2'-methylenebisphenol derivs. are prepared Thus, 5-amino-2-mercaptobenzimidazole in pyridine was reacted with dodecanoyl chloride and the solution was poured into ice-water to obtain 5-dodecanoylamino-2-mercaptobenzimidazole (I) crystals. which was filtered off and purified. Rabbits were fed feed having high cholesterol content and 100 mg I /kg/day for 7 days. The amount of blood total cholesterol decreased by 25% as compared by control. A capsule containing 40 mg I were formulated.
 IT 154201-16-8 154201-18-0
 RL: BIOL (Biological study)
 (as antihyperlipidemic or antiarteriosclerotic agent, pharmaceutical compns. containing)
 RN 154201-16-8 CAPLUS
 CN Acetic acid, [2-[1-(2-hydroxy-3,5-dimethylphenyl)-2-methylpropyl]-4,6-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 154201-18-0 CAPLUS
 CN Benzenepentanamide, 3,3'-methylenebis[N,N-diethyl-2-hydroxy-5,5,8-trimethyl- (9CI)] (CA INDEX NAME)



L8 ANSWER 118 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1994:204700 CAPLUS
 DN 120:204700
 TI Positive-type light-sensitive composition
 IN Yamanaka, Tsukasa; Aoai, Toshiaki; Uenichi, Kazuya; Kondo, Shunichi;
 Kokubo, Tadayoshi
 PA Fuji Photo Film Co., Ltd., Japan
 SO Eur. Pat. Appl., 81 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 541112	A1	19930512	EP 1992-119043	19921106
	EP 541112	B1	20010905		
	R: BE, DE, FR, GB				
				JP 1991-319600	A 19911108
				JP 1992-47705	A 19920205
				JP 1992-47782	A 19920205
				JP 1992-166685	A 19920603
				JP 1992-299093	A 19921013
				JP 1992-299093	19921013
				JP 1991-319600	A1 19911108
				JP 1992-47705	A1 19920205
				JP 1992-47782	A1 19920205
				JP 1992-166685	A1 19920603
	JP 06051519	A2	19940225		

OS MARPAT 120:204700
 AB A pos.-type light-sensitive composition useful in manufacture of a lithog. plate or

a semiconductor device and having less layer shrinkage by baking after exposing, less layer decrease in developing, a good profile, and a high resolution comprises (a) a resin which is insol. in water and soluble in an alkaline

aqueous solution, (b) a compound which generates an acid by irradiation with active

rays or radial rays, and (c) an acid-decomposable dissoln. inhibitor, having a mol. weight of not more than 3000 and having groups decomposable by the action of the generated acid to increase the solubility of said inhibitor in an alkaline developing solution, wherein said inhibitor (c) is at least one compound selected from the group consisting of (i) compds. having two of said acid decomposable groups which are separated by 10 or more bonded atoms excluding the atoms constituting the acid decomposable groups and (ii) compds. having at least three of said acid decomposable groups and two of said groups which are at the farthest positions are separated by 9 or more bonded atoms excluding the atoms constituting the acid decomposable groups.


IT 153698-51-2 153698-52-3 153698-59-0

RL: USES (Uses)

(pos. photoresist compns. containing alkali-soluble resins, photosensitive acid generators and, for lithog. plate and semiconductor device manufacture)


RN 153698-51-2 CAPLUS

CN Acetic acid, 2,2'-[[4-[bis[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3,5-dimethylphenyl]methyl]-1,2-phenylene]bis(oxy)]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 153698-52-3 CAPLUS

CN Acetic acid, 2,2'-[[[3-methoxy-4-[2-(1-methyl-1-phenylethoxy)-2-oxoethoxy]phenyl]methylene]bis[(2,6-dimethyl-4,1-phenylene)oxy]]bis-, bis(1-methyl-1-phenylethyl) ester (9CI) (CA INDEX NAME)



RN 153698-59-0 CAPLUS
 CN Acetic acid, 2,2',2'',2'''-[1,5-pentanediyliidenetetrakis[(2,6-dimethyl-4,1-phenylene)oxy]]tetrakis-, tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L8 ANSWER 119 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1994:136070 CAPLUS
 DN 120:136070
 TI Preparation of bis(meth)allyloxycarbonylmethyl ethers of bisphenol compounds and their polymers
 IN Saiga, Tetsuyuki; Mikami, Masafumi; Nagao, Keishiro
 PA Daisow Co Ltd, Japan
 SO Jpn. Kokai Tokkyo Koho, 17 pp
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05170702	A2	19930709	JP 1991-196557	19910806
				JP 1991-196557	19910806

AB The title compds. I (R = H, Me; Z = C1-2 alkylene; Y = direct bond, R1CR2, CR3, S, SO2, SO; R1-2 = H, Me, Et, Ph, diphenyl; R3 = C3-12 alkylene, cycloalkylene, diphenylene; X = halogen excluding F; l, m = 0-4) have low refractive index and slow polymerization rate, and are suitable for cast moldings for manufacture of transparent optical materials. Thus, cast molding of I (R = H; Z = CH2; Y = PhCMe) gave test pieces having n 1.591, and light transmittance 89%.

IT 151542-68-6 151542-74-4 151564-17-9

RL: USES (Uses)

(cast moldings, transparent, with low refractive index, for optical materials)


RN 151542-68-6 CAPLUS

CN Acetic acid, 2,2'-[ethylidenebis(2,6-dibromo-4,1-phenylene)oxy]bis-, di-2-propenyl ester, polymer with 2-propenyl (2,4-dibromophenoxy)acetate (9CI) (CA INDEX NAME)

CM 1

CRN 151542-67-5


CMF C11 H10 Br2 O3



CM 2

CRN 151542-66-4

CMF C24 H22 Br4 O6



PAGE 1-A

PAGE 1-B

—CH=CH2


RN 151542-74-4 CAPLUS

CN 1,4-Benzenedicarboxylic acid, di-2-propenyl ester, polymer with (Z)-bis(phenylmethyl) 2-butenedioate and di-2-propenyl 2,2'-[(1-phenylethylidene)bis[(2-bromo-4,1-phenylene)oxy]]bis[acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 151542-73-3
CMF C30 H28 Br2 O6

PAGE 1-A




PAGE 1-B

—CH=CH2

CM 2


CRN 1026-92-2
CMF C14 H14 O4



CM 3

CRN 622-06-0
CMF C18 H16 O4

Double bond geometry as shown.



RN 151564-17-9 CAPLUS


CN 1,3-Benzenedicarboxylic acid, di-2-propenyl ester, polymer with di-2-propenyl 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis[acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 151487-34-2

CMF C25 H24 Br4 O6

PAGE 1-A




PAGE 1-B

—CH=CH₂

CM 2

CRN 1087-21-4

CMF C14 H14 O4



IT 151487-34-2P 151542-66-4P 151542-73-3P
152587-71-8P 152587-72-9P 152587-76-3P
152587-77-4P


RL: PEP (Physical, engineering or chemical process); PREP (Preparation);
PROC (Process)

(preparation and polymerization of, for manufacture of optical materials)

RN 151487-34-2 CAPLUS

CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis-, di-2-propenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH=CH₂

RN 151542-66-4 CAPLUS
CN Acetic acid, 2,2'-[ethylidenebis(2,6-dibromo-4,1-phenylene)oxy]bis-, di-2-propenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH=CH₂


RN 151542-73-3 CAPLUS
CN Acetic acid, 2,2'-[(1-phenylethylidene)bis[(2-bromo-4,1-phenylene)oxy]]bis-, di-2-propenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




—CH=CH₂

RN 152587-71-8 CAPLUS
 CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis-, bis(2-methyl-2-propenyl) ester (9CI) (CA INDEX NAME)




RN 152587-72-9 CAPLUS
 CN Acetic acid, 2,2'-[(1-methylpropylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis-, di-2-propenyl ester (9CI) (CA INDEX NAME)




—CH=CH₂

RN 152587-76-3 CAPLUS
 CN Acetic acid, 2,2'-[(1-phenylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis-, di-2-propenyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




RN 152587-77-4 CAPLUS
 CN Acetic acid, 2,2'-[(1-phenylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis-, bis(2-methyl-2-propenyl) ester (9CI) (CA INDEX NAME)



IT 47612-39-5 152587-81-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with allyl alc.)
 RN 47612-39-5 CAPLUS
 CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



RN 152587-81-0 CAPLUS
 CN Acetic acid, 2,2'-[(1-phenylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



L8 ANSWER 120 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1993:672540 CAPLUS
 DN 119:272540
 TI Manufacture of resins for lens with high refractive index
 IN Mikami, Masafumi; Saiga, Tetsuyuki; Nagao, Keishiro
 PA Daisow Co Ltd, Japan
 SO Jpn. Kokai Tokkyo Koho, 10 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05202133	A2	19930810	JP 1991-196558	19910806
				JP 1991-196558	19910806

AB The title resins are manufactured by polymerization of bisphenols I (R = H, Me; A =


C1-2 linear or branched alkylene; B = direct bond, O, S, CR1R2, SO2, SO, Q; R1-2 = H, Me, Et, Ph, biphenyl; R3 = C3-12 alkylene, cycloalkylene, diphenylene; X = Me, halo other than F; l, m = 0-4) and optionally other vinyl monomers in the presence of radical polymerization initiators. Thus, polymerization of 2,2-bis(4-allyloxycarbonylmethoxy-3,5-dibromophenyl)propane with diallyl isophthalate in the presence of diisopropyl peroxydicarbonate gave a copolymer with refractive index 1.590, Abbe number 33, and light transmittance 88%.

IT 151487-34-2P
 RL: PEP (Physical, engineering or chemical process); PREP (Preparation); PROC (Process)
 (preparation and polymerization of, for plastic lens manufacture)

RN 151487-34-2 CAPLUS


CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis-, di-2-propenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




—CH=CH₂

IT 151542-68-6P 151542-74-4P 151564-17-9P
 RL: PREP (Preparation)
 (preparation of, transparent, with high n, for lens)
 RN 151542-68-6 CAPLUS
 CN Acetic acid, 2,2'-[ethylidenebis(2,6-dibromo-4,1-phenylene)oxy]bis-,
 di-2-propenyl ester, polymer with 2-propenyl (2,4-dibromophenoxy)acetate
 (9CI) (CA INDEX NAME)
 CM 1
 CRN 151542-67-5
 CMF C11 H10 Br2 O3



CM 2
 CRN 151542-66-4
 CMF C24 H22 Br4 O6

PAGE 1-A



PAGE 1-B


—CH=CH₂

RN 151542-74-4 CAPLUS
 CN 1,4-Benzenedicarboxylic acid, di-2-propenyl ester, polymer with
 (Z)-bis(phenylmethyl) 2-butenedioate and di-2-propenyl
 2,2'-[(1-phenylethylidene)bis[(2-bromo-4,1-phenylene)oxy]]bis[acetate]
 (9CI) (CA INDEX NAME)


CM 1

CRN 151542-73-3
CMF C30 H28 Br2 O6

PAGE 1-A




PAGE 1-B



CM 2


CRN 1026-92-2
CMF C14 H14 O4



CM 3

CRN 622-06-0
CMF C18 H16 O4

Double bond geometry as shown.



RN 151564-17-9 CAPLUS


CN 1,3-Benzenedicarboxylic acid, di-2-propenyl ester, polymer with di-2-propenyl 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis[acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 151487-34-2

CMF C25 H24 Br4 O6

PAGE 1-A




PAGE 1-B

—CH=CH2

CM 2

CRN 1087-21-4

CMF C14 H14 O4



L8 ANSWER 121 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1993:191343 CAPLUS
 DN 118:191343
 TI Preparation of aromatic oligomeric compounds useful as mimics of bioactive macromolecules
 IN Regan, John R.; McGarry, Daniel G.; Chang, Michael N.; Barton, Jeffrey N.; Newman, Jack; Ben-Sasson, Schmuël
 PA Rhone-Poulenc Rorer International (Holdings) Inc., USA
 SO PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

PI	WO 9220350	A1	19921126	WO 1992-US4274	19920520
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
	AU 9220107	A1	19921230	US 1991-703061	A2 19910520
				AU 1992-20107	19920520
				US 1991-703061	A 19910520
				WO 1992-US4274	A 19920520
	EP 585371	A1	19940309	EP 1992-912715	19920520
	EP 585371	B1	20020417		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL				
				US 1991-703061	A 19910520
				WO 1992-US4274	W 19920520
	AT 216247	E	20020515	AT 1992-912715	19920520
				US 1991-703061	A 19910520
				WO 1992-US4274	W 19920520
	ES 2174834	T3	20021116	ES 1992-912715	19920520
				US 1991-703061	A 19910520
	US 5571506	A	19961105	US 1993-119456	19930910
				US 1989-393873	B2 19890814
				US 1989-440584	B2 19891122
				US 1989-440586	B2 19891122
				US 1991-703061	B1 19910520

PATENT FAMILY INFORMATION:



FAN 1991:550384

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9103226	A2	19910321	WO 1990-US4580	19900814
	WO 9103226	A3	19910530		
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
				US 1989-393873	A 19890814
	IL 95353	A1	19950124	IL 1990-95353	19900813
				US 1989-393873	A 19890814
	CA 2064575	AA	19910215	CA 1990-2064575	19900814
				US 1989-393873	A 19890814
	AU 9063375	A1	19910408	AU 1990-63375	19900814
	AU 649963	B2	19940609		
				US 1989-393873	A 19890814
				WO 1990-US4580	A 19900814
	EP 489102	A1	19920610	EP 1990-913407	19900814
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
				US 1989-393873	A 19890814
				WO 1990-US4580	W 19900814
	JP 05503506	T2	19930610	JP 1990-512506	19900814
				US 1989-393873	A 19890814
				WO 1990-US4580	W 19900814
	US 5571506	A	19961105	US 1993-119456	19930910
				US 1989-393873	B2 19890814
				US 1989-440584	B2 19891122
				US 1989-440586	B2 19891122
				US 1991-703061	B1 19910520

FAN 1992:46289


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9107183	A1	19910530	WO 1990-US6847	19901121
	W: AU, CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
				US 1989-440584	A2 19891122

AU 9169191	A1	19910613	US 1989-440586	A	19891122
AU 658133	B2	19950406	AU 1991-69191		19901121
			US 1989-440584	A	19891122
			US 1989-440586	A	19891122
			WO 1990-US6847	A	19901121
EP 502117	A1	19920909	EP 1991-901098		19901121
EP 502117	B1	19990623			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE					
			US 1989-440584	A	19891122
			US 1989-440586	A	19891122
			WO 1990-US6847	W	19901121
JP 05508665	T2	19931202	JP 1991-501518		19901121
			US 1989-440584	A	19891122
			US 1989-440586	A	19891122
			WO 1990-US6847	W	19901121
AT 181506	E	19990715	AT 1991-901098		19901121
			US 1989-440584	A	19891122
			US 1989-440586	A	19891122
IL 96441	A1	19950124	IL 1990-96441		19901122
			US 1989-440584	A	19891122
			US 1989-440586	A	19891122
US 5571506	A	19961105	US 1993-119456		19930910
			US 1989-393873	B2	19890814
			US 1989-440584	B2	19891122
			US 1989-440586	B2	19891122
			US 1991-703061	B1	19910520
FAN 1997:684140					
PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
-----	----	-----	-----		-----
PI US 5674482	A	19971007	US 1991-742794		19910809
			US 1989-393873	B2	19890814
			US 1989-440584	B2	19891122
			US 1989-440586	B2	19891122
US 5571506	A	19961105	US 1993-119456		19930910
			US 1989-393873	B2	19890814
			US 1989-440584	B2	19891122
			US 1989-440586	B2	19891122
			US 1991-703061	B1	19910520
OS MARPAT 118:191343					
AB	Title compds. M(M1)MM2 (m = 2-50; M, M1, M2 = substituted aromatic carbocyclyl or aromatic heteterocyclyl), useful as mimics of bioactive macromols. (glycosaminoglycans), are prepared 4-HOC6H4(CH2)2CO2Me (preparation given) in MeOH at 0° was treated with H2SO4 followed by HCOH to give bis[5-(2-methoxycarbonylethyl)-3-[5-(2-methoxycarbonylethyl)-2-hydroxybenzyl]-2-hydroxyphenyl]methane which was stirred with NaOH, quenched with HCl, and then treated with NH4OH to give title compound (I) as the ammonium salt. In the APTT anticoagulation assay, the concentration required to double clotting time for the title compds. was 35-700 µg/mL.				
IT	147067-39-8 147067-40-1 147067-41-2 147067-42-3 147067-44-5 147067-45-6 RL: RCT (Reactant); RACT (Reactant or reagent) (glycosaminoglycan mimetic)				
RN	147067-39-8 CAPLUS				
CN	Acetic acid, [2-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-[[5-(carboxymethoxy)-4-(hydroxymethyl)-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-4-hydroxyphenoxy]- (9CI) (CA INDEX NAME)				



RN 147067-40-1 CAPLUS



Acetic acid, 2,2'-[1,2-ethanediyl]bis[[5-(carboxymethoxy)-2-hydroxy-4,1-phenylene]methylene(4-hydroxy-2,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 147067-41-2 CAPLUS

Acetic acid, [2-[[[5-(carboxymethoxy)-4-[[[5-(carboxymethoxy)-4-[[[5-(carboxymethoxy)-4-[[[5-(carboxymethoxy)-4-[[[5-(carboxymethoxy)-4-[[[5-(carboxymethoxy)-4-(hydroxymethyl)-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-2-(phenylmethoxy)phenyl]methyl]-4-hydroxyphenoxy]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




RN 147067-42-3 CAPLUS
 CN Acetic acid, 2,2'-[1,2-ethanediylbis[[5-(carboxymethoxy)-2-hydroxy-4,1-phenylene]methylene[4-(phenylmethoxy)-2,1-phenylene]oxy]]bis- (9CI) (CA INDEX NAME)



RN 147067-44-5 CAPLUS
 CN Acetic acid, [3-[[5-(carboxymethoxy)-3-[[5-(carboxymethoxy)-3-[[5-(carboxymethoxy)-3-ethyl-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


—CO₂H

RN 147067-45-6 CAPLUS
 CN Acetic acid, [3-[[5-(carboxymethoxy)-3-[[5-(carboxymethoxy)-3-[[5-(carboxymethoxy)-3-[[5-(carboxymethoxy)-3-[[5-(carboxymethoxy)-3-ethyl-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




IT 147067-82-1P 147067-83-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of, in preparation of oligomeric hydrocinnamate
 derivs.

as glycosaminoglycan mimetics)
 RN 147067-82-1 CAPLUS
 CN Benzoic acid, 3-[[5-(2-amino-2-oxoethoxy)-3-[[5-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2-methoxy-3-methylphenyl]methyl]-2-methoxyphenyl]methyl]-5-[[5-(2-amino-2-oxoethoxy)-2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]methyl]-4-methoxy-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 147067-83-2 CAPLUS
 CN Acetic acid, [4-(2-amino-2-oxoethoxy)-2-[[3-[[5-(2-amino-2-oxoethoxy)-3-[[5-(carboxymethoxy)-2-methoxy-3-methylphenyl]methyl]-2-methoxyphenyl]methyl]-5-(carboxymethoxy)-2-methoxyphenyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




[[5-[[[(1,1-dimethylethoxy)carbonyl]oxy]-3-[[5-[[[(1,1-dimethylethoxy)carbonyl]oxy]-3-[[5-[[[(1,1-dimethylethoxy)carbonyl]oxy]-3-[[5-[[[(1,1-dimethylethoxy)carbonyl]oxy]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-2-methoxyphenyl]methyl]-5-ethyl-4-methoxyphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L8 ANSWER 122 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1993:184241 CAPLUS
 DN 118:184241
 TI Blockade of natural and neuropeptide Y-induced carbohydrate feeding by a
 receptor antagonist PYX-2
 AU Leibowitz, Sarah F.; Xuereb, Mark; Kim, Taewan
 CS Rockefeller Univ., New York, NY, 10021, USA
 SO NeuroReport (1992), 3(11), 1023-6
 CODEN: NERPEZ; ISSN: 0959-4965
 DT Journal
 LA English
 AB Neuropeptide Y (NPY) injected into the paraventricular nucleus (PVN) of
 rats has a potent stimulatory effect specifically on carbohydrate intake.
 This study examined the behavioral effects of a newly synthesized NPY
 antagonist, PYX-2. After PVN injection of PYX-2 (50-900 pmoles) alone, a

strong dose-dependent reduction in spontaneous carbohydrate intake at the onset of the dark cycle was observed in freely-feeding rats. Moreover, at even lower doses (12.5 and 25.0 pmoles), PYX-2 also blocked the stimulatory action of PVN NPY (100 pmoles) on carbohydrate ingestion. These results provide the first evidence for the existence of endogenous NPY receptors in mediating the action of exogenous NPY in the hypothalamus. They also constitute a crucial step in demonstrating a physiol. function of these PVN NPY receptors specifically in controlling carbohydrate ingestion at the onset of the natural feeding cycle.

IT 146999-93-1

RL: BIOL (Biological study)


(carbohydrate appetite suppression by paraventricular nucleus administration of)

RN 146999-93-1 CAPLUS


CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutaminyl-L-arginyl-3-[(2,6-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




L8 ANSWER 123 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1993:148650 CAPLUS
 DN 118:148650
 TI Syntheses and properties of halogen reactive flame retardants and flame retarded unsaturated polyester resins
 AU Jin, Shu; Liang, Shiyi
 CS Dep. Chem., East China Inst. Chem. Technol., Shanghai, 200237, Peop. Rep. China
 SO Huadong Huagong Xueyuan Xuebao (1992), 18(1), 128-34
 CODEN: HHKPDM; ISSN: 0253-9683
 DT Journal
 LA Chinese
 AB 2,2-Bis[3,5-dibromo-4-(2-hydroxyethoxy)phenyl]propane, 2,2-bis[3,5-dichloro-4-(2-hydroxyethoxy)phenyl]propane, 2,2-bis[3,5-dibromo-4-(carboxymethoxy)phenyl]propane, 2,2-bis[3,5-dichloro-4-(carboxymethoxy)phenyl]propane, and bis[3,5-dibromo-4-(2-hydroxyethoxy)phenyl] sulfone flame retardants were prepared from halogenated bisphenol A and bisphenol S. Polyesters were prepared from these flame retardants and characterized by thermal mech. measurements, O index, TGA, and DTA. The flame retardancy of Br-containing compds. was better than those of Cl-containing compds. The performance of carboxymethoxy-containing compds. was better than those of hydroxyethoxy-containing compds.
 IT 13937-23-0P 47612-39-5P
 RL: SPN (Synthetic preparation); PREP (Preparation) (fireproofing agents, preparation and polymerization of)
 RN 13937-23-0 CAPLUS
 CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dichloro-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



RN 47612-39-5 CAPLUS
 CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



L8 ANSWER 124 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1992:207925 CAPLUS
 DN 116:207925
 TI Synthesis of receptor antagonists of neuropeptide Y
 AU Tatemoto, Kazuhiko; Mann, Michael J.; Shimizu, Meikyo
 CS Sch. Med., Stanford Univ., Stanford, CA, 94305, USA
 SO Proceedings of the National Academy of Sciences of the United States of

America (1992), 89(4), 1174-8

CODEN: PNASA6; ISSN: 0027-8424

DT Journal

LA English

AB The authors report the synthesis of receptor antagonists of neuropeptide Y (NPY) by a strategy based on synthesis of mixts. of analogs and the subsequent isolation and identification of receptor antagonists from these mixts. After screening a series of mixts. of NPY analogs by using an NPY antagonist assay, two potent receptor antagonists, designated PYX-1 and PYX-2, were isolated from an antagonist-containing mixture. The receptor antagonists inhibited release of intracellular calcium elicited by NPY in human erythroleukemia cells and displaced 3H-labeled NPY from NPY receptors in rat brain membrane. The approach of screening and identifying useful analogs from synthetic mixts. may significantly reduce the time and resources previously required for development of receptor antagonists.

IT 140842-17-7P 146999-93-1P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and neuropeptide Y antagonist activity of)


RN 140842-17-7 CAPLUS

CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutamyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 146999-93-1 CAPLUS

CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutamyl-L-arginyl-3-[(2,6-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L8 ANSWER 125 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1991:691031 CAPLUS

DN 115:291031

TI Silver halide color photographic light-sensitive material containing polymeric fading inhibitor

IN Kita, Hiroshi; Hirabayashi, Shigeto

PA Konica Co., Japan

SO Jpn. Kokai Tokkyo Koho, 12 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03069934	A2	19910326	JP 1989-206172	19890809
				JP 1989-206172	19890809

AB A silver halide color photog. material contains a fading inhibitor having a H₂O-soluble polymeric part and a fading-inhibitory part, e.g. I, II, and III (Q = gelatin residue). This photog. material provides a good stability of a color image with excellent fading-resistance against heat and light.


IT 137740-42-2DP, gelatin-bound

RL: PREP (Preparation)

(preparation of, as photog. fading inhibitor)

RN 137740-42-2 CAPLUS

CN Propanoic acid, 3,3'-[butylidenebis[[2-(1,1-dimethylethyl)-5-methyl-4,1-phenylene]oxy]]bis- (9CI) (CA INDEX NAME)



L8 ANSWER 126 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:633932 CAPLUS

DN 111:233932

TI Heat-shrinkable polyester packaging films

IN Yoshinaka, Yasuo; Kuze, Katsuro; Matsuyama, Jujiro; Hamano, Akito;
 Makimura, Osamu
 PA Toyobo Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 10 pp.
 CODEN: JKXXAF

DT Patent
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01136723	A2	19890530	JP 1987-296892	19871125
	JP 07098358	B4	19951025		

JP 1987-296892 19871125

AB The title films, with shrinkage >30% in the longitudinal (A) or transverse (B) direction at 100°, are prepared from copolymers of terephthalic acid (I), ethylene glycol (II), and the diesters R1O2CZ1OC6H4-x(Rx)Z2C6H4-y(Ry)OZ3CO2R2 [R = alkyl, halogen; R1-2 = H, alkyl, alkylidene; Z1, Z3 = C1-5 alkylene, Z2 = direct bond, CH2, CMe2, C(CF3)2, S, SO2, O; x, y = 0-4]. A polymer from I 60, II 100, and Me2C(C6H4OCH2CO2H)2 40 mol was extruded at 290° to a 180-μm film which was drawn 1.1-fold in the A direction, 4.6-fold in the B direction, and .apprx.20% in the A direction after cooling to give a film with shrinkage 62% in the B and -2.2% in the A direction at 100°.

IT 123860-68-4

RL: USES (Uses)

(films, preparation of heat-shrinkable, for packaging)


RN 123860-68-4 CAPLUS

CN 1,4-Benzenedicarboxylic acid, polymer with 1,2-ethanediol and 2,2'-[(1-methylethylidene)bis(2,6-dimethyl-4,1-phenylene)oxy]bis[acetic acid] (9CI) (CA INDEX NAME)

CM 1

CRN 123860-67-3

CMF C23 H28 O6



CM 2

CRN 107-21-1


CMF C2 H6 O2



CM 3

CRN 100-21-0


CMF C8 H6 O4



- L8 ANSWER 127 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1989:631576 CAPLUS
 DN 111:231576
 TI Synthesis, x-ray crystal structures, and cation-binding properties of alkyl calixaryl esters and ketones, a new family of macrocyclic molecular receptors
 AU Arnaud-Neu, Francoise; Collins, Elizabeth M.; Deasy, Mary; Ferguson, George; Harris, Stephen J.; Kaitner, Branko; Lough, Alan J.; McKervey, M. Anthony; Marques, Elizabeth; et al.
 CS Dep. Chem., Univ. Coll., Cork, Ire.
 SO Journal of the American Chemical Society (1989), 111(23), 8681-91
 CODEN: JACSAT; ISSN: 0002-7863
 DT Journal
 LA English
 OS CASREACT 111:231576
 AB Calix[N]arenes (N = 4, 6, 8) have been converted into polyfunctional esters and ketones in a search for new macrocycles capable of showing ionophoric activity. Treatment with alkyl bromoacetates furnished the calixaryl acetate series; chloroacetone-potassium iodide, phenacyl chloride, 1-adamantyl bromomethyl ketone, and bromopinacolone ketone were used to make the calixaryl ketones series. The crystal structures of Et calix[4]aryl acetate, Me calix[4]aryl acetate, Et calix[6]aryl acetate (I), and calix[4]aryl Me ketone have been determined. The anal. establishes that all three tetramer derivs. possess the cone configuration in the solid state where the pendant-functionalized side chains are mutually syn with respect to the calixarene substructure and are thus preorganized for ion reception. NMR measurement confirm the existence of the cone conformation for these tetramers in solution at room temperature. In contrast, the centrosym. hexamer ester (I) has three adjacent groups syn, but the inversion symmetry places the other three ester groups in the anti position on the opposite side of the macrocycle. Extraction studies with alkali metal picrates from aqueous solution into dichloromethane, transport studies with alkali metal thiocyanates through a dichloromethane membrane, and stability constant measurements with alkali metal salts by UV absorption spectroscopy in methanol and acetonitrile were used to assess the ionophoric activity of these calixarene derivs. The tetramer esters and ketones display peak selectivity for the sodium ion, the tetraketones being generally more efficient binders than the tetraesters. The hexaester exts. K⁺ better than Na⁺ and displays a plateau selectivity after K⁺. The octamers are the least effective ionophores. The selectivities shown by the picrate extraction technique are broadly mirrored in the transport studies. Stability consts. range from 2 to 6, with a clear maximum for Na⁺ with most of the tetramers, and for K⁺ with hexamer; the values are of the same order of magnitude as for dibenzo-18-crown-6. The thermodyn. results are in fairly good agreement with the extraction and transport rate data. They enable a comparison of these new calixarene receptors with respect to crown and cryptands: they are looser binders than cryptands 221 and 222; most tetramers offer in methanol a better Na⁺/K⁺ selectivity than cryptand 221, and in acetonitrile, the hexamer is at least as selective for K⁺ as cryptand 222.

IT 118984-71-7
 RL: PRP (Properties)
 (extraction by, of alkali metal picrates)
 RN 118984-71-7 CAPLUS
 CN Acetic acid, 2,2'-[methylenebis[4-(1,1-dimethylethyl)-6-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)-3-[(2-ethoxy-2-oxoethoxy)methyl]phenyl]methyl]-2,1-phenylene]oxy]bis-, diethyl ester
 (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


—OEt

L8 ANSWER 128 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1989:77029 CAPLUS
 DN 110:77029
 TI Acyclic phenol-formaldehyde oligomer accelerators for cyanoacrylate
 adhesive compositions
 IN Harris, Stephen J.; Kneafsey, Brendan J.
 PA Loctite (Ireland) Ltd., Ire.
 SO Brit. UK Pat. Appl., 10 pp.
 CODEN: BAXXDU

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2200124	A1	19880727	GB 1987-27837 IE 1986-3146	19871127 A 19861201
AB	An acyclic phenol-formaldehyde oligomer (I, R = H, halogen, hydrocarbyl, aryl, hydrocarbylaryl, and a = 1, b = 0; or a = b = 0; or a = b = 1; R1 = CH2COR2, H, or CH2CO2H; R2 = hydrocarbyl, aryl, hydrocarbylaryl, hydrocarbyloxy, aryloxy, hydrocarbylaryloxy, and their substituted derivs.; n = 0-10) is useful as an accelerator for cyano acrylate adhesives for bonding wood and other deactivating surfaces, e.g., paper, leather, ceramics, plastics, and metals. I is prepared by etherification of an open-chain oligomer (G.W. Cornforth et al., 1955). Thus, an open chain oligomer (prepared by the Cornforth procedure was refluxed with Et bromoacetate in presence of anhydrous K2CO3 and Me2CO to give a product which was worked up to an etherified oligomer (m.p. 67-68.5°). A stabilized Et cyanoacrylate adhesive was mixed with 0.5% etherified oligomer showing fixture time on copy paper 30-40 s and white Deal 30-40 s, compared with 60 and 300-360, resp., for an adhesive without the accelerator.				
IT	118984-71-7 RL: USES (Uses) (accelerators, for cyanoacrylate adhesives)				
RN	118984-71-7 CAPLUS				
CN	Acetic acid, 2,2'-[methylenebis[4-(1,1-dimethylethyl)-6-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)-3-[(2-ethoxy-2-oxoethoxy)methyl]phenyl]methyl]-2,1-phenylene]oxy]bis-, diethyl ester (9CI) (CA INDEX NAME)				

PAGE 1-A



—OEt

L8 ANSWER 129 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1987:169796 CAPLUS

DN 106:169796

TI Radioimmunoassays and reagents for the determination of serum thymic factor (FTS)

IN Erickson, Bruce W.; Fok, Kam Fook; Incefy, Genevieve S.; Ohga, Kazuhiro

PA Sloan-Kettering Institute for Cancer Research, USA

SO U.S., 6 pp. Cont. of U.S. Ser. No. 445,382, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 4634682	A	19870106	US 1985-737177	19850523
				US 1982-445382	A1 19821130

AB RIAs for the quantitation of FTS, a thymic peptide hormone, are disclosed. Each assay employs an antibody (monoclonal or antiserum-derived) specific for FTS; synthetic FTS or a FTS analog I (X = H; Y = H, halo- or dihalophenylalkyl; A = H, NH₂; B = amino acid; m = 0, 1, 2) as the hormones standard; and a radiolabeled FTS analog as tracer. Preferred hormone stds. I (X = Y = H, A = NH₂, B = Ala, m = 2) (II) and I (X = H, Y = CH₂C₆H₃Cl₂-2,6, A = NH₂, B = Ala, m = 2) (III) was synthesized by the solid-phase method. II and III were radioiodinated with carrier-free Na¹²⁵I and chloramine T to provide tracers having X = ¹²⁵I. Use of radiolabeled II with a rabbit antiserum to FTS allowed detection of ≥ 1.0 pg FTS in 50 μL of fluid. Interfering substances in plasma from normal donors, which inhibited binding of radiolabeled II to the antibodies, were removed by filtering the plasma through an Amicon CF-50 membrane, which excludes proteins of mol. weight > 50,000.

IT 85532-65-6P 85532-67-8P

RL: PREP (Preparation)


(preparation of, as reagent in serum thymic factor determination by RIA)

RN 85532-65-6 CAPLUS


CN Thymulin (swine peptide moiety), 1-[N-[3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl]-L-alanine]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 85532-67-8 CAPLUS


CN Thymulin (swine peptide moiety), 1-[N-[3-[(2,6-dichlorophenyl)methyl]-5-(iodo-125I)-L-tyrosyl]-L-alanine]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L8 ANSWER 130 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1985:487618 CAPLUS
 DN 103:87618
 TI Synthesis, x-ray crystal structures, and cation transfer properties of
 alkyl calixaryl acetates, a new series of molecular receptors
 AU McKervey, M. Anthony; Seward, Eileen M.; Ferguson, George; Ruhl, Barbara;
 Harris, Stephen J.
 CS Dep. Chem., Univ. Coll., Cork, Ire.
 SO Journal of the Chemical Society, Chemical Communications (1985), (7),
 388-90
 CODEN: JCCCAT; ISSN: 0022-4936
 DT Journal
 LA English
 OS CASREACT 103:87618
 AB BrCH₂CO₂Et reacted with the calixarenes I (R = H, R₁ = H, CMe₃, n = 1,3,5)
 to give I (R = CH₂CO₂Et, R₁, n as before), which on treatment with MeOH



and 4-MeC₆H₄SO₃H gave I (R = CH₂CO₂Me, R₁, n as before). The phase-transfer activity and selectivity towards alkali metal picrates showed a wide range of phase-transfer efficiency which suggests that it is a size-related phenomenon. The structure of I (R = CH₂CO₂Et, R₁ = CMe₃, n = 4; R = CH₂CO₂Et, R₁ = H, n = 6) were determined by x-ray crystallog.

IT 97600-50-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(cation transfer properties of)

RN 97600-50-5 CAPLUS

CN Acetic acid, [4-(1,1-dimethylethyl)-2-[[5-(1,1-dimethylethyl)-3-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)phenyl]methyl]-2-(2-ethoxy-2-oxoethoxy)phenyl]methyl]-6-[[5-(1,1-dimethylethyl)-2-(2-ethoxy-2-oxoethoxy)-3-[(2-ethoxy-2-oxoethoxy)methyl]phenyl]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 131 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1984:591261 CAPLUS

DN 101:191261

TI Synthesis of aliphatic-aromatic dicarboxylic acids

AU Kazakova, G. S.; Machtina, K. A.; Mironov, G. S.; Smirnova, T. M.

CS Yarosl. Politekh. Inst., Yaroslavl, USSR

SO Osnovnoi Organicheskii Sintez i Neftekhimiya (1982), 16, 26-8

CODEN: OOSNDC; ISSN: 0321-2386

DT Journal

LA Russian


OS CASREACT 101:191261

AB Nucleophilic substitution of (MO)₂X [X = m- and p-C₆H₄, (p-C₆H₄)₂Z, (4,3-MeC₆H₃)₂Z; Z = CMe₂, cyclohexylidene; M = Na, K] with MO₂CCH₂Cl (same M) in 1:2.5 ratio in DMSO at 100-130° gave 80-90% (HO₂CCH₂O)₂X (same X) after acidification.

IT 92758-77-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)
 RN 92758-77-5 CAPLUS
 CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2-methyl-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




L8 ANSWER 132 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1983:539494 CAPLUS
 DN 99:139494
 TI Diphenyl ether, diphenyl thioether and diphenyl methane phenol Mannich bases
 IN Plattner, Jacob J.
 PA Abbott Laboratories, USA
 SO U.S., 10 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4389416	A	19830621	US 1981-310164 US 1981-310164	19811009 19811009

OS CASREACT 99:139494; MARPAT 99:139494
 AB The title compds. [I; R = H, alkyl, H₂NCH₂, halo; Z = O, CH₂, S, S(O); R₁ = H, alkyl, halo; Z₁ = O, CH₂, S, bond; R₂ = CO₂H, carboxyalkyl, H₂NCO, HOCH₂, PhNHCH₂, H₂NCH₂], with diuretic activity, were prepared. Thus, phenoxyacetate II (R₃ = H, Z = CH₂), obtained by NaBH₄ reduction of II (R₃ = H, Z = CO), was treated with ClCH₂CONHCH₂OH in AcOH containing H₂SO₄ to give II (R₃ = ClCH₂CONHCH₂, Z = CH₂), which on acid hydrolysis gave II.HCl (R₃ = H₂NCH₂, Z = CH₂). Natriuretic activities of I (R = H, Cl; R₁ = Cl; Z = Z₁ = O; R₂ = CONH₂, CO₂Et, CH₂OH) in rats were greater than that of Bumetanide.


IT 87181-11-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and diuretic activity of)

RN 87181-11-1 CAPLUS
 CN Acetic acid, [4-[[3-(aminomethyl)-5-chloro-4-hydroxyphenyl]methyl]-2,3-dichlorophenoxy]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 87181-59-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 87181-59-7 CAPLUS
 CN Acetic acid, [4-[[3-(aminomethyl)-5-chloro-4-hydroxyphenyl]methyl]-2,3-dichlorophenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




L8 ANSWER 133 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1983:405341 CAPLUS
 DN 99:5341
 TI Phenols
 IN McGarry, Errol James; Forsyth, Bruce Adam
 PA ICI Australia Ltd., Australia
 SO Pat. Specif. (Aust.), 33 pp.
 CODEN: ALXXAP
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	AU 523158	B2	19820715	AU 1979-52502	19791105
	AU 7952502	A1	19800320		
				AU 1979-52502	A 19791105


OS CASREACT 99:5341
 AB Phenols (I; R1, R2, R3 same or different are H, C2-6 alkanoyl; R4-R8 same or different are halo; R9, R10 same or different are H, C1-6 alkyl) were prepared. Thus, a mixture of 4-chloro-2,6-bis(hydroxymethyl)phenol, 4-FC6H4OH, C6H6, and HCl was heated on a water bath until all the C6H6 had evaporated; on cooling the mixture deposited colorless crystals of I (R1 = R2 = R3 = R4 = R8 = H; R5 = R7 = F; R6 = Cl; R9 = R10 = H). I were useful as anthelmintics; compns. containing I were effective in controlling sheep liver fluke eggs.

IT 71643-23-7P 71643-24-8P 71643-31-7P
 71643-32-8P 71643-37-3P 71643-38-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 71643-23-7 CAPLUS


CN Acetic acid, 2,2'-[[2-(carboxymethoxy)-5-chloro-1,3-phenylene]bis[methylene(6-bromo-4-fluoro-2,1-phenylene)oxy]]bis- (9CI)
(CA INDEX NAME)




RN 71643-24-8 CAPLUS
CN Acetic acid, 2,2'-[[5-chloro-2-(2-ethoxy-2-oxoethoxy)-1,3-phenylene]bis[methylene(6-bromo-4-fluoro-2,1-phenylene)oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 71643-31-7 CAPLUS
CN Acetic acid, 2,2'-[[2-(carboxymethoxy)-5-chloro-1,3-phenylene]bis[methylene(6-bromo-4-chloro-2,1-phenylene)oxy]]bis- (9CI)
(CA INDEX NAME)




RN 71643-32-8 CAPLUS
 CN Acetic acid, 2,2'-[[5-chloro-2-(2-ethoxy-2-oxoethoxy)-1,3-phenylene]bis[methylene(6-bromo-4-chloro-2,1-phenylene)oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 71643-37-3 CAPLUS
 CN Acetic acid, 2,2'-[[2-(carboxymethoxy)-5-fluoro-1,3-phenylene]bis[methylene(6-bromo-4-chloro-2,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



RN 71643-38-4 CAPLUS
 CN Acetic acid, 2,2'-[[2-(2-ethoxy-2-oxoethoxy)-5-fluoro-1,3-phenylene]bis[methylene(6-bromo-4-chloro-2,1-phenylene)oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 134 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1983:181086 CAPLUS
 DN 98:181086
 TI Flame-resistant finishing of wool goods
 IN Gega, Henryk; Tokarzewski, Ludomir; Leonowicz, Leopold; Wojcik, Zofia
 PA Centralny Ośrodek Badańczo-Rozwojowy Przemysłu Welnianego "Południe", Pol.
 SO Pol., 3 pp.
 CODEN: POXXA7
 DT Patent
 LA Polish
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	PL 114023	B1	19810131	PL 1977-203202	19771219
				PL 1977-203202 A	19771219

AB Wool is fireproofed by impregnation with aqueous solution comprising 1-3% 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis[acetic acid] (I) [47612-39-5] or its Na salt (II) [74886-28-5] and 1-2% K₂TiF₆ or 1-3% K₂ZrF₆, optionally together with dyeing with acid or 1:1 metal complex dyes or with impregnation with reactive brominated organic compds. Thus, the fireproofing bath consisted of II 3, K₂TiF₆ 2, and 37% HCl 5%. The pH of this bath was 3-4 and the bath ratio was 1:30. Impregnated wool fabrics had good resistance to dry cleaning and washing in aqueous solns.; five-fold dry cleaning and washing in aqueous solns. did not diminish the fire resistance of the impregnated fabrics.


IT 47612-39-5 74886-28-5

RL: USES (Uses)

(fireproofing agents, containing potassium hexafluorotitanate or potassium hexafluorozirconate, for wool)


RN 47612-39-5 CAPLUS

CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



RN 74886-28-5 CAPLUS

CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis-, disodium salt (9CI) (CA INDEX NAME)



●2 Na

L8 ANSWER 135 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1983:173326 CAPLUS

DN 98:173326

TI Radioimmunoassays for the thymic hormone serum thymic factor (FTS)

AU Ohga, Kazuhiro; Incefy, Genevieve S.; Fok, Kam Fook; Erickson, Bruce W.; Good, Robert A.

CS Mem. Sloan-Kettering Cancer Cent., New York, NY, 10021, USA

SO Journal of Immunological Methods (1983), 57(1-3), 171-84

CODEN: JIMMBG; ISSN: 0022-1759

DT Journal

LA English

AB Four radioimmunoassays (RIA) are described for the quantitation of serum thymic factor (FTS) [63958-90-7], a thymic peptide hormone. Each assay employed an antibody specific for FTS, synthetic FTS as the hormone standard, and a radioiodinated FTS analog as the tracer. Since FTS lacks a tyrosine residue, 2 FTS analogs were synthesized by the solid-phase method with tyrosyl-alanyl or 3-(2,6-dichlorobenzyl)tyrosyl-alanyl in place of the aminoterminal pyroglutamyl residue. They showed full FTS immunoreactivity and their radioiodinated derivs. served as FTS tracers. Two assays used the antiserum from a rabbit immunized with an FTS-protein conjugate. Two other assays used a monoclonal antibody against FTS produced by a hybridoma derived from mouse myeloma cells and splenocytes from a BALB/c mouse immunized with an FTS-mouse IgG conjugate. All 4 RIAs were specific for FTS. The more sensitive rabbit antiserum could detect as little as 1 pg of FTS in a 50-μL sample, which may allow quantitation of the FTS circulating in human peripheral blood.

IT 85532-65-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation and radioiodination of, for radioimmunoassay)

RN 85532-65-6 CAPLUS


CN Thymulin (swine peptide moiety), 1-[N-[3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl]-L-alanine]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




IT 85532-67-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, for radioimmunoassay)
 RN 85532-67-8 CAPLUS
 CN Thymulin (swine peptide moiety), 1-[N-[3-[(2,6-dichlorophenyl)methyl]-5-(
 (iodo-125I)-L-tyrosyl]-L-alanine]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L8 ANSWER 136 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1982:199313 CAPLUS
 DN 96:199313
 TI Tetrabromodianoxydiacetic acid
 IN Gega, Henryk; Tokarzewski, Ludomir; Leonowicz, Leopold; Kowalska-Kiedik, Alina; Bekierz, Gerard; Skotnicki, Edward
 PA Centralne Laboratorium Przemysłu Welnianego Południe, Pol.; Instytut Ciekłej Syntezy Organicznej "Blachownia"
 SO Pol., 2 pp.
 CODEN: POXXA7
 DT Patent
 LA Polish
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	PL 110218	B1	19800731	PL 1977-200306	19770815
				PL 1977-200306	A 19770815

AB [3,5,4-Br₂(HO₂CCH₂O)C₆H₂]₂Me₂ (I) was prepared by treating tetrabromodian (II) with 2 equiv NaOH or KOH in H₂O or MeOH, followed by 2 equiv ClCH₂CO₂Na (III) at 80-100° for 3-4 h, and then neutralizing with mineral acid and crystallizing. Thus, II 544 weight parts was treated with 1800 mL aqueous solution containing NaOH 80 and then anhydrous III 233 weight parts in 300-400 mL H₂O, the mixture stirred 3-4 h at 80-100°, cooled, filtered and the solid dried at 60-70° to give 94.5% I as the Na salt, which was acidified as above.

IT 47612-39-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by carboxymethylation of tetrabromodian)

RN 47612-39-5 CAPLUS

CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



L8 ANSWER 137 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1981:30350 CAPLUS

DN 94:30350

TI Process for killing internal parasites, and certain bis(benzyl)benzene derivatives for use therein

PA ICI Australia Ltd., Australia

SO Brit., 21 pp.
CODEN: BRXXAA

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1569819	A	19800618	GB 1977-27215	19770629
	AU 2621577	A1	19790104	AU 1976-6576	A 19760707
	AU 508047	B2	19800306	AU 1977-26215	19760707
				AU 1976-6576	A 19760707

PATENT FAMILY INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4163801	A	19790807	US 1977-812471	19770705
	AU 2621577	A1	19790104	AU 1976-6576	A 19760707
	AU 508047	B2	19800306	AU 1977-26215	19760707
				AU 1976-6576	A 19760707
	US 4282390	A	19810804	US 1979-25675	19790330
				AU 1976-6576	A 19760707
				US 1977-812471	A3 19770705

AB The bis(benzyl)benzene derivs. I (R, R₁, R₂ = H, C₁-6 alkyl, C₂-6 alkenyl, C₂-6 alkanoyl, C₃-6 alkenoyl, aroyl, or CO₂H or its C₁-6 alkyl esters; R₃, R₄, R₅ = halo, optionally substituted (o.s.) alkyl, o.s. aryl, o.s.


alkenyl, alkoxy, CN, OH, NO₂, CO₂H, ester, NH₂, or alkylamino; R₆-R₁₀ = H or as R₃-R₅; R₁₁, R₁₂ = H, C₁-6 alkyl, o.s. aryl, CN, NO₂, CCl₃, or together with the geminal H = C:CCl₂) were prepared and used to kill trematodes and nematodes in warm-blooded animals. E.g., 4-chloro-2,6-bis(hydroxymethyl)phenol with 4-FC₆H₄OH (HCl-C₆H₆, 100°) gave I (R, R₁, R₂, R₆-R₁₂ = H; R₃, R₅ = F; R₄ = Cl). The flukicidal activity of compns. containing I was assessed in sheep infected with liver fluke.

IT 71643-23-7P 71643-24-8P 71643-32-8P
71643-37-3P 71643-38-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as parasiticide)


RN 71643-23-7 CAPLUS

CN Acetic acid, 2,2'-[[2-(carboxymethoxy)-5-chloro-1,3-phenylene]bis[methylene(6-bromo-4-fluoro-2,1-phenylene)oxy]]bis- (9CI)
(CA INDEX NAME)




RN 71643-24-8 CAPLUS

CN Acetic acid, 2,2'-[[5-chloro-2-(2-ethoxy-2-oxoethoxy)-1,3-phenylene]bis[methylene(6-bromo-4-fluoro-2,1-phenylene)oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 71643-32-8 CAPLUS


CN Acetic acid, 2,2'-[[5-chloro-2-(2-ethoxy-2-oxoethoxy)-1,3-phenylene]bis[methylene(6-bromo-4-chloro-2,1-phenylene)oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 71643-37-3 CAPLUS
 CN Acetic acid, 2,2'-[[2-(carboxymethoxy)-5-fluoro-1,3-phenylene]bis[methylene(6-bromo-4-chloro-2,1-phenylene)oxy]]bis- (9CI)
 (CA INDEX NAME)




RN 71643-38-4 CAPLUS
 CN Acetic acid, 2,2'-[[2-(2-ethoxy-2-oxoethoxy)-5-fluoro-1,3-phenylene]bis[methylene(6-bromo-4-chloro-2,1-phenylene)oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 138 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1980:533756 CAPLUS

DN 93:133756
 TI Synergetic action of potassium hexafluorotitanate or -zirconate and aromatic bromine derivatives in the reduction of the flammability of wool
 AU Gega, H.
 CS Res. Dev. Cent., Pol. Wool Ind., Bielsko-Biala, PL-43 300, Pol.
 SO Textilveredlung (1980), 15(6), 211-13
 CODEN: TXLVAE; ISSN: 0040-5310
 DT Journal
 LA German
 AB The flame retardancy of wool treated with Na salt of 2,2-bis[4-(carboxymethoxy)-3,5-dibromophenyl]propane or tribromophenoxyacetic acid is enhanced and the concentration of agents applied can be lowered if K₂TiF₆ or K₂ZrF₆ is added to the finishing bath. The flame retardancy enhancement may be due to the oxidation of Ti and Zr by consuming the O needed for combustion.
 IT 74886-28-5
 RL: USES (Uses)
 (fireproofing agents, synergistic mixts. with potassium hexafluorotitanate or hexafluorozirconate, for wool)
 RN 74886-28-5 CAPLUS
 CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis-, disodium salt (9CI) (CA INDEX NAME)



● 2 Na

L8 ANSWER 139 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1980:533346 CAPLUS
 DN 93:133346

TI Fire-resistant resin compositions

PA Asahi-Dow Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 55056140	A2	19800424	JP 1978-129453	19781023
				JP 1978-129453	A 19781023

AB 3,5,3',5'-Tetrabromobisphenol A bis(carboxymethyl ether) bis(2,4-dibromophenyl) ester (I) [74815-52-4] or 3,5,3',5'-tetrabromobisphenol A bis(β-carboxyethyl) ether bis(2,4,6-tribromophenyl) ester [74815-53-5] and Sb2O3 are used as fireproofing agents for butadiene-styrene copolymer (II) [9003-55-8]. Thus, a molding containing II (Styron 475 K) 100, I 20, and Sb2O3 5 parts had UL94 rating V-0 and retention of Izod impact strength 72% after a 400-h weathering test, compared with 23% for a molding containing 15 parts

IT decabromodiphenyl ether in place of I.
 74815-52-4 74815-53-5
 RL: USES (Uses)
 (fireproofing agents, containing antimony oxide, for butadiene-styrene copolymer)
 RN 74815-52-4 CAPLUS
 CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis-, bis(2,4-dibromophenyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


—Br

RN 74815-53-5 CAPLUS
 CN Propanoic acid, 3,3'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis-, bis(2,4,6-tribromophenyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L8 ANSWER 140 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1980:216702 CAPLUS
 DN 92:216702

TI Fire-resistant wool products
 IN Gega, Henryk; Tokarzewski, Ludomir; Leonowicz, Leopold; Wojcik, Zofia
 PA Centralne Laboratorium Przemyslu Welnianego Poludnie, Bielsko-Biala, Pol.
 SO Pol., 2 pp.
 CODEN: POXXA7

DT Patent
 LA Polish

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	PL 105475	P	19791031	PL 1977-196453	19770304
				PL 1977-196453	A 19770304

AB Textiles are fireproofed by impregnation in aqueous bath containing 5-20% I or I

Na salt (II) [73644-45-8]. The pH of the bath is 3-4 and the bath ratio is 1:20-40. The fireproofing may be conducted simultaneously with dyeing with acid or metal complex dyes. Thus, II was dissolved in water at 80-90° and the solution was acidified to pH 3-4 with HCl producing milky, colloidal dispersion of I. A wool fabric as impregnated in the bath at 90-100° until the bath become clear (40 min), rinsed in water, and dried.


IT 73644-45-8

RL: USES (Uses)

(fireproofing agents, for wool)

RN 73644-45-8 CAPLUS

CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis-, sodium salt (9CI) (CA INDEX NAME)



●x Na

L8 ANSWER 141 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1979:557442 CAPLUS

DN 91:157442

TI Treatment of animals with 2,6-bis(2-hydroxybenzyl)phenols to eradicate trematodes

IN McGarry, Errol J.; Forsyth, Bruce A.

PA ICI Australia Ltd., Australia

SO U.S., 11 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4163801	A	19790807	US 1977-812471	19770705
				AU 1976-6576	A 19760707
	AU 2621577	A1	19790104	AU 1977-26215	19760707

AU 508047 B2 19800306
US 4282390 A 19810804

AU 1976-6576 A 19760707
US 1979-25675 19790330
AU 1976-6576 A 19760707
US 1977-812471 A3 19770705

PATENT FAMILY INFORMATION:

FAN 1981:30350

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1569819	A	19800618	GB 1977-27215	19770629
	AU 2621577	A1	19790104	AU 1976-6576	A 19760707
	AU 508047	B2	19800306	AU 1977-26215	19760707
				AU 1976-6576	A 19760707

OS MARPAT 91:157442


AB Trisphenols I [R, R1, and R2 are H, alkyl, alkenyl; R3, R4, and R5 are halo, alkyl, alkenyl, alkoxy, OH, cyano, NO2, COR13 (R13 = OH, alkoxy); R6, R7, R8, R9, and R10 are H, alkyl, alkenyl, alkoxy, OH, cyano, NO2, COR13 (same as above); R11 and R12 are H, alkyl, CCl3 (or the :CCl2 analog)] were prepared from 2,6-bis(hydroxymethyl)- and - (chloromethyl)phenols and phenols. I showed flukicidal activity. A mixture of 4,2,6-Cl(HOCH2)2C6H2OH, 4-FC6H4OH, HCl, and C6H6 was heated until evaporation to give I (R4 = Cl, R3 = R5 = F, other R groups are H).

IT 71643-24-8P 71643-32-8P 71643-38-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and saponification of)


RN 71643-24-8 CAPLUS

CN Acetic acid, 2,2'-[[5-chloro-2-(2-ethoxy-2-oxoethoxy)-1,3-phenylene]bis[methylene(6-bromo-4-fluoro-2,1-phenylene)oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 71643-32-8 CAPLUS


CN Acetic acid, 2,2'-[[5-chloro-2-(2-ethoxy-2-oxoethoxy)-1,3-phenylene]bis[methylene(6-bromo-4-chloro-2,1-phenylene)oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 71643-38-4 CAPLUS
 CN Acetic acid, 2,2'-[[2-(2-ethoxy-2-oxoethoxy)-5-fluoro-1,3-phenylene]bis[methylene(6-bromo-4-chloro-2,1-phenylene)oxy]]bis-, diethyl ester (9CI) (CA INDEX NAME)




IT 71643-23-7P 71643-31-7P 71643-37-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 71643-23-7 CAPLUS
 CN Acetic acid, 2,2'-[[2-(carboxymethoxy)-5-chloro-1,3-phenylene]bis[methylene(6-bromo-4-fluoro-2,1-phenylene)oxy]]bis- (9CI)
 (CA INDEX NAME)




RN 71643-31-7 CAPLUS
 CN Acetic acid, 2,2'-[[2-(carboxymethoxy)-5-chloro-1,3-phenylene]bis[methylene(6-bromo-4-chloro-2,1-phenylene)oxy]]bis- (9CI)
 (CA INDEX NAME)



RN 71643-37-3 CAPLUS
 CN Acetic acid, 2,2'-[[2-(carboxymethoxy)-5-fluoro-1,3-phenylene]bis[methylene(6-bromo-4-chloro-2,1-phenylene)oxy]]bis- (9CI)
 (CA INDEX NAME)



L8 ANSWER 142 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1978:442699 CAPLUS
 DN 89:42699
 TI Synthesis of dicarboxylic acids and their derivatives with ether groups
 AU Derbisher, V. E.; Val'dman, D. I.
 CS USSR
 SO Funkts. Organ. Soedineniya i Polimery (1977) 17-21
 From: Ref. Zh., Khim. 1978, Abstr. No. 6Zh100
 DT Journal
 LA Russian
 OS CASREACT 89:42699
 AB Title only translated.
 IT 67045-24-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and conversion of, to acid chloride)
 RN 67045-24-3 CAPLUS
 CN Acetic acid, 2,2'-[methylenebis[[2,6-bis(1,1-dimethylethyl)-4,1-phenylene]oxy]]bis- (9CI) (CA INDEX NAME)



L8 ANSWER 143 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1977:469655 CAPLUS
 DN 87:69655
 TI Copolyesters
 IN East, Anthony J.; McIntyre, James E.
 PA Imperial Chemical Industries Ltd., UK
 SO Brit., 4 pp.
 CODEN: BRXXAA
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1459139	A	19761222	GB 1974-23317	19750502
				GB 1974-23317	A 19750502A
AB	Fire-resistant filaments and fabrics were manufactured from terephthalic acid bis(ethylene glycol ester)-tetrabromobisphenol A bis[β-hydroxyethoxy)carbonylmethyl ether] copolymer (I) [63322-88-3] containing <25 mole % of the Br-containing monomer. Thus, tetrabromobisphenol				
A	bis[(hydroxyethoxy)carbonylmethyl ether] [63318-08-1], prepared in 2 stages from tetrabromobisphenol A [79-94-7] and Et bromoacetate [105-36-2], was copolymd. at 190-286° with the ester interchange product of di-Me terephthalate and HO(CH ₂) ₂ OH to give I containing 11 mole % Br monomer. A piece of hoseleg was manufactured from spun yarn of I and wrapped around a 10 + 3 in. piece of glass-fiber cloth. After treatment 20 sec with 1.5 in. of a 3 in. butane flame at the bottom of the sample the total burn time, burn length, and burn area were 32 sec, 5 in., and 40 in. ² , resp., compared with 44 sec, 6 in., and 50 in. ² , resp., for a conventional polyester sample.				
IT	63322-88-3P RL: IMF (Industrial manufacture); PREP (Preparation) (fiber, preparation of, fire-resistant)				
RN	63322-88-3 CAPLUS				
CN	1,4-Benzenedicarboxylic acid, bis(2-hydroxyethyl) ester, polymer with bis(2-hydroxyethyl) 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis[acetate] (9CI) (CA INDEX NAME)				

CM 1

CRN 63318-08-1

CMF C23 H24 Br4 O8

PAGE 1-A




PAGE 1-B

—CH₂—OH


CM 2

CRN 959-26-2
CMF C12 H14 O6



IT 63318-08-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and copolymn. of, with hydroxyethyl terephthalate)
RN 63318-08-1 CAPLUS
CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis-, bis(2-hydroxyethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



—CH₂—OH

L8 ANSWER 144 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1977:462536 CAPLUS

DN 87:62536

TI The effect of deoxycholic acid on the excretion of methylenebis(3,4,6-trichlorophenoxyacetic acid)

AU Yu, Hwan Moo; Kim, Chong Suk

CS Dep. Pharmacol., Kyungpook Natl. Univ., Taegu, S. Korea

SO Taehan Yakrihak Chapchi (1965-1984) (1976), 12(2), 133-41

CODEN: TYCPAQ; ISSN: 0372-3461

DT Journal

LA Korean

AB In rabbits, the largest amount of biliary excretion of 2,2'-methylenebis(3,4,6-trichlorophenoxyacetic acid) (I) [52569-21-8] occurred within a short period of time after administration of I or the I-deoxycholic acid mixture [63313-19-9]. However, deoxycholic acid increased I blood levels and decreased biliary excretion of I. There was an increase in bilirubin [635-65-4] excretion 1-2.5 h after both treatments; however, the bilirubin excretion was greater after the combined treatment. In addition, the amount of bile excreted was decreased in both treated groups to the same extent. Thus, deoxycholic acid appears to interfere with the biliary excretion of I. In addition, there was no close relation between the increased excretion of MTPA and bilirubin excretion. However, there was a close relation between I blood level and biliary excretion of I. Deoxycholic acid would appear to enhance the effect of I if the Clonorchis parasites take the drug from the blood, but diminish its effectiveness if they take the drug from the bile.


IT 52569-21-8

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(metabolism of, deoxycholic acid effect on, bilirubin biliary excretion in relation to)

RN 52569-21-8 CAPLUS

CN Acetic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



IT 63313-19-9

RL: BIOL (Biological study)


(methylene bis(trichlorophenoxy acetic acid) metabolism after

administration of, bilirubin biliary excretion in relation to)
 RN 63313-19-9 CAPLUS
 CN Cholan-24-oic acid, 3,12-dihydroxy-, (3 α ,5 β ,12 α)-, mixt.
 with 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis[acetic
 acid] (9CI) (CA INDEX NAME)

CM 1

CRN 52569-21-8

CMF C17 H10 Cl6 O6




CM 2

CRN 83-44-3

CMF C24 H40 O4

Absolute stereochemistry.



L8 ANSWER 145 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1976:6356 CAPLUS

DN 84:6356

TI Flame-repellant polyester compositions

IN Kato, Yasuo; Kato, Katsuhiko; Sugino, Masahiro; Ikegami, Jun; Harukawa, Junichi

PA Toyobo Co., Ltd., Japan

SO Ger. Offen., 31 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

PI	-----	-----	-----	-----	-----
	DE 2458967	A1	19750619	DE 1974-2458967	19741213
	JP 50091651	A2	19750722	JP 1973-141650	A 19731217
				JP 1973-141650	19731217
	GB 1461629	A	19770113	GB 1974-53970	A 19741213
	CA 1045739	A1	19790102	JP 1973-141650	A 19731217
	US 4046724	A	19770906	CA 1974-216012	19741213
				JP 1973-141650	A 19731217
				US 1974-533067	19741216
				JP 1973-141650	A 19731217

AB Fire-resistant polyester fibers are prepared from poly(alkylene terephthalates) containing 3,5-dibromophenyl groups in the main chain and having high mol. weight. For example, bis(2-hydroxyethyl) terephthalate was condensed with 2,2'-bis[4-(2-hydroxyethoxy)-3,5-dibromophenyl]]propane at 270° and 0.5 torr in the presence of Sb2O3 as polycondensation catalyst. After cooling, 4% organophosphorus compound (I) [25949-23-9] with mol. weight 10,000 was added to the 2,2'-bis[4-(2-hydroxyethoxy)-3,5-dibromophenyl]]propane-bis(hydroxyethyl)terephthalate polymer [50318-63-3], under N₂, and the composition was spun into self-extinguishing fibers.

IT 57502-25-7

RL: USES (Uses)

(fiber, fireproofing of, by polyphosphates and polyphosphonates)


RN 57502-25-7 CAPLUS

CN 1,4-Benzenedicarboxylic acid, dimethyl ester, polymer with dimethyl 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis[acetate] and 1,2-ethanediol (9CI) (CA INDEX NAME)

CM 1

CRN 19947-84-3


CMF C21 H20 Br4 O6



CM 2

CRN 120-61-6


CMF C10 H10 O4




CM 3

CRN 107-21-1
CMF C2 H6 O2HO-CH₂-CH₂-OH

L8 ANSWER 146 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1975:480100 CAPLUS
 DN 83:80100
 TI Kinetics of thermal degradation and fire retardant efficiency of polyesters
 AU Gupta, S. K.; Thampy, R. T.
 CS Shri Ram Inst. Ind. Res., Delhi, India
 SO Angewandte Makromolekulare Chemie (1975), 44(1), 47-65
 CODEN: ANMCBO; ISSN: 0003-3146
 DT Journal
 LA English
 AB The kinetics of thermal degradation and fire retardant efficiency of chlorendic acid-isophthalic acid-maleic anhydride-propylene glycol polymer [28406-91-9] (0.25-4:1:1:2) and bisphenol A-based polyesters indicate degradation takes place in 2 stages. The first stage ranged from 250-450° and the second stage ranged from 450-600°. The first stage range is narrowed by increasing halogen content with Br more effective than Cl. The activation energy for degradation showed the same trend as thermal stability but the flame resistance tends to be in the reverse order. These studies confirm a cyclic mechanism for flame retardants.
 IT 19933-66-5 19947-84-3
 RL: USES (Uses)
 (thermal degradation and fire retardant efficiency of)
 RN 19933-66-5 CAPLUS
 CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dichloro-4,1-phenylene)oxy]]bis-, dimethyl ester (9CI) (CA INDEX NAME)



RN 19947-84-3 CAPLUS
 CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis-, dimethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 147 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1975:437462 CAPLUS

DN 83:37462

TI Absorption distribution and excretion of 2,2'-methylenebis(3,4,6-trichlorophenoxyacetic acid) (MTPA) in rabbits

AU Kim, Chong Suk; Pock, Joon Hyoun; Kim, Yu Moon; Kang, Yung-Ho

CS Sch. Med., Kyungpook Natl. Univ., Taegu, S. Korea

SO Taehan Yakrihak Chapchi (1965-1984) (1973), 9(1), 39-46

CODEN: TYCPAQ; ISSN: 0372-3461

DT Journal

LA Korean


AB After oral administration ¹⁴C-labeled 2,2'-methylenebis(3,4,6-trichlorophenoxyacetic acid) (I) [52569-21-8] concns. in blood and urine increased slowly, suggesting poor absorption by the gastrointestinal tract. I excretion after i.v. administration was slow and large amts were excreted in the bile. The highest concns. of I, in decreasing order, were found in the kidney and liver, heart, lung, spleen and muscle, and brain. After daily administration of 20 mg I/kg for 6 days, I concentration gradually increased in the urine and particularly in the feces, suggesting enterohepatic circulation. Thus, the accumulation of large amts. of I in liver and tissues and excretion of large amts. of I in the bile are favorable properties of I for the treatment of clonorchiasis.

IT 52569-21-8

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metabolism of)

RN 52569-21-8 CAPLUS

CN Acetic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis-
(9CI) (CA INDEX NAME)



L8 ANSWER 148 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:553619 CAPLUS

DN 81:153619

TI Polyoxymethylene composition

IN Ishii, Takayoshi; Yoshikawa, Toshio; Inaike, Toshihiro; Kuroda, Kazuhiro;
Kido, Kunio; Tokunaga, Kiyoaki

PA Ube Industries, Ltd.

SO Jpn. Tokkyo Koho, 6 pp.

CODEN: JAXXAD

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 48013706	B4	19730428	JP 1970-71780	19700818
				JP 1970-71780	19700818


AB Polyamides containing 2,2'-methylenebis[4-(2-carboxyethyl)-6-tert-butylphenol] or 2,2'-butylidenebis[4-(2-carboxyethyl)-6-tert-butylphenol] or sole acid component, and 2,2'-methylenebis[4-(3-aminopropyl)-6-tert-butylphenol]-adipic acid polyamide [51121-92-7] were heat stabilizers for polyoxymethylenes (I). For example, I containing 1% hexamethylenediamine-2,2'-methylenebis[4-(2-carboxyethyl)-1-tert-butylphenol] polyamide [50586-51-1] had heat resistance (weight loss rate at 222.deg.) 0.035%/min, compared with 0.060%/min for I stabilized with 36:36:28 nylon 6-nylon 66-nylon 610 copolymer.

IT 51122-06-6
RL: PEP (Physical, engineering or chemical process); PROC (Process) (heat stabilizers, for polyoxymethylenes)

RN 51122-06-6 CAPLUS

CN Poly[imino-1,6-hexanediylimino(1-oxo-1,3-propanediyl)[5-(1,1-dimethylethyl)-4-hydroxy-1,3-phenylene]methylene[5-(1,1-dimethylethyl)-6-hydroxy-1,3-phenylene](3-oxo-1,3-propanediyl)] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

]


L8 ANSWER 149 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1974:553461 CAPLUS
DN 81:153461
TI Polyacids and polyesters from halogenated polyphenols
IN Maki, Hirohisa
PA Daiichi Kogyo Seiyaku Co., Ltd.
SO Jpn. Kokai Tokkyo Koho, 2 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 49047327	A2	19740508	JP 1972-91997	19720912
	JP 52018696	B4	19770524		


JP 1972-91997

A 19720912


- AB Carboxylic compds. (I, R1 = H, C1-4 alkyl, alkyl-containing Polyoxyalkylene, hydroxyalkyl; R2 = C1-4 divalent hydrocarbon; A = CMe2, SO2, S, O; X = halo) are prepared by etherification of halopolyphenols with alkali salts of halo carboxylic acids or esters. I is a starting material or an additive for fire-retardant polymer compns. Thus, a mixture of Na 2-chloroacetate [3926-62-3] and tetrabromobisphenol A [79-94-7] in aqueous NaOH gave on heating 2,2-bis[4-(carboxymethyl)-3,5-dibromophenyl]propane (I, R1 = H, R2 = CH2, A = CMe2, X = Br) [47612-39-5].
- IT 47612-39-5P
RL: PREP (Preparation)
(preparation of)
- RN 47612-39-5 CAPLUS
- CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



- L8 ANSWER 150 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
- AN 1974:514787 CAPLUS
- DN 81:114787
- TI Effect of methylene bis(trichlorophenoxy acetic acid) on bilirubin excretion
- AU Woo, Chong Doo; Kim, Chong Suk
- CS Dep. Intern. Med., Daegu Fatima Hosp., S. Korea
- SO Taehan Naekwa Hakhoe Chapchi (1974), 17(4), 285-8
CODEN: TNHCA3; ISSN: 0494-4712
- DT Journal
- LA Korean
- AB 2,2'-Methylenebis(3,4,6-trichlorophenoxyacetic acid) (I) [52569-21-8] (5-10mg/kg i.v.) decreased bile flow and increased serum bilirubin [635-65-4] excretion in rabbits.
- IT 52569-21-8
RL: BIOL (Biological study)
(bile flow decrease and bilirubin excretion increase by)
- RN 52569-21-8 CAPLUS
- CN Acetic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



L8 ANSWER 151 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1974:128717 CAPLUS
 DN 80:128717
 TI Synthesis of Mannich bases of 2,2'-methylenebis(3,4,6-trichlorophenoxyacetic acid) and their antimicrobial activities
 AU Kim, Jong Ho
 CS Dep. Chem., Kyung Hee Univ., Seoul, S. Korea
 SO Yakhak Hoechi (1972), 16(2), 97-107
 CODEN: YAHOA3; ISSN: 0513-4234
 DT Journal
 LA Korean
 AB Mannich bases of 2,2'-methylene bis(3,4,6-trichlorophenoxy)acetic acid were synthesized as potential antimicrobial agents and were tested against a variety of organisms. The 34 compds. studied differed in their min. inhibitory concns. for different bacterial and fungal species, but 2,2'-methylene bis[α -(3,4,6-trichlorophenoxy)- β -(m-hydroxy-p-carboxyphenylamine)propionic acid] [50884-24-7] seemed to be most active over the entire spectrum of organisms.
 IT 52569-21-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and antimicrobial activity of)
 RN 52569-21-8 CAPLUS
 CN Acetic acid, 2,2'-[methylenebis[(3,4,6-trichloro-2,1-phenylene)oxy]]bis-(9CI) (CA INDEX NAME)




L8 ANSWER 152 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1974:121376 CAPLUS
 DN 80:121376
 TI Formaldehyde polymers. 15. Isolation and mass spectral behavior of 3,3'-methylenebis(5-methyl-1,2-phenyleneoxy)dipropionic acid and 3-{2,6-bis[2-(2-carboxyethoxy)-5-methylbenzyl]-4-methylphenoxy}propionic acid
 AU Ninagawa, Akira; Katsuya, Yasuo; Matsuda, Haruo; Matsuda, Sumio
 CS Fac. Eng., Osaka Univ., Osaka, Japan
 SO Makromolekulare Chemie (1973), 174, 225-9
 CODEN: MACEAK; ISSN: 0025-116X
 DT Journal
 LA English
 AB 3,3'-[2,2'-Methylenebis(p-tolyloxy)]dipropionic acid [51473-64-4] and 3-[2,6-bis[2-[2-carboxyethoxy)-5-methylbenzyl]-4-methylphenoxy]propionic acid (I) [51473-65-5] were isolated from reaction products of 3-(p-tolyloxy)propionic acid [25173-37-9] with formaldehyde [50-00-0] by chromatog. and their mass spectrum obtained.
 IT 51473-64-4 51473-65-5

RL: USES (Uses)


(chromatog. isolation of, from reaction products of (toluoxo)propionic acid with formaldehyde)

RN 51473-64-4 CAPLUS

CN Propanoic acid, 3,3'-[methylenebis[(4-methyl-2,1-phenylene)oxy]]bis- (9CI)
(CA INDEX NAME)

RN 51473-65-5 CAPLUS

CN Propanoic acid, 3,3'-[[2-(2-carboxyethoxy)-5-methyl-1,3-phenylene]bis[methylene(5-methyl-2,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



L8 ANSWER 153 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1973:404725 CAPLUS

DN 79:4725

TI Wittig rearrangement of (diarylmethoxy)acetamides

AU Van Der Stelt, C.; Heus, W. J.; Haasjes, A.

CS Res. Dev., Gist-Brocades N.V., Haarlem, Neth.

SO Recueil des Travaux Chimiques des Pays-Bas (1973), 92(4), 493-512


CODEN: RTCPA3; ISSN: 0165-0513

DT Journal

LA English

AB N,N-Dialkyl-2-(arylmethoxy)- or N,N-dialkyl-2-(diarylmethoxy)acetamides were found to undergo a Wittig rearrangement under the influence of bases such as NaH to form either N,N-dialkyl-3-aryl- or -3,3-diaryllactamides. When the diarylmethoxy group was asymmetric, the rearrangement resulted in diastereoisomeric reaction products. Ortho substitution in one or both aryl rings altered the course of rearrangement to give addnl., or even exclusively, p-benzylmandelamide derivs. Not only rearrangement products but also byproducts like diaryl ketones, diarylmethanes and tetraarylethanes were formed and in several cases byproducts with the structure of a substituted p-benzylbenzoic acid were isolated. These acids arose from the para rearrangement products by further decomposition under the influence of the basic catalyst. The scope of the reaction was explored by studying the rearrangement of some 30 ethers.

IT 41858-58-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 41858-58-6 CAPLUS
 CN Benzeneacetamide, 4-[(2,6-dimethylphenyl)methyl]- α -hydroxy-N,N,3,5-tetramethyl- (9CI) (CA INDEX NAME)




L8 ANSWER 154 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1972:99354 CAPLUS
 DN 76:99354
 TI Alkylenebis(phenoxyacetic acid) derivatives as herbicides
 IN Gutttag, Alvin
 PA Weston Chemical Corp.
 SO U.S., 7 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3630715	A	19711228	US 1968-785404	19681219
				US 1968-785404	A 19681219

AB Postemergence herbicides with improved selectivity were prepared comprising the di-Bu ester or the dimethylamine salt of compds. such as 4,4'-isopropylidenebis(2,6-di-chlorophenoxyacetic acid) (I). Thus, tetrachlorobisphenol A di-Na salt and ClCH₂CO₂Na reacted to give 78% I. I was esterified with BuOH in PhMe in the presence of H₂SO₄ to give the di-Bu ester (II). An emulsion of II in Butyl Carbitol Acetate and Velsicol can be applied to growing crops such as tomatoes and cotton to rid the crops of common weeds without their damage. ,4'-(2,2,2-Trichloroethylidene)bis(2,6-dichlorophenoxy-acetic acid) (III) was prepared and used in insecticide compns. against Musca domestica (housefly).

IT 13937-23-0P 35364-52-4P 35364-54-6P
 35364-55-7P 35364-56-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 13937-23-0 CAPLUS
 CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dichloro-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




RN 35364-52-4 CAPLUS
 CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dichloro-4,1-phenylene)oxy]]bis-, disodium salt (9CI) (CA INDEX NAME)



●2 Na


RN 35364-54-6 CAPLUS
 CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dichloro-4,1-phenylene)oxy]]bis-, dibutyl ester (9CI) (CA INDEX NAME)



RN 35364-55-7 CAPLUS
 CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dichloro-4,1-phenylene)oxy]]bis-, compd. with N-methylmethanamine (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 13937-23-0
 CMF C19 H16 Cl4 O6




CM 2


CRN 124-40-3
 CMF C2 H7 N

H3C-NH-CH3

RN 35364-56-8 CAPLUS
 CN Acetic acid, 2,2'-[(2,2,2-trichloroethylidene)bis[(2,6-dichloro-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)




L8 ANSWER 155 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1971:510177 CAPLUS
 DN 75:110177
 TI Synthesis of 2,3,4,5-tetrahydro-7,8-dimethoxy-1H-2-benzazepines
 AU Wittekind, Raymond R.; Lazarus, Sam
 CS Dep. Org. Chem., Warner-Lambert Res. Inst., Morris Plain, NJ, USA
 SO Journal of Heterocyclic Chemistry (1971), 8(3), 495-501
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 AB 3-(3,4-Dimethoxyphenyl)propionamide (I) is treated with benzaldehydes RCHO or s-trioxanes to give 1-substituted 6,7-dimethoxy-2,3,4,5-tetrahydro-1H-2-benzazepin-3-ones (II) which are converted to the corresponding benzazepines (III). Thus, I is treated with BzH to give II (R = Ph) which is treated with LiAlH₄ to give III (R = Ph). I is treated with s-trioxane to give II (R = H) which is reduced to III (R = H). The alkaline hydrolysis of II (R = aryl) gives 4,5,2-(MeO)₂[RCH(NH₂)]C₆H₂(CH₂)₂CO₂H. 1-(3,4-Dimethoxyphenyl)-6,7-dimethoxy-2-formyl-2,3,4,5-tetrahydro-1H-2-benzazepine (IV) is prepared by the reaction of 3,4-(MeO)₂C₆H₃(CH₂)₃NHCHO with 3,4-(MeO)₂C₆H₃CHO.
 IT 33567-01-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 33567-01-0 CAPLUS
 CN Hydrocinnamamide, 2,2'-methylenebis[4,5-dimethoxy- (8CI) (CA INDEX NAME)]



L8 ANSWER 156 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1971:510036 CAPLUS
 DN 75:110036
 TI [4,5-dimethoxy- α -(3,4-dimethoxyphenyl)-o-tolyl]acetonitrile.
 By-product from the reaction of 3,4-dimethoxybenzyl chloride with sodium cyanide
 AU Fujii, Tozo; Ueno, Yukiko; Mitsukuchi, Morihiro


CS Fac. Pharm. Sci., Kanazawa Univ., Kanazawa, Japan
 SO Chemical & Pharmaceutical Bulletin (1971), 19(7), 1374-80
 CODEN: CPBTAL; ISSN: 0009-2363
 DT Journal
 LA English
 OS CASREACT 75:110036
 AB [4,5-Dimethoxy- α -(3,4-dimethoxyphenyl)-o-tolyl]acetonitrile (I) is a by-product in the metathesis of 3,4-dimethoxybenzyl chloride with NaCN in Me₂SO or DMF. I gave 4,5-dimethoxy - 2 - (3,4 - dimethoxybenzyl) - N,N - dimethylphenethylamine via [4,5-dimethoxy- α -(3,4-dimethoxyphenyl)-o-tolyl]acetic acid and 2-[4,5-dimethoxy- α -(3,4-dimethoxyphenyl)-o-tolyl]-N,N-dimethylacetamide. The reaction of PhCH₂Cl with NaCN in dipolar aprotic solvents gave a small amount of 2,3-diphenylpropionitrile, besides PhCH₂CN.
 IT 33490-74-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 33490-74-3 CAPLUS
 CN Acetamide, 2-[α -(3,4-dimethoxyphenyl)-4,5-dimethoxy-o-tolyl]-N,N-dimethyl- (8CI) (CA INDEX NAME)



L8 ANSWER 157 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1971:32033 CAPLUS
 DN 74:32033
 TI Studies on maleate-fumarate isomerization in unsaturated polyesters by infrared spectroscopy
 AU Gupta, Sudesh Kumar; Thampy, Ramakrishna T.
 CS High Polym. Div., Shri Ram Inst. Ind. Res., Delhi, India
 SO Makromolekulare Chemie (1970), 139, 103-13
 CODEN: MACEAK; ISSN: 0025-116X
 DT Journal
 LA English
 AB The isomerization of maleate to fumarate in polyesters increased with increasing maleate-saturated acid ratio, was higher in polyesters containing phthalate than in those containing isophthalate and adipate groups, was low in polyester based on bisphenol A and more pronounced in those based on 2,2-bis(3,5-dibromo-4-hydroxyphenyl)propane or 2,2-bis(3,5-dichloro-4-hydroxyphenyl)propane, and increased as the proportion of chlorendic acid (I) increased in polyesters containing I and maleic anhydride. These results were explained by steric and catalytic effects. Equations for determining the proportions of fumarate and maleate from ir spectra were given.
 IT 28450-27-3 28571-47-3
 RL: USES (Uses)
 (rearrangements in)
 RN 28450-27-3 CAPLUS
 CN Maleic anhydride, polyester with dimethyl [isopropylidene[(2,6-dibromo-p-phenylene)oxy]]diacetate and 1,2-propanediol (8CI) (CA INDEX NAME)


CM 1

CRN 19947-84-3
CMF C21 H20 Br4 O6




CM 2

CRN 108-31-6
CMF C4 H2 O3



CM 3


CRN 57-55-6
CMF C3 H8 O2



RN 28571-47-3 CAPLUS
CN Maleic anhydride, polyester with dimethyl [isopropylidenebis[(2,6-dichloro-p-phenylene)oxy]]diacetate and 1,2-propanediol (8CI) (CA INDEX NAME)

CM 1


CRN 19933-66-5
CMF C21 H20 Cl4 O6




CM 2

CRN 108-31-6

CMF C4 H2 O3



CM 3


CRN 57-55-6
CMF C3 H8 O2

L8 ANSWER 158 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1969:403991 CAPLUS
 DN 71:3991
 TI Effect of chlorination and bromination on the dielectric characteristics of bisphenol A polyesters
 AU Gupta, Sudesh K.; Thampy, Ramakrishna T.
 CS Shri Ram Inst. Ind. Res., Delhi, India
 SO Angewandte Makromolekulare Chemie (1969), 6, 161-70
 CODEN: ANMCBO; ISSN: 0003-3146
 DT Journal
 LA English
 AB The temperature dependence of the dielec. constant was studied for crosslinked polyesters prepared by treating Me chloroacetate with bisphenol A (I), 2,2-bis(3,5-dichloro-4-hydroxyphenyl)propane (II) and 2,2-bis(3,5-dibromo-4-hydroxyphenyl)propane (III), giving diester ethers, which were then transesterified with propylene glycol to give diols, which were polycondensed with maleic anhydride. These resins were mixed with styrene in a 7:3 weight ratio, catalyzed with 0.3% Co octoate and 1% Me Et ketone peroxide, cured at room temperature, and post cured 30 min. at 100° with ir heating. The dielec. consts. were determined in the microwave-frequency region at a wavelength of 3.21 cm., and were 2.93, 2.91, and 2.77, resp. for the polyesters based on I, II, and III. The dielec. constant showed no temperature dependence at 30-85°. The decrease in the dielec. consts. for the polyesters based on II and III was attributed to the decrease in the number of ester and ether groups in the polyester chain per unit of cured polymer. The loss factor for the I-based resin was a maximum at 55°, and the polymer had a relaxation time 1.7×10^{-11} sec. at 55°. This was assigned to free motion of the ether linkages in the absence of the 3,5-halo substituents. The II-based polyesters had less variation in loss factor than the III-based polyesters, possibly resulting from large polystyrene segments present in the latter case. Hydrolysis stability and heat-distortion-temperature studies supported these results.

IT 25987-36-4 26716-98-3
 RL: PRP (Properties)
 (dielec. properties of)
 RN 25987-36-4 CAPLUS
 CN Maleic anhydride, polyester with [isopropylidenebis[(2,6-dibromo-p-phenylene)oxy]]diacetic acid and 1,2-propanediol (8CI) (CA INDEX NAME)


CM 1

CRN 47612-39-5
CMF C19 H16 Br4 O6




CM 2

CRN 108-31-6
CMF C4 H2 O3



CM 3


CRN 57-55-6
CMF C3 H8 O2



RN 26716-98-3 CAPLUS
CN Maleic anhydride, polyester with [isopropylidenebis[(2,6-dichloro-p-phenylene)oxy]]diacetic acid and 1,2-propanediol (8CI) (CA INDEX NAME)

CM 1


CRN 13937-23-0
CMF C19 H16 Cl4 O6




CM 2

CRN 108-31-6


CMF C4 H2 O3



CM 3


CRN 57-55-6
CMF C3 H8 O2

L8 ANSWER 159 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1969:48139 CAPLUS
 DN 70:48139
 TI Chemical-resistant polyesters based on bisphenol-A- derivatives
 AU Gupta, Sudesh K.; Sharma, Yoginder N.; Thampy, Ramakrishna T.
 CS Shri Ram Inst. Ind. Res., Delhi, India
 SO Makromolekulare Chemie (1968), 120, 137-47
 CODEN: MACEAK; ISSN: 0025-116X
 DT Journal
 LA English
 AB Bisphenol A, 2,2-bis(4-hydroxy-3,5-dibromophenyl)propane, and 2,2-bis(4-hydroxy-3,5-dichlorophenyl)propane were condensed with Me chloroacetate to give di-Me 2,2-isopropylidenebis(p-phenyleneoxy)diacetate (I) and its bromo (II) and chloro derivative (III), resp. Three new polyesters were synthesized based on I, II, and III. They had Vicat hardnesses comparable with hexachloroendomethylenetetrahydrophthalic acid (IV)-based polyesters. Resins based on II and III had 20 times better hydrolytic stability than IV isophthalate resin. Thermogravimetric anal. showed that a resin based on I had the maximum 50% higher decomposition temperature of the polyester resins tested.
 IT 28450-27-3 28571-47-3
 RL: USES (Uses)
 (chemical-resistant)
 RN 28450-27-3 CAPLUS
 CN Maleic anhydride, polyester with dimethyl [isopropylidene[(2,6-dibromo-p-phenylene)oxy]]diacetate and 1,2-propanediol (8CI) (CA INDEX NAME)
 CM 1
 CRN 19947-84-3
 CMF C21 H20 Br4 O6




CM 2

CRN 108-31-6
CMF C4 H2 O3



CM 3


CRN 57-55-6
CMF C3 H8 O2



RN 28571-47-3 CAPLUS
CN Maleic anhydride, polyester with dimethyl [isopropylidenebis[(2,6-dichloro-p-phenylene)oxy]]diacetate and 1,2-propanediol (8CI) (CA INDEX NAME)


CM 1

CRN 19933-66-5
CMF C21 H20 Cl4 O6




CM 2

CRN 108-31-6
CMF C4 H2 O3




CM 3

CRN 57-55-6
CMF C3 H8 O2




IT 19933-66-5P 19947-84-3P 28571-47-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 19933-66-5 CAPLUS
CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dichloro-4,1-phenylene)oxy]]bis-, dimethyl ester (9CI) (CA INDEX NAME)




RN 19947-84-3 CAPLUS
CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxy]]bis-, dimethyl ester (9CI) (CA INDEX NAME)



RN 28571-47-3 CAPLUS
CN Maleic anhydride, polyester with dimethyl [isopropylidenebis[(2,6-dichloro-p-phenylene)oxy]]diacetate and 1,2-propanediol (8CI) (CA INDEX NAME)


CM 1

CRN 19933-66-5
CMF C21 H20 Cl4 O6




CM 2

CRN 108-31-6
CMF C4 H2 O3




CM 3


CRN 57-55-6
CMF C3 H8 O2



L8 ANSWER 160 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1967:115386 CAPLUS
 DN 66:115386
 TI Derivatives of 4,4'-isopropylidenebis(2,6-dichlorophenol)
 AU Godt, Henry C., Jr.; Freerks, Marshall C.
 CS Org. Chem. Div., Monsanto Co., St. Louis, MO, USA
 SO Journal of Chemical and Engineering Data (1967), 12(2), 252-4
 CODEN: JCEAAX; ISSN: 0021-9568
 DT Journal
 LA English
 AB Nine bis esters, 6 bis ethers, 3 bis amides, and one bis acid of 4,4'-isopropylidenebis(2,6-dichlorophenol) are described along with significant ir spectral data.
 IT 13937-23-0P 13975-62-7P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 13937-23-0 CAPLUS
 CN Acetic acid, 2,2'-[(1-methylethylidene)bis[(2,6-dichloro-4,1-phenylene)oxy]]bis- (9CI) (CA INDEX NAME)



RN 13975-62-7 CAPLUS
 CN Acetic acid, [isopropylidenebis[(2,6-dichloro-p-phenylene)oxy]]di-, diethyl ester (8CI) (CA INDEX NAME)




L8 ANSWER 161 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1966:51830 CAPLUS
 DN 64:51830
 OREF 64:9646g-h,9647a-b
 TI Derivatives of bis(4-hydroxyphenyl)acetic acid
 PA Nobel-Bozel
 SO 26 pp.
 DT Patent
 LA Unavailable
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	NL 6505534	----	19651101	NL 1965-5534 FR	19650429 19640429


AB The title compds. of the general formula I, in which X = Cl, Br, or H; Y = Cl, OH, OMe, NMe₂, NEt₂, OR; A = H, CH₂CO₂H(R), COR (R is alkyl, cycloalkyl, aryl, glycidyl), are useful as herbicides, fungicides, bactericides, and as components for epoxy resins and thermosetting acrylic paints. Thus, to a refluxing mixture of 126 g. bis(4-hydroxyphenyl)acetic acid, 694 g. epichlorohydrin, and 75 g. isopropanol is added in 45 min. a solution of 63 g. NaOH in 67 g. H₂O. The mixture is refluxed 0.5 hr. and distilled to 110°. It is cooled, filtered (NaCl), and distilled to 110°/35 mm. to give 165 g. glycidyl ester of bis(4-glycidyloxyphenyl)acetic acid. The following I have been prepared (A, Y, X, and m.p. given): H, OH, Cl, 210-15° (decomposition) (II); H, OMe, Cl, 174-5° (III); CH₂CO₂H, OH, H, 95-6°; Ac, OH, Cl, --; Ac, Cl, Cl, --; Ac, NMe₂, Cl, 175-82°; H, NMe₂, Cl, 210-13°; glycidyl, OBU, H, --; 3,4-epoxybutyl, OBU, H, --; CH₂CO₂H, OH, Cl, 219-21°; CH₂CO₂Et, OMe, H, --; CH₂CO₂Et, OMe, Cl, -- (IV); the 2-methylimidazole salt of II m. 223-4° (decomposition). III is useful for selective weed control of cereals, lawns, vineyards. IV is a strong phytocide against Gramineae; other plants are not affected, and it is non-toxic for animals and people.

IT 4917-48-0, Acetic acid, [(carboxymethylene)bis[(2,6-dichloro-p-phenylene)oxy]]di- 4917-50-4, Acetic acid, [(carboxymethylene)bis[(2,6-dichloro-p-phenylene)oxy]]di-, diethyl Me ester

(preparation of)
 RN 4917-48-0 CAPLUS
 CN Acetic acid, bis[4-(carboxymethoxy)-3,5-dichlorophenyl]- (8CI) (CA INDEX NAME)



RN 4917-50-4 CAPLUS
 CN Acetic acid, bis[4-(carboxymethoxy)-3,5-dichlorophenyl]-, diethyl methyl ester (8CI) (CA INDEX NAME)



L8 ANSWER 162 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1963:461935 CAPLUS

DN 59:61935

OREF 59:11350c-d

TI Oxyacids of bisphenol type

IN Uetani, Iwao; Hasegawa, Kenji; Nagao, Sohichi

PA Daiwa Chem. Ind. Co.

SO 3 pp.

DT Patent


LA Unavailable

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 38002266		19630318	JP	19590725


AB To a boiling solution of 40 g. Na 2,2'-thiobis(4,6-dichlorophenol) in 300 cc. EtOH is added 27.0 g. ClCH₂CO₂Et, the mixture refluxed 3-6 hrs., cooled, filtered, 20 g. 50% NaOH solution added to the filtrate, the mixture boiled 30 min., evaporated, 500 cc. H₂O added to the residue, and the mixture acidified with HCl to give 43.7 g. 2,2'-thiobis(4,6-dichlorophenoxyacetic acid). Similarly prepared are: 2,2'-methylenebis(3,4,6-trichlorophenoxypropionic acid), 2,2'-thiobis(4,6-dichlorophenoxypropionic acid), 2,2'-dithiobis(4,6-dichlorophenoxy-β-oxobutyric acid), 2,2'-benzylidenebis(6-chlorophenoxypropionic acid), 4,4'-ethylidenebis(2,6-dichlorophenoxyacetic acid), and 4,4'-vinylidenebis(2,6-dichlorophenoxyacetic acid), useful as anthelmintics.

IT 98527-89-0, Propionic acid, 3,3'-[methylenebis[(3,4,6-trichloro-o-phenylene)oxy]]di- 100148-47-8, Acetic acid, [ethylidenebis[(2,6-dichloro-p-phenylene)oxy]]di- (preparation of)

RN 98527-89-0 CAPLUS
 CN Propionic acid, 3,3'-[methylenebis[(3,4,6-trichloro-o-phenylene)oxy]]di- (7CI) (CA INDEX NAME)



RN 100148-47-8 CAPLUS
 CN Acetic acid, [ethylidenebis[(2,6-dichloro-p-phenylene)oxy]]di- (7CI) (CA INDEX NAME)




L8 ANSWER 163 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1958:113454 CAPLUS
 DN 52:113454
 OREF 52:20035g-i,20036a-c
 TI Regulators of plant growth
 AU Mirek, Julian
 CS Univ. Krakow, Pol.
 SO Zeszyty Nauk. Uniw. Jagiel., Set. Nauk Mat.-Przyrod., Mat., Fiz., Chem. (1957), No. 3, 117-46
 DT Journal
 LA English
 AB Biol. activity with regard to plant growth is discussed. A number of derivs. of phenoxyethanol were prepared The alcs. (0.2 mole) in 400 ml. PhMe with 4.6 g. Na heated 2-5 hrs., the Na removed, 0.2 mole BrCH₂CO₂Et added, the mixture heated 1.5-2 hrs., washed with H₂O, dried, and distilled gave Et esters which, when hydrolyzed with 25% NaOH for 10-15 min. at the b.p., afforded Na salts which gave with concentrated HCl the following RC₆H₄OCH₂OCH₂CO₂H (R, b.p., Et ester b.p., and yield, and amide m.p. given): H, b16 207°, b16 177-8°, 22 g., 104-5°; o-Me, b8 202-4°, b8 178-9°, 24 g., 56-8°; m-Me, b16 214-16°, b15 181-3°, 27 g., 64-5°; p-Me, m. 54-6°, b16 185-6°, 25 g., 87-8°; o-Cl, b16 224-6°, b16 180-5°, 26 g., 66-7°; p-Cl(I), b7 214-16°, b11 188-90°, 27 g., 98-9°. Derivs. of diphenylmethane are prepared 4,4'-Dihydroxydiphenylmethane (6 g.) melted with 8 g. ClCH₂CO₂H (II), 8 g. NaOH in 18 ml. H₂O added portionwise, the mixture heated 2 hrs. on the water bath, HCl added, the precipitate washed, and crystallized from AcOH and

dilute EtOH gave 3.2 g. methanebis(4-phenoxyacetic acid), m. 101-2°; di-Me ester, m. 65-6°; di-Et ester, m. 43-4°; di-amide, m. 232-3° (50% AcOH). From the filtrate p-(p-hydroxybenzyl)phenoxyacetic acid hydrate, m. 166-7°, was isolated by crystallization from H₂O and dilute EtOH: Me ester, m. 119-20°. Similarly, 5 g. 3,3'-dihydroxydiphenylmethane with 6.5 g. II gave 4.6 g. methanebis(3-methyl-4-phenoxyacetic acid), m. 189-90°; di-Me ester, m. 79-80°; di-Et ester, m. 46-7°; diamide, m. 210-11°. 3,3'-Dichloro-4,4'-dihydroxydiphenylmethane (6.5 g.) with 6.5 g. II gave 5.3 g. methanebis(3-chloro-4-phenoxyacetic acid), m. 211-12°; di-Me ester, m. 93-4°; di-Et ester, m. 69-70°; diamide, m. 263-4°. 3,3'-Dinitro-4,4'-dihydroxydiphenylmethane (10 g.) melted with 9 g. II, 9 g. NaOH in 18 ml. H₂O added, the mixture heated on a water bath for 2 hrs. and cooled, HCl added, the precipitate filtered off, dried, and extracted with 1.5 l. hot H₂O gave 2.5 g. yellow 4-(3-nitro-4-hydroxybenzyl)-2-nitro-phenoxyacetic acid, m. 146-7°; yellow Me ester, m. 89-90°. According to current theories of plant-hormone action, the acids prepared should be active; eight-days' growth of pea shoots, however, was not affected by 0.001M Na salts of all acids prepared, except for I which stopped further growth after 3 days. 60 references.

IT 114793-55-4, Acetic acid, [methylenebis[(3-chloro-p-phenylene)oxy]]di-
(esters (di-))

RN 114793-55-4 CAPLUS


CN Acetic acid, [methylenebis[(3-chloro-p-phenylene)oxy]]di- (6CI) (CA INDEX NAME)



IT 121677-14-3, Acetic acid, [methylenebis[(3-methyl-p-phenylene)oxy]]di-
(esters (di-))

RN 121677-14-3 CAPLUS


CN Acetic acid, [methylenebis[(3-methyl-p-phenylene)oxy]]di- (6CI) (CA INDEX NAME)




IT 100881-21-8, Acetic acid, [α-(4-hydroxy-3-nitrophenyl)-2-nitro-p-tolyloxy]- 101351-67-1, Acetic acid, [α-(4-hydroxy-3-nitrophenyl)-2-nitro-p-tolyloxy]-, methyl ester
114793-55-4, Acetic acid, [methylenebis[(3-chloro-p-phenylene)oxy]]di- 121677-14-3, Acetic acid, [methylenebis[(3-methyl-p-phenylene)oxy]]di-
(preparation of)

RN 100881-21-8 CAPLUS


CN Acetic acid, [α -(4-hydroxy-3-nitrophenyl)-2-nitro-p-tolyloxy]- (6CI)
(CA INDEX NAME)




RN 101351-67-1 CAPLUS
CN Acetic acid, [α -(4-hydroxy-3-nitrophenyl)-2-nitro-p-tolyloxy]-, methyl ester (6CI) (CA INDEX NAME)



RN 114793-55-4 CAPLUS
CN Acetic acid, [methylenebis[(3-chloro-p-phenylene)oxy]]di- (6CI) (CA INDEX NAME)



RN 121677-14-3 CAPLUS
CN Acetic acid, [methylenebis[(3-methyl-p-phenylene)oxy]]di- (6CI) (CA INDEX NAME)



L8 ANSWER 164 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1952:17731 CAPLUS
DN 46:17731
OREF 46:3082c-d
TI 2,2'-Methylenebis(4-chlorophenoxyacetic acid)
IN Faith, Herman E.
PA Allied Laboratories, Inc.
DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2565171		19510821	US 1950-170475	19500626


AB 2,2'-Methylenebis(4-chlorophenoxyacetic acid) (I) is used as fungicide and bactericide in the form of its water-soluble Na salt. I, m. 242-5° (from EtOH), is prepared by refluxing 7 g. of 2,2'-methylenebis(4-chlorophenol) and 5.28 g. NaOH in 33 ml. water, 2 hrs. with 6.3 g. ClCH₂CO₂H, precipitating I by HCl, and purifying it by repptn. from NaHCO₃.

The hemi-Pb salt is prepared by adding 16.5 g. Pb(NO₃)₂ in 400 cc. water to the alkaline solution of 38.7 g. I in 900 ml. Me₂CO, the mono-Pb salt is prepared by addition of twice the amount of Pb(NO₃)₂.

IT 791629-95-3, Acetic acid, [methylenebis(4-chloro-o-phenyleneoxy)]di-(salts)

RN 791629-95-3 CAPLUS

CN Acetic acid, [methylenebis(4-chloro-o-phenyleneoxy)]di- (5CI) (CA INDEX NAME)



L8 ANSWER 165 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1951:21762 CAPLUS

DN 45:21762

OREF 45:3826g-i,3827a-h

TI Aldehyde-phenol reaction products and derivatives

AU Faith, H. Eldridge

CS Pitmen-Moore Co., Indianapolis, IN

SO Journal of the American Chemical Society (1950), 72, 837-9

CODEN: JACSAT; ISSN: 0002-7863

DT Journal

LA Unavailable

AB The Baeyer and Lederer-Manasse reactions were applied successfully by different methods to a variety of phenols and aldehydes to produce a number of sym. and mixed methylenebisphenols and phenol alcs. Direct substitutions were made in several methylenebisphenol derivs. One-step condensation of phenols with aldehydes, 2:1 ratio. Method A. To 20 g. concentrated H₂SO₄ in 40 cc. AcOH and 0.1 mol substituted phenol in 20 cc.

AcOH, 4.2 cc. 40% HCHO was added during 2.5 h. at 0-5°, the mixture stirred cold 3 h., then 18.5 h. at room temperature, poured into cold water, and the precipitate filtered off and neutralized with NaHCO₃. Method B. Paraldehyde

(18 g.) was added to 0.8 mol p-ClC₆H₄OH (I) in 400 g. 75% H₂SO₄ at 0-5° during 4 h., the mixture stirred 3 h., water added, and the unreacted I removed by adjusting the solution to pH 8 and filtering off the precipitate

Method

C. HCHO (0.116 mol 40%) was added during 3 h. to 0.209 mol p-HOC₆H₄AsO₃H₂ in 180 g. 90% H₂SO₄ at 0-5°, the mixture kept cold 21 h., water added, the precipitate washed with cold dilute H₂SO₄, dissolved in NaHCO₃, dilute HCl

added, and the precipitate washed with dilute HCl. Method D. I (0.215 mol) and

BzH in 135 g. 90% H₂SO₄ were treated as in Method C, the product washed with water, dissolved in ether, neutralized with NaHCO₃, the solution concentrated,

and the product precipitated with petr. ether. Method E. Paraformaldehyde (1.58

g.) was added to 0.1 mol of the phenol in 15 cc. AcOH, the mixture saturated with dry HCl at 5°, allowed to stand 4 h. in an ice bath, then at room temperature 20 h., and the product precipitated with petr. ether. Method


F.

Equimol. ams. of I and HCHO yielded 54% 2,6-bis(hydroxymethyl)-4-chlorophenol, m. 154-5° (from water). 6-Chlorothymol and HCHO yielded 54% 2-hydroxymethyl-6-chlorothymol (II), m. 62-4° (from petr. ether). 2,2'-Methylenebis(4-chlorophenol) (III) (0.1 mol) treated with 0.2 mol HCHO for 4 days yielded 2,2'-dihydroxy - 3 - hydroxymethyl - 5,5' - dichlorodiphenylmethane. Condensations of phenol alcs. with phenols. Method G. (a) II (0.1 mol) and 0.1 mol of the phenol were allowed to react in 60 cc. AcOH. (b) 6-(Hydroxymethyl)thymol and thymol condensed by G (a) to yield 6,6'-methylenedithymol. Direct substitution of methylene-, ethylidene-, and benzylidenebisphenols. Method H. Methylation in Me₂CO with Me₂SO₄ and K₂CO₃. Method I. ClCH₂CO₂H was refluxed with the methylenebisphenol in NaOH for 2 h. Method J. Iodination by the method of Burger, et al. (C.A. 39, 4855.9). Method K. (a) The methylenebisphenol (40 g.) was heated at 100° for 4 h. with 31 g. concentrated H₂SO₄, 500 cc. water added, the mixture filtered, adjusted


to

pH 5.6 with NaOH, and the Ca salt formed from the precipitate in EtOAc. (b) Concentration of the filtrate from K (a) yielded an EtOAc-insol. Na salt from which the Ba salt was formed. Method L. (a) Fuming HNO₃ (d. 1.5) (34 g.) and 0.25 mol III in 550 cc. AcOH were allowed to stand 1.5 h. at 25°. (b) The dinitro derivative was reduced with SnCl₂ in HCl-alc. at 80° for 1 h. (c) The diamino compound was selectively acetylated. p-ClC₆H₄SH and HCHO by method A yielded 75% bis(4-chlorophenylmercapto)methane, m. 44-5° (from MeOH). ar-Substituted diphenylmethanes of the general formula Ph₂CHR were prepared (the substituents and their positions on the rings of the diphenylmethanes, R, method and yield (%), m.p. (uncor.), and solvent given): x,x'-di-OH, x,x'-di-Cl (x,x'-methylenebis(4-chlororesorcinol)), H, A 60 (kept cold 24 h.), 150-1°, (CH₂Cl)₂; x,x'-di-OH, x,x'-di-OMe, x,x'-di-Cl, (x,x'-methylenebis(3-methyl-4-chlorophenol)), H, A -, 180-2°, heptane; 2,2'-di-OH, 5,5'-di-Cl, Me, B 65, 170-1°, heptane-C₆H₆; 2,2'-di-OH, 5,5'-di-AsO₃H₂, H, C 22, >300°, dilute HCl; 2,2'-di-OH, 5,5'-di-Cl, Ph, D 46, 168-9.5°, xylene; 2,2'-di-OH, 3,3'-di-iso-Pr, 5,5'-di-Cl, 6,6'-di-Me, H, E 44, 128-9°, naphtha; 2,2'-di-OH, 3-CH₂OH, 5,5'-di-Cl, H, F 36, 165-7°, C₆H₆; 2,2'-di-OH, 3-iso-Pr, 5-Cl, 5'-tert-Bu, 6-Me, H, Ga 64, 158-9°, heptane; 2,2'-di-OH, 3-iso-Pr, 5,5'-di-Cl, 6-Me, H, Ga 44, 134.5-5.5°, heptane-C₆H₆; 2,4'-di-OH, 6,2'-di-Me, 3,5'-di-iso-Pr, 5-Cl, H, Ga 23, 174-6°, heptane-C₆H₆; 2,2'-di-Me, 4,4'-di-OH, 5,5'-di-iso-Pr, H, Gb 78 (42% by E), 162-4°, C₆H₆-petr. ether; 2,2'-di-MeO, 5,5'-di-Cl, H, H 70, 95-7°, MeOH (fungicidal activity reported); 2,2'-di-OCH₂CO₂H, 5,5'-di-Cl, H, I 71, 242-5°, EtOH; 2,2'-di-OH, 3,3'-di-I, 5,5'-di-Cl, H, J 38, 195-6°, AcOH; same substituents, Ph, J 66, 193-4.5°, AcOH; same substituents, Me, J 53, 123-4.5°, AcOH; 2,2'-di-OH, 3-iso-Pr, 3'-I, 5-Cl, 5'-tert-Bu, 6-Me, H, J 28, 126-7°, naphtha; 2,2'-di-OH, 3-SO₃H, 5,5'-di-Cl, H, Ka 33, -, water (Ca salt, dihydrate); 2,2'-di-OH, 3,3'-di-SO₃H, 5,5'-di-Cl, H, Kb 27, -, water (Ba salt, dihydrate); 2,2'-di-OH, 3,3'-di-NO₂, 5,5'-di-Cl, H, La 63, 181-2°, AcOH; 2,2'-di-OH, 3,3'-di-NH₂, 5,5'-di-Cl, H, Lb 83, 230-2°, EtOH; 2,2'-di-OH, 3,3'-(AcNH)₂, 5,5'-di-Cl, H, Lc 29,

IT 228-9°, EtOH.
 791629-95-3, Acetic acid, [methylenebis(4-chloro-o-phenyleneoxy)]di-
 (preparation of)
 RN 791629-95-3 CAPLUS
 CN Acetic acid, [methylenebis(4-chloro-o-phenyleneoxy)]di- (5CI) (CA INDEX NAME)




L8 ANSWER 166 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1950:10965 CAPLUS
 DN 44:10965
 OREF 44:2157i,2158h-i
 TI Fungicidal activity of bisphenols
 AU Marsh, Paul B.; Butler, Mary L.; Clark, Bernice S.
 SO Journal of Industrial and Engineering Chemistry (Washington, D. C.)
 (1949), 41, 2176-84
 CODEN: JIECAD; ISSN: 0095-9014
 DT Journal
 LA Unavailable
 AB Data from expts. on 39 bisphenols not previously tested and new comparative data on several compds. tested in earlier work (C.A. 40, 5188.5) are presented. The test methods were similar to or identical with those described in the previous paper, Bisphenolic bridges consisting of -CH2-, -CHCH3-, -CHC6H5-, -CH:CH-, and -S- have been found compatible with high activity, whereas -SO- and -SO2- bridges are less active. Halogens in all 4 positions ortho to the bisphenolic OH groups causes low activity. Br contributes less than Cl to fungicidal activity in bisphenols of high halogen content. Bisphenols with a chlorothymol type of structure, with very high mol. wts., with no halogen, or with ether linkages blocking both phenolic OH groups showed low activity.
 IT 791629-95-3, Acetic acid, [methylenebis(4-chloro-o-phenyleneoxy)]di-
 (as fungicide)
 RN 791629-95-3 CAPLUS
 CN Acetic acid, [methylenebis(4-chloro-o-phenyleneoxy)]di- (5CI) (CA INDEX NAME)



L8 ANSWER 167 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1950:10964 CAPLUS
 DN 44:10964
 OREF 44:2157h-i

TI Control of *Uromyces caryophyllinus* and *Heterosporium echinulatum* of pinks and *Sphaerotheca pannosa* of roses
 AU Borzini, Giovanni
 SO Notiziario sulle Malattie delle Piante (1949), No. 2, 1-3
 CODEN: NOMPA8; ISSN: 0468-9291
 DT Journal
 LA Unavailable
 AB A preliminary report of satisfactory results of expts. with various S and Cu or S-Cu com. products.
 IT 791629-95-3, Acetic acid, [methylenebis(4-chloro-o-phenyleneoxy)]di- (as fungicide)
 RN 791629-95-3 CAPLUS
 CN Acetic acid, [methylenebis(4-chloro-o-phenyleneoxy)]di- (5CI) (CA INDEX NAME)



L8 ANSWER 168 OF 168 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1949:4573 CAPLUS
 DN 43:4573
 OREF 43:1053h-i,1054a-c
 TI β -Aryloxy carboxylic acids
 IN Gresham, Thomas L.; Shaver, Forrest W.
 PA The B. F. Goodrich Co.
 DT Patent
 LA Unavailable
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2449991		19480928	US 1945-620659	19451005


AB The acids are prepared by condensation of a phenol with β -propionolactone (I) or its analogs. The phenol may carry substituents such as halogens, CN, CO, -N.tplbond.N, thio, and sulfone compds., and many others. The presence of reactive H in the substituent, however, complicates the reaction, since this group itself may enter the condensation. Refluxing I with PhOI 10 hrs., followed by the addition of H₂O and distillation of the separated oil, gives 39% β -phenoxypropionic acid, b₂₆ 188-9°, m. 97-8°. Condensation in C₆H₆ solution or using PhONa in H₂O, followed by acidification, gives smaller yields. o-ClC₆H₄OH in aqueous NaOH slowly mixed with I and kept at 25-30° for 2 hrs. gives on acidification 80% white crystals of β -(o-chlorophenoxy)propionic acid, m. 109-11°. β -(p-Chlorophenoxy)propionic acid, m. 135-6°. β -(2,4-Dichlorophenoxy)propionic acid, m. 92-3°, is an excellent plant-growth promoter, o-NO₂C₆H₄OH and NaOH in water with I at 20-40° give, after addition of HCl, 48% β -(o-nitrophenoxy)propionic acid, m. 120-2°, as an oil. By the same procedure were prepared the p- and m-nitro compds. and derivs. with 2-naphthol, m. 140-3°, m-cresol, m. 100-3°, and o-methoxyphenol, m. 136-7°. Treating [3,4-Cl(HO)C₆H₃]₂CMe₂ with 2 mols. I in water in the presence of NaOH for 1 hr., passing CO₂ through the solution, and extracting the nonreacted dihydric phenol with EtOAc,

gives bis[3-chloro-4-(2-carboxyethoxy)phenyl]dimethylmethane, useful as a plasticizer.

IT 857226-90-5, Propionic acid, 3,3'-[isopropylidenebis(2-chloro-p-phenyleneoxy)]di-
(preparation of)

RN 857226-90-5 CAPLUS

CN Propionic acid, 3,3'-[isopropylidenebis(2-chloro-p-phenyleneoxy)]di- (5CI)
(CA INDEX NAME)



=>